Scientific Program Committee

CR I 

2OO8 

15th Conference on Retroviruses 

and Opportunistic p 

Infections 

Pocket 

Program 

February 25 -28, 2007 

Los Angeles Convention Center 

Los Angeles, California, US 

February 3-6, 2008 

Hynes Convention Center 

Boston, MA, US

Scientifi c Program Committee 

Mario Stevenson, PhD, Chair 

Univ of Massachusetts Med Sch, 

Worcester, US 

John W Mellors, MD, Vice Chair 

Univ of Pittsburgh, PA, US 

Elaine J Abrams, MD 

Columbia Univ, Mailman Sch of Publ 

Hlth, New York, NY, US 

Constance A Benson, MD 

Univ of California, San Diego Antiviral 

Res Ctr, US 

Susan P Buchbinder, MD 

San Francisco Dept of Publ Hlth, CA, US 

Dennis R Burton, PhD 

The Scripps Res Inst, La Jolla, CA, US 

Andrew Carr, MD 

St Vincent’s Hosp, Sydney, Australia 

Ellen G Chadwick, MD 

Northwestern Univ, Feinberg Sch of 

Med, Chicago, IL, US 

Richard E Chaisson, MD 

Johns Hopkins Univ, Baltimore, MD, US 

John M Coffin, PhD 

Tufts Univ, Boston, MA, US 

Judith S Currier, MD, MSc 

Univ of California, Los Angeles, US 

Kevin M De Cock, MD 

World Hlth Org, Geneva, Switzerland 

Wafaa El-Sadr, MD, MPH 

Columbia Univ, Harlem Hosp Ctr, New 

York, NY, US 

Courtney V Fletcher, PharmD 

Univ of Nebraska Med Ctr, Omaha, US 

Dana H Gabuzda, MD 

Dana-Farber Cancer Inst, Boston, MA, 

US 

Francisco Gonzalez-Scarano, MD 

Univ of Pennsylvania, Philadelphia, US 

Community Liaison Subcommittee 

Beatrice H Hahn, MD 

Univ of Alabama at Birmingham, US 

James G Hakim, MBChB 

Univ of Zimbabwe Coll of Hlth Sci, 

Harare 

Scott M Hammer, MD 

Columbia Univ, Coll of Physicians & 

Surgeons, New York, NY, US 

Sharon L Hillier, PhD 

Univ of Pittsburgh, Magee-Womens 

Res Inst, PA, US 

David D Ho, MD 

Aaron Diamond AIDS Res Ctr, The 

Rockefeller Univ, New York, NY, US 

Harold W Jaffe, MD 

Univ of Oxford, UK 

Richard A Koup, MD 

Vaccine Res Ctr, NIAID, NIH, 

Bethesda, MD, US 

Nathaniel R Landau, PhD 

New York Univ Sch of Med, NY, US 

Norman L Letvin, MD 

Beth Israel Deaconess Med Ctr, 

Boston, MA, US 

Michael H Malim, DPhil 

King’s Coll London Sch of Med, UK 

Julio S G Montaner, MD 

St Paul’s Hosp and Univ of British 

Columbia, Vancouver, Canada 

Douglas D Richman, MD 

Univ of California, San Diego, US 

Robert T Schooley, MD 


Melissa A Sordyl, MBA 

Conference Secretariat, Alexandria, 

VA, US 

Amalio Telenti, MD, PhD 

Univ of Lausanne, Switzerland 

David Thomas, MD 


Michael Marco, MPH 

Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, New York, NY, US 

Lina Sheth, MPH 

Asian & Pacific Islander Wellness Ctr, San Francisco, CA, US 

Nelson R Vergel, MBA 

Res Access Network, Houston, TX, US 

CROI Message Center 

617-954-2594 

3rd Level 

General Sessions Balcony 

Breakout Rooms Ballroom A 

Ballroom B/C 

Balcony 

302-304 

311 

312 

Speaker Services Room 300 

2 nd Level 

General Sessions Auditorium 

Breakout Room Auditorium 

Media Center 207 

CyberCafé Hall C 

Posters 200-504 Hall D 

Plaza Level 

Registration Main Lobby 

Message Center Main Lobby 

First Aid Main Lobby 

Computer Lab/ 100 

Poster Drop-Off 

Meeting Headquarters 102 

Coat Check 107 

Posters 505-773 Hall A 

Posters 774-1084 Hall B 

300 

Speaker 

Services 

100 

Computer 

Lab 

Dining 

Lounge 

The Hynes Convention Center 

900 Boylston St, Boston, MA 02115 • 617-954-2000 

Balcony 

Balcony 

Auditorium 

Message Center 

Main 

Lobby 

Registration 

Balcony 

Boylston Street 

Entrance 

First 

Aid 

Ballroom B/C 

Ballroom A 

302-304 312 

207 

Media Ctr 

Hall A 

Posters 505-773 

107 

Coat 

Check 

Hall C 

102 

Headquarters 

3 rd LEVEL 

208 

Press Conf 

2 nd LEVEL 

Entrance from Prudential Center 

and Copley Place Mall 

PLAZA LEVEL 

311 

Hall D 

Posters 200-504 

Hall B 

Posters 774-1084

iv 

General Information CROI 2008 2007 

INTRODUCTION 

The 15 th Conference on Retroviruses and Opportunistic Infections 

(CROI) is a research meeting created to provide a forum for basic 

scientists, clinical investigators, and global health researchers to present, 

discuss, and critique their investigations into the epidemiology and 

biology of human retroviruses and the diseases they produce with the 

ultimate goal of translating laboratory and clinical research into progress 

against the AIDS epidemic. 

To support the goals of the meeting and the preferences of the 

scientific community the conference serves, the Scientific Program 

Committee has limited registration to researchers actively participating 

as investigators in basic science or clinical studies of retroviral diseases 

and their complications and clinician-teachers (full-time academic faculty 

members responsible for HIV/AIDS training and research programs). 

Preference will be accorded to doctoral and professional degree level 

researchers/clinicians. In addition, a limited number of slots have 

been reserved for press, AIDS treatment and prevention community 

educators, and senior clinical development personnel from industry who 

have product development planning responsibilities. 

At the conclusion of CROI 2008, attendees will again be polled 

to determine their programmatic and logistical preferences for future 

conferences. The CME Worksheet and/or Conference Evaluation 

should be completed (online at www.retroconference.org) no later than 

March 6, 2008. The Scientific Program Committee welcomes your 

opinions on how to continue to improve the conference. The committee 

will use the survey results to determine the venue and policies for future 

meetings, so your feedback is important. 

ABBREVIATIONS AND ICONS USED IN THE PROGRAM 

International Scholarship Awardee 

(a listing appears in the Program & Abstracts book) 

Young Investigator Awardee 

(a listing appears in the Program & Abstracts book) 

LB Late Breaker Abstract Presentation 

CME 

Workshop Oral Abstracts 

Plenary Poster Discussion 

Symposium Poster Abstracts 

Session will be Webcast 

Session will be Podcast 

Session is eligible for CME credit 

AMERICANS WITH DISABILITIES ACT 

Each participating hotel is in compliance to some degree with the 

Americans with Disabilities Act. Special services (e.g., wheelchairaccessible 

transportation and sign interpreters for the hearing impaired) 

are available if requested in advance. Should you require assistance on 

site, please visit the Headquarters Office located on the Plaza Level in 

Room 102. 

BADGES 

All registered meeting attendees, after showing photo identification, will 

be issued a meeting badge when they pick up their registration materials 

onsite and will be required to wear their badge at all official functions. 

Due to enhanced security measures, attendees will need to present 

their badges for admittance into the convention center at all times. In 

the event of a lost badge, the attendee will be required to pay another 

registration fee, in order for their badge to be reissued. 

CROI 2008 2007 General Information 

CHILD CARE 

Due to the professional nature of this meeting, children are not allowed 

in sessions, poster halls, or the Welcome Reception, so please plan 

accordingly. Child care arrangements can usually be made through 

the hotel concierge. Alternatively, the Boston Convention and 

Visitors Bureau has suggested the daycare center Parents in a Pinch 

(617-739-5437 phone). 

CONFERENCE COURTESIES 

In consideration of all meeting attendees: 

• Make sure all cell phones and pagers are silent (in the off position or 

in vibrate mode) in session rooms; kindly step out of the room prior to 

answering or initiating a cell phone call. 

• Refrain from photography in sessions and the poster hall (as a 

reminder, all sessions will be available online). 

• In keeping with the scientific nature of the conference, and to ensure 

a productive meeting experience, no disruptions and/or protests are 

allowed. 

• The Hynes Convention Center is a smoke-free facility. Individuals who 

wish to smoke should do so outside of the entrance to the building. 

CONTINUING MEDICAL EDUCATION (CME) CREDITS CME 

CROI 2008 has been planned and implemented in accordance with the 

Essential Areas and policies of the Accreditation Council for Continuing 

Medical Education through the joint sponsorship of the Conference on 

Retroviruses and Opportunistic Infections and University of California, 

San Diego School of Medicine. The University of California, San Diego 

School of Medicine is accredited by the ACCME to provide continuing 

medical education for physicians. The University of California, San 

Diego School of Medicine designates this educational activity for a 

maximum of 27 AMA PRA Category 1 Credits . Physicians should 

only claim credit commensurate with the extent of their participation 

in the activity. 

To be eligible for CME credit, registrants must complete the CME 

Worksheet and Conference Evaluation (online at www.retroconference. 

org) no later than March 6, 2008. Your badge number will be required to 

access the forms. CME certificates will be mailed after June 1, 2008. 

Session participants must disclose to the program audience any 

financial interest or other relationship with the manufacturer(s) of any 

commercial product(s) and/or provider(s) of commercial services related 

to the content of their presentations. The Program Committee does not 

view the existence of these interests or commitments as implying bias or 

decreasing the value of speakers’ participation in CME programming. 

For the list of authors who have nothing to disclose and those who 

have disclosed that either they or their departments have received 

support from the commercial parties, please see the CME Disclosures 

Addendum. 

California Assembly Bill 1195 requires continuing medical education 

activities with patient care components to include curriculum in the subjects of 

cultural and linguistic competency. It is the intent of the bill, which went into 

effect on July 1, 2006, to encourage physicians and surgeons, CME providers in 

the state of California, and the Accreditation Council for Continuing Medical 

Education to meet the cultural and linguistic concerns of a diverse patient 

population through appropriate professional development. The planners, speakers 

and authors of this CME activity have been encouraged to address issues relevant 

in the topic area. In addition, a variety of resources are available that address 

cultural and linguistic competency, some of which are included in your syllabus 

or handout materials. Additional resources and information about AB1195 can 

be found on our website at http://cme.ucsd.edu. 

v

vi 

General Information CROI 2008 2007 CROI 2008 2007 General Information 

MEALS 

Complimentary continental breakfast and morning coffee breaks will 

be available to conference registrants in Hall C (to the rear of the 

auditorium overflow seating on the 2 nd Level). 

Complimentary afternoon refreshments will be available to conference 

registrants in Poster Halls A and B (Plaza Level) and Poster Hall D 

(2 nd Level). 

Attendees are on their own for lunch during the hours of 12 noon to 

1 pm each day. Below is a list of food service options located in the 

Convention Center or within a short walking distance. 

At the Convention Center 

Coffee House and Cafe (Plaza Level across from Registration): 

In Copley Plaza and Prudential Center 

• Au Bon Pain 

• California Pizza Kitchen 

• Legal Sea Foods 

• PF Chang’s China Bistro 

• The Cheesecake Factory 

• The Terrace Food Court includes Gourmet India, Boston Chowda, 

Panda Express, Pizzeria Regina, Sakkio Japan, Qdoba Mexican 

Grill, and more 

WEBCASTS AND PODCASTS 

www.retroconference.org 

Plenaries, symposia, scientific overviews, and oral abstract sessions will 

be Webcast and Podcast. In addition, electronic versions of abstracts and 

posters from CROI 2008 as well as Webcasts, abstracts, and posters from 

previous meetings (CROI 1994-2007) will be available online. 

WELCOME RECEPTION 

Sunday, February 3, 6-8 pm, Halls C and D 

A Welcome Reception will immediately follow the Opening Plenaries. 

There will be large screens available for football fans to enjoy the Super 

Bowl while socializing with colleagues. 

WI-FI ACCESS 

CROI will be offering complimentary wireless connectivity within the 

Hynes Convention Center. Coverage in the facility includes CROI 

general session and breakout rooms, poster halls, registration area, and 

CyberCafé. No additional equipment is required beyond the wireless 

access card already installed in a client device (Wi-Fi enabled laptop, 

PDA, or telephone). 

Offices 

& Services 

Boston Information, 

Restaurant 

Reservations and 

Pre-/Post- 

Conference 

Activities 

617-954-2597 

Coat & Baggage 

Check 

Computer Lab & 

Poster Drop-off 

617-954-2611 

Location Hours of Operation Information 

Main Lobby 

Plaza Level 

107 

Plaza Level 

100 

Plaza Level 

CyberCafé Hall C 

2 nd Level 

Media Center 

617-954-2604 

Meeting 

Headquarters 

617-954-2599 

Message Center 

617-954-2594 

Registration & 

Housing 

617-954-2595 

Speaker Services 

617-954-2610 

207 

2 nd Level 

102 

Plaza Level 

Main Lobby 

Plaza Level 

Main Lobby 

Plaza Level 

300 

3 rd Level 

Saturday 12 n-5 pm 

Sunday 9 am-7 pm 

Monday 9 am-7 pm 

Tuesday 9 am-7 pm 

Wednesday 9 am-7 pm 

Sunday 7 am-8:30 pm 

Monday 7 am-7:15 pm 

Tuesday 7 am-7:15 pm 

Wednesday 7 am-6:30 pm 


Sunday 7-9 am, 1-6 pm 










Monday 8 am-6:30 pm 

Tuesday 8 am-6:30 pm 

Wednesday 8 am-6:30 pm 





















For maps, information on local 

attractions, restaurant 

reservations, and to make 

reservations for tours and other 

Boston recreational activities, 

visit the Boston Convention and 

Visitors Bureau kiosk. 

Coat & Baggage Check service is 

complimentary. 

Computers are available for 

attendees to view webcasts, 

search the abstracts and posters, 

and check email. This location is 

also where electronic versions of 

posters may be submitted for 

placement on the CROI web site. 

The Host Genomics Hands-on 

Computer Workshop is 

scheduled on Sunday 10 am-1 

pm. 

Computers will be available for 

attendees to view webcasts, 

search the abstracts and 

posters, and check email. In 

addition, Wi-Fi service will be 

available throughout the 

convention center. 

Pre-registered journalists 

should pick up press kits and 

convene for daily press 

conferences in the Media 

Center. There is no on-site 

press registration. 

To contact staff and Program 

Committee members or for lostand-found 

items, please go to 

the Meeting Headquarters. 

Voice and text messages may 

be left for attendees at the 

Message Center. 

Pre-registered attendees 

should pick up conference 

materials including badges, 

Program & Abstracts, and 

Addenda during registration 

hours. There is no on-site 

registration. 

Speakers should bring their 

presentation (in MS Power Point 

only) to the Speaker Services 

Room on a disk or drive at least 4 

hours prior to presentation. CROI 

supports both MacIntosh and PC 

platforms. The Speaker Services 

Room will be equipped with 

workstations, and an art director 

and AV technicians will be 

available to assist speakers. 

vii

viii 

Hotel Information CROI 2007 2008 

Map 

Key 

Hotels 

1 Boston Back Bay Hilton 

40 Dalton St 

Boston, MA 02115 

617-236-1100 

2 Boston Marriott Copley Place 

110 Huntington Ave 


617-236-5800 

3 Boston Park Plaza 

50 Park Plaza at Arlington St 


617-426-2000 

4 Fairmont Copley Place 

138 St James Ave 


617-267-5300 

5 Sheraton Boston 

39 Dalton St 


617-236-2000 

6 Taj Boston 

15 Arlington St 


617-536-5700 

Newbury Street 

7 Westin Copley Place 

10 Huntington Ave 


617-262-9600 

Beacon Street 

Hynes Convention 

Center 2 

1 

5 

Back 

Bay 

Commonwealth Ave 

Boyston Street 

Huntington Ave 

7 

Clarendon Street 

4 

Back Bay 

South End 

Columbus Ave 

St James Ave 

Distance 

to Convention Center 

1 block 

cross the street into the Sheraton, which 

is connected to the convention center 

3 minute walk 

2 blocks 

connected via enclosed sky bridge 

5 minute walk 

8 blocks 

4 blocks to the Copley Square Mall, 

the remainder inside mall 

15 minute walk 

Or take the T green line, 2nd stop 

(T vouchers available to hotel guests) 

3 blocks 

cross the street to the Westin, 

through the enclosed sky bridge and 

the remainder inside mall 

9 minute walk 

connected to the convention center 

1 minute walk 

7 blocks 

4½ blocks to the Copley Square Mall, 

the remainder inside the mall 

15 minute walk 

Or take the T green line, 2 nd stop 

(T vouchers available to hotel guests) 

3 blocks 

connected via enclosed sky bridge 

8 minute walk 

6 

Arlington 

Massachusetts Turnpike 

3 

Arlington Street 

Rates* 

*scholarship 

rates are half off 

the general rate 

$148 

$168 

$114 

$168 

$153 

$188 

$168 

CROI 2008 2007 Travel and Ground Transportation Information 

TRAVEL AND GROUND TRANSPORTATION 

Boston Logan International Airport to downtown Boston is 

approximately 4 miles and can take up to 30 minutes by car depending 

on traffic. 

Taxi Service 

Available 24 hours a day and service to all of New England. All areas 

within 12 mile radius of downtown Boston are charged a metered rate. 

Taxi fare from the airport is approximately $25-$30. Taxi fare from the 

train station is approximately $15–$20. 

Shuttle Service 

Discounts have been arranged with Star Shuttle (from Boston Logan to 

downtown) at a rate of $10 one way, $20 round trip (regular $15/$25) by 

mentioning convention code 703 to the shuttle driver. 

• Toll-free number for Star Shuttle is 877-970-STAR (7827). 

• Option of pre-paying for shuttle service at http://www. 

starshuttleboston.com/.com in the reservation option by entering the 

convention code 703. 

Amtrak 

Discounts have been arranged with Amtrak and are available from 

January 3 through February 9. For reservations, call Amtrak 

at 800-872-7245 or contact your local travel agent and refer to 

convention fare code X69R-93. This discount cannot be accessed via 

the internet. 

Back Bay Station 

145 Dartmouth St 


This station is located in downtown Boston and can be accessed 

through the Copley Place Mall via the Prudential Center. 

Amtrak South Station 

Atlantic Ave & Summer St 


This station is approximately 2–3 miles from downtown Boston 

and can take up to 20 minutes by car depending on traffic. 

MBTA (Mass Bay Transportation Authority) aka the “T” 

Runs daily service on buses, trains, and trolleys throughout Boston. 

T-stations can be identified by a black “T” on a white circular sign. 

Charlie cards can be bought at booths at each station. Purchase 1 and 7 

Day Passes at the Visitor Information Center on Boston Common. For 

transport from Logan Airport to Hynes Convention Center or hotels, 

there are 3 options: 

• Closest stop to the Taj, Marriott, Westin, and Fairmont - Take the 

Blue Line to State Street, transfer to the Orange Line and get off at 

Back Bay. 

• Closest stop to the Hilton, Sheraton and Convention Center - Take 

the Blue Line to Government Center, transfer to the Green Line and 

get off at Hynes Convention Center. 

• Closest stop to the Park Plaza - Take the Blue Line to Government 

Center, transfer to the Green Line and get off at Arlington. 

The cost is $2.00 one way. 

Hertz 

Discounts on car rental have been arranged with Hertz and are 

available from January 28 through February 13. For reservations, call 

Hertz in the US and Canada at 800-654-2240 or outside these areas at 

405-749-4434. You or your travel agent may make your reservations by 

phone or on line at hertz.com. To receive the discounted rates listed on 

the CROI website, refer to CV #04040002. 

ix

x 

Conference Supporters CROI 2008 

The 15 th Conference on Retroviruses and Opportunistic Infections 

acknowledges and appreciates the support of the companies listed 

below. Their support is integral to the success of the CROI scholarship 

programs.

CROI 2008 Session 1 

j Sunday, 9 am-1:40 pm; Room 302-304 

Session 1–Workshop CME 

Program Committee Workshop for New 

Investigators and Trainees 

The purpose of this workshop is to educate and engage new investigators and 

trainees, to spark interest in the field, to provide opportunities for interaction 

among trainees and faculty, and to orient trainees to the science being 

presented at the conference. 

Presentations during the Program Committee Workshop will be geared 

toward new trainees (e.g., graduate students, postdoctoral fellows, and 

physician fellows) and new investigators (both international and domestic) 

who have been conducting active research in the field for less than 3 years. 

The lunch presentation is limited to awardees from the young investigator, 

international scholar, and community educator programs. Other CROI 

registrants may attend the workshop (on a space available basis). No preregistration 

is required. 

The workshop format is designed to be interactive. Each presenter will 

provide a state-of-the-art summary of a research area being covered at 

the conference and then outline the top 3-5 research issues in their field. 

The floor will then be open for questions from the audience and panel 

discussion. 

9-9:10 am 

Opening Comments 

John Mellors 


9:10-9:40 am 

1a 

Cellular and Viral Factors in HIV-host 

Cell Interplay 

Mario Stevenson 

Univ of Massachusetts Med Sch, Worcester, US 

9:40-10:10 am 

1b 

New Insights into Immunopathogenesis 

and Vaccine Design 

Rick Koup 

Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US 

10:30-11 am 

1c 

Genomics–a Door to a New Biology 

Amalio Telenti 


11-11:30 am 

1d 

Pharmacologic Contributions to Therapeutic 

Success with Antiretroviral Agents 

Courtney Fletcher 


11:30 am-12:30 pm (Ballroom A) 

1e 

Special Luncheon for Young Investigators, 

International Scholars and Community Educators 

The Early AIDS Epidemic in the US: 

Views from Atlanta and Hollywood 

Harold Jaffe 


12:30-1 pm 

1f 

The State of ART—Current and Future 

Constance Benson 


1-1:30 pm 

1g 

HIV/AIDS–Where Is It Going and 

What Does It Mean? 

Kevin De Cock 

World Hlth Org, Geneva, Switzerland 

1:30-1:40 pm 

Closing Comments 

Scott Hammer 

Columbia Univ Coll of Physicians and Surgeons, New York, NY, US 

Program 1 

Sunday 

February 3 Sessions

Sunday 

February 3 Sessions 

Session 2 CROI 2008 

k Sunday, 10 am-1 pm; Room 100 (Computer Lab) 

Session 2–Workshop 

Host Genomics Hands-on Computer Workshop 

The purpose of this workshop is to engage investigators in the emerging field 

of host genome analysis (candidate gene and genome-wide analyses). This 

workshop can accommodate 30 participants on a first-come, first-served basis. 

No pre-registration is required. 

The workshop will be a hands-on, interactive short course, with an 

introduction to some of the search and analysis tools the host genome 

databases provide. Participants will explore ways the database tools can 

facilitate a study by working through a hypothetical research problem. The 

faculty will answer questions about how the database might be usefully 

applied to the work of those attending the workshop. The course will include 

a series of short presentations that will introduce several database tools. 

Attendees will each have a computer terminal available, and there will be time 

for working through example problems and queries. 

Convener: 

Amalio Telenti 


I Introduction 

Defining Phenotypes for Host Genetic and 

Genomic Studies 

Jacques Fellay 

Duke Univ, Durham, NC, US 

II PLINK 

Samuel Deutsch 

Univ of Geneva Med Sch, Switzerland 

III WGAviewer 

IV Covariantes and Strategies for Stratification 

Control 

Dongliang Ge 


2 15th Conference on Retroviruses and Opportunistic Infections 

CME 

c Sunday, 2-4 pm; Auditorium 

Session 3–Symposium CME 

Scale-up of HIV Prevention and Treatment in the 

Developing World 

Conveners: 

James Hakim, Univ of Zimbabwe, 

Coll of Hlth Sci, Harare 

Marie Laga, Inst of Tropical Med, Antwerp, 

Belgium 

2 

Implementing Circumcision for HIV Prevention in 

Sub-Saharan Africa 

Bertran Auvert* 1 , E Marseille 2 , and J Kahn 2 

1 INSERM U687, Univ of Versailles, and Hosp Ambroise Pare, 

France and 2 Philip R Lee Inst for Hlth Policy Studies, Univ of 

California, San Francisco, US 

3 

Scale-up of HIV Testing in Africa 

Elizabeth Marum 

Global AIDS Prgm, CDC, Atlanta, GA, US 

4 

ART in Africa: Beyond the Roll-out 

Gary Maartens 

Univ of Cape Town, South Africa 

5 

Prevention of Cervical Cancer in the HAART Era 

Silvia Franceschi 

Intl Agency for Res on Cancer, Lyon, France 

Objectives: This session is directed to clinicians and scientists interested in 

the prevention and treatment of HIV infection and its complications in the 

developing world. It is assumed participants are familiar with the magnitude 

and basic epidemiology of HIV/AIDS in Sub-Saharan Africa. At the 

completion of the session, participants will understand the roles of testing and 

circumcision in HIV prevention, strategies for prevention of cervical cancer, 

and the challenges of implementing HIV treatment in the developing world.


e Sunday, 4-6 pm; Auditorium 

CME 

Session 4–Opening Plenaries 

Greetings from the Program Committee 

Mario Stevenson 


13th Bernard Fields Memorial Lecture 

The Bernard Fields Memorial Lectureship recognizes a scientist whose body 

of work has significantly contributed to the understanding of virology and viral 

pathogenesis as exemplified by the career of Bernard Fields. 

6 

Contending with Evolution and Escape by HIV 

Douglas Richman 

VA San Diego Hlthcare System and Univ of California, San 

Diego, US 


the pathogenesis, treatment, and prevention of HIV disease. It is assumed 

participants are familiar with the basic principles and state-of-the-art of 

pathogenesis, treatment, and prevention. At the completion of the session, 

participants will be knowledgeable about HIV evolution and escape 

with regard to the selective pressures of antiretroviral therapy, anatomic 

compartmentalization, and the neutralizing antibody response. 

2nd N’Galy-Mann Lecture 

The N’Galy-Mann lectureship was established in 2006 to recognize 

an individual researcher or team who has made important and timely 

contributions in epidemiology and clinical research as exemplified by the 

collaborative careers of Bosenge N’Galy and Jonathan Mann. The 2008 

N’Galy-Mann Lectureship has been awarded to David Serwadda, Nelson 

Sewankambo, Ronald Gray, and Maria Wawer from The Rakai Health 

Sciences Program for their seminal research on HIV transmission. 

7 

A Population-based Approach to Understanding a Very Clever 

Virus: A Brief History of HIV Research and Services in the Rakai 

Health Sciences Program, Uganda 

David Serwadda* 

Makerere Univ Sch of Publ Hlth, Kampala, 

Uganda 

Nelson Sewankambo 

Makerere Univ Sch of Med, Kampala, 

Uganda 

Maria Wawer* 

Johns Hopkins Univ Bloomberg Sch of Publ 

Hlth, Baltimore, MD, US 

Ron Gray 

Johns Hopkins Univ Bloomberg Sch of Publ 

Hlth, Baltimore, MD, US 


HIV epidemiology, prevention, and care. It is assumed that participants are 

familiar with basic HIV biology and epidemiology. At the completion of the 

session, participants will be knowledgeable about the value of longitudinal 

population-based research in elucidating HIV and human interactions and 

how this serves in the development and testing of HIV prevention and care 

strategies. 


Sunday 

February 3 Sessions

Monday 



i Monday, 8:30-9 am; Auditorium 

Session 5–Plenary CME 

Morbidity and Mortality in the HAART Era 

8 

Andrew Phillips 

Royal Free and Univ Coll Med Sch, Univ Coll London, UK 


gaining greater appreciation of the extent of continued morbidity and mortality 

occurring during the HAART era, the surprisingly broad spectrum of clinical 

disease that might be influenced by HIV infection, and measures that might be 

needed to further reduce morbidity and mortality. It is assumed participants in 

this session are familiar with basic concepts of HIV progression, such as CD4 

count decline and the link between CD4 count level and risk of AIDS, and the 

effects of HAART in suppressing viral load and raising the CD4 count, leading 

to a reduction in AIDS risk. Participants are further assumed to be broadly 

familiar with current guidelines for treating individuals with HIV infection 

in developed countries. At the completion of the session, participants should 

have greater knowledge of the 3 areas outlined above. 

j Monday, 9-9:30 am; Auditorium 


Searching the Genome for Determinants 

of Response to HIV 

9 

David Goldstein 



how genome-wide association is being applied to study HIV host genetics, 

and what has been found with this approach. It is assumed that participants are 

familiar with basic genetics, but not with the details of statistical genomics. At 

the completion of the session, participants will be knowledgeable about how 

genome-wide association studies work, how they are being applied in HIV 

genetics, and what new studies are being carried out as part of the CHAVI 

program. 


k Monday, 10 -11:45 am; Room 302-304 

CME 

Session 7–Oral Abstracts 

Epidemiology of SIV/HIV Infection and 

AIDS-related Malignancies 

Moderators: 

Marie-Laure Chaix, Hosp Necker, Paris, France 

Harold Jaffe, Univ of Oxford, UK 

10:00 10 Geographic Distribution of SIV gor in Wild-living 

Gorillas from Cameroon 

Cecile Neel* 1,2 , F Van Heuverswyn 1 , E Mpoudi Ngole 2 , Y Li 3 , 

B Keele 3 , F Liegeois 1 , C Butel 1 , E Delaporte 1 , B Hahn 3 , and 

M Peeters 1 

1 UMR145, Inst for Res and Devt, Univ of Montpellier 1, France; 

2 PRESICA, Yaounde, Cameroon; and 3 Univ of Alabama at 

Birmingham, US 

10:15 11 Diagnosis and Monitoring of HIV-1 Group O Infections 

in Cameroon 

Aurelia Vessiere* 1 , D Rousset 1 , M Leoz 2 , A Depatureaux 2 , 

F Simon 3 , and JC Plantier 2 

1 Ctr Pasteur of Cameroon, Yaounde; 2 Hosp Charles Nicolle, Rouen, 

France; and 3 Hosp St Louis, Paris, France 

10:30 12 New and Old Complex Recombinant HIV-1 Strains 

Entering in France among Patients with Primary 

Infection in 2004 to 2006: The French ANRS CO06 

Primo Cohort Study 

P Frange1 , J Galimand1 , M Peeters2 , C Goujard3 , C Deveau4 , 

V Avettand - Fenoel1 , F Souala5 , L Meyer4 , C Rouzioux1 , and 

Marie-Laure Chaix* 1 

1 2 Ctr Hosp Univ Necker, Paris, France; Inst for Res and Devt, 

Montpellier, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre, 

France; 4INSERM, Le Kremlin Bicetre, France; and 5Ctr Hosp Univ 

Pontchaillou, Rennes, France 

10:45 13 Recent Phylodynamics of the HIV Epidemic among 

MSM in the UK 

Gareth Hughes* 1 , A Leigh Brown1 , A Rambaut1 , S Lycett1 , F Lewis2 , 

E Fearnhill3 , and UK Collaborative Group on HIV Drug Resistance 

1 2 Univ of Edinburgh, Scotland; Scottish Agricultural Coll, Inverness, 

UK; and 3Med Res Council Clinical Trials Unit, London, UK 

11:00 14 Changes Over Time in the Risk of Death following 

HIV Seroconversion Compared with Mortality in the 

General Population 

Kholoud Porter* 1 , O Hamouda2 , M Sannes3 , F Boufassa4 , 

A Johnson5 , S Walker1 , and CASCADE Collaboration 

1 2 Med Res Council Clinical Trials Unit, London, UK; Robert Koch 

Inst, Germany; 3Ulleval Univ Hosp, Oslo, Norway; 4INSERM, Paris, 

France; and 5Univ Coll London, UK 

11:15 15 Immunodeficiency and Risk of AIDS-defining and Non- 

AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort, 

1998 to 2006 

M Bruyand1,2 , R Thiebaut1,2,3,4 , S Lawson-Ayayi1,2 , P Joly3,4 , 

A Sasco5 , JL Pellegrin2,4 , D Neau2,4 , P Morlat1,2,4 , G Chene1,2,4 , 

Fabrice Bonnet* 1,2,4 , and Groupe d’Epidémiologie Clinique du SIDA 

en Aquitaine (GECSA) 

1 2 INSERM U593 and CIC-EC7, Bordeaux, France; Ctr Hosp Univ 

Bordeaux, France; 3INSERM U875, Bordeaux, France; 4Univ Victor 

Segalen, Bordeaux, France; and 5INSERM U897, Bordeaux, France 

11:30 16 Insufficient Virus Suppression during HAART Is a 

Strong Predictor for the Development of AIDS-related 

Lymphoma: German CLINSURV Cohort 

Alexander Zoufaly* 1 , HJ Stellbrink2 , M an der Heiden3 , 

C Kollan3 , J van Lunzen1 , O Hamouda3 , and CLINSURV Study Group 

1 2 Univ Med Ctr Hamburg-Eppendorf, Germany; IPM Study Ctr, 

Hamburg, Germany; and 3Robert Koch Inst, Berlin, Germany


k Monday, 10 am-12:15 pm; Ballroom A 

CME 


Viral Pathogenesis and Immune Surveillance 

Moderators: 

Amitinder Kaur, New England Primate Res Ctr, Harvard Med Sch, Southborough, 

MA, US 

David Watkins, Univ of Wisconsin, Madison, US 

10:00 18 Patterns of CD8 + Immunodominance May Influence the 

Ability of Mamu-B*08 + Macaques to Naturally Control 

SIVmac239 Replication 

John Loffredo* 1 , A Bean1 , D Beal1 , E Leon1 , S Piaskowski1 , 

S Musani2 , E Rakasz1 , N Wilson1 , D Allison2 , and D Watkins1 1Wisconsin Natl Primate Res Ctr, Univ of Wisconsin, Madison, US 

and 2Univ of Alabama at Birmingham, US 

10:15 19 CD20 + Cell Depletion Results in Abbreviated Cellmediated 

Immune Responses, Higher Viral Set-points and 

Shortened Survival in SIV-infected Pigtailed Macaques 

Lu-Ann Pozzi*, D Pauley, S Sato, H Knight, D Walsh, 

A Carville, W Johnson, S Westmoreland, and S O’Neil 

New England Primate Res Ctr, Harvard Med Sch, Southborough, 

MA, US 

10:30 20 Humoral Immune Responses Have Little Effect on 

Controlling Viremia during SIVagm Infection of African 

Green Monkeys 

Thaidra Gaufin* 1 , M Pattison1 , C Stoulig1 , R Gautam1 , M Barnes1 , 

C Monjure1 , M Marx1 , D Montefiori2 , C Apetrei1 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US and Duke Univ, 

Durham, NC, US 

10:45 21aLB Experimentally Induced Immune Activation in Natural 

Hosts of SIV Results in Significant Increases in Viral 

Replication 

Ivona Pandrea*, C Coleman, T Gaufin, R Gautam, M Pattison, 

C Monjure, A Lackner, and C Apetrei 

Tulane Natl Primate Res Ctr, Tulane Univ, Covington, LA, US 

11:00 21bLB Depletion of CD8 + T Cells Does Not Change the in vivo Life 

Span of Infected Cells during Pathogenic SIV Infection of 

Rhesus Macaques 

Nichole Klatt* 1,2 , E Shudo3 , A Ortiz1 , J Engram1 , S Gordon1,2 , 

B Lawson2 , J Else2 , J Schmitz4 , A Perelson3 , and G Silvestri1 1 2 Univ of Pennsylvania, Philadelphia, US; Yerkes Natl Primate Res 

Ctr, Emory Univ, Atlanta, GA, US; 3Los Alamos Natl Lab, NM, US; 

and 4Beth Israel Deaconess Med Ctr, Boston, MA, US 

11:15 22 Functionality of HIV-1-specific CD8 + T Cells Is Dependent 

on Antigen Load and Sequence Diversification 

Hendrik Streeck* 1 , Z Brumme1 , M Anastario2 , K Cohen1 , J Jolin1 , 

G Alter1 , A Meier1 , T Allen1 , B Walker1 , and M Altfeld1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med 

Sch, Boston, US and 2 Ctr for Disaster and Humanitarian Assistance 

Med, Univ of the Hlth Sci, Bethesda, MD, US 

11:30 23 Kinetics of Escape within HLA-restricted CTL Epitopes 

in the First Year of HIV Infection Is Consistent with 

Early Immunodominant CTL Response Patterns 

Zabrina Brumme* 1 , C Brumme1 , H Streeck1 , J Carlson2,3 , 

M Markowitz4 , H Jessen5 , A Kelleher6 , M John7 , D Heckerman2 , and 

B Walker1,8 1 2 Partners AIDS Res Ctr, Boston, MA, US; Microsoft Res, Redmond 

WA, US; 3Univ of Washington, Seattle, US; 4Aaron Diamond AIDS 

Res Ctr, The Rockefeller Univ, New York, NY, US; 5Jessen-Praxis, Berlin, Germany; 6Univ of New South Wales, Sydney, Australia; 

7 8 Murdoch Univ, Perth, Australia; and Howard Hughes Med Inst, 

Chevy Chase, MD, US 

11:45 24 Intracellular Epitope Stability Contributes to HIV 

Epitope Hierarchy and Can Be Altered to Modulate 

Epitope Presentation 

E Lazaro1 , P Stamegna1 , D Heckerman2 , B Walker1,3 , and 

Sylvie Le Gall* 1,3 

1Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; 

2 3 Microsoft Res, Seattle, WA, US; and Howard Hughes Med Inst, 

Chevy Chase, MD, US 

12:00 25 Mapping Escape Mutations Arising under HLArestricted 

CTL Selection Pressure in HIV-1 Gag: 

Correlations with Plasma Viral Load and CD4 Count in 

Untreated Chronic Infection 

Chanson Brumme* 1 , I Tao2 , S Szeto2 , Z Brumme1 , J Carlson3,4 , 

N Frahm1 , R Hogg2,5 , B Walker1,6 , D Heckerman3 , and R Harrigan2,7 1 2 Partners AIDS Res Ctr, Boston, MA, US; BC Ctr for Excellence in 

HIV/AIDS, Vancouver, Canada; 3Microsoft Res, Redmond WA, US; 

4 5 Univ of Washington, Seattle, US; Simon Fraser Univ, Burnaby, 

Canada; 6Howard Hughes Med Inst, Chevy Chase, MD, US; and 

7Univ of British Columbia, Vancouver, Canada 

k Monday, 10 am-12 noon; Ballroom B/C 

CME 


Prevention Strategies 

Moderators: 

Myron Cohen, Univ of North Carolina at Chapel Hill, US 

Jeanne Marrazzo, Univ of Washington, Harborview Med Ctr, Seattle, US 

10:00 26 Comprehensive Pre-clinical Assessment of Microbicide 

Safety Using in vitro and Murine Models 

Pedro Mesquita*, S Wilson, N Cheshenko, M Keller, B Galen, 

and B Herold 

Albert Einstein Coll of Med, Bronx, NY, US 

10:15 27LB Protective Effect of Vaginal Lactobacillus on Genital 

HIV-1 RNA Concentrations: Longitudinal Data from a 

US Cohort Study 

Jane Hitti* 1 , K Paul1 , K Agnew1 , R Gausman1 , D Lockhart1 , S Cohn2 , 

A Luque2 , and R Coombs1 1 2 Univ of Washington, Seattle, US and Univ of Rochester, NY, US 

10:30 28LB Trial of Male Circumcision: Prevention of HSV-2 in Men 

and Vaginal Infections in Female Partners, Rakai, Uganda 

Aaron Tobian* 1 , D Serwadda2 , T Quinn1,3 , G Kigozi4 , S Reynolds1,3 , 

F Makumbi4 , T Suntoke1 , S Watya5 , M Wawer1 , and R Gray1 1 2 Johns Hopkins Univ, Baltimore, MD, US; Makerere Univ Sch of 

Publ Hlth, Kampala, Uganda; 3NIAID, NIH, Bethesda, MD, US; 

4 5 Rakai Hlth Sci Prgm, Entebbe, Uganda; and Makerere Univ, 

Kampala, Uganda 

10:45 29 3-Year Follow-up of Sexual Behavior and HIV 

Transmission Risk of Persons Taking ART in Rural 

Uganda 

Rebecca Bunnell* 1 , J Ekwaru1 , R King1 , S Bechange1 , D Moore2 , 

K Khana1 , W Were1 , A Coutinho3 , J Tappero1 , and J Mermin1 1 2 Global AIDS Prgm, CDC Uganda, Kampala; Univ of California, 

San Francisco, US; and 3AIDS Support Org, Kampala, Uganda 

11:00 30 Effect of a Novel Behavioral Intervention to Promote 

Condom Use among Female Sex Workers along Lagos, 

Nigeria–Cotonou, Benin International Border 

Olusegun Busari*, O Busari, G Oligbu, and HIV Study Group 

Federal Med Ctr, Ido-Ekiti, Nigeria 

11:15 31 Serosorting, but Not Seropositioning, Is Associated 

with Decreased Risk of HIV Seroconversion in the 

EXPLORE Study Cohort 

Susan Philip* 1 , D Donnell2 , X Yu2 , E Vittinghoff3 , and S Buchbinder1 1 2 San Francisco Dept of Publ Hlth, CA, US; Statistical Ctr for HIV/ 

AIDS Res and Prevention, Seattle, WA, US; and 3Univ of California, 

San Francisco, US 

11:30 32LB HSV-2 Suppressive Therapy for Prevention of HIV 

Acquisition: Results of HPTN 039 

Connie Celum* 1 , A Wald1 , J Hughes1 , J Sanchez2 , S Reid3 , 

S Delaney-Moretlwe4 , F Cowan5 , J Fuchs6 , B Koblin7 , L Corey8 , and 

HPTN 039 

1 2 3 Univ of Washington, Seattle, US; Impacta, Lima, Peru; Univ of 

Alabama at Birmingham, Ctr for Infectious Disease Res in Zambia, 

Lusaka; 4Univ of the Witwatersrand, Johannesburg, South Africa; 5Univ of California, San Francisco, US and Univ of Zimbabwe, Harare; 6San Francisco Dept of Publ Hlth, CA, US; 7New York Blood Ctr, New York, 

US; and 8Fred Hutchinson Cancer Res Ctr, Seattle, WA, US 

11:45 33LB Trial of Male Circumcision in HIV+ Men, Rakai, 

Uganda: Effects in HIV+ Men and in Women Partners 

Maria Wawer* 1 , G Kigozi2 , D Serwadda3 , F Makumbi3 , F Nalugoda2 , 

S Watya4 , D Buwembo2 , V Ssempijja2 , L Moulton1 , and R Gray1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, 

US; 2Rakai Hlth Sci Prgm, Kalisizo, Uganda; 3Makerere Univ Sch of 

Publ Hlth, Kampala, Uganda; and 4Makerere Univ Faculty of Med, 



Monday 

February 4 Sessions

Monday 



k Monday, 10 am-12 noon; Auditorium 

CME 


New Antiretrovirals and Clinical Trials 

Moderators: 

Constance Benson, Univ of California, San Diego, US 

Patrick Yeni, Hosp Bichat, Paris, France 

10:00 34 Structure of HIV-1 CA N in Complex with CAP-1, an 

Assembly Inhibitor 

Brian Kelly* 1 , S Kyere 2 , I Kinde 2 , C Tang 2 , B Howard 3 , 

H Robinson 4 , W Sundquist 1 , M Summers 2 , and C Hill 1 

1 Univ of Utah, Salt Lake City, US; 2 Univ of Maryland, Baltimore, 

US; 3 Southern Utah Univ, Cedar City, US; and 4 Brookhaven Natl 

Lab, Upton, NY, US 

10:15 35 A Prospective, Randomized, Controlled, Open-label Trial 

Evaluating the Effect of Therapeutic Drug Monitoring 

and Protease Inhibitor Dose Escalation on Viral Load 

Responses in Antiretroviral-experienced, HIV-infected 

Patients with a Normalized Inhibitory Quotient 

Lisa Demeter* 1 , H Jiang2 , L Mukherjee2 , G Morse3 , R DiFrancesco3 , 

K Klingman4 , L Bacheler5 , R DiCenzo3 , A Rinehart6 , M Albrecht7 , 

and the A5146 Study Team 

1 2 Univ of Rochester Sch of Med Dentistry, NY, US; Harvard Sch 

of Publ Hlth, Boston, MA, US; 3State Univ of New York at Buffalo, 

US; 4Div of AIDS, NIAID, NIH Bethesda, MD, US; 5VircoLab Inc, 

Durham, NC, US; 6Tibotec Therapeutics, Bridgewater, NJ, US; and 

7Beth Israel Deaconess Med Ctr, Boston, MA, US 

10:30 36 Re-initiation of ART in the CD4-guided ART 

Interruption Group in the SMART Study Lowers Risk 

of Opportunistic Disease or Death 

Wafaa El-Sadr and SMART Study Group 

Harlem Hosp Ctr, Columbia Univ, New York, NY, US 

10:45 37 Efficacy and Safety of Once-daily Atazanavir/Ritonavir 

Compared to Twice-daily Lopinavir/Ritonavir, Each 

in Combination with Tenofovir and Emtricitabinein 

ARV-naïve HIV-1-infected Subjects: The CASTLE 

Study, 48-week Results 

Jean-Michel Molina* 1 , J Andrade-Villanueva2 , J Echevarria3 , 

P Chetchotisakd4 , J Corral5 , N David6 , M Mancini7 , L Percival7 , 

A Thiry7 , and D McGrath7 1 2 Hosp St Louis, Paris, France; Hosp Civil de Guadalajara, Mexico; 

3 4 Hosp Natl Cayetano Heredia, Lima, Peru; Khonkaen Univ, 

Thailand; 5Hosp Intl Gral de Agudos Oscar Alende, Buenos Aires, 

Argentina; 6Brooklyn Med Ctr, Western Cape, South Africa; and 

7Bristol-Myers Squibb R&D, Wallingford, CT, US 

11:00 38 Safety and Activity of SCH532706, a Small Molecule 

Chemokine Receptor 5 Antagonist in HIV-1-infected 

Individuals 

Sarah Pett* 1 , S Emery1 , K MacRae2 , R Norris2 , M McCarthy3 , 

A Tendlokar3 , J Tseng3 , K Williams2 , and D Cooper1 1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South 

Wales, Australia; 2St Vincent’s Hosp, Sydney, Australia; and 

3Schering-Plough Res Inst, Kenilworth, NJ, US 

11:15 39LB Vicriviroc, a Next Generation CCR5 Antagonist, 

Exhibits Potent, Sustained Suppression of Viral 

Replication in Treatment-experienced Adults: 

VICTOR-E1 48-week Results 

Barry Zingman* 1 , J Suleiman2 , E DeJesus3 , J Slim4 , M McCarthy5 , 

E Lee5 , N Case5 , C Mak5 , and L Dunkle5 1 2 Montefiore Med Ctr, Bronx, NY, US; Brazilmed Assistencia 

Medica e Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US; 

4 5 St Michael’s Med Ctr, Newark, NJ, US; and Schering-Plough Res 

Inst, Kenilworth, NJ, US 

11:30 40LB Virological Correlates Associated with Treatment 

Failure at Week 48 in the Phase 3 Study of Maraviroc 

in Treatment-naïve Patients 

J Heera1 , M Saag2 , P Ive3 , J Whitcomb4 , M Lewis5 , 

L McFadyen5 , J Goodrich1 , H Mayer1 , E van der Ryst5 , and Mike 

Westby* 5 

1 2 Pfizer Global R&D, New London, CT, US; Univ of Alabama at 

Birmingham, US; 3Univ of the Witwatersrand, Johannesburg, South 

Africa; 4Monogram Biosci, South San Francisco, CA, US; and 

5Pfizer Global R&D, Sandwich, UK 

11:45 41 Trends in Second Virologic Failure and Predictors 

of Subsequent Mortality among ART-experienced 

Patients: North American Experience 

Stephen Deeks and North American AIDS Cohort Collaboration on 

Res and Design (NA-ACCORD) of the IeDEA 

Univ of California, San Francisco, US 


c Monday, 1-4 pm; Poster Hall 

Poster Abstracts 

(see full session listings starting on page 25) 

Session 46. Cellular Co-factors 

Session 47. Cellular Restrictions 

Session 48. Viral Accesory Genes 

Session 57. Factors Impacting Disease Progression 

Session 58. Factors Impacting Viral Replication in vivo 

Session 59. Studies on Viral Evolution in vivo 

Session 67. Therapy and CNS Infection 

Session 68. Clinical Developments in Neuropathogenesis 

Session 73. Studies on T Cell Responses in Viral Infection 

Session 74. Studies on Cytokines and HIV Infection 

Session 84. Molecular Epidemiology: The Americas 

Session 85. Molecular Epidemiology: Europe 

Session 86. Molecular Epidemiology: Africa and Asia 

Session 87. Epidemiology and Transmission in Adult Populations 

Session 91. Novel PrEP Agents and Evaluation Strategies 

Session 95. Pharmacokinetics and Children 

Session 96. Response to and Efficacy of ART in Children 

Session 97. Resistance after First-line Failure in Children 

Session 105. Antiretroviral Pharmacokinetics during Pregnancy 

Session 106. Resistance Associated with ART for PMTCT 

Session 112. Health Outcomes in Women 

Session 113. Infertility in HIV-infected Women 

Session 116. Acute HIV/SIV Infection: Characterization of Transmitted Viruses 

Session 117. Acute HIV/SIV Infection: Immune Responses 

Session 118. Acute HIV Infection: Treatment 

Session 119. Acute HIV Infection: Recognition and Correlates of Transmission 

Session 127. ART: Treatment-naïve Patients 

Session 128. ART: Treatment-experienced Patients 

Session 131. Treatment Outcomes in Scale-up Programs 

Session 135. New Mechanisms of HIV-1 Drug Resistance 

Session 142. Viral Rebound and Emergence of Drug Resistance 

Session 143. HIV-1 Drug Resistance after First-line Therapy 

Session 144. Changing Prevalence of HIV-1 Drug Resistance 

Session 145. Impact of Subtype on HIV-1 Drug Resistance 

Session 146. Simplified Diagnostics for Resource-limited Settings 

Session 147. Evaluation of Serodiagnostic Assays 

Session 148. HLA Testing: Refinements and Cost-effectiveness 

Session 152. Dyslipidemia: Role of ART and Interventions for Management 

Session 153. Lipoatrophy/Lipohypertrophy: Predictors and Interventions 

Session 154. Atherosclerosis, Cardiovascular Risk and HIV Infection 

Session 169. Hepatitis B Co-infection 

Session 170. Hepatitis C Co-infection: Cellular Immune Responses and Pathogenesis 

Session 171. Hepatitis C Co-infection: Fibrosis


c Monday, 2-3 pm; Room 311 

CME 

Session 11–Poster Discussion 

(see Session 65 on Wednesday for corresponding Poster Abstracts) 

Lymphocyte Depletion in the Gut 

Discussants: 

Cristian Apetrei, Tulane Natl Primate Res Ctr, Covington , LA, US 

Martin Markowitz, Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, 

NY, US 

372 HIV Pathogenesis: Viral Blitzkrieg or 10 Years’ War? 

Cristian Apetrei* 1 , R Gautam1 , T Gaufin1 , R Ribeiro2 , M Pattison1 , 

M Barnes1 , C Monjure1 , A Perelson2 , G Silvestri3 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl Lab, 

NM, US; and 3Univ of Pennsylvania, Philadelphia, US 

373 Collagen Deposition Limits Immune Reconstitution in the Gut 

J Estes 1 , J Brenchley 2 , A Khoruts 3 , J Barthold 3 , C Reilly 3 , G Beilman 3 , 

D Douek 2 , A Haase 3 , and Timothy Schacker* 3 

1 NCI-Frederick, MD, US; 2 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, 

US; and 3 Univ of Minnesota, Minneapolis, US 

374 Disruption of Intestinal Epithelial Integrity and Increased 

Microbial Translocation and Systemic Dissemination in 

HIV and SIV Infections Are Linked to Impaired IL-17expressing 

Mucosal T Cell Responses 

Satya Dandekar*, M Rafatellu, M Macal, S Sankaran, D Verhoeven, 

M George, R Santos, and A Baumler 

Univ of California, Davis, US 

375a Differential Mucosal Pathogenesis of SIV Infection in 

Progressing and Long-term Nonprogressing Rhesus 

Macaques 

Binhua Ling*, M Mohan, T Ooms, A Lackner, P Marx, and R Veazey 

Tulane Natl Primate Res Ctr, Covington, LA, US 

375b Disturbed Gut Microbiota in HAART-naïve HIV + Adults: 

Effect of Intervention with a Specific Prebiotic Oligosaccharide 

Mixture 

Kaouther Ben Amor* 1 , G Rizzardini 2 , C Torti 3 , T Quirino 4 , M Moroni 2 , 

J Knol 1 , D Bray 5 , A Vriesema 1 , M Clerici 6 , and A Gori 7 

1 Numico Res, Wageningen, The Netherlands; 2 Hosp Luigi Sacco, Milan, 

Italy; 3 Univ of Brescia, Italy; 4 Hosp Busto Arsizio, Italy; 5 ImmunoClin, 

Paris, France; 6 Univ of Milan, Italy; and 7 Hosp San Gerardo, Univ of 

Milan-Bicocca, Monza, Italy 

376 Functional Analysis of Intestinal Epithelial Cells Isolated by 

Laser Dissection from SIV-infected Rhesus Macaques in vivo 

Michael George*, S Sankaran, I Grishina, and S Dandekar 


377 Microbial Translocation Is a Determinant of Persisting T Cell 

Hyperactivation in HIV-infected Patients Failing to Recover 

CD4 following Long-term HAART 

Giusi Maria Bellistri* 1 , V Pegorer 1 , C Tincati 1 , L Meroni 2 , A Gori 3 , 

A d’Arminio Monforte 1 , and G Marchetti 1 

1 San Paolo Hosp, Univ of Milan, Italy; 2 Luigi Sacco Hosp, Univ of Milan, 

Italy; and 3 San Gerardo Hosp, Monza, Italy 

c Monday, 2-3 pm; Room 312 

CME 


(see Session 88 on Tuesday for corresponding Poster Abstracts) 

New Approaches to HIV Testing 

Discussants: 

Susan Buchbinder, San Francisco Dept of Publ Hlth, CA, US 

Carlos Del Rio, Emory Univ Ctr for AIDS Res, Atlanta, GA, US 

531 Partner Counseling and Referral Outcomes after Acute HIV 

Identification in North Carolina 

Sandra McCoy* 1 , J Kuruc 1 , C Gay 1 , C Hurt 1 , J Anderson 1 , C Pilcher 2 , 

J Barnhart 3 , J Eron 1 , P Leone 1,3 , and the North Carolina STAT Team 

1 Univ of North Carolina at Chapel Hill, US; 2 Univ of California, San 

Francisco, US; and 3 North Carolina Dept of Hlth and Human Svcs, 

Raleigh, US 

532 Acceptance of Routine HIV Testing in Medical Inpatients in 

Nigeria: Implications for a New HIV Testing Approach in 


Olusegun Busari* 1 , M Nakayima 2 , O Busari 1 , G Oligbu 1 , A Adeyemi 3 , 

L Onigbogi 4 , and HIV Study Group 

1 Federal Med Ctr, Ido-Ekiti, Nigeria; 2 AIDS Support Org, Masaka, 

Uganda; 3 Hlthmatch Intl, Lagos, Nigeria; and 4 Univ Coll Hosp, Ibadan, 

Nigeria 

533 Interim Findings from a Multi-site Evaluation of HIV 

Testing in Emergency Departments 

James Heffelfinger* 1 , R Rothman 2 , H Pollack 3 , J Brown 4 , M Lyons 5 , 

G Almond 6 , P Sullivan 1 , S Barera 7 , and G Williams Torres 7 

1 CDC, Atlanta, GA, US; 2 Johns Hopkins Univ, Baltimore, MD, US; 3 Sch 

of Social Svc Admin, Ctr for Hlth Admin Studies, Univ of Chicago, IL, 

US; 4 George Washington Univ, Washington, DC, US; 5 Univ of Cincinnati 

Coll of Med, OH, US; 6 Metropolitan Hosp Ctr, New York, NY, US; and 

7 Hlth Res and Ed Trust, Chicago, IL, US 

534 Revisiting Expectations from Rapid HIV Test and 

Confirmation in the Emergency Department 

Rochelle Walensky* 1,2,3 , C Arbelaez 2 , W Reichmann 2 , R Walls 2 , J Katz 2,4 , and 

E Losina 1,2,5 

1 Massachusetts Gen Hosp, Boston, US; 2 Brigham and Women’s Hosp, 

Boston, MA, US; 3 Harvard Med Sch, Boston, MA, US; 4 Harvard Sch of 

Publ Hlth, Boston, MA, US; and 5 Boston Univ Sch of Publ Hlth, MA, US 

535a Patient Perspectives and Testing Uptake with Abbreviated 

versus Standard Pre-test HIV Counseling in the Prenatal 

Setting: A Randomized-Controlled, Non-inferiority Trial 

Deborah Cohan* 1,2 , E Gomez1,2 , and E Charlebois1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp, 

CA, US 

535b Using Multiple Rapid HIV Tests at the Point of Care: 

Implications for Clinicians Receiving Referrals 

Kevin Delaney* 1 , T Knoble2 , J Rurangirwa3 , A Scribner4 , E Hopkins5 , 

B Boyett1 , D White4 , J Haukoos5 , T Dowling2 , and J King3 1 2 CDC, Atlanta, GA, US; HIV Prevention Prgm, City and County of San 

Francisco, CA, US; 3Los Angeles County Dept of Hlth, CA, US; 4Highland Hosp, Alameda County Hlth Ctr, Oakland, CA, US; and 5Denver Hlth 

Med Ctr, CO, US 


Monday 

February 4 Sessions

Monday 



c Monday, 2-3 pm; Room 302-304 

CME 



Emerging Patterns of Resistance to New 

Antiretrovirals 

Discussants: 

Victoria Johnson, Univ of Alabama at Birmingham, US 

Rob Schuurman, Univ Med Ctr Utrecht, The Netherlands 

869 An Enhanced Version of the Trofile HIV Co-receptor 

Tropism Assay Predicts Emergence of CXCR4 Use in 

ACTG5211 Vicriviroc Trial Samples 

Jacqueline Reeves* 1 , D Han 1 , T Wilkin 2 , T Wrin 1 , D Kuritzkes 3 , 

C Petropoulos 1 , J Whitcomb 1 , N Parkin 1 , R Gulick 2 , and E Coakley 1 

1 Monogram Biosci, South San Francisco, CA, US; 2 Weill Med Coll of 

Cornell Univ, New York, NY, US; and 3 Brigham and Women’s Hosp, 

Cambridge, MA, US 

870 Emergence in vivo of Vicriviroc Resistance in HIV-1 

Subtype C: Role of V3 Loop and Susceptibility to Other 

CCR5 Antagonists 

Athe Tsibris* 1,2 , M Sagar 2,3 , Z Su 4 , C Flexner 5 , W Greaves 6 , P Skolnik 7 , 

E Coakley 8 , M Subramanian 9 , R Gulick 10 , and D Kuritzkes 2,3 

1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA, 

US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Harvard Sch of 

Publ Hlth, Boston, MA, US; 5 Johns Hopkins Univ, Baltimore, MD, US; 

6 Schering-Plough Res Inst, Kenilworth, NJ, US; 7 Boston Med Ctr, MA, 

US; 8 Monogram Biosci, South San Francisco, CA, US; 9 Human Genome 

Sci, Rockville, MD, US; and 10 Weill Med Coll of Cornell Univ, New York, 

NY, US 

871 Changes in V3 Loop Sequence Associated with Failure 

of Maraviroc Treatment in Patients Enrolled in the 

MOTIVATE 1 and 2 Trials 

Marilyn Lewis* 1 , J Mori 1 , P Simpson 1 , J Whitcomb 2 , X Li 3 , D Roberston 1 , 

and M Westby 1 

1 Pfizer Global R&D, Sandwich Labs, Kent, UK; 2 Monogram Biosci, South 

San Francisco, CA, US; and 3 Faculty of Life Sci, Univ of Manchester, UK 

872 Naturally Occurring Polymorphisms in HIV-1 Group M, N, 

and O Integrase: Implications for Integrase Inhibitors 

John Hackett*, B Harris, V Holzmayer, J Yamaguchi, KC Luk, 

C Brennan, G Schochetman, S Devare, and P Swanson 

Abbott Diagnostics, Abbott Park, IL, US 

873 Development of vircoTYPE HIV-1 Resistance Analysis, 

Including Clinical Cutoffs for TMC125, a New NNRTI 

Bart Winters* 1 , J Vingerhoets2 , M Peeters2 , J Villacian1 , 

E Van Craenenbroeck1 , and L Bacheler3 1 2 Virco BVBA, Mechelen, Belgium; Tibotec BVBA, Mechelen, Belgium; 

and 3VircoLab Inc, Durham, NC, US 

874 Characterization of Virologic Failures on Darunavir/ 

Ritonavir in the Randomized, Controlled, Phase III TITAN 

Trial in Treatment-experienced Patients 

Sandra De Meyer* 1 , E Lathouwers1 , I Dierynck1 , E De Paepe1 , 

B Van Baelen1 , T Vangeneugden1 , S Spinosa-Guzman1 , G Picchio2 , and 

MP de Bethune1 1 2 Tibotec BVBA, Mechelen, Belgium and Tibotec Inc, Yardley, PA, US 


e Monday, 4-6 pm; Room 302-304 

CME 


PMTCT 

Moderators: 

Grace Aldrovandi, Children’s Hosp Los Angeles and Univ of Southern California, US 

Wafaie Fawzi, Harvard Sch of Publ Hlth, Boston, MA, US 

4:00 42LB Extended Infant Post-exposure Prophylaxis with 

Antiretroviral Drugs Significantly Reduces Postnatal 

HIV Transmission: The PEPI-Malawi Study 

Taha Taha* 1 , M Thigpen2 , N Kumwenda1 , D Hoover3 , G Kafulafula4 , 

Q Li1 , L Mipando5 , K Nkanaunena5 , M Fowler6 , and L Mofenson7 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, 

MD, US; 2CDC, Atlanta, GA, US; 3Rutgers Univ, Piscataway, NJ, 

US; 4Univ of Malawi Coll of Med, Blantyre; 5Johns Hopkins Univ 

Coll of Med, Blantyre, Malawi; 6Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US; and 7Natl Inst of Child Hlth and Human Devt, 

NIH, Bethesda, MD, US 

4:15 43 Extended-dose Nevirapine to 6 Weeks of Age for 

Infants in Ethiopia, India, and Uganda: A Randomized 

Trial for Prevention of HIV Transmission through 

Breastfeeding 

Jayagowri Sastry* 1,2,3,4 and the SWEN Study Team 

1 2 BJ Med Coll, Pune, India; Johns Hopkins Univ, Baltimore, MD, 

US; 3Addis Ababa Univ Faculty of Med, Ethiopia; and 4Makerere Univ Sch of Med, Kampala, Uganda 

4:30 44 Timing of Infection Is Critical for Nevirapine 

Resistance Outcomes among Breastfed Subtype C HIV- 

1-infected Infants Exposed t o Extended vs Single-dose 

Nevirapine Prophylaxis: The India SWEN Study 

Anitha Moorthy* 1 , A Gupta2 , J Sastry3 , V Venkatramani4 , 

R Bhosale4 , V Kulkarni3 , N Gupte3 , C Ziemniak2 , R Bollinger2 , and 

D Persaud2 on behalf of the India SWEN Study Team 

1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, 

US; 2Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 3BJ Med 

Coll and Johns Hopkins Univ, Pune, India; and 4BJ Med Coll, Pune, 

India 

4:45 45aLB PMTCT of HIV-1 among Breastfeeding Mothers Using 

HAART: The Kisumu Breastfeeding Study, Kisumu, 

Kenya, 2003-2007 

Timothy Thomas* 1 , R Masaba2 , R Ndivo2 , C Zeh1 , C Borkowf3 , 

M Thigpen3 , K De Cock1 , P Amornkul1 , A Greenberg3 , M Fowler3 , 

and Kisumu Breastfeeding Study Team 

1 2 3 CDC Kenya, Kisumu; Kenya Med Res Inst, Kisumu; and CDC, 

Atlanta, GA, US 

5:00 45b The TEmAA ANRS 12109 Phase II Trial, Step 1: 

Tolerance and Viral Resistance after Single-dose 

Nevirapine and Short-course of Tenofovir Disoproxil 

Fumarate and Emtricitabine to Prevent Mother-to- 

Child Transmission of HIV-1 

Elise Arrive* 1 , ML Chaix2 , E Nerrienet3 , S Blanche4 , C Rouzioux2 , 

J McIntyre5 , P Coffie6 , K Sim7 , D Ekouevi6 , and F Dabis1 1INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor 

Segalen, Bordeaux, France; 2Ctr Hosp Univ Necker, Univ Paris 

Descartes, Paris, France; 3Inst Pasteur, Phnom Penh, Cambodia; 

4 5 Hosp Necker for Sick Children, Paris, France; Univ of the 

Witwatersrand, Soweto, South Africa; 6Prgm PACCI, Abidjan Côte 

d’Ivoire; and 7Hosp Calmette, Phnom Penh, Cambodia 

5:15 46 Duration and Pattern of Breastfeeding and Postnatal 

Transmission of HIV: Pooled Analysis of Individual 

Data from a West and South African Cohort Study 

Renaud Becquet* 1,2,3 , R Bland1,4 , V Leroy2,3 , N Rollins1,5 , 

D Ekouevi2,3,6 , A Coutsoudis5 , F Dabis2,3 , H Coovadia7 , 

R Salamon2,3 , and ML Newell1,8 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu 

Natal, Somkhele, South Africa; 2INSERM U593, Bordeaux, France; 

3Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, Bordeaux, 

France; 4Univ of Glasgow, UK; 5Univ of KwaZulu Natal, Durban, 

South Africa; 6Ctr Hosp Univ of Treichville, Abidjan, Côte d’Ivoire; 

7Ctr for HIV/AIDS Networking, Univ of KwaZulu Natal, Durban, 

South Africa; and 8Ctr for Pediatric Epi and Biostatistics, Inst of 

Child Hlth, Univ Coll London, UK 

5:30 47LB Population Pharmacokinetics of Tenofovir in HIV- 

1-infected Pregnant Women and Their Neonates: 

TEmAA ANRS 12109 

Deborah Hirt* 1,2 , S Urien1,2 , E Rey1 , D Ekouevi3 , S Blanche2 , 

G Gray4 , P Coffie3 , K Leang Sim5 , F Dabis6 , and JM Treluyer1,2 1 2 3 Hosp Cochin, France; Univ Paris Descartes, France; Prgm 

PACCI, Abidjan, Côte d’Ivoire; 4Univ of the Witwatersrand, 

Soweto, South Africa; 5Hosp Calmette, Phnom Penh, Cambodia; 

and 6INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor 

Segalen, Bordeaux, France


5:45 48 Effectiveness of NNRTI-containing ART in Women 

Previously Exposed to a Single Dose of Nevirapine: A 

Multi-country Cohort Study 

Paul Weidle* 1 , J Stringer 2 , M McConnell 1,3 , J Kiarie 4 , 

T Anekthananon 5 , T Jariyasethpong 6 , D Potter 2 , W Mutsotso 7 , 

C Borkowf 1 , O Bolu 1 , and the NNRTI Response Study Team 

1 CDC, Atlanta, GA, US; 2 Univ of Alabama at Birmingham, Ctr 

for Infectious Disease Res in Zambia, Lusaka; 3 Thailand Ministry 

of Publ Hlth-US CDC Collaboration, Nonthaburi; 4 Kenyatta 

Natl Hosp, Univ of Nairobi, Kenya; 5 Siriraj Hos., Mahidol Univ, 

Bangkok, Thailand; 6 Rajavithi Hosp, Bangkok, Thailand; and 7 CDC 

Kenya, Nairobi 

e Monday, 4-6 pm; Ballroom A 


Voyages through the Cell: Imaging Viral Traffic 

Conveners: 

Thomas Hope, Northwestern Univ, Chicago, 

IL, US 

Marilyn Resh, Memorial Sloan-Kettering 

Cancer Ctr, New York, NY, US 

49 

Pre-integration Complex Transport to the Nucleus 

Nathalie Arhel* and P Charneau 

Pasteur Inst, Paris, France 

50 

Live Imaging of Cell-to-Cell Transmission of 

Retroviruses 

N Sherer, M Lehmann, J Jin, and Walther Mothes* 

Yale Univ, New Haven, CT, US 

51 

Electron Cryotomography of HIV Virions 

Grant Jensen 

California Inst of Tech, Pasadena, US 

52 

Electron Tomography of Immunodeficiency Viruses 

and Structural Mechanisms of Cellular Entry 

Sriram Subramaniam 

Ctr for Cancer Res, NCI, NIH, Bethesda, MD, US 

Objectives: This session is directed to those interested in learning about 

HIV structure, mechanisms of virus entry into cells, and trafficking of virus 

particles from cell to cell and from the cytoplasm to the nucleus. The session 

will emphasize recent discoveries resulting from the use of state-of-the-art 

imaging technologies. It is assumed that participants are familiar with basic 

concepts of HIV replication. At the completion of the session, participants will 

be knowledgeable about the structure of HIV virus particles, molecular events 

that lead to virus entry and trafficking into the nucleus, and host cell factors 

that regulate these processes. 


Monday 

February 4 Sessions

Monday 



e Monday, 4-6 pm; Ballroom B/C 


Curbing the US Epidemic 

Conveners: 

Kenneth Mayer, Brown Univ Sch of Med, 

Miriam Hosp, Providence, RI, US 

Mary Ann Chiasson, Med and Hlth Res Assn 

of New York City, NY, US 

53 

What’s Driving the US Epidemic in Men Who Have 

Sex with Men 

Ron Stall*, M Friedman, M Marshal, and S Wisniewski 

Univ of Pittsburgh Sch of Publ Hlth, PA, US 

54 

What’s Driving the US Epidemic among Women 

Adaora Adimora 

Univ of North Carolina at Chapel Hill, US 

55 

Prevention for Positives 

Simon Rosser 

Univ of Minnesota, Minneapolis, US 

56 

Addressing Substance Abuse 

David Vlahov 

New York Academy of Med, NY, US 

Objectives: This session is directed to clinicians and scientists interested 

in prevention of HIV infection in the US. It is assumed that participants 

are familiar with the groups at highest risk for HIV/AIDS in the US. At 

the completion of the session, participants will be knowledgeable about 

prevention strategies for men who have sex with men, women at risk, injection 

drug users, and persons already infected with HIV. 


e Monday, 4-6 pm; Auditorium 

CME 


Hepatitis Co-infection 

Moderators: 

Ray Chung, Massachusetts Gen Hosp, Boston, US 

Karine Lacombe, Hosp St Antoine, Paris, France 

4:00 57 HIV Entry and Replication in Stellate Cells Promotes 

Cellular Activation and Fibrogenesis: Implications for 

Hepatic Fibrosis in HIV/HCV Co-infection 

Ana Tuyama*, F Hong, A Mosoian, P Chen, B Chen, I Fiel, 

A Schecter, M Klotman, and M Bansal 

Mt Sinai Sch of Med, New York, NY, US 

4:15 58 HIV-related Microbial Translocation, a Mechanism for 

Liver Disease 

A Balagopal1 , F Philp1 , J Astemborski1 , T Block2 , A Mehta2 , G Kirk1 , 

S Mehta1 , A Cox1 , S Ray1 , and David Thomas* 1 

1 2 Johns Hopkins Med Inst, Baltimore, MD, US and Drexel Inst for 

Biotech and Virology Res, Doylestown, PA, US 

4:30 59 Sustained Long-term Antiviral Maintenance with 

Pegylated Interferon in HCV/HIV-co-infected Patients: 

Early Viral Response and Effect on Fibrosis in Treated 

and Control Subjects 

Kenneth Sherman* 1 , J Andersen2 , A Butt3 , Z Goodman4 , T Umbleja2 , 

B Alston6 , M Koziel5 , M Peters7 , M Sulkowski8 , R Chung9 , and 

ACTG A5178 Study Team 

1 2 Univ of Cincinnati, OH, US; Harvard Sch of Publ Hlth, Boston, 

MA, US; 3Univ of Pittsburgh, PA, US; 4Armed Forces Inst of 

Pathology, Washington, DC, US; 5Beth Israel Deaconess Med 

Ctr, Boston, MA, US; 6NIAID, NIH, Bethesda, MD, US; 7Univ of 

California, San Francisco, US; 8Johns Hopkins Univ, Baltimore, 

MD, US; and 9Massachusetts Gen Hosp, Boston, US 

4:45 60 Sustained Virological Response to Interferon plus 

Ribavirin Reduces Liver-related Complications and 

Mortality in HIV/HCV-co-infected Patients 

Juan Berenguer* 1 , J Alvarez-Pellicer2 , J Lopez Aldeguer3 , 

M Von-Wichman4 , C Quereda5 , J Mallolas6 , J Sanz7 , C Tural8 , 

J Bellon1 , J Gonzalez2 , and the GESIDA 3603 Study Group 

1 2 Hosp Gregorio Maranon, Madrid, Spain; Hosp La Paz, Madrid, 

Spain; 3Hosp La Fe, Valencia, Spain; 4Hosp Donostia, San 

Sebastian, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Clin, 

Barcelona, Spain; 7Hosp Principe de Asturias, Alcala de Henares, 

Madrid; and 8Hosp Germans Trías i Pujol, Badalona, Spain 

5:00 61LB Hepatitis C Viremia following Sustained Virological 

Response to Pegylated Interferon and Ribavarin in 

HIV + Men Who Have Sex with Men–Re-infection or 

Late Relapse? 

Rachael Jones* 1 , D Brown2 , M Nelson1 , S Bhagani2 , M Atkins1 , 

M Danta3 , G Dusheiko2 , O Pybus4 , and D Asboe1 1 2 Chelsea and Westminster NHS Fndn Trust, London, UK; Royal 

Free and Univ Coll Med Sch, London, UK; 3Univ of New South 

Wales, Sydney, Australia; and 4Univ of Oxford, UK 

5:15 62 3 Interlinked Mechanisms of Inhibition of HIV-1 

Reverse Transcriptase by the HBV Drug Entecavir 

Egor Tchesnokov* 1 , A Obikhod2 , R Schinazi2 , and M Gotte1 1 2 McGill Univ, Montreal, Canada and Emory Univ Sch of Med, 


5:30 63 The Anti-HIV Activity of Entecavir: Serum HIV RNA 

Decreases and Selection of the M184V Mutation Occurs 

in both ART-naïve and -experienced HIV/HBV-coinfected 

Individuals 

Jennifer Audsley* 1,2,3 , J Sasadeusz1,3 , A Mijch1,2 , R Baden4 , J Caro4,5 , 

H Hunter6 , G Matthews7 , S Olender8 , S Lewin1,2,3 , and C Thio9 1 2 Alfred Hosp, Melbourne, Australia; Monash Univ, Melbourne, 

Australia; 3CCREID, Univ of Melbourne, Australia; 4Harvard Med 

Sch, Boston, MA, US; 5Fenway Community Hlth, Boston, MA, US; 

6 7 AID Atlanta, GA, US; Natl Ctr in HIV Epi and Clin Res, Sydney, 

Australia; 8Columbia Univ Med Ctr, New York, NY, US; and 9Johns Hopkins Univ Sch of Med, Baltimore, MD, US 

5:45 64 MELD is the Best Predictor of Pre-transplant Mortality 

in HIV-infected Liver Transplant Candidates 

Aruna Subramanian* 1 , M Sulkowski1 , B Barin2 , D Stablein2 , 

M Curry3 , N Nissen4 , L Dove5 , M Roland6 , P Stock7 , and M Ragni8 1 2 Johns Hopkins Univ, Baltimore, MD US; EMMES Corp, Rockville, 

MD, US; 3Beth Israel Deaconess Med Ctr, Boston, MA, US; 

4 5 Cedars-Sinai Med Ctr, Los Angeles, CA, US; Columbia Univ, New 

York, NY, US; 6California Dept of Publ Hlth, Sacramento, US; 7Univ of California, San Fransisco, US; and 8Univ of Pittsburgh, PA, US


i Tuesday, 8:30-9 am; Auditorium 


Challenges in Pediatric and Adolescent HIV Care 

65 

Lynne Mofenson 

Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, 

US 


in treatment and management of HIV-infected children and adolescents in 

resource-rich and resource-limited settings. It is assumed that participants 

are familiar with interventions to prevent mother-to-child HIV transmission, 

the principles of ART, and the clinical course of pediatric HIV infection. 

At the completion of the session, participants will be knowledgeable about 

differences between pediatric and adult HIV infection, factors associated with 

response to ART and choice of antiretroviral drugs in children, including 

maternal antiretroviral drug exposure, long-term complications of ART in 

children, issues related to the aging of infected children into adulthood, and 

barriers to treatment of children in resource-limited countries. 

j Tuesday, 9-9:30 am; Auditorium 


Natural Enhancers and Inhibitors of HIV Infection 

66 

J Munch 1 , L Standker 2,3 , WG Forssmann 2,3 , and Frank Kirchhoff* 1 

1 Univ Clin of Ulm, Germany; 2 VIRO Pharma GmbH & Co, 

Hannover, Germany; and 3 Hannover Med Sch, Ctr of Pharma, 

Hannover, Germany 


sexual transmission of HIV/AIDS. It is assumed that participants are familiar 

with the basic aspects of HIV entry into target cells. At the completion of 

the session, participants will be knowledgeable about the presence of factors 

enhancing the infectiousness of HIV in semen, the mechanisms underlying the 

enhancement of HIV infection, and the potential relevance of amyloid fibrils 

in the transmission of HIV and other viruses. 

k Tuesday, 10-11:30 am; Room 302-304 

CME 


Insights into Neuropathogenesis 

Moderators: 

Paola Cinque, San Raffaele Sci Inst, Milan, Italy 

David Clifford, Washington Univ Sch of Med, St Louis, MO, US 

10:00 67 Reducing the Prevalence of Primary HIV Brain 

Pathology by Antiretrovirals 

Ian Everall* 1 , F Vada1 , S Letendre1 , D Lazzaretto1 , B Gelman2 , 

S Morgello3 , E Singer4 , R Ellis1 , E Masliah1 , I Grant1 , and 

Natl NeuroAIDS Tissue Consortium and the UCSD HIV 

Neurobehavioral Res Ctr 

1 2 Univ of California, San Diego, US; Univ of Texas Med Branch, 

Galveston, US; 3Mt Sinai Med Ctr, New York, NY, US; and 4Univ of 

California, Los Angeles, US 

10:15 68 Low-grade Immune Restoration Disease May Limit 

Recovery from HIV-associated Neurocognitive 

Impairment 

Scott Letendre*, R Ellis, L Cysique, M Cherner, S Gibson, 

R Heaton, A McCutchan, and the HNRC Group 


10:30 69 Elevated Plasma Endotoxin Associated with Monocyte 

Activation and Reduced BDNF in AIDS Patients with 

Dementia 

Petronela Ancuta* 1 , K Kunstman2 , EY Kim2 , P Autissier3 , 

M Mefford4 , D Stone5 , S Wolinsky2 , and D Gabuzda4 1 2 Univ of Montreal, Canada; Northwestern Univ, Chicago, IL, US; 

3 4 Beth Israel Deaconess Med Ctr, Boston, MA, US; Dana-Farber 

Cancer Inst, Boston, MA, US; and 5Lemuel Shattuck Hosp, Jamaica 

Plain, MA, US 

10:45 70 HIV Infection of the Cerebrospinal Fluid of Elite 

Controllers 

John Probasco*, S Deeks, E Lee, R Hoh, T Liegler, R Price, and 

S Spudich 


11:00 71 Influence of Immunological, Virological, and 

Radiological Determinants in the Clinical 

Outcome of Patients with Progressive Multifocal 

Leukoencephalopathy 

A Marzocchetti1 , T Tompkins1 , D Clifford2 , R Gandhi3 , S Kesai4 , 

J Berger5 , D Simpson6 , A DeLuca7 , and Igor Koralnik* 1 

1Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA, 

US; 2Washington Univ Sch of Med, Seattle, US; 3Massachusetts Gen 

Hosp, Harvard Med Sch, Boston, US; 4Brigham and Women’s Hosp, 

Boston, MA, US; 5Univ of Kentucky Coll of Med, US; 6Mt Sinai Med 

Ctr, New York, NY, US; and 7Catholic Univ, Rome, Italy 

11:15 72 Natural Genetic Resistance to Lentiviral CNS Disease: 

A Neuroprotective MHC Class I Allele in SIV-infected 

Macaques 

Joseph Mankowski* 1 , S Queen1 , C Fernandez2 , P Tarwater3 , 

J Karper1 , R Adams1 , and S Kent2 1 2 Johns Hopkins Univ, Baltimore, MD, US; Univ of Melbourne, 

Australia; and 3Univ of Texas Hlth Sci Ctr at Houston, Sch of Publ 

Hlth, El Paso, US 


Tuesday 

February 5 Sessions

Tuesday 



k Tuesday, 10-11:30 am; Ballroom A 

CME 


HIV in Women and Children 

Moderators: 

Linda-Gail Bekker, Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa 

Addy Kekitiinwa, Mulago Hosp, Kampala, Uganda 

10:00 73 Alternatives to Prolonged Breastfeeding and Incidence 

of Pregnancies among HIV-infected Women: The 

ANRS 1201-1202 Ditrame Plus Cohort in Abidjan, Côte 

d’Ivoire, 2001 to 2005 

I Viho1 , R Becquet2,3 , D Ekouevi1,2 , H Brou1 , A Yao1 , F Dabis2,3 , 

C Amani-Bosse1 , A Desgree-du-Lou4 , M Timite-Konan5 , 

Valeriane Leroy* 2,3 , and ANRS 1201-1202 DITRAME PLUS Study 

Group 

1Natl Agency for AIDS Res Ditrame Plus Project, PACCI 

Collaboration, Abidjan, Côte d’Ivoire; 2INSERM U593, Bordeaux, 

France; 3Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, 

Bordeaux, France; 4Inst for Res and Devt, UMR 151, Nogent-sur- 

Marne, France; and 5Ctr Hosp Univ of Yopougon, Abidjan, Côte 

d’Ivoire 

10:15 74 Incidence and Determinants of Pregnancy among 

Women Receiving ART in Rural Uganda 

Jaco Homsy* 1,2 , R Bunnell2 , D Moore2,3 , R King2 , S Malamba2 , 

R Nakityo2 , D Glidden1 , C Likicho2 , J Tappero2 , and J Mermin2 1Inst for Global Hlth, Univ of California, San Francisco, US; 

2 3 Global AIDS Prgm, CDC Uganda, Entebbe; and BC Ctr for 

Excellence in HIV/AIDS, Vancouver, Canada 

10:30 75 Immune Reconstitution Inflammatory Syndrome in 

HIV-infected Infants and Young Children Initiating 

ART 

1 2 3 4 3 Kelly Smith* , L Kuhn , A Coovadia , T Meyers , B Marais , 

G Barry3 , and E Abrams2 1Columbia Univ Coll of Physicians and Surgeons, New York, 

NY, US; 2Columbia Univ Mailman Sch of Publ Hlth, New York, 

NY, US; 3Coronation Women and Children’s Hosp, Univ of the 

Witwatersrand, Johannesburg, South Africa; and 4Chris Hani 

Baragwanath Hosp, Univ of the Witwatersrand, Johannesburg, 

South Africa 

10:45 76 Clinical and Immunological Characteristics of Very 

Young Infants with HIV Infection: Children with HIV 

Early Antiretroviral Study 

Heather Jaspan* 1 , L Myer2 , A Violari3 , S Madhi4 , J Steyn3 , 

R van Niekerk3 , W Stevens3 , and M Cotton1 1Faculty of Hlth Sci, Univ of Stellenbosch, Cape Town, South Africa; 

2 3 Univ of Cape Town, South Africa; Univ of the Witwatersrand, 

Johannesburg, South Africa; and 4Chris Hani Baragwanath Hosp, 

Johannesburg, South Africa 

11:00 77LB Randomized, Controlled Trial of 3 Approaches to 

Management of HIV-infected Infants 

Andrew Prendergast* 1 , F Chonco2 , G Tudor-Williams3 , W Mphatswe2 , 

A Cengimbo2 , C Thobakgale2 , K Dong4 , H Coovadia2 , B Walker4 , and 

P Goulder1 1 2 Univ of Oxford, UK; Univ of KwaZulu Natal, Durban, South 

Africa; 3Imperial Coll, London, UK; and 4Partners AIDS Res Ctr, 


11:15 78LB Safety and Efficacy of Darunavir Co-administered 

with Low-dose Ritonavir in Treatment-experienced 

Children and Adolescents at Week 24 

R Bologna1 , S Rugina2 , P Cahn3 , P Flynn4 , S Blanche5 , 

B Van Baelen6 , R De Greef6 , L Lavreys6 , T Van De Casteele6 , and 

Sabrina Spinosa-Guzman* 6 

1Hosp de Pediatria “JP Garrahan”, Buenos Aires, Argentina; 

2 3 Spitalul Clinic de Boli Infectioase, Constanta, Romania; Fndn 

Huesped, Buenos Aires, Argentina; 4St Jude Children’s Res Hosp, 

Memphis, TN, US; 5Hosp Necker-Enfants Malades, Paris, France; 

and 6Tibotec, Inc, Mechelen, Belgium 


k Tuesday, 10-11:30 am; Ballroom B/C 

CME 


New Mechanisms of Resistance and Virologic 

Failure 

Moderators: 

Bonaventura Clotet, Fndn irsiCaixa, Barcelona, Spain 

Karin Metzner, Univ of Erlangen-Nuremberg, Germany 

10:00 79 Mechanism by which N348I in HIV-1 Reverse 

Transcriptase Confers Dual Zidovudine/Nevirapine 

Resistance 

Soo-Huey Yap* 1,2 , J Radzio3,4 , N Sluis-Cremer3 , and 

G Tachedjian1,5 1 2 Burnet Inst, Melbourne, Australia; Monash Univ, Churchill, 

Australia; 3Univ of Pittsburgh Sch of Med, PA, US; 4Univ of 

Pittsburgh Grad Sch of Publ Hlth, PA, US; and 5Monash Univ, 

Clayton, Australia 

10:15 80 Molecular Mechanisms for 3’-Azido-3’- 

Dideoxythymidine-resistance Conferred by Mutations 

in the Connection and RNase H Domains of HIV-1 

Reverse Transcriptase 

Jessica Brehm*, N Sluis-Cremer, and J Mellors 


10:30 81 Connection Domain Mutations N348I and A360V in 

HIV-1 RT Selectively Facilitate Excision of AZT by 

Improving Access to Transiently Formed RNA/DNA 

Hybrids 

Maryam Ehteshami*, G Beilhartz, B Scarth, E Tchesnokov, and 

M Gotte 

McGill Univ, Montreal, Canada 

10:45 82 Circumventing Drug Resistance: Using the Substrate 

Envelope Hypothesis to Develop Robust Novel HIV-1 

Protease Inhibitors 

M Nalam1 , A Ali1 , K Reddy1 , M Altman2 , S Chellappan3 , S Anjum1 , 

T Rana1 , M Gilson3 , B Tidor2 , and Celia Schiffer* 1 

1 2 Univ of Massachusetts Med Sch, Worcester, US; Massachusetts 

Inst of Tech, Cambridge, US; and 3Ctr for Advanced Res in Biotech, 

Univ of Maryland, Baltimore, US 

11:00 83 Presence of Minor Populations of Y181C Mutants 

Detected by Allele-specific PCR and Risk of Efavirenz 

Failure in Treatment-naïve Patients: Results of an 

ACTG 5095 Case-cohort Study 

Roger Paredes* 1,2 , C Lalama3 , H Ribaudo3 , B Schackman4 , 

C Shikuma5 , W Meyer6 , F Giguel1 , K Squires7 , R Gulick4 , and 

D Kuritzkes1 1Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA, 

US; 2Fndns irsiCaixa and Lluita contra la SIDA, Badalona, Spain; 

3 4 Harvard Sch of Publ Hlth, Boston, MA, US; Weill Med Coll of 

Cornell Univ, New York, NY, US; 5Univ of Hawaii, Honolulu, US; 

6 7 Quest Diagnostics, Baltimore, MD, US; and Jefferson Med Coll, 

Philadelphia, PA, US 

11:15 84LB Emergence of HIV-1 Drug Resistance among 

Breastfeeding Infants Born to HIV-infected Mothers 

Taking Antiretrovirals for Prevention of Mother-to- 

Child Transmission of HIV: The Kisumu Breastfeeding 

Study, Kenya 

Clement Zeh* 1 , P Weidle2 , L Nafisa1 , H Musuluma1 , J Okonji1 , 

E Anyango1 , P Bondo1 , R Masaba1 , M Thigpen2 , and T Thomas1 1 2 CDC Kenya, Kisumu and CDC, Atlanta, GA, US


k Tuesday, 10-11:30 am; Auditorium 

CME 


HIV Vaccines 

Moderators: 

John Mellors, Univ of Pittsburgh, PA, US 

Mario Stevenson, Univ of Massachusetts Med Sch, Worcester, US 

10:00 85 GeoVax Clade B DNA/MVA HIV/AIDS Vaccine Is 

Well Tolerated and Immunogenic when Administered 

to Healthy Seronegative Adults (HVTN 065 part A) 

Harriet Robinson* 1 , P Goepfert2 , C Hay3 , S Frey4 , W Blattner5 , 

P Wright6 , M Elizaga7 , L Qin7 , B Moss8 , and HVTN 065 Protocol Team 

1 2 GeoVax Inc, Atlanta, GA, US; Univ of Alabama at Birmingham, 

US; 3Univ of Rochester, NY, US; 4St Louis Univ, MO, US; 5Inst of 

Human Virology, Univ of Maryland, Baltimore, US; 6Vanderbilt Univ, Nashville, TN, US; 7Fred Hutchinson Cancer Res Ctr, Seattle, 

WA, US; and 8NIAID, NIH, Bethesda, MD, US 

10:15 86 Cellular Immune Responses in HIV-1 Uninfected 

Adult Tanzanian Volunteers Enrolled in a Phase I/ 

II Multiclade HIV-1 DNA Plasmid Vaccine (VRC- 

HIVDNA016-00-VP)/Adenovirus-5 Vector (VRC- 

HIVADV014-00-VP) Boost Vaccine Trial 

Alexandra Schuetz* 1,2 , A Haule1 , M Schunk1 , L Maboko1 , 

M Hoelscher1 , M Robb2 , N Michael2 , B Graham3 , J Cox2 , and 

M de Souza2,4 1 2 Mbeya Med Res Prgm, Tanzania; US Military HIV Res Prgm, 

Rockville, MD, US; 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, 

US; and 4Armed Forces Res Inst of Med Sci, Bangkok, Thailand 

10:30 87 Therapeutic Vaccination with a Replication Defective 

Adenovirus Type 5 HIV-1 gag Vaccine in a Prospective, 

Double-blinded, Placebo-controlled Trial (ACTG 5197) 

Robert Schooley* 1 , H Wang2 , J Spritzler2 , M Lederman3 , D Havlir4 , 

D Kuritzkes5 , C Battaglia6 , C Godfrey7 , M Robertson8 , B Schock9 , 

and AIDS Clinical Trials Group 

1 2 Univ of California, San Diego, US; Harvard Sch of Publ Hlth, 

Boston, MA, US; 3Case Western Reserve Univ, Cleveland, OH, 

US; 4Univ of California, San Francisco, US; 5Partners Hlthcare, 

Boston, MA, US; 6Social & Sci Systems, Silver Spring, MD, US; 7Div of AIDS, NIAID, NIH, Bethesda, MD, US; 8Merck Res Labs, North 

Wales, PA, US; and 9Frontier Sci and Tech Res Fndn, Amherst, 

NY, US 

10:45 88LB Efficacy Results from the STEP Study (Merck V520 

Protocol 023/HVTN 502): A Phase II Test-of-Concept 

Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent 

Vaccine 

M Robertson1 , D Mehrotra1 , D Fitzgerald2 , A Duerr3 , D Casimiro1 , 

J McElrath3 , D Lawrence4 and Susan Buchbinder* 5 

1 2 Merck Res Labs, West Point, PA, US, GHESKIO, Port-au-Prince, 

Haiti; 3HIV Vaccine Trials Network, Seattle, WA, US; 4NIAID, NIH, 

Bethesda, MD, US; and 5San Francisco Dept of Publ Hlth, CA, US 

11:05 89LB Immunological Characterization of Subjects from the 

STEP Study: A Phase IIB Test-of-Concept Trial of the 

MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine 

Michael Robertson* 1 , D Casimiro1 , S De Rosa2 , S Dubey1 , L 

Kierstead1 , and J McElrath2 1 2 Merck Res Labs, West Point, PA, US and Fred Hutchinson Cancer 

Res Ctr, HIV Vaccine Trials Network, Seattle, WA, US 

l Tuesday, 11:30 am-12 noon; Auditorium 


Scientific Obstacles to an Effective HIV Vaccine 

91 

Ronald Desrosiers 

New England Primate Res Ctr, Harvard Med Sch, Boston, 

MA, US 

Objectives: This session is directed to clinicians, scientists, and administrators 

interested in the development of a safe, effective, preventive vaccine for 

HIV-1. It is assumed that participants are familiar with the fundamentals 

of immunology and the historic role of vaccines in limiting the spread of 

viral disease. At the completion of the session, participants will have gained 

knowledge of the formidable scientific obstacles that confront development 

of an effective AIDS vaccine. They will also have learned of critical questions 

currently facing the field, particularly with respect to the degree of emphasis 

that should be placed on discovery research versus product development and 

clinical testing. 

a Tuesday, 12 noon-12:30 pm; Auditorium 


AIDS Vaccine at the Crossroads 

92 

Neal Nathanson 

Univ of Pennsylvania Med Ctr, Philadelphia, US 


in the status of AIDS vaccine development. It is assumed that participants 

are familiar with HIV infection and the pathogenesis of AIDS, and with the 

history of attempts to develop an AIDS vaccine, as well as the general basis 

of vaccines against other viral infections. At the completion of the session, 

the participants will be knowledgeable about some of the problems with 

development of an AIDS vaccine. Also, they will be acquainted with some 

of the proposed strategies to make a more effective candidate immunogen to 

protect against HIV infection. 


Tuesday 

February 5 Sessions

Tuesday 



c Tuesday, 1-4 pm; Poster Hall 



Session 49. New Insights into APOBEC Proteins 

Session 50. Viral Replication Cycle: Molecular Studies 

Session 51. Viral Envelope: Tropism and Co-receptor Studies 

Session 52. Viral Fitness, Evolution and Recombination 

Session 60. CTL Studies and Consequences of Immune Escape 

Session 61. Factors Influencing CD4 Counts 

Session 62. HIV Superinfection and Viral Co-infection 

Session 69. Virologic Parameters in NeuroAIDS 

Session 70. Studies into Mechanisms of HIV Neuropathogenesis 

Session 75. Immune Activation and Lymphocyte Function 

Session 76. Studies on Regulatory T Cells 

Session 77. Immune Responses and Control of Viremia 

Session 88. New Approaches to HIV Testing 

Session 92. HIV-1 Prevention for Positives 

Session 93. Modeling the Cost-effectiveness and Impact of PrEP on Resistance 

Session 98. Complications, Neurodevelopment and ART-related Toxicities in 

Children 

Session 99. Mycobacterial Disease in Children 

Session 100. Prevention, Identification and Treatment of at-Risk and HIV-infected 

Adolescents 

Session 107. Maternal ART and Feeding Practices: Impact on Infant Outcomes 

Session 108. Infant Feeding, PMTCT and Infant Outcome 

Session 109. Properties of Breast Milk 

Session 114. Influence of Gender on HIV Replication and Viremia 

Session 115. HIV Replication, Immune Activation, HIV-2 Co-infection, and 

Genital Shedding in Women 

Session 123. ART: Novel Approaches I 

Session 124. ART: Novel Approaches II 

Session 125. Clinical Pharmacology of Reverse Transcriptase Inhibitors 

Session 126. Clinical Pharmacology of Protease Inhibitors 

Session 132. Switching Therapy/Treatment Failure in Scale-up Programs 

Session 136. Resistance to New Antiretrovirals 

Session 137. Emerging Patterns of Resistance to New Antiretrovirals 

Session 138. Minor Drug-resistant Variants: Detection and Clinical Significance 

Session 149. Impact of Subtype on HIV Quantification 

Session 150. New Diagnostic and Monitoring Tools 

Session 155. Hepatic Complications 

Session 156. Markers of Inflammation, Immunodeficiency and Complications 

Session 157. Changes in Bone Mineral Density 

Session 158. Renal Disease 

Session 172. Hepatitis C Co-infection: Markers, Outcome and Effect of ART 

Session 173. Hepatitis C Co-infection: Treatment 

Session 174. Hepatitis Co-infection: Cardiovascular and Malignancy Association 


c Tuesday, 2-3 pm; Room 311 

CME 


(see Session 68 on Monday for corresponding Poster Abstracts) 

Clinical Developments in Neuropathogenesis 

Discussants: 

Dennis Kolson, Univ of Pennsylvania, Philadelphia, US 

Richard Price, Univ of California, San Francisco, US 

391 Changes in Cognition during HAART: Comparison of 2 

Different Scoring Systems to Measure Antiretroviral Drug 

Efficacy on HIV Dementia 

Valerio Tozzi*, P Balestra, M Salvatori, C Vlassi, G Liuzzi, S Menichetti, 

M Zaccarelli, S Cerilli, A Antinori, and P Narciso 

Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy 

392 CSF Neural Marker Profile Distinguishes AIDS Dementia 

Complex from Alzheimer’s Disease 

Magnus Gisslen* 1 , K Blennow 1 , B Brew 2 , P Cinque 3 , L Hagberg 1 , R Price 4 , 

and H Zetterberg 1 

1 Sahlgrenska Univ Hosp, Gothenburg, Sweden; 2 St Vincent’s Hosp, Univ 

of New South Wales, Sydney, Australia; 3 San Raffaele Hosp, Milan, Italy; 

and 4 Univ of California, San Francisco, US 

393 HIV Protease Inhibitors and Risk of Peripheral Neuropathy 

Ronald Ellis* 1 , J Marquie-Beck 1 , P Delaney 1 , T Alexander 1 , D Clifford 2 , 

J McArthur 3 , D Simpson 4 , C Ake 1 , A Collier 5 , B Gelman 6 , and the 

CHARTER Group 

1 Univ of California, San Diego, US; 2 Washington Univ, St Louis, MO, US; 

3 Johns Hopkins Univ, Baltimore, MD, US; 4 Mt Sinai Sch of Med, New 

York, NY, US; 5 Univ of Washington, Seattle, US; and 6 Univ of Texas Med 

Branch, Galveston, US 

394 ART Resistance Influences CSF HIV RNA Levels and 

Neuropsychological Performance in HIV-infected Individuals 

George Hightower* 1 , S Letendre 1 , M Cherner 1 , S Gibson 1 , R Ellis 1,2 , 

C Ignacio 1 , R Heaton 1 , I Grant 1,2 , D Richman 1,2 , D Smith 1,2 , and San Diego 

HIV Neurobehavioral Res Ctr (HNRC) Group 

1 Univ of California, San Diego, US and 2 San Diego VA Hlthcare Systems, 

CA, US 

395 CSF t-τ/p-τ and Amyloid-β 1-42 in HIV Infection 

Bruce Brew* 1 , M Gisslen 2 , L Pemberton 1 , P Cinque 3 , L Hagberg 2 , R Price 4 , 

K Blennow 2 , H Zetterberg 2 , and S Spudich 4 

1 St Vincent’s Hosp, Sydney Australia; 2 Gothenburg Univ, Sweden; 3 San 

Raffaele Hosp, Milan, Italy; and 4 Univ of California, San Francisco, US 

396a Comparative Analysis of HIV-specific CD8 + T Cells 

in Cerebrospinal Fluid and Peripheral Blood among 

Treatment-naïve HIV-immune Controllers 

Shanmugalakshmi Sadagopal*, S Lorey, L Barnett, R Basham, L Lebo, 

H Erdem, K Haman, M Avison, D Haas, and S Kalams 

Vanderbilt Univ, Nashville, TN, US 

396b Abnormal CSF Amyloid β42 Levels Link HIV-associated 

Cognitive Disease and Alzheimer’s Disease 

David Clifford*, J Kauwe, M Teshome, A Shah, M Spinner, J Morris, 

D Holtzman, and A Fagan 

Washington Univ, St Louis, MO, US


c Tuesday, 2-3 pm; Room 312 

CME 



Risk Factors for Lost-to-Follow-up in Resourcelimited 

Settings 

Discussants: 

Wafaa El-Sadr, Harlem Hosp Ctr, Columbia Univ, New York, NY, US 

Charles Gilks, World Hlth Org, Geneva, Switzerland 

838 Characteristics of Facilities and Programs Delivering HIV 

Care and Treatment Services Are Associated with Loss to 

Follow-up Rates in Programs from 7 Sub-Saharan African 

Countries 

Denis Nash* 1 , C Korves 1 , S Saito 1 , S Sherman 1 , B Elul 1 , D Hoos 1 , 

V Mugisha 2 , M Sheriff 3 , W El Sadr 1 , and Intl Ctr for AIDS Care and 

Treatment Prgms (ICAP) 

1 Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; 2 Columbia 

Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, Rwanda; and 

3 Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Nairobi, 

Kenya 

839 Loss to Care and Death before ART: Patients Eligible for 

Treatment Who Do Not Make It in Durban, South Africa 

Ingrid Bassett* 1,2,3 , B Wang 1 , S Chetty 4 , J Giddy 4 , Z Lu 1 , E Losina 2,3,5 , 

R Walensky 1,2,3,6 , and K Freedberg 1,3,5,6 

1 Massachusetts Gen Hosp, Boston, US; 2 Brigham and Women’s Hosp, 

Boston, MA, US; 3 Harvard Med Sch, Boston, MA, US; 4 McCord Hosp, 

Durban, South Africa; 5 Boston Univ Sch of Publ Hlth, MA, US; and 

6 Harvard Sch of Publ Hlth, Boston, MA, US 

840 Losses to Follow-up in a Large ART Program in Uganda 

A Muwanga, Philippa Easterbrook*, P Schaefer, M Wandera, D Okello, 

B Castelnuovo, M Kamya, and A Kambugu 

Infectious Disease Inst, Kampala, Uganda 

841 Loss to Follow-up in Community Clinics in South Africa: 

Role of CD4 Count, Gender, and Pregnancy 

Bingxia Wang* 1,2 , E Losina 1,3,4 , R Stark 5 , A Munro 5 , R Walensky 1,2,3 , 

M Wilke 5 , D Martin 5 , Z Lu 1 , K Freedberg 1,2,4,6 , and R Wood 7 

1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA, 

US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Boston Univ Sch of 

Publ Hlth, MA, US; 5 South Africa Catholic Relief Svcs; 6 Harvard Sch of 

Publ Hlth, Boston, MA, US; and 7 Univ of Cape Town, South Africa 

842 What Becomes of the Defaulters? A Sampling-based 

Approach to Determine Outcomes of Patients Who Become 

Lost to Follow-up in ART Scale-up Programs in Africa 

Elvin Geng* 1 , D Bangsberg 1 , N Musinguzi 2 , N Emenyonu 1 , M Bwana 2 , 

D Glidden 1 , C Yiannoutsos 3 , S Deeks 1 , J Martin 1 , and East Africa IeDEA 

Consortium 

1 Univ of California, San Francisco, US; 2 Mbarara Univ of Sci and Tech, 

Uganda; and 3 Indiana Univ, Indianapolis, US 

c Tuesday, 2-3 pm; Room 302-304 

CME 



Novel PrEP Agents and Evaluation Strategies 

Discussants: 

Walid Heneine, CDC, Atlanta, GA, US 

Sharon Hillier, Univ of Pittsburgh, Magee-Womens Res Inst, PA, US 

556 An Engineered Bi-functional HIV-1 Neutralizing Protein as 

a Potential Microbicide 

Vadim Villarroel* 1 , L Lagenaur1,2 , and E Berger1 1 2 NIAID, NIH, Bethesda, MD, US and Osel, Inc, Santa Clara, CA, US 

557 Better Protection against HIV-1 Infection in vitro with 

Candidate Microbicide Compounds in Combination 

Susan Schader* 1,2 , B Scarth2 , S Colby-Germinario1 , J Schachter1 , 

J Nuttall3 , M Gotte2 , and M Wainberg1,2 1 2 McGill Univ AIDS Ctr, Lady Davis Inst, Montreal, Canada; McGill 

Univ, Montreal, Canada; and 3Intl Partnership for Microbicides, Silver 

Spring, MD, US 

558 Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal 

Transmission of HIV-1 in Humanized BLT Mice 

Paul Denton* 1 , J Estes 2 , Z Sun 1 , F Othieno 1 , D Powell 1 , A Haase 2 , and 

V Garcia 1 

1 Univ of Texas Southwestern Med Ctr, Dallas, US and 2 Univ of 

Minnesota, Minneapolis, US 

559a Size-fitting of Intravaginal Rings for Macaques and in vitro 

Release Kinetics of Zinc Finger Inhibitors 

James Smith* 1 , K Malcolm 2 , E Appella 3 , C McConville 2 , M Schito 3 , 

D Woolfson 2 , R Hayashi 3 , N Lanier 1 , R Otten 1 , and S Butera 1 

1 CDC, Atlanta, GA, US; 2 Queen’s Univ of Belfast, Sch of Pharmacy, 

Northern Ireland; and 3 NCI, NIH, Bethesda, MD, US 

559b Safety and Pharmacokinetic Assessment of 28-Day Anti-HIV 

Dapivirine Intravaginal Microbicide Rings 

Annalene Nel* 1 , S Smythe 1 , K Young 1 , K Malcolm 2 , Z Rosenberg 1 , and 

J Romano 1 

1 Intl Partnership for Microbicides, Silver Spring, MD, US and 2 Queen’s 

Unive, Belfast, Northern Ireland 

560 Topical Application of Fully Recombinant RANTES Analogs 

Protect Macaques from Vaginal SHIV Transmission 

Ronald Veazey* 1 , M Lederman 2 , B Ling 1 , L Green 1 , E Ribka 1 , D Mosier 3 , 

R Offord 4,5 , and O Hartley 4 

1 Tulane Natl Primate Res Ctr, Covington, LA, US; 2 Case Western 

Reserve Univ, Cleveland, OH, US; 3 Scripps Res Inst, La Jolla, CA, US; 

4 Univ of Geneva, Switzerland; and 5 Mintaka Fndn for Med Res, Geneva, 

Switzerland 


Tuesday 

February 5 Sessions

Tuesday 



c Tuesday, 2-3 pm; Ballroom A 

CME 



TB-associated Immune Reconstitution 

Inflammatory Syndrome 

Discussants: 

Philippa Easterbrook, Infectious Disease Inst, Kampala, Uganda 

Andrew Zolopa, Stanford Univ, Palo Alto, CA, US 

1006 M. tuberculosis-specific T Cell Expansions and the 

Pathogenesis of the HIV-TB-associated Immune 

Reconstitution Inflammatory Syndrome 

G Meintjes 1 , K Wilkinson 2 , K van Veen 1 , K Rebe 3 , D Pepper 3 , 

K Skolimowska 4 , M Rangaka 1 , R Seldon 1 , G Maartens 5 , and Robert Wilkinson* 1 

1 Inst of Infectious Disease and Moleculr Med, Univ of Cape Town, South 

Africa; 2 Natl Inst of Med Res, London, UK; 3 GF Jooste Hosp, Manenberg, 

South Africa; 4 Imperial Coll London, UK; and 5 Univ of Cape Town, South 

Africa 

1007 Biomarkers of Immune Activation Are Predictors of HIV 

Immune Reconstitution Inflammatory Syndrome 

David Boulware* 1 , D Meya 2 , T Bergemann 1 , I Vlasova 1 , A Kambugu 2 , 

K McAdam 2 , E Janoff 3 , and P Bohjanen 1 

1 Univ of Minnesota, Minneapolis, US; 2 Infectious Disease Inst, Makerere 

Univ, Kampala, Uganda; and 3 Univ of Colorado Hlth Sci Ctr, Denver, US 

1008 Immunologic Markers as Predictors of TB-associated 

Immune Reconstitution Inflammatory Syndrome in HIV 

and TB Co-infected Persons in Thailand 

Hong Van Tieu* 1 , J Ananworanich 2 , A Avihingsanon 3,4 , 

W Apateerapong 2 , S Sirivichayakul 4,5 , S Klongugkara 6 , B Boonchokchai 2 , 

U Siangphoe 2 , S Hammer 1 , and W Manosuthi 6 

1 Columbia Univ Coll of Physicians and Surgeons, New York, NY, US; 

2 South East Asia Res Collaboration with Univ of Hawaii, Bangkok, 

Thailand; 3 HIV Netherlands Australia Thailand Res Collaboration, 

Bangkok; 4 Thai Red Cross AIDS Res Ctr, Bangkok; 5 Chulalongkorn 

Univ, Bangkok, Thailand; and 6 Bamrasnaradura Infectious Diseases Inst, 

Nonthaburi, Thailand 

1009 High Rates of Drug-resistant TB among Patients with 

Suspected TB Immune Reconstitution Inflammatory 

Syndrome in South Africa 

Kevin Rebe* 1,2 , G Meintjes 1,2 , M Rangaka 1 , D Pepper 2 , C Morroni 1 , 

G Maartens 1 , and R Wilkinson 1,2,3 

1 Univ of Cape Town, South Africa; 2 GF Jooste Hosp, Manenberg, South 

Africa; and 3 Imperial Coll, London, UK 


e Tuesday, 4-6 pm; Room 302-304 


The Emerging Science of HIV Prevention in Women 

Conveners: 

Sharon Hillier, Univ of Pittsburgh, Magee- 

Womens Res Inst, PA, US 

Renee Ridzon, Bill and Melinda Gates Fndn, 

Seattle, WA, US 

93 

Vaginal Flora, Co-infections, and Immune Cells 

in the Genital Mucosa: Implications for HIV 

Transmission 

Rupert Kaul, Univ of Toronto, Canada 

94 

Impact of Hormonal Contraception on HIV 

Acquisition, Cervico-Vaginal Viral Shedding, and 

Disease Progression 

Elizabeth Stringer 

Univ of Alabama at Birmingham, Lusaka, Zambia 

95 

Genital Compartmentalization of Orally and 

Topically Administered Antiretrovirals 

Angela Kashuba 


96 

Microbicides: Rapid Evolution since 2000 

Quarraisha Abdool Karim 

Columbia Univ, NY, New York, US and Univ of Kwazulu Natal, 

Durban, South Africa 


gender-specific issues related to genital distribution of antiretrovirals, immune 

cells in the genital tract, the effect of female reproductive hormones on HIV, 

and new biomedical HIV prevention options for women. It is assumed that 

participants are familiar with risk factors for HIV transmission to women. At 

the completion of the session, participants will be knowledgeable about the 

effect of the vaginal ecology on immune cells in the female reproductive tract, 

the influence of contraceptives on HIV susceptibility and disease progression, 

the pharmacokinetics of orally and vaginally administered antiretrovirals in the 

female genital tract, and ongoing research in topical microbicides.


e Tuesday, 4-6:15 pm; Ballroom A 

CME 


HIV Molecular Biology and Host Cell Interactions 

Moderators: 

Alan Engelman, Dana-Farber Cancer Inst, Boston, MA, US 

Dana Gabuzda, Dana-Farber Cancer Inst, Boston, MA, US 

4:00 97 Early Interactions of Fluorescently Labeled HIV with 

the Female Genital Tract 

Scott McCoombe* 1 , A Trull1 , M McRaven1 , N Byers1 , 

M Anderson1 , J Kowalski1 , M Dinh1 , R Veazey2 , and T Hope1 1 2 Northwestern Univ, Chicago, IL, US and Tulane Natl Primate Res 

Ctr, Covington, LA, US 

4:15 98 Identification of LEDGF/p75 PWWP Domain Amino 

Acids Residues Critical for Chromatin Binding and 

HIV-1 Infection 

Michelle Shun*, F Di Nunzio, and A Engelman 

Dana-Farber Cancer Inst, Boston, MA, US 

4:30 99 Host-specific Adaptation of the HIV-1/SIVcpz Gag 

Matrix Protein 

Frederic Bibollet-Ruche* 1 , J Decker1 , J Easlick1 , B Keele1 , Y Li1 , 

J Takehisa1 , M Krauss1 , G Shaw1 , P Sharp2 , and B Hahn1 1 2 Univ of Alabama at Birmingham, US and Univ of Edinburgh, UK 

4:45 100 Vpr Binds to DCAF1 and to DDB1 to Mediate Its 

Biological Functions in a Species-specific Interaction 

Yoshiyuki Hakata* and N Landau 

New York Univ Sch of Med, New York, US 

5:00 101 The Role of Human Staufen in the Intracellular 

Trafficking of Unspliced HIV-1 RNA 

Nan Yan* and J Lieberman 

Immune Disease Inst, Boston, MA, US and Harvard Med Sch, 


5:15 102 Identification of a Novel ESCRT-I Subunit and Other 

ESCRT-I Binding Factors Required for Efficient HIV-1 

Release 

Virginie Sandrin* 1 , E Morita1 , MA Karren1 , S Gygi2 , S Morham3 , 

and W Sundquist1 1 2 Univ of Utah, Salt Lake City, US; Harvard Med Sch, Boston, MA, 

US; and 3Myriad Genetics Inc, Salt Lake City, UT, US 

5:30 103 Role of GGA and Arf Proteins in HIV-1 Assembly and 

Release 

A Joshi1 , J Bonifacino2 , and Eric Freed* 1 

1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US and Natl Inst 

of Child Hlth and Human Devt, NIH, Bethesda, MD, US 

5:45 104a Modulation of Viral Assembly and Virion Release by Vpu 

John Guatelli* 1,2 , D Goff1 , and N Van Damme2 1 2 Univ of California, San Diego, US and VA Hlthcare System, San 

Diego, CA, US 

6:00 104bLB Identification of Host Proteins Required for HIV 

Infection through a Functional Genomic Screen 

Abraham Brass* 1,2,3 , D Dykxhoorn3,4 , Y Benita3 , N Yan3,4 , A Engelman5 , 

R Xavier3 , J Lieberman3,4 , and S Elledge2,3 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s 

Hosp, Boston, MA, US; 3Harvard Med Sch, Boston, MA, US; 

4 5 Immune Disease Inst, Boston, MA, US; and Dana-Farber Cancer 

Inst, Boston, MA, US 

e Tuesday, 4-6 pm; Ballroom B/C 


Aging and AIDS 

Conveners: 

Amy Justice, Yale Univ Sch of Med, New 

Haven, CT, US 

Michael Lederman, Case Western Reserve 

Univ, Sch of Med, Cleveland, OH, US 

105 

Immune Exhaustion in Aging and AIDS: Parallel 

Mechanisms and Possible Solutions 

Rita Effros 

David Geffen Sch of Med, Univ of California, Los Angeles, US 

106 

The Effect of Aging on Human Pharmacology 

Charles Flexner 


107 

Contributions of Age-related Morbidities 

William Powderly 

Univ Coll Dublin, Ireland 

108 

Epidemiology of HIV, including Response to ART, in 

Older Populations 

Bruno Ledergerber 

Univ Hosp Zurich, Switzerland 

Objectives: This session is directed to clinicians and researchers interested 

in the immunopathogenesis of HIV infection and aging and in the clinical 

management of HIV infection in older individuals. The session will describe 

the effects of aging on the normal immune system and the interactions between 

the effects of aging and of HIV infection on immune function.; identify 

changes in drug metabolism and pharmacodynamics with age; list strategies 

for overcoming the challenges in managing diseases of aging in the context of 

HIV infection; and enable the participant to recognize the effect of aging on 

response to treatment with ART. It is assumed that participants are familiar 

with basic HIV-related immunology and management of HIV disease. At the 

completion of the session, participants will be able to identify the challenges of 

managing HIV infection in an aging population, the complex interrelationships 

between management of HIV disease and of diseases of aging, and will 

understand some of the immunologic issues that underlie changes due to aging 

and their effect on HIV and its complications. 


Tuesday 

February 5 Sessions

Tuesday 



e Tuesday, 4-6 pm; Auditorium 


Targeting TB: New Opportunities and Challenges 

Conveners: 

Richard Chaisson, Johns Hopkins Univ Sch 

of Med, Baltimore, MD, US 

Betina Durovni, Dept of Publ Hlth, Rio de 

Janeiro, Brazil 

109 

How Can Scientific Advances Contribute to TB 

Control 

William Bishai 

Johns Hopkins Univ Sch of Med, Baltimore, MD, US 

110 

Prospects for New Drugs for TB 

Timothy Sterling 

Vanderbilt Univ Sch of Med, Nashville, TN, US 

111 

Concurrent Management of TB and HIV 

Stephen Lawn 

Univ of Cape Town, South Africa and London Sch of Hygiene & 

Tropical Med, UK 

112 

Confronting the Catastrophe of M/XDR TB 

Gerald Friedland and TF CARES 

Yale Univ, New Haven, CT, US 


in controlling TB and TB/HIV co-infection, using new tools and strategies. 

It is assumed that participants are familiar with the natural history and 

clinical manifestations of TB and TB/HIV, as well as with conventional 

treatment paradigms. At the completion of the session, participants with be 

knowledgeable about scientific advances in TB genomics, new drugs in the 

pipeline for treating and preventing TB, special challenges in co-managing 

TB and HIV disease, and the prospects for controlling multi-drug resistance 

(MDR) and extremely drug-resistant (XDR) TB. 

18 15th Conference on Retroviruses and Opportunistic Infections


i Wednesday, 8:30-9 am; Auditorium 


Advances in the Management of Treatmentexperienced 

Patients: A 2 nd Wave of HAART 

113 

Sharon Walmsley 

Univ of Toronto, Canada 


in the current clinical management of persons living with HIV who have 

developed resistant viruses. It is assumed that participants are familiar with 

the major classes of antiretroviral agents and their mechanism of action. At the 

completion of the session, participants will be knowledgeable about the goal 

of maximal viral suppression in treatment-experienced patients, and the role 

of new agents within existing classes and new targets for ART to help achieve 

this goal. 

j Wednesday, 9-9:30 am; Auditorium 


New Insights into Retrovirus-Host-cell 

Interactions 

114 

Paul Bieniasz 

Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New 

York, NY, US 


in retrovirus-host interactions, in particular how host cells mount a defense 

against retrovirus infection and how HIV-1 has evolved strategies to evade 

or counteract these host defenses. It is assumed that participants are familiar 

with the basic features of HIV-1 and its replication cycle. At the completion 

of the session, participants will be knowledgeable about concepts associated 

with intrinsic and innate cellular defenses that inhibit the HIV-1 replication 

cycle, about a newly discovered cellular inhibitor called “tetherin” that blocks 

the release of HIV-1 and other virus particles from infected cells, and how an 

HIV-1 accessory gene antagonizes the function of this antiviral molecule. 

k Wednesday, 10 am-12 noon; Room 302-304 

CME 


New Insights into Mechanisms of Viral 

Pathogenicity 

Moderators: 

Satya Dandekar, Univ of California, Davis, US 

Ivona Pandrea, Tulane Natl Primate Res Ctr, Covington, LA, US 

10:00 115 Preferential Loss of Th17 CD4 T Cells in the 

Gastrointestinal Tract of HIV-infected Individuals but 

Not SIV-infected Sooty Mangabeys 

Barbara Cervasi* 1 , J Brenchley2 , M Paiardini1 , S Gordon1 , 

A Asher2 , I Frank1 , J Else3 , D Douek2 , and G Silvestri1 1 2 Univ of Pennsylvania, Philadelphia, US; Vaccine Res Ctr, NIAID, 

NIH, Bethesda, MD, US; and 3Yerkes Natl Primate Res Ctr, Emory 

Univ, Atlanta, GA, US 

10:15 116 Preferential Loss of Th17 T Cells at Mucosal Sites 

Predicts AIDS Progression in Simian Immunodeficiency 

Virus-infected Macaques 

Valentina Cecchinato* 1 , C Trindade1 , JM Heraud1 , A Laurence2 , 

J Brenchley3 , E Tryniszewska1,4 , D Venzon1 , D Douek3 , J O’Shea2 , 

and G Franchini1 1 2 NCI, NIH, Bethesda, MD, US; Natl Inst of Arthritis and 

Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, US; 

3 4 NIAID, NIH, Bethesda, MD, US; and Med Univ of Bialystok, 

Poland 

10:30 117LB Primary SIV Infection Causes Rapid Loss of the Balance 

between TH17 and T Regulatory Cell Populations in 

Pathogenic Infection of Non-human Primates 

David Favre* 1 , S Lederer2 , B Kanwar1 , ZM Ma3 , S Proll2 , Z Kasakow1 , 

C Miller3 , M Katze2 , and J McCune1 1 2 Univ of California, San Francisco, US; Univ of Washington, 

Seattle, US; and 3Univ of California, Davis, US 

10:45 118 SIVrcm, a Unique CCR2-tropic Virus, Selectively 

Depletes Memory CD4 + T Cells in Pigtailed Macaques 

Due to Rapid Co-receptor Expansion in vivo 

Rajeev Gautam*, T Gaufin, I Butler, A Gautam, C Monjure, 

M Barnes, M Pattison, P Marx, I Pandrea, and C Apetrei 


11:00 119 Bacterial DNA Are Measurable in Plasma of HIVinfected 

Patients and Are Diminished by ART 

Wei Jiang* 1 , K Haley1 , S Sieg1 , M Lederman1 , A Aasher2 , 

D Douek2 , and J Brenchley2 1 2 Case Western Reserve Univ, Cleveland, OH, US and Vaccine Res 

Ctr, NIAID, NIH, Bethesda, MD, US 

11:15 120 Evidence for Persistent Viral Replication in Lymph 

Node and GALT of ARV-treated Persons 

Timothy Schacker* 1 , M Stevenson2 , J Brenchley3 , D Douek3 , and 

A Haase1 1 2 Univ of Minnesota, Minneapolis, US; Univ of Massachuesetts, 

Boston, US; and 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US 

11:30 121 HIV-1 Rebound during ART Interruption Is Associated 

with a Preferential Depletion of CD4 + T Cells from the 

Gastrointestinal Tract 

Saurabh Mehandru* 1,2 , M Poles1,3 , K Tenner-Racz4 , M LaRoche1 , 

K Rodriguez1 , T Evering1 , D Castor1 , A Lloyd1 , P Racz4 , and 

M Markowitz1 1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, 

NY, US; 2Mt Sinai Sch of Med, New York, NY, US; 3New York Univ 

Sch of Med, New York, US; and 4Bernhard Nocht Inst for Tropical 

Med, Hamburg, Germany 

11:45 122 Syndecan-3 Is a Dendritic Cell-specific Attachment 

Receptor for HIV-1 

L De Witte1 , M Bobardt2 , T Geijtenbeek1 , and Philippe Gallay* 2 

1 2 VU Univ Med Ctr, Amsterdam, The Netherlands and Scripps Res 

Inst, La Jolla, CA, US 


Wednesday 

February 6 Sessions

Wednesday 



k Wednesday, 10-11:45 am; Ballroom A 

CME 


Epidemiology of HIV Infection and Scale-up of ART 

in Developing Countries 

Moderators: 

Kevin De Cock, World Hlth Org, Geneva, Switzerland 

Dorothy Mbori-Ngacha, Global AIDS Prgm, CDC Kenya, Nairobi 

10:00 123 Determinants for HIV Acquisition among Adults in 

Uganda: A Population-based, Nationally Representative 

Study 

Wolfgang Hladik* 1 , J Musinguzi2 , A Opio2 , W Kirungi2 , J Ekwaru1 , 

F Kaharuza1 , R Downing1 , R Bunnell1 , and J Mermin1 1 2 CDC Uganda, Entebbe and AIDS Control Prgm, Ministry of Hlth, 


10:15 124 Measuring the Force of the HIV Epidemic in a Rural 

Area of South Africa: The Africa Centre 

Till Barnighausen* 1,2 , ML Newell1,3 , F Tanser1 , C Mbizana1 , 

C Wallrauch1 , G Cooke1,4 , Z Gqwede1 , and K Herbst1 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal, 

Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, 

US; 3Inst of Child Hlth, Univ Coll London, UK; and 4Imperial Coll, 

London, UK 

10:30 125 Utility of Routine Viral Load, CD4 Cell Count, and 

Clinical Monitoring among HIV-infected Adults in 

Uganda: A Randomized Trial 

Alex Coutinho* 1 , J Mermin2,3 , J Ekwaru2 , W Were2 , R Bunnell2,3 , 

F Kaharuza2 , L Alexander2 , P Solberg2 , J Tappero2 , and D Moore2,4 1 2 TASO and Infectious Disease Inst, Kampala, Uganda; CDC 

Uganda, Entebbe; 3CDC Kenya, Nairobi; and 4Univ of British 

Columbia, Vancouver, Canada 

10:45 126 Long-term CD4 Response to Potent ART among ARTnaïve 

Patients in Several Low-income Countries 

Denis Nash* 1 , M Katyal1 , M Brinkhof2 , S Tuboi3 , P Braitstein4 , 

E Balestre5 , M May6 , E Sprinz7 , N Kumarasamy8 , M Egger2 , and 

the Antiretroviral Therapy in Low Income Countries (ART-LINC) 

Collaboration of IEDEA 

1Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; 

2 3 4 Univ of Berne, Switzerland; Univ of Pittsburgh, PA, US; Indiana 

Univ Sch of Med, Indianapolis, US; 5Univ Victor Segalen, Bordeaux, 

France; 6Univ of Bristol, UK; 7Federal Univ of Rio Grande do Sul, 

Porte Alegre, Brazil; and 8YRGCARE, Chennai, India 

11:00 127 Evaluation of Clinical and Immunologic Outcomes from 

the National ART Program in Rwanda, 2004 to 2005 

Francois Ndamage* 1 , D Lowrance1,2,3 , A Rukundo1 , E Kayirangwa4 , 

F Ndagije2 , D Hoover5 , J Hanson6 , W Lo7 , A Ayaba4 , and T Ellerbrock3 1Treatment and Res on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda; 

2Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, 

Kigali, Rwanda; 3Global AIDS Prgm, CDC, Atlanta, GA, US; 

4 5 Global AIDS Prgm, CDC Rwanda, Kigali; Rutgers Univ, New 

Brunswick, NJ, US; 6Global AIDS Prgm, CDC Namibia, Windhoek; 

and 7Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, 

New York, NY, US 

11:15 128 Early Detection of Effect on Adult Mortality of a 

Government ART Program in Rural KwaZulu Natal, 

South Africa 

Till Barnighausen* 1,2 , G Cooke1,3 , K Herbst1 , A Kany Kany1 , and 

ML Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal, 

Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, 

US; 3Imperial Coll, London, UK; and 4Univ Coll London, UK 

11:30 129LB High HIV Prevalence among Males in Discordant 

Partnerships in a Full Access Door–Door VCT 

Program in Rural Uganda 

E Tumwesigye* 1 , S Asiimwe1 , E Muganzi1 , M Achom2 , D Kabatesi2 , 

and J Tappero2 1 2 Integrated Community Based Initiatives and CDC Uganda 


k Wednesday, 10-11:45 am; Ballroom B/C 

CME 

Session 38–Oral Abstracts and Scientific Overview 

Drug Delivery, Interactions and Genetic Variability 

Moderators: 

Giovanni Di Perri, Univ of Turin, Italy 

Courtney Fletcher, Univ of Nebraska Med Ctr, Omaha, US 

10:00 131 Low Tenofovir Concentrations in Cerebrospinal Fluid 

Brookie Best* 1 , S Letendre 1 , P Koopmans 2 , D Clifford 3 , A Collier 4 , 

B Gelman 5 , J McArthur 6 , D Simpson 7 , E Capparelli 1 , R Ellis 1 , and the 

CHARTER Group 

1 Univ of California, San Diego, US; 2 Radboud Univ Nijmegen Med 

Ctr, The Netherlands; 3 Washington Univ, St Louis, MO, US; 4 Univ 

of Washington, Seattle, US; 5 Univ of Texas Med Branch, Galveston, 

US; 6 Johns Hopkins Univ, Baltimore, MD, US; and 7 Mt Sinai Sch of 

Med, New York, NY, US 

10:15 132 Drug Interaction between Antimalarial Drugs and 

Lopinavir/Ritonavir 

Polina German* 1 , S Parikh 2 , J Lawrence 2 , N Lindegardh 3 , 

P Rosenthal 2 , D Havlir 2 , E Charlebois 2 , G Dorsey 2 , and F Aweeka 1 

1 Univ of California, San Francisco, Sch of Pharmacy, US; 2 San 

Francisco Gen Hosp, Univ of California, US; and 3 Faculty of 

Tropical Med, Mahidol Univ, Bangkok, Thailand 

10:30 133 Genetic Variation in Accessory Metabolic Pathways 

Is Associated with Extreme Efavirenz Exposure in 

Individuals with Impaired CYP2B6 Function 

Julia di Iulio* 1 , M Rotger1 , R Lubomirov1 , L Decosterd1 , CB Eap2 , 

and A Telenti1 1 2 Univ Hosp Ctr, Univ of Lausanne, Switzerland and Cery Hosp, 

Lausanne, Switzerland 

10:45 134 Long-acting TMC278, a Parenteral Depot Formulation 

Delivering Therapeutic NNRTI Concentrations in 

Preclinical and Clinical Settings 

Gerben van ‘t Klooster* 1 , R Verloes1 , L Baert1 , F van Velsen1 , 

MP Bouche2 , K Spittaels1 , J Leempoels3 , P Williams1 , G Kraus1 , and 

P Wigerinck1 1 2 Tibotec BVBA, Mechelen, Belgium; Johnson & Johnson Pharma 

R&D, Beerse, Belgium; and 3Johnson & Johnson Pharma R&D, 

Merksem, Belgium 

11:00 135LB Maraviroc Pharmacokinetics in Blood Plasma, Genital 

Tract Fluid and Tissue in Healthy Female Volunteers 

J Dumond1 , Kristine Patterson* 1 , A Pecha1 , R Werner1 , E Andrews2 , 

B Damle2 , R Tressler2 , J Worsley3 , K Boggess1 , and A Kashuba1 1 2 Univ of North Carolina at Chapel Hill, US; Pfizer Inc, New York, 

NY, US; and 3Pfizer Global R&D, Sandwich, Kent, UK 

11:15 136 

The Evolution of Therapeutic Drug Monitoring in 

ART 

Giovanni Di Perri* and S Bonora 

Univ of Turin, Italy


k Wednesday, 10 am-12 noon; Auditorium 

CME 


Cardiovascular Risk, Mortality and TB 

Complicating HIV Infections 

Moderators: 

Ian Sanne, Univ of the Witwatersrand, Johannesburg, South Africa 

Christine Wanke, Tufts Univ Sch of Med and Tufts–New England Med Ctr, Boston, 

MA, US 

10:00 139 Elevated Levels of Interleukin-6 and D-dimer Are 

Associated with an Increased Risk of Death in Patients 

with HIV 

Lewis Kuller and SMART Study Group 


10:15 140 HIV Activates Markers of Cardiovascular Risk in a 

Randomized Treatment Interruption Trial: STACCATO 

Alexandra Calmy* 1 , A Nguyen1 , F Montecucco1 , 

A Gayet-Ageron1 , F Burger1 , F Mach1 , A Carr2 , S Ubolyam3 , 

B Hirschel1 , and J Ananworanich3,4 for the STACCATO Study Team 

1 2 Geneva Univ Hosp, Switzerland; St Vincent’s Hosp, Sydney, 

Australia; 3HIV Netherlands Australia Thailand Res Collaboration, 

Bangkok; and 4South East Asia Res Collaboration with Hawaii, 

Bangkok, Thailand 

10:30 141 Age- and Sex-specific Death Rates in ART-naïve 

Patients with CD4 Count above 350 cells/mm3 Compared with the General Population 

Rebecca Lodwick* 1 , K Porter2 , C Sabin1 , B Ledergerber3 , 

A Cozzi-Lepri1 , P Khaykin4 , A Mocroft1 , L Jacobson5 , S de Wit6 , 

A Phillips1 , and Study Group on Death Rates at High CD4 Count in 

Antiretroviral-naïve Patients 

1 2 Univ Coll London, UK; Med Res Council Clinical Trials Unit, 

London, UK; 3Univ Hosp Zurich, Switzerland; 4JW Goethe Univ, 

Frankfurt, Germany; 5Johns Hopkins Univ, Baltimore, MD, US; and 

6St Pierre Univ Hosp, Brussels, Belgium 

10:45 142 Immediate vs Deferred ART in the Setting of Acute 

AIDS-related Opportunistic Infection: Final Results of 

a Randomized Strategy Trial, ACTG A5164 

Andrew Zolopa* 1 , J Andersen2 , L Komarow2 , A Sanchez3 , 

C Suckow4 , I Sanne5 , E Hogg6 , W Powderly7 , and ACTG A5164 

Study Team 

1 2 Stanford Univ, Palo Alto, CA, US; Statistical and Data Analysis 

Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Southern 

California, Los Angeles, US; 4Frontier Sci & Tech Res Fndn, 

Buffalo, NY, US; 5Univ of the Witswatersrand, Johannesburg, South 

Africa; 6Social & Sci Systems, Silver Spring, MD, US; and 7Univ Coll Dublin, Ireland 

11:00 143 Exogenous Re-infection with Multidrug- and 

Extensively Drug-resistant TB among TB/HIV 

Co-infected Patients in Rural South Africa 

J Andrews1 , Neel Gandhi* 2 , P Moodley3 , S Shah2 , L Bohlken3 , 

T Moll4 , M Pillay3 , G Friedland1 , W Sturm3 , and Tugela Ferry Care 

and Res Collaboration 

1 2 Yale Univ Sch of Med, New Haven, CT, US; Albert Einstein Coll of 

Med, Bronx, NY, US; 3Nelson R Mandela Sch of Med, Durban, South 

Africa; and 4Philanjalo and Church of Scotland Hosp, Tugela Ferry, 

South Africa 

11:15 144 HIV Infection and Drug-resistant TB in Ukraine: A 

Threatening Convergence of 2 Epidemics? 

I Dubrovina1 , K Miskinis2 , S Lyepshina3 , Y Yann4 , H Hoffmann5 , 

R Zaleskis6 , P Nunn7 , and Matteo Zignol* 7 

1 2 WHO, Project Office, Donetsk, Ukraine; WHO, Country Office, 

Kiev, Ukraine; 3Donetsk State Med Univ, Ukraine; 4Donetsk TB 

Reference Lab, Ukraine; 5Inst of Microbio and Lab Med, Asklepios 

Fachkliniken München-Gauting, Germany; 6WHO, European 

Regional Office, Copenhagen, Denmark; and 7WHO Headquarters, 

Geneva, Switzerland 

11:30 145 The Influence of TB on Early Mortality in the Themba 

Lethu Clinical Cohort, Johannesburg, South Africa 

Daniel Westreich* 1 , S Badal-Faesen2 , B Malope2 , D Rubel2 , 

Z Akiy2 , P MacPhail2 , A Van Rie1 , and I Sanne2 1Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and 

2Univ of the Witwatersrand, Johannesburg, South Africa 

11:45 146LB Effects of 18-Month Physiological GH Replacement in 

Relatively GH-deficient Patients with HIV Lipodystrophy 

J Lo, S You, B Canavan, J Liebau, G Beltrani, P Koutkia, H Lee, and 

Steven Grinspoon* 

Massachusetts Gen Hosp, Boston, US 

c Wednesday, 1-4 pm; Poster Hall 



Session 53. HIV-1 Macrophage Studies 

Session 54. Co-infection: Virus/Virus Interactions 

Session 55. Viral Reservoirs 

Session 56. Viral Transmission: Molecular Studies 

Session 63. Studies on Elite Controllers and Exposed Uninfected 

Session 64. Studies of Non-progressive Infection 

Session 65. Lymphocyte Depletion in the Gut 

Session 66. Monocyte/Macrophage Studies 

Session 71. Co-infection with HCV 

Session 72. PML and JC Virus 

Session 78. B Cell and Immunoglobulin Studies 

Session 79. Studies on NK and Plasmacytoid Dendritic Cells 

Session 80. HIV Vaccines: Induction of Neutralizing Antibodies and Responses 

Session 81. HIV Vaccines: Induction of Cellular Immune Responses 

Session 82. HIV Vaccines: Novel Viral Vectors 

Session 83. HIV Vaccines: Clinical Trials 

Session 89. Expanding HIV Testing 

Session 90. Behavioral Risk in HIV Infection 

Session 94. Preclinical and Clinical Studies of Topical and Oral PrEP 

Session 101. Special Considerations in Laboratory Studies for Children 

Session 102. Transmission and Diagnosis of HIV Infection in Infants and Children 

Session 103. Immune Response in Children 

Session 104. Viral and Host Factors Associated with Pediatric Disease Progression 

Session 110. Risk, Timing and Viral Genetics of MTCT 

Session 111. Co-infections during Pregnancy 

Session 120. Immune-Based Therapies: Cytokines 

Session 121. Immune-Based Therapies: Therapeutic Vaccines 

Session 122. Immune-Based Therapies: Novel Approaches 

Session 129. ART: Adherence 

Session 130. HIV Care in Different Settings 

Session 133. Risk Factors for Lost-to-Follow-up in Resource-limited Settings 

Session 134. Complications in Resource-limited Settings 

Session 139. New Resistance Technologies 

Session 140. HIV-1 Drug Resistance: Genital Shedding and Recombination 

Session 141. HIV-2 Drug Resistance 

Session 151. Diagnosis and Monitoring Using Dried Specimens 

Session 159. Impact on Cardiac Function 

Session 160. Hypersensitivity Reactions: Other Drug Toxicities 

Session 161. in vitro and Animal Studies of Metabolic Toxicity 

Session 162. ART Toxicity in Resource-limited Settings 

Session 163. TB Screening and Diagnostics 

Session 164. HIV/TB Co-infection 

Session 165. TB-associated Immune Reconstitution Inflammatory Syndrome 

Session 166. Cryptococcal and Herpesvirus Infections 

Session 167. Infectious Complications 

Session 168. Malignancies 


Wednesday 

February 6 Sessions

Wednesday 



c Wednesday, 2-3 pm; Room 311 

CME 



New Insights into APOBEC Proteins 

Discussants: 

Francois Clavel, Hosp Bichat, Paris, France 

Welkin Johnson, New England Primate Res Ctr, Harvard Med Sch, Southborough, 

MA, US 

229 Deamination in 3D: Intra- and Intersegmental Transfer of 

APOBEC3G Cytidine Deaminase 

Roni Nowarski*, M Kotler, and E Britan 

Hebrew Univ, Hadassah Med Sch, Jerusalem, Israel 

230 APOBEC3G’s Cytoplasmic Localization Is Actively 

Regulated but Not Required for HIV-1 Restriction 

Mark Stenglein* and R Harris 


231 Enzymatically Active APOBEC3G Is Required for Efficient 

Inhibition of HIV-1 

E Miyagi, S Opi, H Takeuchi, M Khan, R Goila-Gaur, S Kao, and 

Klaus Strebel* 


232 Distinct Packaging Mechanisms of Human Cytidine 

Deaminase APOBEC3 Proteins into HIV-1 Virions 

Lindi Tan*, T Wang, and X Yu 


233 Effect of Impaired Processivity of HIV-1 Reverse 

Transcriptase on the G-to-A Mutation Rate Induced by 

APOBEC-3G/-3F 

Stefanie Knoepfel*, P Rauch, N Salisch, K Allers, P Huelsmann, and 

K Metzner 

Univ of Erlangen-Nuremberg, Germany 

234 Protein Kinase A-mediated Phophorylation of APOBEC3G 

Antagonizes Its Degradation by Vif 

Kotaro Shirakawa*, A Takaori-Kondo, T Izumi, K Io, M Matsui, and 

T Uchiyama 

Kyoto Univ, Japan 


c Wednesday, 2-3 pm; Room 312 

CME 



Molecular Epidemiology: The Americas 

Discussants: 

Beatrice Hahn, Univ of Alabama at Birmingham, US 

Andrew Leigh Brown, Univ of Edinburgh, Scotland 

505 HIV-1 Transmission Dynamics in Quebec in the HAART Era 

Bluma Brenner* 1 , M Roger 2 , D Moisi 1 , J Cox 3 , JP Routy 1 , M Wainberg 1 , and 

Quebec PHI Study Group 

1 McGill AIDS Ctr, Jewish Gen Hosp, Montreal, Canada; 2 Ctr Hosp Univ 

Montreal, Canada; and 3 Quebec Agency of Publ Hlth and Social Svcs, 

Canada 

506 Tracking Molecular Epidemiology of HIV-1 in Mexico: 

Emergence of BG Intersubtype Recombinant 

Eduardo Vazquez-Valls* 1 , M Escoto-Delgadillo 1 , R Carabez-Hernandez 2 , 

and B Torres-Mendoza 2 

1 UMAE Specialties Hosp, Western Biomed Res Ctr, Mexican Inst of Social 

Security, Guadalajara and 2 Univ Hlth Sci Ctr, Univ of Guadalajara, 

Mexico 

507 Evolutionary Dynamics of HIV-1 BF and CB Recombinants 

in South America 

Elcio Leal* 1 , L Martins 2 , M Janini 1 , and R Diaz 1 

1 Federal Univ of Sao Paulo, Brazil and 2 Grad Sch of Agriculture and Life 

Sci, Univ of Tokyo, Japan 

508 A Foothold for Subtype C in the Americas: Risk Factors 

Associated with Subtype C and Non-Subtype C HIV 

Infection among HIV Testing Clients in South Brazil 

Oliver Bacon* 1 , R da Silva de Souza 2 , K Page Shafer 1 , R Diaz 3 , V Debastiani 4 , 

G Preussler 5 , M Leticia Ikeda 6 , N Barcellos 7 , W Steward 1 , and C Pilcher 1 

1 Univ of California, San Francisco, US; 2 Univ de Caxias do Sul, Rio 

Grande, Brazil; 3 Paulista Sch of Med, Federal Univ of Sao Paulo, Brazil; 

4 Ambulatorio de DST/AIDS, Caxias do Sul, Rio Grande do Sul, Brazil; 

5 Svc de Assistencia Especializado, Ctr de Saude Vila dos Comercarios, 

Rio Grande do Sul, Brazil; 6 Svc Especializado de DST/AIDS Herbert de 

Souza, Rio Grande do Sul, Brazil; and 7 Hosp Sanatorio Partenon, Rio 

Grande do Sul, Brazil 

509 Timing the Introduction of HIV-1 Subtype C in Brazil 

Gonzalo Bello*, R Lorete, M Guimaraes, C Bittencourt Passaes, and 

M Morgado 

Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil


c Wednesday, 2-3 pm; Room 302-304 

CME 



Maternal ART and Feeding Practices: Impact on 

Infant Outcomes 

Discussants: 

Elaine Abrams, Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US 

Francois Dabis, Univ Victor Segalen, Bordeaux, France 

636 18-Month HIV-free Survival by Infant Feeding Practices 

in Children of HIV-infected Women in South Africa: The 

Vertical Transmission Study 

Nigel Rollins* 1 , R Becquet 2,3,4 , R Bland 2,5 , A Coutsoudis 1 , H Coovadia 6 , and 

ML Newell 2,7 

1 Univ of KwaZulu Natal, Durban, South Africa; 2 Africa Ctr for Hlth and 

Population Studies, Univ of KwaZulu Natal, Somkhele, South Africa; 

3 INSERM U593, Bordeaux, France; 4 Inst for Publ Hlth, Epi and Devt, 

Univ Victor Segalen, Bordeaux, France; 5 Univ of Glasgow, UK; 6 Ctr for 

HIV/AIDS Networking, Univ of KwaZulu Natal, Durban, South Africa; 

and 7 Ctr for Pediatric Epi and Biostatistics, Inst of Child Hlth, Univ Coll 

London, UK 

637 Risk Factors for Mother-to-Child Transmission of HIV-1 

from Breastfeeding in a Randomized Clinical Trial in 

Botswana: The Mashi Study 

Roger Shapiro* 1 , L Smeaton 2 , S Lockman 3 , I Thior 4 , R Rossenkhan 4 , 

C Wester 4 , L Stevens 4 , J Leidner 2 , J Makhema 4 , and M Essex 5 

1 Beth Israel Deaconess Med Ctr, Boston, MA, US; 2 Harvard Sch of Publ 

Hlth, Ctr for Biostatistics in AIDS Res, Boston, MA, US; 3 Brigham and 

Women’s Hosp, Boston, MA, US; 4 Botswana Harvard Sch of Publ Hlth 

AIDS Initiative Partnership for HIV Res and Ed, Gaborone; and 5 Harvard 

Sch of Publ Hlth, Boston, MA, US 

638 HIV-free Survival at 12 Months among Children Born to 

HIV-infected Women Receiving Antiretrovirals from 34 to 

36 Weeks of Pregnancy 

Isabelle de Vincenzi* and the Kesho Bora Study Group 

WHO, Geneva, Switzerland 

639 Decrease in HIV-1 Mother-to-Child Transmission in Women 

Receiving Postnatal HAART: 12-Month Follow-up Data 

M Marazzi 1 , L Palombi 2 , G Liotta 2 , P Germano 3 , N Abdul Majid 4 , I Zimba 4 , 

A Doro Altan 2 , G Bortolot 3 , and Karin Nielsen-Saines* 5 

1 LUMSA Univ, Rome, Italy; 2 Univ of Tor Vergata, Rome, Italy; 3 DREAM 

Prgm, Community of St Egidio, Italy; 4 Benfica Hlth Ctr, Maputo, 

Mozambique; and 5 David Geffen Sch of Med, Univ of California, Los 

Angeles, US 

640 Comparison of Adverse Fetal Outcomes in HIV-1-infected 

Antiretroviral- naïve Pregnant Women Who Have 

Received Combivir and Either Nevirapine or Nelfinavir for 

Prevention of Mother-to-Child Transmission Antenatally 

Rose Masaba* 1 , R Ndivo 1 , I Nyangau 1 , K Achola 1 , C Zeh 2 , M Thigpen 3 , 

P Weidle 3 , and T Thomas 2 

1 Kenya Med Res Inst, Kisumu; 2 CDC Kenya, Kisumu; and 3 CDC, Atlanta, 

GA, US 

641 Low Birth Weight with Nevirapine-based ART in Abidjan, 

Côte d’Ivoire: The ANRS Ditrame Plus Cohort and MTCT- 

Plus Initiative, 2001 to 2007 

Didier Koumavi Ekouevi* 1,2 , B Tonwe-Gold 1,3 , R Becquet 1 , P Coffie 1,2 , 

P Toure 3 , V Leroy 1 , I Viho 2 , S Blanche 4 , F Dabis 1 , and E Abrams 5 

1 INSERM U593, Inst for Publ Hlth, Epi and Devt, Bordeaux, France; 

2 Natl Agency for AIDS Res Ditrame Plus Project, Abidjan, Côte d’Ivoire; 

3 ACONDA, NGO, Abidjan, Côte d’Ivoire; 4 Hosp Necker, Paris France; 

and 5 MTCT-Plus Initiative, New York, NY, US 

e Wednesday, 4-6 pm; Ballroom A 


Accessory Proteins and Intrinsic Resistance 

Conveners: 

Ned Landau, New York Univ, NY, US 

Aine McKnight, Barts and The London Sch 

of Med and Dentistry, UK 

147 

Vif and APOBEC: What We Know 

Xiao-Fang Yu 


148 

The Role of Vpu in Retrovirus Particle Release 

Paul Spearman 

Emory Univ Sch of Med, Atlanta, GA, US 

149 

Genetic Variation in TRIM5α and Related Genes 

Sara Sawyer* 1 , M Emerman 2 , and H Malik 2 

1 Univ of Texas, Austin, US and 2 Fred Hutchinson Cancer Res Ctr, 


150 

HIV Vpr Protein as a Mediator of Ubiquitylation 

Carlos de Noronha*, X Wen, L Casey, J Sharifi, and K Duus 

Albany Med Coll, NY, US 


HIV molecular biology, viral accessory genes, mechanisms of intracellular 

resistance to viruses and co-evolution of viruses and hosts. It is assumed that 

participants are familiar with basic cell and molecular biology, and the HIV 

genome and replication cycle. At the completion of the session participants 

will be knowledgeable about the HIV Vif, Vpr, and Vpu accessory proteins 

and about the APOBEC3 and Trim-5a host restriction factors. 


Wednesday 

February 6 Sessions

Wednesday 



e Wednesday, 4-6 pm; Ballroom B/C 


Frontiers in Vaccine Research 

151 

Advances in Vaccines Scaffolds 

Bill Schief 

Univ of Washington, Seattle, US 

Conveners: 

David Ho, Aaron Diamond AIDS Res Ctr, 

The Rockefeller Univ, New York, NY, US 

Lynn Morris, Natl Inst for Communicable 

Diseases, Johannesburg, South Africa 

152 

Lessons Learned from HIV-1 Envelope Glycoprotein 

Immunogenicity Analysis 

M Forsell 1,2 , B Dey 1 , A Moerner 3 , G Voss 4 , R Thorstensson 3 , 

P Kwong 1 , G Shaw 5 , J Mascola 1 , G Karlsson Hedestam 2,3 , and 

Richard Wyatt* 1 

1 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US; 2 Karolinska 

Inst, Stockholm, Sweden; 3 Swedish Ctr for Infectious Disease 

Control, Solna; 4 GlaxoSmithKline, Rixensart, Belgium; and 

5 Univ of Alabama at Birmingham, US 

153 

Identification and Characterization of Transmitted 

and Early Founder Viruses in Primary HIV-1 Infection 

B Keele 1 , E Giorgi 2,3 , J Salazar-Gonzalez 1 , F Gao 4 , R Swanstrom 5 , 

M Busch 6 , B Haynes 4 , B Korber 2,7 , B Hahn 1 , and George Shaw* 1 

1 Univ of Alabama at Birmingham, US; 2 Los Alamos Natl Lab, 

NM, US; 3 Univ of Massachusetts, Amherst, US; 4 Duke Univ, 

Durham, NC, US; 5 Univ of North Carolina at Chapel Hill, US; 

6 Blood Systems Res Inst, San Francisco, CA, US; and 7 Santa Fe 

Inst, NM, US 

154 

Attenuated SIV Models and Protection from 

Pathogenic Heterologous Challenges 

James Hoxie* 1 , A Jordan1 , B Haggarty1 , J Romano1 , M Piatak2 , 

J Lifson2 , D Montefiori3 , M Marsh4 , and P Fultz5 1 2 Univ of Pennsylvania Sch of Med, Philadelphia, US; NCI- 

Frederick, MD, US; 3Duke Univ, Durham, NC, US; 4Univ Coll 

London, UK; and 5Univ of Alabama at Birmingham, US 


immunology and vaccine development. It is assumed that participants are 

familiar with basic HIV biology, acute infection, principles of cellular and 

humoral immunology, and how antibodies recognize foreign antigens. At the 

completion of the session, participants will be knowledgable about how HIV 

evades the early immune response to HIV during acute infection, animals 

models of vaccine-induced protection against disease progression, problems 

associated with eliciting neutralizing antibodies against HIV, and some of the 

promising strategies to overcome these roadblocks. In particular, the promise 

and limitations of rational vaccine design, and how those such vaccines are 

evaluated, will be better understood. 


e Wednesday, 4-6 pm; Auditorium 


Individualizing Patient Management 

Conveners: 

Elly Katabira, Makerere Univ, Kampala, 

Uganda 

Caroline Sabin, Royal Free and Univ Coll 

Med Sch, London, UK 

155 

Optimizing Patient Management in Resource-limited 

Settings 

Jonathan Mermin 

CDC Kenya, Nairobi 

156 

Individualizing Patient Management: Host Genetics 

Jacques Fellay 


157 

Individualized Management of Therapy: Virologic 

Complications 

Carlo-Federico Perno 

Univ of Rome Tor Vergata, Italy 

158 

Individualized Management of Therapy: The Issue 

of Complications 

Jennifer Hoy 

Alfred Hosp, Monash Univ, Melbourne, Australia 


in gaining an understanding of the optimal management of HIV-infected 

patients. The session will address this issue in a global context. It is assumed 

that participants are familiar with natural history of HIV infection and basic 

principles of HIV management. At the completion of the session, participants 

will be able to identify key host-related factors, virological consideration, 

and patient complications that determine outcome of HIV/AIDS. Participants 

will also gain a better understanding of individual management strategies in 

resource-limited settings.


b Monday, 1-4 pm; Hall D 

Session 46–Poster Abstracts 

Cellular Co-factors 

200 Visualization of the HIV Host Protein Interaction Network 

Jonathan Dickerson* 1 , J Pinney1 , R Ptak2 , W Fu2 , B Sanders-Beer2,3 , and 

D Robertson1 1 2 Univ of Manchester, UK; Southern Res Inst, Frederick, MD, US; and 

3Bioqual, Inc, Rockville, MD, US 

201 ADAM10: A Cellular Metalloprotease Required at or Just 

Prior to HIV Integration 

B Friedrich1 , J Murray2 , D Rubin3 , T Hodge2 , and William O’Brien* 1 

1 2 Univ of Texas Med Branch, Galveston, US; Zirus, Buford, GA, US; and 

3VA Tennessee Valley Hlthcare System and Vanderbilt Univ, Nashville, US 

202 Transient Knockdown of the Von Hippel Lindau Binding 

Protein 1 in HeLaP4 Cells Enhances HIV-1 Replication 

Wannes Thys*, F Christ, J De Rijck, and Z Debyser 

Katholieke Univ Leuven, Flanders, Belgium 

203 Activator Protein 1 Synergizes with NF-κB to Activate Latent 

HIV Provirus Transcription following T Cell Receptor 

Activation 

Joseph Hokello*, YK Kim, R Pearson, and J Karn 

Case Western Reserve Univ, Cleveland, OH, US 

204 Overexpression of NF90 or Its Mutants Together with Its 

N-ter Region, Decrease Rev Export Activity and HIV-1 

Replication 

Claudia Patino* 1 , X Zapata1 , G St Laurent2 , A Kumar2 , 

D Hernandez-Verdun3 , and S Urcuqui-Inchima1 1 2 Univ de Antioquia, Colombia; George Washington Univ, Washington, 

DC, US; and 3UMR 7592, Univ Paris VI and VII, France 

205 The Receptor Tyrosine Kinase RON Represses HIV-1 

Transcription by Targeting RNA Polymerase II Processivity 

A Klatt1 , Z Zhang2 , P Kalantari1 , P Hankey1 , D Gilmour1 , and 

Andrew Henderson* 3 

1 2 Penn State Univ, Univ Park, US; Fox Chase Cancer Ctr, Philadelphia, 

PA, US; and 3Boston Univ Sch of Med, MA, US 

206 Dominant Negative Cyclin T1 Protein That Inhibits HIV 

Transcription by Specifically Degrading Tat 

Julie Jadlowsky* 1 , K Fujinaga1 , M Nojima1 , M Geyer2 , and 

T Okamoto3 1 2 Case Western Reserve Univ, Cleveland, OH, US; Max-Planck-Inst for 

Molecular Physiology, Dortmund, Germany; and 3Nagoya City Univ 

Graduate Sch of Med Sci, Japan 

207 PRMT6 Fine-tunes Localization Patterns of HIV-1 Proteins 

Tat and Rev 

Rita Schildknecht*, C Invernizzi, S Colby-Germinario, K Dahl, 

J Martinez, B Spira, B Brenner, and M Wainberg 

McGill Univ AIDS Ctr, Montreal, Canada 

208 Roles for IST1 in VPS4 Regulation and HIV-1 Budding 

Monika Bajorek*, E Morita, J Skalicky, M Babst, and W Sundquist 

Univ of Utah, Salt Lake City, US 

209 Functional Role of Alix in HIV-1 Replication 

Ken Fujii*, U Munshi, S Ablan, and E Freed 

NCI-Frederick, MD, US 

210 Structure of Yeast Vps4p by Electron Microscopy and X-ray 

Crystallography 

Malgorzata Gonciarz* 1 , Z Yu2 , F Whitby1 , C Kieffer1 , G Jensen2 , 

W Sundquist1 , and C Hill1 1 2 Univ of Utah, Salt Lake City, US and California Inst of Tech, Pasadena, 

US 

211 Role of Kinases of the PIKK Family in Retroviral Replication 

Y Yang, V Guen, and Lionel Berthoux* 

Univ of Quebec, Trois-Rivieres, Canada 



Cellular Restrictions 

212 APOBEC3G Protein Expression in Blood Resting and 

Activated CD4 + and CD8 + T Cells: Its Effect on Susceptibility 

to HIV Infection and Progression 

H Oliva1 , Montserrat Plana* 1 , A Lopez1 , J Martinez-Navio2 , R Franco2 , 

J Miro1 , F Garcia1 , J Gatell1 , N Navaratnam3 , and T Gallart1 1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; Faculty of Bio, Univ of 

Barcelona, Spain; and 3Med Res Council, Hammersmith Hosp, London, 

UK 

213 Target Cell APOBEC3C Can Induce Limited G-to-A 

Mutation in HIV-1 

K Bourara1 , T Liegler2 , and Robert Grant* 1,2 

1Gladstone Inst of Virology and Immunology, San Francisco, CA, US and 

2Univ of California, San Francisco, US 

214 Determinants of HIV-1 Vif Regulation of APOBEC3 Proteins 

Anna Maria Niewiadomska*, W Zhang, and XF Yu 

Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

215 The Anti-HIV-1 Potency of APOBEC1 Cytidine Deaminase 

from Small Animal Species 

Terumasa Ikeda* 1 , T Ohsugi 2 , T Kimura 1 , S Matsushita 3 , Y Maeda 1 , 

S Harada 1 , and A Koito 1 

1 Grad Sch of Med Sci, Kumamoto Univ, Japan; 2 Ctr for Animal Resources 

and Devt, Kumamoto Univ, Japan; and 3 Ctr for AIDS Res, Kumamoto 

Univ, Japan 

216 A Single Amino Acid of the HIV-2 Capsid Determines Its 

Replication in the Presence of Cynomolgus Monkey and 

Human TRIM5α 

Haihan Song* 1 , E Nakayama1 , M Yokoyama2 , H Sato2 , J Levy3 , and 

T Shioda1 1 2 Res Inst for Microbial Diseases, Osaka Univ, Japan; Natl Inst of 

Infectious Diseases, Tokyo, Japan; and 3Univ of California, San 

Francisco Sch of Med, Cancer Res Inst, US 

217 Analysis of the Role of Cytoplasmic Bodies in TRIM5α 

Restriction 

Cindy Danielson*, E Campbell, M McRaven, and T Hope 

Northwestern Univ, Chicago, IL, US 

218 Using a Restriction-deficient Cell Line in the Search for 

Cellular Proteins Important for TRIM5α Activity 

Julie Berube*, A Bouchard, and L Berthoux 

Univ of Quebec, Trois-Rivieres, Canada 



Viral Accessory Genes 

219 Co-variation Networks in HIV-1 Nef Sequences from 

Phylogenetic and Mixtures Analysis 

Art Poon* 1 , R Harrigan2 , and S Frost1 1 2 Univ of California, San Diego, US and BC Ctr for Excellence in HIV/ 

AIDS, Vancouver, Canada 

220 Nef Proteins Derived from HIV-1 Subtypes C and F Fail to 

Up-regulate Invariant Chain Cell Surface Expression 

Gabriela Turk* 1 , P Benaroch2 , and H Salomon1 1Natl Reference Ctr for AIDS, Univ of Buenos Aires, Argentina and 

2INSERM U653, Inst Curie, Paris, France 

221 Nucleo-cytoplasmic Transport of Vpx Play a Critical Role in 

HIV-2/SIV Replication in Non-dividing Cells 

P Singhal1 , P Rajendra Kumar1 , and Sundarasamy Mahalingam* 1,2 

1Ctr for DNA Fingerprinting and Diagnostics, Hyderabad, India and 

2Indian Inst of Tech Madras, Chennai 

222 CTIP2 Inhibits HIV-1 Vpr-induced Cell Cycle Arrest by 

Repressing p21WAF1 Gene Expression 

Stella Suzanne* 1 , T Cherrier1 , C Marban1 , B Samah2 , R Mukerjee3 , 

C Schwartz1 , S Zeichner4 , D Aunis1 , C Van Lint5 , and O Rohr1 1 2 INSERM U575, Univ Strasbourg 1, France; CEA, Fontenay aux Roses, 

France; 3Ctr for Neurovirology and Cancer Bio, Coll of Sci and Tech, 

Temple Univ, Philadelphia, PA, US; 4NCI, NIH, Bethesda, MD, US; and 

5Inst for Molecular Bio and Med, Univ of Bruxelles, Gosselies, Belgium 

223 Functional Properties of Naturally Occurring Truncated 

Forms of HIV-1 Vif 

Mohammad Khan* 1 , R Goila-Gaur1 , N Choudry2 , E Miyagi1 , S Kao1 , 

and K Strebel1 1 2 NIAID, NIH, Bethesda, MD, US and Univ of Maryland, US 

224 HIV-1 Vif Causes G2 Cell Cycle Arrest via the p53 Pathway 

Taisuke Izumi*, A Takaori-Kondo, K Shirakawa, K Io, M Matsui, and 

T Uchiyama 


225 Genetic Patterns Associated with Functional Adaptation of 

Nef to Down-regulate MHC-I and Evade CTL 

Martha Lewis*, P Lee, A Rusmevichientong, L Hultin, and O Yang 


226 HIV-1-mediated Cell Cycle Arrest and Apoptosis in Human 

CD4 + T Cells Is Independent of HIV-1 Env and Vpr 

Alicja Dabrowska*, N Kim, and A Aldovini 

Children’s Hosp Boston, MA, US 

227 Importance of SIVmac239 Vpr Induced Cell Cycle Arrest for 


Sandra Mueller* 1,2 , B Scholz3 , S Weiler4 , N Stolte-Leeb5 , 

C Stahl-Hennig5 , B Fleckenstein3 , S Lang6 , and German Competence 

Network on HIV/AIDS 

1 2 Univ Hosp Erlangen, Germany; German Competence Network on 

HIV/AIDS; 3Inst of Clinical and Molecular Virology, Univ Hosp 

Erlangen, Germany; 4Univ of Erlangen, Germany; 5German Primate Ctr, 

Goettingen; and 6Yale Univ Sch of Med, New Haven, CT,US 

228 Vpr-mediated Inhibition of IL-12 and Disruption of 

Upstream Signaling Receptors CD14, TLR4, and the 

Glucocorticoid Receptor 

Fiona Frappier* 1,2 , J Boucher1,2 , A O’Connor1,2 , and J Angel1,2 1 2 Univ of Ottawa, Canada and Ottawa Hlth Res Inst, Canada 


Poster Listings

Poster Litings 


b Tuesday, 1-4 pm; Hall D 


(see Session 40 on Wednesday for corresponding Poster Discussion) 

New Insights into APOBEC Proteins 

229 Deamination in 3D: Intra- and Intersegmental Transfer of 

APOBEC3G Cytidine Deaminase 

Roni Nowarski*, M Kotler, and E Britan 

Hebrew Univ, Hadassah Med Sch, Jerusalem, Israel 

230 APOBEC3G’s Cytoplasmic Localization Is Actively 

Regulated but Not Required for HIV-1 Restriction 

Mark Stenglein* and R Harris 


231 Enzymatically Active APOBEC3G Is Required for Efficient 

Inhibition of HIV-1 

E Miyagi, S Opi, H Takeuchi, M Khan, R Goila-Gaur, S Kao, and 

Klaus Strebel* 


232 Distinct Packaging Mechanisms of Human Cytidine 

Deaminase APOBEC3 Proteins into HIV-1 Virions 

Lindi Tan*, T Wang, and X Yu 


233 Effect of Impaired Processivity of HIV-1 Reverse 

Transcriptase on the G-to-A Mutation Rate Induced by 

APOBEC-3G/-3F 

Stefanie Knoepfel*, P Rauch, N Salisch, K Allers, P Huelsmann, and 

K Metzner 

Univ of Erlangen-Nuremberg, Germany 

234 Protein Kinase A-mediated Phophorylation of APOBEC3G 

Antagonizes Its Degradation by Vif 

Kotaro Shirakawa*, A Takaori-Kondo, T Izumi, K Io, M Matsui, and 

T Uchiyama 




Viral Replication Cycle: Molecular Studies 

235 Dimerization of HIV-1 Spliced RNA in vitro 

Lucile Sinck* 1 , D Richer1 , J Howard2 , M Alexander2 , D Purcell2 , 

R Marquet1 , and JC Paillart1 1 2 Inst of Molecular and Cellular Bio, CNRS, Strasbourg, France and Univ 

of Melbourne, Parkville, Australia 

236 Equine Infectious Anemia Virus Entry Occurs through 

Clathrin-mediated Endocytosis 

Melinda Brindley* and W Maury 

Univ of Iowa, Iowa City, US 

237 Changes to the HIV Long Terminal Repeat and to HIV 

Integrase Differentially Affect HIV Integrase Assembly, 

Activity, and the Binding of Strand Transfer Inhibitors 

Ira Dicker* 1 , H Samanta1 , Z Li1 , Y Hong2 , Y Tian2 , J Banville1 , 

R Remillard1 , M Walker1 , D Langley1 , and M Krystal1 1 2 Bristol-Myers Squibb, Wallingford, CT, US and Bristol-Myers Squibb, 

Princeton, NJ, US 

238 Examination of HIV Integration Sites in Quiescent CD4 

T Cells: Implications for Viral Mechanisms of Infection and 

Gene Therapy 

Dimitrios Vatakis*, S Kim, G Bristol, S Chow, and J Zack 


239 TRBP Directs HIV-1 mRNA to Polysomes for Efficient 

Translation 

S Campbell1 , F Fangsi Ke1 , J Waters1 , H Christensen1 , J Howard1 , 

M Alexander1 , A Gatignol2 , and Damian Purcell* 1 

1 2 Univ of Melbourne, Parkville, Australia and McGill Univ, Lady Davis 

Inst for Med Res, Montreal, Canada 

240 The Effect of Episomal Overexpression of the HIV Wild Type 

NC Protein on the Viral Particle Formation 

Seonhee Kim*, S Jang, and J You 

Catholic Univ of Korea, Sch of Med, Seoul, South Korea 




Viral Envelope: Tropism Co-receptor Studies 

241 Selection of Replication-competent Strains of Simian 

Immunodeficiency Virus Which Are Deficient in Sites for 

Carbohydrate Attachment 

Elizabeth Stansell* and R Desrosiers 

New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US 

242 A Single Residue in the HIV-1 Envelope V3 Domain 

Modulates Exposure of the CD4 Binding Site 

Rebecca Lynch* 1 , R Rong1 , W Honnen2 , J Mulenga3 , S Allen1 , 

J Blackwell1 , A Pinter2 , S Gnanakaran4 , and C Derdeyn1 1 2 Emory Univ, Atlanta, GA, US; Univ of Med and Dentistry of New 

Jersey, New Jersey Med Sch, Newark, US; 3Zambia Blood Transfusion 

Svc, Lusaka; and 4Los Alamos Natl Lab, NM, US 

243 Functional Analysis of Intracellular Targeting Motifs within 

HIV-1 Envelope Cytoplasmic Domain 

Sushma Bhakta*, E Hunter, P Spearman, and N Tsurutani 

Emory Univ, Atlanta, GA, US 

244 Cross-reactive HIV-neutralizing Human Monoclonal 

Antibody Recognizes Novel Conformational Epitope on gp41 

and Lacks Reactivity against Self-antigens 

Mei-Yun Zhang* 1,2 , B Vu1 , M Alam3 , R Ruprecht4 , G Quinnan5 , S Jiang6 , 

D Montefiori7 , C Broder5 , B Haynes3 , and D Dimitrov1 1 2 3 NCI-Frederick, MD, US; SAIC-Frederick MD, US; Human Vaccine 

Inst, Durham, NC, US; 4Dana-Farber Cancer Inst, Boston, MA, US; 

5 6 Uniformed Svcs Univ of the Hlth Sci, Bethesda, MD, US; Lindsley F 

Kimball Res Inst, New York Blood Ctr, NY, US; and 7Duke Univ Med Ctr, 

Durham, NC, US 

245 Genotypic and Phenotypic Analysis of HIV-1 env Gene 

Populations in Subjects with Dual or Mixed Entry 

Phenotypes 

Milloni Patel* 1,2 , G Schnell1,2 , M Pagan1,2 , and R Swantrom1,2 1 2 Univ of North Carolina at Chapel Hill, US and Ctr For AIDS Res, Univ 

of North Carolina at Chapel Hill, US 

246 Characterization of V2 and V3 Envelope Determinants and 

their Correlation with Co-receptor Usage from a Cohort of 

East London Patients Infected with HIV-1 Clade CRF02_AG 

Ronald D’Amico* 1,2 , H Dreja2 , K Aubin3 , C Orkin4 , J Hand4 , C DeSouza4 , 

M Dittmar2 , and A McKnight2 1 2 London Sch of Hygiene and Tropical Med, UK; Barts and the London, 

Queen Mary’s Univ, UK; 3Wohl Virion Ctr, Univ Coll London, UK; and 

4St Bartholomew’s Hosp, London, UK 

247 X4-tropic and Dualtropic Subtype C Biological Clones from 

Syncytia Inducing Isolates 

Elizabeth Johnston White*, B McColgan, S Kassaye, and D Katzenstein 

Stanford Univ, Palo Alto, CA, US 

248 Variation in HIV-1 R5 Macrophage-tropism Correlates 

with Sensitivity to Reagents that Block Envelope: CD4 

Interactions 

P Peters1 , M Duenas-DeCamp1 , M Sullivan1 , R Brown2 , 

C Ankghuambom2 , K Luzuriaga1 , J Robinson3 , D Burton4 , J Ball2 , and 

Paul Clapham* 1 

1 2 Univ of Massachusetts Med Sch, Worcester, US; Univ of Nottingham, 

UK; 3Tulane Univ Med Ctr, New Orleans, LA, US; and 4Scripps Res Inst, 

La Jolla, CA, US 

249 HIV-1 Viruses with Different Co-receptor Tropisms Are Not 

Highly Compartmentalized in the Peripheral Blood 

William Ince*, P Harrington, K Dang, G Schnell, J Eron, C Burch, and 

R Swanstrom 


250 Low CCR5 Expression Levels on Primary CD4 + 

Lymphocytes Are a Major Obstacle to CCR5-mediated 

Infection by R5X4 Viruses 

Lamorris Loftin*, L Wang, Y Yi, J Isaacman-Beck, M Kienzle, and 

R Collman 


251 The gp41 Transmembrane Subunit of HIV-1 Envelope 

Influences CD4 Receptor-dependent Virus Entry 

Jonathan Toma*, S Fransen, T Wrin, J Whitcomb, N Parkin, 

C Petropoulos, and W Huang 

Monogram Biosci, South San Francisco, CA, US 

252 Susceptibility of Human Prostate to HIV-1 Infection 

Anna le Tortorec1 , AP Satie1 , H Denis1 , L Havard2 , N Rioux-Leclercq2 , 

A Ruffault2 , B Jegou1 , and Nathalie Dejucq-Rainsford* 1 

1 2 INSERM U625, Rennes, France and Ctr Hosp Univ Regional 

Pontchaillou, Rennes, France




Viral Fitness, Evolution and Recombination 

253 Molecular Characterization of SIV in Wild Gorillas 

gor 

Jun Takehisa* 1 , M Kraus1 , Y Li1 , R Rudicell1 , B Keele1 , J Decker1 , 

E Bailes2 , P Sharp3 , M Peeters4 , and B Hahn1 1 2 3 Univ of Alabama at Birmingham, US; Univ of Nottingham, UK; Univ of 

Edinburgh, Scotland; and 4Univ of Montpellier, France 

254 Generation of in vivo Intersubtype BG Recombinants 

of HIV-1 and Analysis of Intersubtype Breakpoints: 

Comparison to BG Recombinants Generated in vivo 

Mercedes Munoz-Nieto* 1 , L Perez-Alvarez1 , M Pinilla1 , Y Vega1 , 

E Delgado1 , V Garcia1 , M Sierra1 , M Thomson1 , C Miralles2 , and 

R Najera1 1 2 Inst Salud Carlos III, Madrid, Spain and Hosp Xeral-Cies, Vigo, 

Pontevedra, Spain 

255 Immune-driven HIV-1 Recombination and Loss of Control 

following Superinfection 

Hendrik Streeck* 1 , B Li1 , A Poon2 , A Schneidewind1 , A Gladden1 , 

K Power1 , B Walker1 , M Altfeld1 , S Frost2 , and T Allen1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, 

Boston, US and 2Univ of California, San Diego, US 

256 Identifying the Important HIV-1 Recombination Breakpoints 

John Archer* 1 , J Pinney1 , J Fan1 , E Simon-Loriere2 , E Arts3 , 

M Negroni2 , and D Robertson1 1 2 3 Univ of Manchester, UK; Pasteur Inst, Paris, France; and Case 

Western Reserve Univ, Cleveland, OH, US 

257 Molecular Characterization of Recombinant CCR5- and 

CXCR4-utilizing HIV-1 Subtype C gp120 

Katherine Michler*, W Stevens, M Papathanasopoulos, and 

A Capovilla 

Univ of the Witwatersrand Med Sch, Johannesburg, South Africa 

258 A New Algorithm to Detect HIV-1 Intra-patient Recombinant 

Sequences and Investigate the Role of Recombination in the 

Emergence of CXCR4-using Viral Variants 

M Salemi1 , R Gray1 , J Sleasman2 , S Koch1 , and Maureen Goodenow* 1 

1 2 Univ of Florida, Gainsville, US and Univ of South Florida, St 

Petersburg, US 

259 Meta-evolutionary Analysis of Selection on HIV and Other 

Viruses: Functional and Subtype Correlates 

Sergei Kosakovsky Pond* 1 , C Woelk1 , A Poon1 , S Pillai2,3 , D Richman1,4 , 

and S Frost1 1 2 Univ of California, San Diego, US; Univ of California, San Francisco, 

US; 3VAMC, San Francisco, CA, US; and 4VA San Diego Hlthcare 

System, La Jolla, CA, US 

260 Analysis of HIV-1 CA Residues under Positive Selective 

Pressure 

Angela Ciuffi*, K Zhang, M Munoz, R Martinez, and A Telenti 

Inst of Microbio, Univ Hosp Ctr and Univ of Lausanne, Switzerland 

261 Models of Neutralization and Sequence Variation in HIV-1 

Selene Zarate* 1 , D Richman2,3 , J Overbaugh4,5 , and S Frost2 1 2 Univ Autonoma de la Ciudad de Mexico, Mexico City; Univ of 

California, San Diego, US; 3VA Hlthcare System, San Diego, CA, 

US; 4Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; and 5Univ of 

Washington, Seattle, US 

262 Construction of Replication-competent Chimeric HIV-1 

Reporter Viruses to Study Fitness Costs of Mutations in Non- 

Clade B Contexts 

Markus Bickel*, M Lewis, A Ali, and O Yang 


263 Differential Evolution of HIV-1 Reverse Transcriptase in 

Treatment-naïve Female Genital Tract and Plasma 

Uma Shanmugasundaram*, N Kumarasamy, K Murugavel, S Solomon, 

and P Balakrishnan 

YRGCARE, Voluntary Hlth Svcs, Chennai, India 

b Wednesday, 1-4 pm; Hall D 


HIV-1 Macrophage Studies 

264 Visualization of HIV-1 Gag Trafficking to the Virological 

Synapse in Living Infected Macrophages 

K Gousset1 , S Ablan1 , L Coren2 , D Ott2 , and Eric Freed* 1 

1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US and SAIC- 

Frederick and NCI-Frederick, MD, US 

265 Galectin-1 Increases Transfer of HIV-1 from Macrophages to 

CD4 + T Cells 

Simon Mercier*, C St-Pierre, M Ouellet, M Tremblay, and S Sato 

Laval Univ, Canada 

266 Links between Cellular Factors Expressed during Monocyte 

Differentiation and Productive HIV-1 Replication 

Irena Kadiu* 1 , T Wang1 , M Ricardo-Dukelow2 , J Schlautman1 , 

P Ciborowski1 , and H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US and Univ of Hawaii at Manoa, 

Honolulu, US 

267 HIV-1 Replication Is Enhanced by Macrophage Migration 

Inhibitory Factor 

Eduardo Regis* 1 , V Barreto-de-Souza1 , L Leng2 , R Bucala2 , M Bozza3 , 

and D Bou-Habib1 1 2 Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil; Yale Univ Sch of 

Med, New Haven, CT, US; and 3Federal Univ of Rio de Janeiro, Brazil 

268 Entry Co-receptor Use and Fusion Inhibitor T20 Sensitivity 

of Dual-tropic R5X4 HIV-1 in Primary Macrophage 

Infection 

Yanjie Yi*, L Loftin, L Wang, S Ratcliffe, J Issacman-Beck, and 

R Collman 

Univ of Pennsylvania Sch of Med, Philadelphia, US 



Co-infection: Virus/Virus Interactions 

269 HIV Post-entry Inhibition by Non-structural GBV-C Proteins 

Susan Jung*, R Muller, N Donhauser, B Fleckenstein, and H Reil 

Univ Hosp, Erlangen, Germany 

270 E2, a Novel and Potent HIV Entry Inhibitor Derived from the 

Non-pathogenic GBV-C—Characterization of the Detailed 

Mechanism 

Kristin Hanel*, S Jung, B Fleckenstein, and H Reil 

Univ Hosp Erlangen, Germany 

271 Establishment of a Cord Blood Lymphocytes-based Cell 

Culture System to Study GBV-C and HIV in vitro 

Susan Jung*, S Weber, B Fleckenstein, and H Reil 

Univ Hosp Erlangen, Germany 

272 Interference between HSV-2 and HIV-1 in Co-infected 

Human Lymphoid Tissue ex vivo 

Christophe Vanpouille*, A Lisco, JC Grivel, A Biancotto, 

B Brichacek, and L Margolis 


273 GBV-C Infection Is Associated with Less T Cell Activation 

in Recently HIV-1-infected Subjects and Is Independent of 

HIV-1 Viral Load 

Maria Teresa Maidana Giret* 1 , T Silva1 , E Levi2 , H Tomiyama1 , 

K Bassichetto3 , A Nishiya4 , E Sabino4 , R Palacios1 , and E Kallas1 1 2 Federal Univ of Sao Paulo, Brazil; Inst of Tropical Diseases of Sao 

Paulo, Brazil; 3Publ Hlth Dept of Sao Paulo, Brazil; and 4Blood Ctr of 

Sao Paulo, Brazil 



Viral Reservoirs 

274 Phylodynamic Analysis of SIV Populations in Lymphoid 

Tissues Reveals the Central Role of the Gut-associated 

Lymphoid Tissue as a Reservoir during Suppressive ART 

Thomas Ndolo* 1 , M Syvanen1 , J Pan1 , D Verhoeven1 , C Bedford2 , 

R Donovan2 , and S Dandekar1 1 2 Univ of California, Davis, US and California Dept of Hlth Svcs, 

Richmond, US 

275 HIV-1 Transmission from Infected Dendritic Cells and 

Infection of Primary CD4 + T Lymphocytes in the Presence of 

Entry Inhibitors Targeting Co-receptors or gp41 

Jose Este* 1,2 , I Clotet1 , B Bosch1 , M Fernandez-Figueras2 , R Pena1 , 

M Bofill1 , and B Clotet1,2 1 2 Fndn irsiCaixa, Spain and Hosp Germans Trials i Pujol, Badalona, Spain 

276 Different Activation Stimuli Induce Differential 

Sequestration of HIV-1 in Human Dendritic Cells 

Morgan Reuter*, H Yu, and D McDonald 


277 A Novel Model for the Establishment of HIV Latency 

in Primary CD4 + Cells Demonstrates Epigenetic 

Transcriptional Shutdown Due to Chromatin Restrictions 

Mudit Tyagi* and J Karn 

Case Western Reserve Univ Sch of Med, Cleveland, OH, US 

278 CCL2 Enhances Permissiveness of Resting CD4 + T Cells to 

Infection with X4-tropic HIV-1 

Grant Campbell* and S Spector 


279 HIV-1 Tat Association with Cellular Promoters in Human 

Immature Dendritic Cells 

Nayoung Kim*, S Kukkonen, and A Aldovini 

Children’s Hosp Boston, MA, US 


Poster Listings


Session 55 

280a Latent/Persistent HIV-1 Infection Is Most Likely to Develop 

in Minimally Activated Bystander CD4 T Cells 

Paula Soto*, V Terry, and C Spina 

Univ of California, San Diego and VA San Diego Hlthcare System, US 

280b HIV-1 Replicates Locally in Sub-compartments of Female 

Genital Tract 

MariaPia De Pasquale* 1 , L Sutton2 , J Ingersoll3 , A Caliendo3 , 

J Kurpewski1 , S Chapman1 , S Cu-Uvin1 , and R D’Aquila2 1 2 Brown Univ, Providence, RI, US; Vanderbilt Univ, Nashville, TN, US; 

and 3Emory Univ, Atlanta, GA, US 



Viral Transmission: Molecular Studies 

281 Visualization of HIV Interaction with Adult Human Foreskin 

Explants 

Minh Dinh* 1 , S McCoombe2 , M McRaven2 , N Byers2 , and T Hope2 1Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US and 

2Northwestern Univ, Chicago, IL, US 

282 The DCIR Lectin, a New Receptor Involved in the 

Transmission of HIV-1 from Dendritic Cells to CD4 + T Cells 

Alexandra Lambert*, C Gilbert, and M Tremblay 

Ctr Hosp of Laval Univ, Canada 

283 The Evolutionary History of the CD209 (DC-SIGN) Family in 

Human and Non-human Primates 

Millan Ortiz*, K Zhang, and A Telenti 

Inst of Microbio, Univ of Lausanne, Switzerland 

284 Single Variant Transmission Predominates in HIV-1 Subtype 

C Infection, with Multiple Variant Transmission Associated 

with Increased Genital Inflammatory Cytokines 

Carolyn Williamson* 1 , M Abrahams1 , F Treurnicht1 , C Seioghe1 , 

JA Passmore1 , N Wood1 , K Mlisana2 , B Hahn3 , S Abdool Karim2 , and the 

CAPRISA002 Study and the Ctr for HIV/AIDS Vaccine Immunology 

Consortium 

1 2 Univ of Cape Town, South Africa; Univ of KwaZulu Natal, Durban, 

South Africa; and 3Univ of Alabama at Birmingham, US 

285 Transmission of Simian Immunodeficiency Virus by 

Plasma Collected Prior to Detectable Viremia, and Relative 

Infectivity of Ramp-up versus Chronic Stage Plasma 

ZM Ma1 , M Piatak2 , L Fritts1 , D Lu1 , J Lifson2 , M Busch3 , and 

Christopher Miller* 1 

1California Natl Primate Res Ctr and Ctr for Comparative Med, Univ of 

California, Davis, US; 2SAIC-Frederick and NCI-Frederick, MD, US; and 

3Blood Systems Res Inst and Univ of California, San Francisco, US 

286 Mucosally Transmissible R5 SHIV-2873Nip Encoding 

env from a Child with Rapid Progression of HIV Clade C 

Infection: A Tool for Vaccine Development 

Siddappa Nagadenahalli* 1,2 , R Song1,2 , A Chenine1,2 , R Grisson1,2 , 

V Karmor1 , C Wood3 , G Bhat4 , R Amara5 , F Novembre5 , and R Ruprecht1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US; Harvard Med Sch, Boston, 

MA, US; 3Nebraska Ctr for Virology and Sch of Biological Sci, Univ 

of Nebraska, Lincoln, US; 4Univ Teaching Hosp, Lusaka, Zambia; and 

5Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US 

287 Uptake and Intracellular Behavior of HIV-1 in Human 

Hepatoma Cells Leading to Virus Recycling and Transfer to 

T Cells 

Remi Fromentin*, R Lodge, M Tremblay, and D Leclerc 

Infectious Disease Res Ctr, Quebec, Canada 

288 Nuclear Receptor Ligands Inhibit HIV-1 cis- and transinfection 

Timothy Hanley* and G Viglianti 

Boston Univ Sch of Med, MA, US 

289 Characterization of a Novel Mechanism of an Envelope 

Glycoprotein-independent HIV-1 Capture and Transmission 

Mediated by Mature Dendritic Cells 

Nuria Izquierdo-Useros* 1 , I Erkizia-Jauregi1 , J Blanco1 , R Wiley2 , 

E Newton2 , J Archer2 , S Hatch2 , B Clotet1 , J Martinez-Picado1 , and 

R Gummuluru2 1 2 Fndn irsiCaixa, Badalona, Spain and Boston Univ Sch of Med, MA, US 

290 Cell-type and Envelope/Virion Dependence of Galectin-1mediated 

Enhancement of HIV-1 Infection 

Patrick Hong*, J Fulcher, and B Lee 


291 Mechanism of Human Defensins 5- and 6-mediated 

Enhancement of HIV-1 Infectivity 

A Rapista1 , W Lu2 , and Theresa Chang* 1 

1 2 Mt Sinai Sch of Med, New York, NY, US and Univ of Maryland Biotech 

Inst, Baltimore, US 


CROI 2008 

292 Cell-to-cell HIV Transmission Targets CD45RO + CD4 T Cells 

through LFA-1-dependent and -independent Mechanisms 

Isabel Puigdomenech*, M Massanella, N Izquierdo-Useros, M Curriu, 

R Ruiz-Hernandez, M Bofill, J Martinez-Picado, M Juan, B Clotet, and 

J Blanco 

Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Spain 

293 Impact of TLR2, 4, 5, 7, and 9 Stimulations on Dendritic Cell 

HIV-1 Infection and Transfer to CD4 + T Cells 

Sandra Thibault*, M Tardif, and M Tremblay 

Infectious Diseases Res Ctr, Quebec, Canada 

294 Phylogenetic Clustering of HIV-1 from Acutely Infected 

Individuals Does Not Reflect a Higher per-Act Transmission 

Probability 

Erik Volz* and S Frost 

Univ of California, San Diego AIDS Vaccine Res Ctr, US 



Factors Impacting Disease Progression 

295 Identification of an IL-7RA Risk Allele for Rapid Progression 

to AIDS: Results of a Genomic IL-7/IL-7RA Study in the 

GRIV Cohort 

Sophie Limou* 1,2,3 , C Coulonges1 , H Do2 , A Vasilescu2 , T Labib1,3 , I Gut2 , 

JD Lelievre3 , Y Levy3 , and JF Zagury1,3 1 2 Conservatoire Natl des Arts et Metiers, Paris, France; CEA, Evry, 

France; and 3Hosp Henri Mondor, INSERM U84, Creteil, France 

296 CCL3L1 Variable Gene Copy Number Influence on the 

Susceptibility to HIV-1/AIDS among Estonian Intravenous 

Drug Users 

Maarja Sadam*, K Huik, R Avi, T Karki, K Ruutel, and I Lutsar 

Inst of Microbio, Univ of Tartu, Estonia 

297 Interferon-γ Genotype (874T>A) Is Associated with CCR5 

Expression in HIV + Patients 

N Liptrott, B Chandler, S Khoo, D Back, and Andrew Owen* 

Univ of Liverpool, UK 

298 Use of a Dually Inducible Cell Line Reveals Distinct Patterns 

of CD4 and CCR5 Usage among Laboratory and Primary 

HIV-1 and SIV Strains 

Samantha Johnston* 1 , M Lobritz2 , S Nguyen1 , C Garibay1 , B Ank1 , 

Y Bryson1 , E Arts2 , T Chou1 , and B Lee1 1 2 Univ of California, Los Angeles, US and Case Western Reserve Univ, 

Cleveland, OH, US 

299 Lack of Effect of Short Viremic Episodes in LPS Plasma 

Levels in Chronically HIV-1-infected Subjects 

Emmanouil Papasavvas* 1 , M Pistilli1 , A Hancock1 , G Reynolds1 , 

A Mackiewicz1 , C Gallo2 , J Kostman2,3 , K Mounzer2 , J Shull2 , and 

L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Philadelphia Field Initiating Group 

for HIV Trials, PA, US; and 3Univ of Pennsylvania, Philadelphia, US 

300 Reduction in the Absolute Number of Myeloid Dendritic 

Cells and Plasmacytoid Dendritic Cells in HIV Infection 

Correlates with Disease Progression 

Meera Singh*, M Thakar, S Suregaonkar, M Ghate, and R Paranjape 

Natl AIDS Res Inst, Pune, India 

301 Role of TLR in HIV-1 Pathogenesis 

Beda Brichacek*, A Biancotto, Y Kiselyeva, C Vanpouille, A Lisco, 

J Grivel, and L Margolis 


302 Alternative pre-mRNA Splicing and Expression of ILT4 in 

HIV-1 Chronic Infection 

Danlei Mou*, M Lichterfeld, K Williams, D Kavanagh, H Duong, 

B Walker, and X Yu 

Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US 

304 Micro-RNA of Host and HIV Origin Play a Major Role in the 

Pathogenesis of HIV Infection and Its Control 

Zvi Bentwich* 1,2 , E Meiri2 , A Levy2 , O Carmi1 , and Y Shemer1 1 2 Ben Gurion Univ Faculty of Hlth Sci, Beer Sheba, Israel and Rosetta 

Genomics Inc, Rehovot, Israel 

305 Chemokine Receptor Gene (CCR5 and CCR2) Haplotypes as 

Risk Factors for HIV-1 Acquisition and Pathogenesis 

Rakhi Malhotra* 1 , W Song1 , I Brill1 , D Chanda2 , J Mulenga2 , S Allen2,3 , 

E Hunter3 , J Tang1 , and R Kaslow1 1 2 Univ of Alabama at Birmingham, US; Rwanda-Zambia HIV-1 Res 

Group, Lusaka; and 3Emory Univ, Atlanta, GA, US 

306 Viroverse: A Research Database and Bioinformatics Analysis 

Framework 

Brandon Maust* 1 , W Deng1 , J Stoddard1 , Z Frazier2 , M Guerquin1 , 

G Learn1 , R Samudrala1 , R Bumgarner1 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Univ of Southern California, Los 

Angeles, US


307a HIV-specific B Cells Are Enriched in a Dysfunctional Memory 

B Cell Compartment in HIV-infected Viremic Individuals 

Susan Moir*, J Ho, A Malaspina, W Wang, A DiPoto, M O’Shea, 

G Roby, J Arthos, TW Chun, and A Fauci 

NIAID, NIH, Bethesda, MD, US 

307b KIR/HLA Genotypes that Inhibit NK Cell Activation Are 

Associated with Protection against HIV-1 Disease Progression 

Wim Jennes* 1 , S Verheyden2 , C Demanet2 , O Tossou3 , B Vuylsteke1 , and 

L Kestens1 1 2 Inst of Tropical Med, Antwerp, Belgium; Univ Hosp Brussels, Belgium; 

and 3Project RETRO-CI, Abidjan, Côte d`Ivoire 

307c Severe Primary Sexually Transmitted HIV Infection Due to 

Dual-tropic HIV-1 

J Dalmau1 , M Puertas1 , M Azuara2 , A Marino3 , N Izquierdo-Useros1 , 

M Buzon1 , R Paredes1 , C Rodrigo2 , Bonaventura Clotet* 1,2 , and 

J Martinez-Picado1,4 1 2 Fndn irsiCaixa, Badalona, Spain; Hosp Univ Germans Trias i Pujol, 

Badalona, Spain; 3Hosp Arquitecto Marcide, El Ferrol, Spain; and 

4ICREA, Barcelona, Spain 



Factors Impacting Viral Replication in vivo 

308 Increased Levels of APOBEC3G mRNA in Highly Exposed 

Persistently Seronegative Individuals and Individuals with 

Long Term Low Viral Loads 

Joel Vazquez-Perez*, R Hernandez, C Ormsby, and G Reyes-Teran 

Natl Inst of Respiratory Diseases, Mexico City, Mexico 

309 Levels of APOBEC3G and APOBEC3F mRNA Increase Post 

HIV-1 Infection Associated with Low Viral Set-point 

Nzovu Ulenga* 1 , A Dieng Sarr1 , S Thakore-Meloni1 , JL Sankale1 , 

G Eisen1 , A Gueye-NDiaye2 , S MBoup2 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US and Cheikh Anta Diop Univ, 

Dakar, Senegal 

310 Viral Replication is Sustained by Short-lived Infected Cells in 

SIVagm-infected African Green Monkeys 

Ivona Pandrea* 1 , R Ribeiro2 , R Gautam1 , T Gaufin1 , C Monjure1 , 

M Pattison1 , G Silvestri3 , M Miller4 , A Perelson2 , and C Apetrei1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl 

Lab, NM, US; 3Univ of Pennsylvania, Philadelphia, US; and 4Gilead Sci, 

Foster City, CA, US 

311 Evolution in HIV-1 gag and env Is Differentially Associated 

with Viral Load and the Immune Response at Different 

Times in Infection 

Anne Piantadosi* 1,2 , B Chohan1,2 , D Panteleeff1 , Z Jalalian-Lechak1 , 

J Baeten2 , and J Overbaugh1 1 2 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US and Univ of 


312 Genome-wide HLA-associated Selection in HIV-1 and 

Protein-specific Correlations with Viral Load: An ACTG 

5142 Study 

M John1 , D Heckerman2 , L Park1 , S Gaudieri1 , A Chopra1 , J Carlson2 , 

I James1 , D Nolan1 , R Haubrich3 , Simon Mallal* 1 , and ACTG 5142 Study 

Team 

1Ctr for Clinical Immunology and Biomed Statistics, Murdoch Univ, Royal 

Perth Hosp, Australia; 2Microsoft Res, Redmond WA, US; and 3Antiviral Res Ctr, San Diego, CA, US 

313 Contribution of NK Cells to the Control of Primary SIV 

Infection in Rhesus Monkeys 

Elisa Choi*, N Letvin, K Reimann, and Ctr for HIV/AIDS Vaccine 

Immunology (CHAVI) 

Beth Israel Deaconess Med Ctr, Boston, MA, US 

314 Higher Frequencies of γ δ T Cells Are Associated with 

Undetectable Plasma Viral Loads in HIV-2 Infections 

N Zheng1,2 , J McElrath1,2 , S Sow3 , A Mesher1 , S Hawes1 , J Stern1 , 

Geoffrey Gottlieb* 1 , S De Rosa1,2 , and N Kiviat1 1 2 Univ of Washington, Seattle, US; Fred Hutchinson Cancer Res Ctr, 

Seattle, WA, US; and 3Univ of Dakar, Senegal 

315 HIV-1-induced Activation of CD4 + T Cells Creates New Targets 

for HIV-1 Infection in Human Lymphoid Tissue ex vivo 

Angelique Biancotto* 1 , JC Grivel1 , I Hirsch2 , C Vanpouille1 , A Lisco1 , 

and L Margolis1 1Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US and 

2INSERM UMR 599, Marseille, France 

316 Alloantigen Exposure Alters the Susceptibility to Cellassociated 

Mucosal FIV Challenge 

Surender Kumar*, S Leavell, B Assogba, and M Burkhard 

Ohio State Univ, Columbus, US 

317 WFDC1/ps20 Is a Novel Innate Immunomodulatory Signature 

Protein of HIV permissive CD4 + CD45RO + Memory T Cells 

that Promotes Infection by Up-regulating CD54 Integrin 

Expression and Is Elevated in HIV-1 Infection 

Raymond Alvarez*, J Reading, P Easterbrook, and A Vyakarnam 

King’s Coll London, UK 

318 Foreskin Langerhans’ Cell Density of HIV Infected and 

Uninfected Men in Rakai, Uganda 

Kristine Johnson* 1 , J Taube 1 , R Sharma 1 , A Rabkin 2 , D Serwadda 3 , 

G Kigozi 3 , S Watya 3 , M Wawer 3,4 , R Gray 3,4 , and T Quinn 1,5 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2 Stanford Univ, 

Palo Alto, CA, US; 3 Rakai Hlth Sci Prgm, Kalisizo, Uganda; 4 Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; and 

5 NIAID, NIH, Bethesda, MD, US 



Studies on Viral Evolution in vivo 

319 Nonlinear Accumulation of Genetic Diversity in HIV-1 

Infection 

Mary Kearney* 1 , F Maldarelli 1 , W Shao 1 , E Daar 2 , J Margolick 3 , 

V Boltz 1 , J Mellors 4 , J Coffin 5 , and S Palmer 1 

1 NCI-Frederick, MD, US; 2 Univ of California, Los Angeles AIDS Inst, US; 

3 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 

4 Univ of Pittsburgh, PA, US; and 5 Tufts Univ, Boston, MA, US 

320 Sequence Conservation and Viral Fitness in Circulating 

HIV-1 Sequences 

Morgane Rolland* 1 , L Heath 1 , W Deng 1 , D Heckerman 2 , and J Mullins 1 

1 Univ of Washington Sch of Med, Seattle, US and 2 Machine Learning and 

Applied Statistics Group, Microsoft Res, Redmond, WA, US 

321 Increasing Mutations in HIV-1 DNA from Sputum vs 

Peripheral Blood during Effective ART 

Thor Wagner* 1,2 , N Tobin 3 , J McKernnan 2 , K Mohan 2 , A Melvin 1,2 , 

M Xu 1,2 , G Learn 1 , J Mullins 1 , and L Frenkel 1,2 

1 Univ of Washington, Seattle, US; 2 Children’s Hosp and Regional Med Ctr, 

Seattle, WA, US; and 3 Santa Clara Valley Med Ctr, San Jose, CA, US 

322 High Viral Load and Weak Humoral Immunity, but Not 

Target Cell Availability, Are Factors Driving X4 Virus 

Evolution and Emergence in Rhesus Macaques 

Amy Li*, SH Ho, V Sahi, and C Cheng-Mayer 

Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US 

323 Envelope Modifications over the Course of Infection Confer a 

Greater Ability to Utilize the CCR5 Receptor 

A Fellows1 , A Kamat1 , B Kwambana1 , J Overbaugh2 , and Manish Sagar* 1 

1 2 Brigham and Women’s Hosp, Cambridge, MA, US and Fred Hutchinson 

Cancer Res Ctr, Seattle, WA, US 



CTL Studies and Consequences of Immune Escape 

324 Transmission of HIV-1 CTL Escape Variants Provides HLAmismatched 

Recipients with a Survival Advantage 

Denis Chopera* 1 , Z Woodman1 , M Mlotshwa2 , D Martin1 , C Seoighe1 , 

D Assis de Rosa2 , K Mlisana3 , S Abdool Karim3 , C Gray2 , and 

C Williamson1 1 2 Univ of Cape Town, South Africa; Natl Inst for Communicable Diseases, 

Johannesburg, South Africa; and 3Univ of KwaZulu Natal, Durban, South 

Africa 

325 Long-term Stability of Compensated CD8 Escape Mutations 

following HIV Transmission to HLA-Mismatched Individuals 

Arne Schneidewind*, B Li, A Gladden, R Allgaier, E Rosenberg, 

B Walker, and T Allen 

Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, 

Boston, US 

326 HIV-1 CTL Escape Mutation Contribute to Dendritic 

Cell Dysfunction by Increasing pMHC Class I Binding to 

Inhibitory Myelomonocytic Receptors 

Huang Jinghe*, M Lichterfeld, D Kavanagh, K Williams, T Miura, 

F Pereyra, A Trocha, R Gandhi, B Walker, and X Yu 

Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Univ Ctr for 

AIDS Res, Boston, US 

327 Dense Networks of Correlated Substitutions Accompany 

Adaptations to HLA-restricted CTL Epitopes 

Jonathan Carlson* 1,2 , Z Brumme3 , C Brumme3 , L Swenson4 , S Szeto4 , 

I Tao4 , C Kadie1 , B Walker3,5 , R Harrigan4 , and D Heckerman1 1 2 Microsoft Res, Redmond, WA, US; Univ of Washington, Seattle, US; 

3 4 Partners AIDS Res Ctr, Boston, MA, US; BC Ctr for Excellence in HIV/ 

AIDS, Vancouver, Canada; and 5Howard Hughes Med Inst, Chevy Chase, 

MD, US 

328 CTL Escape Mutations within the HIV-1 Nef HLA- 

B8-restricted CTL Epitope FL8 Correlate with Disease 

Progression in HLA-B8 Patients 

Katja Maurer*, E Harrer, A Goldwich, K Eismann, S Bergmann, 

M Schmitt-Haendle, B Spriewald, S Mueller, and T Harrer 

Univ Erlangen-Nuremberg, Germany 


Poster Listings



329 Antiviral Efficacy of a CTL Immune Response Focused on 

Conserved HIV-1 Segments 

Morgane Rolland* 1 , W Deng1 , C Rousseau1 , H Coovadia2 , K Bishop2 , 

P Goulder3,4 , B Walker2,3 , C Brander3 , and J Mullins1 1 2 Univ of Washington, Seattle, US; Doris Duke Med Res Inst, Univ 

of KwaZulu Natal, Durban, South Africa; 3Partners AIDS Res Ctr, 

Massachusetts Gen Hosp, Harvard Med Sch, Charlestown, US; and 4Univ of Oxford, UK 

330 Discordant Neutralization of HIV by CTL Targeting Core 

and Envelope Proteins 

Huabiao Chen* 1,2 , A Trocha1,2 , F Pereyra1 , T Miura1,2 , M Brockman1,2 , 

B Julg1 , B Baker1 , A Rothchild1 , B Block1 , and B Walker1,2 1 2 Massachusetts Gen Hosp, Harvard Med Sch, Boston, US and Howard 

Hughes Med Inst, Chevy Chase, MD, US 

331 Antigenic Escape of SIVmac239 in a SIVmac239-Infected Rhesus 

Macaque in vivo with an Unusually High-titer Neutralizing 

Antibody Response 

Shuji Sato*, E Yuste, H Sanford, A Lauer, E Chang, R Desrosiers, and 

W Johnson 

New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US 

332 Viral Escape from a Novel HLA-C0102-restricted 

Immunodominant Gag CTL Epitope in HIV-1 Subtype 

CRF01_AE-infected Thai Patients 

Supranee Buranapraditkun* 1 , P Chatkulkawin1 , R Allgaier2 , 

SI Lorenzen1 , P Thantiworasit1 , P Pitakpolrat1 , S Sirivichayakul1 , 

B Walker2 , T Allen2 , and K Ruxrungtham1 1 2 Chulalongkorn Univ, Bangkok, Thailand and Partners AIDS Res Ctr, 


333 HIV-1 Escape Driven by HLA-B*13 CD8 T Cell Responses 

Targeting p15 Gag Is Associated with Fitness Cost and 

Modification of the Gag-Pol Frameshift Stem-loop 

Julia Prado*, I Honeyborne, and P Goulder 


334 HLA-B Alleles Selecting Multiple Escape Mutations in Gag 

Are Associated with Reduced Viremia 

Philippa Matthews* 1 , A Prendergast1 , A Leslie1 , R Payne1 , 

H Crawford1 , C Rousseau2 , T Ndung’u3 , B Walker3,4 , D Heckerman5 , and 

P Goulder1,3,4 1 2 3 Univ of Oxford, UK; Univ of Washington, Seattle, US; Univ of KwaZulu 

Natal, Durban, South Africa; 4Harvard Univ, Boston, MA, US; and 

5Microsoft Res, Redmond, WA, US 

335 Accumulation of CTL Escape Variants and HLA-driven 

Convergence of Viral Subtypes 

Dario Alberto Dilernia* 1 , L Lourtau2 , L Jones1,3 , G Turk1 , 

M Gomez-Carrillo1 , C Bautista4 , J Benetucci5 , M Losso2 , P Cahn6 , and 

H Salomon1 1 2 Argentinean Reference Ctr for AIDS, Buenos Aires; Hosp Gen de 

Agudos “Jose Maria Ramos Mejia”, Buenos Aires, Argentina; 3Estacion de Fotobiologia Playa Union, Buenos Aires, Argentina; 4Assn Benefica 

PRISMA, Lima, Peru; 5Hosp de Enfermedades Infecciosas “Francisco 

J Muniz”, Buenos Aires, Argentina; and 6Hosp Gen de Agudos “Juan A 

Fernandez”, Buenos Aires, Argentina 



Factors Influencing CD4 Counts 

336 CD4 Loss Rate in Untreated Chronic HIV-1 Infection May 

Be Better Predicted by PD-1 than HIV RNA and CD38 

M Holm, F Pettersen, and Dag Kvale* 

Ulleval Univ Hosp, Univ of Oslo, Norway 

337 Maintenance of Proliferative PD-1 low Memory CD8 + T Cells 

Specific for Eradicated Virus in HIV-1 Patients with High 

CD4 Count 

Ai Kawana-Tachikawa*, M Motose, T Odawara, T Fuji, and A Iwamoto 

Inst of Med Sci, Univ of Tokyo, Japan 

338 Decline in Regulatory T Cells Is Associated with Generalized 

Immune Activation during HIV Disease Progression 

Andrew Prendergast*, P Klenerman, and P Goulder 


339 Differential Expression of Genes Associated with Apoptosis 

Predicts CD4 Decline after Interruption of ART in ACTG 

A5170 

Maryanne Vahey* 1 , Z Wang2 , Z Su3 , A Krambrink3 , D Skiest4 , and 

D Margolis5 1 2 Walter Reed Army Inst of Res, Washington, DC, US; Henry M Jackson 

Fndn, Rockville, MD, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 

4 5 Baystate Med Ctr, Springfield, MA, US; and Univ of North Carolina at 

Chapel Hill, US 

340 Plasma IL-7 Levels Do Not Evolve in Parallel to CD4 + Counts 

at Early Stages of HIV Infection 

Jose Benito*, M Lopez, S Lozano, J Gonzalez-Lahoz, and V Soriano 

Hosp Carlos III, Madrid, Spain 


341 HIV-1 Proviral Hypermutation Associates with Decline in 

CD4 Count in HIV-infected Kenyan Women 

Allison Land* 1 , B Ball1 , M Luo1 , R Pilon2 , P Sandstrom2 , J Embree1 , 

C Wachihi3 , J Kimani3 , and F Plummer1,4 1 2 Univ of Manitoba, Winnipeg, Canada; Publ Hlth Agency of Canada, 

Ottawa; 3Univ of Nairobi, Kenya; and 4Publ Hlth Agency of Canada, 

Winnipeg 

342 Non-invasive in vivo Imaging of CD4 Cells in SHIV-infected 

Rhesus Monkeys 

Michele Di Mascio* 1 , C Paik2 , J Carrasquillo3 , JS Maeng2 , S Srinivasula4 , 

M Catalfamo1 , Y Nishimura1 , K Reimann5 , M Martin1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US; Warren G Magnuson Clinical Ctr, 

NIH, Bethesda, MD, US; 3Memorial Sloan Kettering Cancer Ctr, New 

York, NY, US; 4SAIC-Frederick, MD, US; and 5Beth Israel Deaconess 

Med Ctr, Boston, MA, US 

343 The Frequency and Clinical Implications of a Discordant 

CD4 Count and CD4 Percentage 

M Gompels1 , Caroline Sabin* 2 , A Phillips2 , D Dunn3 , and the UK 

Collaborative HIV Cohort (CHIC) Study 

1 2 North Bristol NHS Trust, UK; Royal Free and Univ Coll Med Sch, 

London, UK; and 3Med Res Council Clinical Trials Unit, London, UK 



HIV Superinfection and Viral Co-infection 

344 Transmission of HIV-1 in Seroconcordant Couples 

Mary Campbell* 1 , G Gottlieb1 , K Wong1 , S Hawes1 , T Lampinen2 , 

N Kiviat1 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Univ of British Columbia, 

Vancouver, Canada 

345 Estimate of the Frequency of HIV-1 Co-infection in vivo 

Igor Rouzine* 1 , E Gubankova1 , M Kearney2 , S Palmer2 , F Maldarelli2 , and 

J Coffin1 1 2 Tufts Univ, Boston, MA, US and HIV Drug Resistance Prgm, NCI- 

Frederick, MD, US 

346 Down Regulation of β-Chemokines Production in Human T 

Cell Leukemia/Lymphoma Virus Type 2 Subtype 2a-infected 

Subjects, Regardless of HIV-1 or HCV Infections 

I Olah1 , A Brito1 , L Fukumori1 , J Smid2 , A Oliveira2 , A Duarte1 , and 

Jorge Casseb* 1,2 

1 2 Sao Paulo Univ, Sch of Med, Brazil and Inst of Infectious Diseases, Sao 

Paulo, Brazil 



Studies on Elite Controllers and Exposed Uninfected 

347 Longitudinal Measurements of Ultra-sensitive Plasma HIV 

RNA and Quantitative Antibody Levels in HIV-1-infected 

Individuals Who Naturally Maintain Viral Loads below the 

Limit of Conventional Detection 

Hiroyu Hatano* 1 , E Delwart1,2 , P Norris1,2 , R Hoh1 , M Busch1,2 , J Martin1 , 

and S Deeks1 1 2 Univ of California, San Francisco, US and Blood Systems Res Inst, San 

Francisco, CA, US 

348 Low-level Virema in HIV-1-infected Patients Classified as 

Elite Controllers Compared to Patients on Suppressive ART 

Sarah Palmer* 1 , A Wiegand1 , T Miura2 , B Block2 , F Pereyra2 , 

F Maldarelli1 , J Mellors3 , B Walker2 , and J Coffin4 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US; Partners AIDS 

Res Ctr, Massachusetts Gen Hosp, Boston, US; 3Univ of Pittsburgh, PA, 

US; and 4Tufts Univ, Boston, MA, US 

349 Ongoing Low-level Viral Replication and Polyfunctional CD8 

T Cell Responses Detected in the HIV Elite Controllers 

Florencia Pereyra* 1 , T Miura1 , S Palmer2 , B Block1 , A Rothchild1 , 

B Baker1 , J Coffin2 , and B Walker1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown and 

Harvard Med Sch, Boston, US and 2NCI-Frederick, MD, US 

350 Viral Dynamics of Elite Suppressors in HIV-1 Infection 

Jason Dinoso* 1 , S Kim1 , J Blankson1 , and R Siliciano1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard 

Hughes Med Inst, Baltimore, MD, US 

351 Is There a Harmless Level of Plasma Viremia in Untreated 

HIV Infection? CD4 + T Cells in the Long-term Follow-up of 

Elite Controllers and Controls 

Hans-Jurgen Stellbrink* 1 , K Schewe1 , C Hoffmann1 , and E Wolf2 1 2 IPM Study Ctr, Hamburg, Germany and MUC Res, Munich, Germany 

352 HIV-1 Proviral Load in Elite Suppressors with Low or 

Declining CD4 Counts 

J Deayton1,2 , Katherine Groves* 1 , D Bibby2 , H Dreja1 , K Aubin1 , 

C DeSouza2 , J Hand2 , D Clark2 , C Orkin2 , and A McKnight1 1 2 Queen Mary Sch of Med and Dentistry, London, UK and Barts and the 

London NHS Trust, UK


353 Relationship between HIV-specific Immune Response, 

T Cell Activation, and CD4 + T Cell Depletion in HIV-infected 

Patients with Undetectable Plasma HIV RNA Levels in the 

Absence of Therapy 

Peter Hunt* 1 , E Sinclair1 , H Hatano1 , J McCune1 , B Emu1 , Q Tan1 , 

P Norris2 , M Busch2 , J Martin1 , and S Deeks1 1 2 Univ of California, San Francisco, US and Blood Systems Res Inst, San 


354 The Role of APOBEC3G/F-mediated Hypermutation in the 

Control of HIV-1 in Elite Suppressors 

Shiv Gandhi* 1 , J Siliciano1 , J Bailey1 , R Siliciano1,2 , and J Blankson1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard 

Hughes Med Inst, Chevy Chase, MD, US 

355 Polyfunctional HIV-specific T Cells in Rectal Mucosa of HIV 

Controllers 

April Ferre* 1 , P Hunt2 , D Young1 , J Garcia1 , H Yee2 , R Pollard1 , S Deeks2 , 

and B Shacklett1 1 2 Univ of California, Davis, US and Univ of California, San Francisco, US 

356 Rare Gag Variants Selected in B*57/5801 HIV-1 Elite 

Controllers Induce de novo CTL Responses and Reduce Viral 

Replication Capacity 

Toshiyuki Miura* 1 , M Brockman1 , A Schneidewind1 , A Raothod1 , 

B Block1 , F Pereyra1 , T Allen1 , M Lobritz2 , E Arts2 , and B Walker1 1 2 Massachusetts Gen Hosp, Boston, US and Case Western Reserve Univ, 

Cleveland, OH, US 

357 The HLA-B*5701 Allele Is Highly Enriched in Brazilian Elite 

Controllers 

Maria Teresa Maidana Giret* 1 , E Bermudez-Aza1 , H Tomiyama1 , 

M Melillo Sauer1 , D Watkins2 , and E Kallas1,3 1 2 3 Federal Univ of Sao Paulo, Brazil; Univ of Wisconsin, US; and Univ of 

Sao Paulo, Brazil 

358 Regain of Viremic Control after Superinfection of an Elite 

Controller of HIV-1 Infection 

Andrea Rachinger* 1 , M Navis1 , P Groeneveld2 , A van’t Wout1 , and 

H Schuitemaker1 1Sanquin Res and Academic Med Ctr, Univ of Amsterdam, The 

Netherlands and 2Isala Clin, Zwolle, The Netherlands 

359 Increased Expression of KIR3DL1 Subtypes and HLA-B57 in 

HIV-exposed Uninfected vs HIV-susceptible Individuals 

Salix Boulet* 1 , M Kleyman1 , J Kim1 , P Kamya1 , S Sharafi1 , 

C Tsoukas1 , J Bruneau2 , JP Routy1 , and N Bernard1 1 2 Res Inst of the McGill Univ Hlth Ctr, Montreal, Canada and Ctr Hosp 

Univ Montreal, Canada 

360 Prevalence and Characterization of HIV-specific Adaptive 

Immune Responses in Genital Mucosal Secretions from a 

Cohort of High Heterosexual Risk, Seronegative Women in 

Chicago 

Richard Novak* 1 , L Baum2 , P Graham1 , H Chen1 , W Yang1 , and B Parekh3 1 2 3 Univ of Illinois at Chicago, US; Rush Univ, Chicago, IL, US; and CDC, 


361a Stronger Memory and Lower Effector T Cell Responses to 

HIV in Patients with Long-term Undetectable HIV Viral 

Loads under Sustained ART Compared to HIV Controllers 

Amelie Guihot* 1 , G Breton1 , R Tubiana1 , B Amellal1 , AG Marcelin1 , 

D Costagliola2 , A Samri1 , C Katlama1 , B Autran1 , G Carcelain1 , and ALT- 

ANRS CO15 Study Group and DECAMUNE Study Group 

1 2 Hosp Pitie-Salpetriere, Paris, France; and INSERM UMR S720, Paris, 

France 

361b HIV-1 Gag-specific T Cells in Semen but Not in Peripheral 

Blood of HIV High-risk Seronegative Men 

Yan Ding*, G Diaz, J Czartoski, J Lee, H Zhu, T Zhu, and J McElrath 

Fred Hutchinson Cancer Res Ctr, Univ of Washington, Seattle, US 



Studies of Non-progressive Infection 

362 Host Genetics of Long-term Non-progressors 

Milena Nasi* 1 , G Rocco1 , A Riva2 , V Borghi3 , C Casoli4 , M Galli2 , 

G Poli5 , F Prati3 , C Mussini3 , A Cossarizza1 , and Italian Concerted Action 

on LTNP “ELVIS”, Inst Superiore di Sanita, Rome, Italy 

1 2 Univ of Modena and Reggio Emilia, Italy; Hosp Luigi Sacco, Univ of 

Milan, Italy; 3Azienda Ospedaliero Univ, Modena, Italy; 4Univ of Parma, 

Italy; and 5San Raffaele Hosp, Milan, Italy 

363 Long-term Non-progression of HIV-1 Infection Due to a gagdeletion 

Mutation 

CYW Tong* 1 , T Dong2 , Y Peng2 , S Frazao Pinheiro2 , K Barlow3 , J Parry3 , 

and S Rowland-Jones2 1 2 Guy’s and St Thomas’ Hosp, London, UK; Med Res Council, Univ of 

Oxford, UK; and 3Ctr for Infections, Hlth Protection Agency, London, UK 

364 Differential Host Gene Expression in HIV + Long-term Nonprogressors 

and Progressors 

Maria Salgado* 1 , P Lopez-Romero2 , S Callejas2 , M Lopez1 , 

P Labarga1 , A Dopazo2 , V Soriano1 , and B Rodes1 1 2 Hosp Carlos III, Madrid, Spain and CNIC, Madrid, Spain 

365 Characterization of Distinct TRIM5-α mRNA 

Polymorphisms in SIV and HIV-1 Long-term Nonprogressors 

Nele Jensen* 1,2 , I Stahmer1,2 , C Stahl-Hennig3 , I Hauber2 , J Hauber2 , and 

J van Lunzen1,2 1 2 Univ Med Ctr, Hamburg-Eppendorf, Germany; Heinrich Pette Inst 

for Experimental Virology and Immunology, Hamburg, Germany; and 

3German Primate Res Ctr, Gottingen 

366 Anticardiolipin Antibodies, Viral Replication, Anti-HIV 

Neutralizing Antibodies and Immune Activation in Nonprogressors 

HIV-infected Patients 

Valerie Martinez* 1 , MC Diemert1 , M Braibant2 , D Costagliola1 , 

JL Charuel1 , F Barin2 , E Caumes1 , JP Clauvel3 , L Musset1 , B Autran1 , and 

the ALT Study Group 

1 2 Hosp Pitie-Salpetriere, Paris, France; Univ Francois-Rabelais, Tours, 

France; and 3Hosp St Louis, Paris, France 

367 Important Deletions and Extremely Low Viral Evolution in a 

Subset of HIV-1 Long-term Non-progressor Patients 

V Sandonis1 , C Casado1 , G Bello1 , S Garcia2 , C Rodriguez2 , J Romero2 , 

and Cecilio Lopez-Galindez* 1 

1 2 Inst Carlos III, Madrid, Spain and IMSALUD, Univ Autonoma de 

Madrid, Spain 

368 Inhibition of HIV-1 Replication by Freshly Isolated CD8 + 

T Cells from HIV Controllers Is Associated with CTL 

Proliferation 

Boris Julg* 1 , H Chen1,2 , F Pereyra1 , T Miura1,2 , A Piechocka-Trocha1,2 , and 

B Walker1,2 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and 

2Howard Hughes Med Inst, Chevy Chase, MD, US 

369 HIV-specific Perforin Up-regulation by Effector Memory 

CD8 T Cells Is Associated with HIV Non-progression 

George Makedonas* 1 , N Hutnick1 , A Hersperger1 , M Ostrowski2 , 

R Kaul2 , K Weinhold3 , and M Betts1 1 2 Univ of Pennsylvania, Philadelphia, US; Univ of Toronto, Canada; and 

3Human Vaccine Inst, Duke Univ, Durham, NC, US 

370 HIV + Long-term Non-progressors in Rakai, Uganda 

Oliver Laeyendecker* 1,2 , A Redd1,2 , T Lutalo3 , R Gray4 , M Wawer4 , 

JB Bwanika3 , F Makumbi3 , J Shott5 , N Kiwanuka3 , T Quinn1,2 , and Rakai 

Hlth Sci Prgm 

1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US; Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US; 3Rakai Hlth Sci Project, 

Uganda; 4Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, 

MD, US; and 5NIAID-Uganda ICER Prgm, Rakai 

371 Characterization of a Subset of Cynomolgus Macaques 

Spontaneously Controlling SIVmac251 Infection 

S Shin1 , I Karlsson2 , P Versmisse1 , B Malleret2 , O Lambotte3 , 

R Le Grand2 , G Pancino1 , B Vaslin2 , and Asier Saez-Cirion* 1 

1 2 Pasteur Inst, Paris, France; CEA, Fontenay-aux-Roses, France; and 

3Hosp Bicetre, Le Kremlin Bicetre, France 



(see Session 11 on Monday for corresponding Poster Discussion) 

Lymphocyte Depletion in the Gut 

372 HIV Pathogenesis: Viral Blitzkrieg or 10 Years’ War? 

Cristian Apetrei* 1 , R Gautam1 , T Gaufin1 , R Ribeiro2 , M Pattison1 , 

M Barnes1 , C Monjure1 , A Perelson2 , G Silvestri3 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl Lab, 

NM, US; and 3Univ of Pennsylvania, Philadelphia, US 

373 Collagen Deposition Limits Immune Reconstitution in the Gut 

J Estes1 , J Brenchley2 , A Khoruts3 , J Barthold3 , C Reilly3 , G Beilman3 , 

D Douek2 , A Haase3 , and Timothy Schacker* 3 

1 2 NCI-Frederick, MD, US; Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, 

US; and 3Univ of Minnesota, Minneapolis, US 

374 Disruption of Intestinal Epithelial Integrity and Increased 

Microbial Translocation and Systemic Dissemination in HIV 

and SIV Infections Are Linked to Impaired IL-17-expressing 

Mucosal T Cell Responses 

Satya Dandekar*, M Rafatellu, M Macal, S Sankaran, D Verhoeven, 

M George, R Santos, and A Baumler 


375a Differential Mucosal Pathogenesis of SIV Infection in 

Progressing and Long-term Nonprogressing Rhesus 

Macaques 

Binhua Ling*, M Mohan, T Ooms, A Lackner, P Marx, and R Veazey 



Poster Listings



375b Disturbed Gut Microbiota in HAART-naïve HIV + 

Adults: Effect of Intervention with a Specific Prebiotic 

Oligosaccharide Mixture 

Kaouther Ben Amor* 1 , G Rizzardini2 , C Torti3 , T Quirino4 , M Moroni2 , 

J Knol1 , D Bray5 , A Vriesema1 , M Clerici6 , and A Gori7 1 2 Numico Res, Wageningen, The Netherlands; Hosp Luigi Sacco, Milan, 

Italy; 3Univ of Brescia, Italy; 4Hosp Busto Arsizio, Italy; 5ImmunoClin, Paris, France; 6Univ of Milan, Italy; and 7Hosp San Gerardo, Univ of 

Milan-Bicocca, Monza, Italy 

376 Functional Analysis of Intestinal Epithelial Cells Isolated by 

Laser Dissection from SIV-infected Rhesus Macaques in vivo 

Michael George*, S Sankaran, I Grishina, and S Dandekar 


377 Microbial Translocation Is a Determinant of Persisting 

T Cell Hyperactivation in HIV-infected Patients Failing to 

Recover CD4 following Long-term HAART 

Giusi Maria Bellistri* 1 , V Pegorer1 , C Tincati1 , L Meroni2 , A Gori3 , 

A d’Arminio Monforte1 , and G Marchetti1 1 2 San Paolo Hosp, Univ of Milan, Italy; Luigi Sacco Hosp, Univ of Milan, 

Italy; and 3San Gerardo Hosp, Monza, Italy 



Monocyte/Macrophage Studies 

378 Up-regulation of PD-L1 on Monocytes and Dendritic Cells by 

HIV-1-derived ssRNA 

Angela Meier* 1 , A Bagchi2 , H Sidhu1 , G Alter1 , T Suscovich1 , 

H Streeck1 , M Brockman1 , S LeGall1 , J Hellman2 , and M Altfeld1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, 

Charlestown, US and 2Massachusetts Gen Hosp, Harvard Med Sch, 

Boston, US 

379 Monocyte Heterogeneity Underlying Phenotypic Changes in 

Monocytes according to SIV Disease Stage 

Woong-Ki Kim* 1 and K Williams2 1 2 Eastern Virginia Med Sch, Norfolk, US and Boston Coll, Chestnut Hill, 

MA, US 

380 HIV-mediated Dysregulation of Zinc Homeostasis Confers 

Resistance to Apoptosis in Circulating Monocytes during 

Viremia 

A Raymond1 , B Gekonge1 , A Hancock1 , J Chehimi1 , E Papasavvas1 , 

K Mounzer2 , and Luis Montaner* 1 

1 2 Wistar Inst, Philadelphia, PA, US and Philadelphia Field Initiating 

Group for HIV Trials, PA, US 

381 HIV Modulates Host Gene Expression in Macrophages after 

IFN-α2 Treatment 

Melissa Sirois* 1 , L Robitaille1 , M Shah1 , C Woelk2 , and J Corbeil1 1 2 Infectious Disease Res Ctr, Laval Univ, Canada and Univ of California, 

San Diego, US 

382 HIV-1 Activates Macrophages Independent of Toll-like 

Receptors, a Potential Mechanism for Dysregulation of 

Innate Immunity 

Joseph Brown* 1 , J Kohler2 , C Coberley1 , J Sleasman3 , and M Goodenow1 1 2 Univ of Florida Coll of Med, Gainesville, US; Emory Univ, Atlanta, GA, 

US; and 3Univ of South Florida Coll of Med and All Children’s Hosp, St 

Petersburg, US 

383 HIV-1 ssRNA Triggers a Vitamin D-dependent Antiviral 

Pathway in Human Monocytes 

P Hong, K Corcoran, R Modlin, B Lee, and Stephan Krutzik* 




Therapy and CNS Infection 

384 Predictors of Clinical Outcome and Viro-immunological 

Response to cART in an Italian Cohort of HIV-infected Naïve 

Patients Affected by Neurological Disorders 

M Giancola1 , P Lorenzini1 , A Cingolani2 , M Bongiovanni3 , S Bossolasco4 , 

B Vigo5 , M Finazzi6 , S Casari7 , P Cinque4 , Andrea Antinori* 1 , and Italian 

Registry Investigative Neuro AIDS (IRINA) Study Group 

1Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, Rome, 

Italy; 2Univ Cattolica del Sacro Cuore, Rome, Italy; 3Univ of Milan, Italy; 

4 5 6 San Raffaele Sci Inst, Milan, Italy; Niguarda Hosp, Milan, Italy; Hosp 

Riuniti, Bergamo, Italy; and 7Univ degli Studi, Brescia, Italy 

385 Intracerebral Penetrating ART Are More Efficient on 

Survival of HIV + Patients with Progressive Multifocal 

Leukoencephalopathy (ANRS CO4 - FHDH) 

Jacques Gasnault* 1 , E Lanoy2,3 , M Bentata4 , M Guiguet2,3 , and 

D Costagliola2,3 1 2 Hosp Bicetre, Le Kremlin Bicetre, France; INSERM U720, Paris, 

France; 3Univ Pierre and Marie Curie, Paris, France; and 4Hosp Avicenne, Bobigny, France 


386 Effect of Combined ART on Brain and Lymphoid Tissue 

Virus Burden in An Accelerated Model of SIV Encephalitis in 


Lakshmanan Annamalai* 1 , S Westmoreland1 , D Pauley1 , K Williams2 , 

E Ratai3 , M Lentz3 , R Schinazi4 , N Bischofberger5 , G Gonzalez3 , and 

S O’Neil1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2Boston Univ, MA, US; 3AA Martinos Ctr for Biomed Imaging, 

Massachusetts Gen Hosp, Charlestown, US; 4Emory Univ Sch of Med and 

VAMC, Atlanta, GA, US; and 5Gilead Sci, Foster City, CA, US 

387 Intermediate (12 Months) and Long-term (6 Years) Cognitive 

Response to HAART in 2 Thai Cohorts 

V Valcour1,2,3 , P Sithinamsuwan4 , W Pumpradit5 , J Ananworanich1,3 , 

S Nidhinandana4 , W Apateerapong3 , K Robertson6 , R Paul7 , U Siangphoe3 , 

Cecilia Shikuma* 1,3 , and Southeast Asia Res Collaboration with Hawaii 

(SEARCH) 001 Protocol Team 

1 2 Hawaii AIDS Clinical Res Prgm, Univ of Hawaii, Honolulu, US; Univ of 

California, San Francisco, US; 3South East Asia Res Collaboration with 

Univ of Hawaii, Bangkok, Thailand; 4Phramongkutklao Hosp, Bangkok, 

Thailand; 5HIV Netherlands Australia Thailand Res Collaboration, 

Bangkok; 6Univ of North Carolina at Chapel Hill, US; and 7Univ of 

Missouri, St Louis, US 

388 Baseline Data from ACTG 5199: The International 

Neurological Study 

Kevin Robertson* 1 , J Kumwenda2 , K Supparatpinyo3 , S Evans4 , J Jiang4 , 

T Campbell5 , R Price6 , and ACTG 5199 Study Team 

1 2 Univ of North Carolina at Chapel Hill, US; Queen Elizabeths, Blantyre, 

Malawi; 3Chiang Mai Univ, Thailand; 4Harvard Univ, Boston, MA, US; 

5 6 Univ of Colorado Hlth Sci Ctr, Denver, US; and Univ of California, San 

Francisco, US 

389 Adverse Effect of ddI, ddC, and d4T as a Component of 

HAART on Cognitive Function during HIV Infection 

Ingo Husstedt*, B Hudelmeier, U Oelker-Gruneberg, N Gregor, 

K Kloenne, K Biehl, O Summ, and S Evers 

Univ Hosp Muenster, Germany 

390 CEP-1347 as an Adjunctive Therapy for HIV-associated 

Cognitive Impairment 

Dawn Eggert* 1 , S Gorantla1 , H Dou1 , L Poluektova1 , 

D Bozyczko-Coyne2 , L Aimone2 , S Dewhurst3 , S Maggirwar3 , 

H Gelbard3 , and H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US; Cephalon, Inc, West Chester, 

PA, US; and 3Univ of Rochester Med Ctr, NY, US 



(see Session 26 on Tuesday for corresponding Poster Discussion) 

Clinical Developments in Neuropathogenesis 

391 Changes in Cognition during HAART: Comparison of 2 

Different Scoring Systems to Measure Antiretroviral Drug 

Efficacy on HIV Dementia 

Valerio Tozzi*, P Balestra, M Salvatori, C Vlassi, G Liuzzi, 

S Menichetti, M Zaccarelli, S Cerilli, A Antinori, and P Narciso 

Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy 

392 CSF Neural Marker Profile Distinguishes AIDS Dementia 

Complex from Alzheimer’s Disease 

Magnus Gisslen* 1 , K Blennow1 , B Brew2 , P Cinque3 , L Hagberg1 , 

R Price4 , and H Zetterberg1 1 2 Sahlgrenska Univ Hosp, Gothenburg, Sweden; St Vincent’s Hosp, Univ 

of New South Wales, Sydney, Australia; 3San Raffaele Hosp, Milan, Italy; 

and 4Univ of California, San Francisco, US 

393 HIV Protease Inhibitors and Risk of Peripheral Neuropathy 

Ronald Ellis* 1 , J Marquie-Beck1 , P Delaney1 , T Alexander1 , D Clifford2 , 

J McArthur3 , D Simpson4 , C Ake1 , A Collier5 , B Gelman6 , and the 

CHARTER Group 

1 2 Univ of California, San Diego, US; Washington Univ, St Louis, MO, US; 

3 4 Johns Hopkins Univ, Baltimore, MD, US; Mt Sinai Sch of Med, New 

York, NY, US; 5Univ of Washington, Seattle, US; and 6Univ of Texas Med 

Branch, Galveston, US 

394 ART Resistance Influences CSF HIV RNA Levels and 

Neuropsychological Performance in HIV-infected Individuals 

George Hightower* 1 , S Letendre1 , M Cherner1 , S Gibson1 , R Ellis1,2 , 

C Ignacio1 , R Heaton1 , I Grant1,2 , D Richman1,2 , D Smith1,2 , and San Diego 

HIV Neurobehavioral Res Ctr (HNRC) Group 

1 2 Univ of California, San Diego, US and San Diego VA Hlthcare Systems, 

CA, US 

395 CSF t-τ, p-τ and Amyloid-β 1-42 in HIV Infection 

Bruce Brew* 1 , M Gisslen2 , L Pemberton1 , P Cinque3 , L Hagberg2 , 

R Price4 , K Blennow2 , H Zetterberg2 , and S Spudich4 1 2 3 St Vincent’s Hosp, Sydney Australia; Gothenburg Univ, Sweden; San 

Raffaele Hosp, Milan, Italy; and 4Univ of California, San Francisco, US 

396a Comparative Analysis of HIV-specific CD8 + T Cells in 

Cerebrospinal Fluid and Peripheral Blood among Treatmentnaïve 

HIV-immune Controllers 

Shanmugalakshmi Sadagopal*, S Lorey, L Barnett, R Basham, 

L Lebo, H Erdem, K Haman, M Avison, D Haas, and S Kalams 

Vanderbilt Univ, Nashville, TN, US


396b Abnormal CSF Amyloid β42 Levels Link HIV-associated 

Cognitive Disease and Alzheimer’s Disease 

David Clifford*, J Kauwe, M Teshome, A Shah, M Spinner, J Morris, 

D Holtzman, and A Fagan 

Washington Univ, St Louis, MO, US 



Virologic Parameters in NeuroAIDS 

397 Tissue-specific Adaptive Changes in R5X4 HIV-1 Env 

Variants Compartmentalized in Brain and Lymphoid Tissues 

of Individuals with AIDS 

Lachlan Gray* 1,2 , M Churchill1 , D Cowley1,3 , J Sterjovski1,3 , A Ellett1 , 

N Saksena4 , P Poumbourios1 , S Wesselingh1,2,3 , D Gabuzda5,6 , and P Gorry1,2,3 1 2 Burnet Inst, Melbourne, Australia; Univ of Melbourne, Australia; 

3 4 Monash Univ, Melbourne, Australia; Westmead Millenium Inst, 

Australia; 5Dana-Farber Cancer Inst, Boston, MA, US; and 6Harvard Med Sch, Boston, MA, US 

398 Low CD4 Dependence and High Avidity for CD4 Determine 

Macrophage Tropism, Increased Fusogenicity and Reduced 

Sensitivity to Fusion and Other Entry Inhibitors of HIV-1 

Envelope Glycoproteins from Brain Tissue and Brainderived 

Isolates 

F Rossi, B Querido, D Nimmagadda, S Navas-Martin, and 

Julio Martin-Garcia* 

Drexel Univ Coll of Med, Philadelphia, PA, US 

399 Bioinformatic Predictors of Co-receptor Usage Underestimate 

the Frequency of R5X4 HIV-1 in Brain and Other Tissues 

Megan Mefford* 1,2 , P Gorry3 , K Kunstman4 , S Wolinsky4 , and D Gabuzda1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US; Harvard Med Sch, Boston, 

MA, US; 3Macfarlane Burnet Inst for Med Res and Publ Hlth, Melbourne, 

Australia; and 4Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US 

400 Compartmentalization and Evolutionary Dynamics of HIV-1 

NEF Sequences in the Brain of 5 Individuals 

Tulio de Oliveira* 1 , S Lamers2 , M Salemi3 , and M McGrath4 1South African Natl BioInformatics Inst, Univ of Western Cape; 

2 3 4 BioinfoExperts, FL, US; Univ of Florida Gainsville, US; and Univ of 


401 Validation of a V3-based Genetic Biomarker of HIV-1 

Neurovirulence 

Satish Pillai* 1,2 , W Pasutti1 , A McCutchan3 , C Marra4 , D Clifford5 , 

B Gelman6 , D Simpson7 , J McArthur8 , I Grant3 , and J Wong1,2 1 2 VAMC, San Francisco, CA, US; Univ of California, San Francisco, 

US; 3Univ of California, San Diego, US; 4Univ of Washington, Seattle, 

US; 5Washington Univ, St Louis, MO, US; 6Univ of Texas Med Branch, 

Galveston, US; 7Mt Sinai Sch of Med, New York, NY, US; and 8Johns Hopkins Univ, Baltimore, MD, US 

402 Differential Induction of IDO and the Kynurenine Pathway 

by Neurotropic and Non-Neurotropic Viruses 

Apsara Kandanearatchi* 1 , J Wilkinson1 , J Zaunder1 , L Pemberton1 , 

S Maddocks2 , A Cunningham2 , and B Brew1 1Ctr for Immunology, St Vincent’s Hosp, Univ of New South Wales, 

Sydney, Australia and 2Millenium Inst, Univ of Sydney, Westmead, 

Australia 

403 The Neurotrophins NGF, BDNF, and proNGF Induce 

Enhancement of HIV-1 Replication in Primary Human 

Macrophages 

Thiago Souza* 1,2 , D Rodrigues1 , E Araujo3 , C Fontes2 , and D Bou-Habib1 1 2 Oswaldo Cruz Fndn, Rio de Janeiro, Brazil; Federal Univ of Rio de 

Janeiro, Brazil; and 3Fluminense Federal Univ, Niteroi, Brazil 

404a The Spectrum of HIV-1-associated Neurocognitive Diagnoses 

Represents a Continuum of Circulating HIV DNA Levels 

Bruce Shiramizu* 1 , A Williams2 , C Shikuma1 , and V Valcour1 1Hawaii AIDS Clinical Res Prgm, John A Burns Sch of Med, Univ 

of Hawaii, Honolulu, US and 2Kaiser Fndn Hosp, Ctr for Hlth Res, 

Honolulu, Hawaii, US 

404b HIV Subtype D Is Associated with a Higher Risk for Dementia 

than Subtype A in Sub-Saharan Africa 

Ned Sacktor* 1 , N Nakasujja2 , M Rezapour1 , R Skolasky1 , S Musisi2 , 

E Katabira2 , K Robertson3 , D Clifford4 , O Laeyendecker1 , and T Quinn1 1 2 Johns Hopkins Univ, Baltimore, MD, US; Makerere Univ, Kampala, 

Uganda; 3Univ of North Carolina at Chapel Hill, US; and 4Washington Univ, St Louis, MO, US 



Studies into Mechanisms of HIV 

Neuropathogenesis 

405 Pro-inflammatory Cytokine IL-1β Induction by HIV-1 gp120 

in Primary Human Macrophages Requires Activation of 

Multiple Chemokine Receptor-mediated Protein Kinase 

Signaling Pathways 

Rick Cheung*, V Ravyn, A Ptasznik, and R Collman 


406 Links between Monocyte Chemoattractant Protein-1 

Voltage-gated Potassium Channels and Monocyte Mobility in 

the Neuropathogenesis of HIV Infection 

S Ding, S Ramirez, J Liu, N Gong, Huangui Xiong*, Y Persidsky, and 

H Gendelman 


407 CSF B Cells and CXCL13 in Individuals Who Are HIVinfected 

and Have Syphilis or Neurosyphilis 

Christina Marra*, L Tantalo, C Maxwell, K Dougherty, B Wood, and 

S Lukehart 


408 Non-SIV-infected MAC387 + Macrophages Are Major 

Components of CNS Lesions in Rhesus Macaques Infected by 

SIV 

Caroline Soulas* 1 , WK Kim1 , X Alvarez2 , M Lentz3 , EM Ratai3 , 

L Annamalai4 , S Westmoreland4 , G Gonzalez3 , and K Williams1 1Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA, US; 

2 3 Tulane Natl Primate Res Ctr, Covington, LA, US; Massachusetts Gen 

Hosp, Harvard Med Sch, Boston, US; and 4New England Primate Res 

Ctr, Harvard Med Sch, Southborough, MA, US 

409 Increased Autophagy in HIV-1 Infection of Central Nervous 

System 

Dejiang Zhou*, E Masliah, and S Spector 


410 Evidence of Decreased Glutamate in the Frontal Lobe of HIV 

Patients 

Napapon Sailasuta* 1 , K Shriner2 , and B Ross1 1 2 Huntington Med Res Inst, Pasadena, CA, US and The Phil Simon Clin, 

Pasadena, CA, US 

411 Activation of Cerebrospinal Fluid and Blood CD8 + T 

Lymphocytes during Primary HIV-1 Infection 

Serena Spudich*, R Ronquillo, E Ho, E Lee, R Price, and E Sinclair 


412a Current CD4 and Reconstituted CD4, Not Nadir CD4, 

Predict Current Cerebral White Matter Volume 

David Tate* 1,2,3 , J Conley1 , C Guttmann1 , R Paul4 , J Matesan5 , R Cohen3 , 

B Navia6 , and the HIV Neuroimaging Consortium 

1 2 Brigham and Women’s Hosp, Boston, MA, US; Boston Univ Sch of Med, 

MA, US; 3Warren Alpert Med Sch of Brown Univ, Providence, RI, US; 

4 5 Univ of Missouri, St Louis, US; Indiana Univ Sch of Med, Indianapolis, 

US; and 6Tufts Univ, Boston, MA, US 

412b Cerebrospinal Fluid Soluble Urokinase Plasminogen 

Activator Receptor Is Elevated in AIDS Dementia Complex 

and Correlates with Virological, Immune Activation and 

Neuronal CSF Markers 

Paola Cinque* 1 , N Sidenius1 , A Bestetti1 , S Sala1 , A Lazzarin1 , B Brew2 , 

L Hagberg3 , M Gisslen3 , and R Price4 1 2 San Raffaele Sci Inst, Milan, Italy; Univ of New South Wales, Sydney, 

Australia; 3Sahlgrenska Univ Hosp, Goteborg, Sweden; and 4Univ of 




Co-infection with HCV 

413 HIV and HCV Are Associated with Worse 

Neuropsychological Performance in Anhui, China 

Scott Letendre* 1 , L Cysique1 , C Shi2 , X Yu2 , K Hong3 , Z Wu3 , C Ake1 , 

H Jin1 , I Grant1 , R Heaton1 , and the HNRC Group 

1 2 Univ of California, San Diego, US; Inst of Mental Hlth, Peking Univ, 

Beijing, China; and 3Natl Ctr for AIDS/STD Control and Prevention, 

China CDC, Beijing 

414 Molecular and Bioinformatics Evidence of Hepatitis C Virus 

Evolution in Brain in HCV and HCV/HIV Patients 

Sarah Fishman*, J Murray, F Eng, J Walewski, S Morgello, and 

A Branch 

Mt Sinai Med Ctr, New York, NY, US 


Poster Listings



415 Hepatitis C Virus Co-infection Does Not Significantly 

Worsen Neuroimaging Measures of Diffusivity in HIVinfected 

Patients 

David Tate* 1,2,3 , J Conley 1 , R Paul 4 , K Coop 2 , K Bolden 1 , D Laidlaw 5 , 

S Zhang 6 , L Taylor 2 , T Flanigan 2 , and K Tashima 2 

1 Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA, US; 

2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US; 3 Boston 

Univ Sch of Med, MA, US; 4 Univ of Missouri, St Louis, US; 5 Brown Univ, 

Providence, RI, US; and 6 Mississippi St Univ, Starkville, US 



PML and JC Virus 

416 New Pathogenic Role of Human Polyomavirus JC in Neurons 

Xin Dang* and I Koralnik 


417 Role of Immune Reconstitution Inflammatory Syndrome in 

“Unmasked” Progressive Multifocal Leukoencephalopathy 

N Sidhu and Allen McCutchan* 


418 Frequent Infection of Granule Cell Neurons by JC Virus in 

HIV + Progressive Multifocal Leukoencephalopathy Patients 

C Wuethrich1 , J Cheng1 , J Joseph1 , S Kesari2 , C Beckwith3 , E Stopa4 , 

J Bell5 , and Igor Koralnik* 1 

1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Brigham and 

Women’s Hosp and Children Hosp, Boston, MA, US; 3Miriam Hosp, 

Providence, RI, US; 4Rhode Island Hosp, Providence, US; and 5Western Gen Hosp, Edinburgh, UK 

419 JC Virus in Bone Marrow of HIV + and HIV – Patients 

Sabrina Tan*, B Dezube, P Bhargava, C Wuethrich, P Autissier, and 

I Koralnik 


420 Productive SV40 Infection of Neurons in a Monkey Model of 

Progressive Multifocal Leukoencephalopathy 

Xin Dang* 1 , C Wuethrich1 , M Axthelm2 , and I Koralnik1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US and Oregon Natl 

Primate Res Ctr, Beaverton, US 



Studies on T Cell Responses in Viral Infection 

421 Evaluation of Antiviral Activity of HIV-1-specific CTL and 

Epitope Expression Kinetics 

Balamurugan Arumugam*, D Chen, H Ng, A Ali, and O Yang 


422 Early Robust SIV-specific CD8 T Cell Response Detected in 

situ in Genital and Lymph Tissues from Macaques Infected 

with Attenuated SHIV and Subsequently Infected with 

Pathogenic SIV 

J Hong1 , T Mattila1 , A Hage1 , C White1 , H Kim1 , C Miller2 , A Haase3 , and 

Pamela Skinner* 1 

1 2 Univ of Minnesota, St Paul, US; Univ of California, Davis, US; and 

3Univ of Minnesota, Minneapolis, US 

423 Telomerase Up-regulation and Telomere Length Stabilization 

in HIV-1-specific CD8 + T Cells from HIV Controllers 

Maintain Proliferative and Cytotoxic Activities and Is 

Regulated by the PD-1/PDL-1 Pathway 

M Lichterfeld1 , D Mou1 , C Pan1 , K Williams1 , M Waring1 , F Pereyra1 , 

G Freeman2 , E Rosenberg1 , B Walker3 , and Xu Yu* 1 

1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Univ Ctr for 

AIDS Res, Boston, US; 2Dana-Farber Cancer Inst, Boston, MA, US; and 

3Howard Hughes Med Inst, Chevy Chase, MD, US 

424 PBMC Subsets Targeted by HIV Present Differential Antigen 

Processing Activities Affecting the Production of Epitopes 

Estibaliz Lazaro*, S Godfrey, P Stamegna, J Ho, B Walker, and S Le Gall 

Massachusetts Gen Hosp, Harvard Med Sch, Boston, US 

425 Lack of CD57 Expression on Terminally Differentiated 

HIV-specific Clonotypes Provides a Mechanism for in vivo 

Persistence 

Dirk Meyer-Olson* 1,2,3 , B Simons4 , J Conrad4 , R Smith2 , L Barnett2 , 

S Lorey2 , R Ramalingam2 , S Sadagopal2 , R Schmidt1,3 , and S Kalams2,4 1 2 Medizinische Hochschule Hannover, Germany; Vanderbilt Univ, 

Nashville, TN, US; 3Kompetenznetz HIV/BMBF, Germany; and 

4Vanderbilt Univ Med Ctr, Nashville, TN, US 

426 Antiviral Immunity in HIV-infected vs HIV-naïve Kidney 

Transplant Recipients: A Prospective Cohort Study 

Olivier Gasser* 1 , F Bihl1 , S Sanghavi2 , C Rinaldo2 , D Rowe2 , S Schaub3 , 

M Roland4 , P Stock4 , C Hess3 , and C Brander1 1 2 Massachusetts Gen Hosp, Harvard Univ, Boston, US; Univ of 

Pittsburgh, PA, US; 3Univ Hosp Basel, Switzerland; and 4Univ of 



427 HIV-Nef but Not HIV Gag-specific CD8 T Cells Increase 

Breadth and Magnitude during Intermittent ART Compared 

to Continuous Treatment in Patients with Chronic HIV 

Infection: The WINDOW-ANRS 106 Trial 

Assia Samri* 1 , E Nemes1,2 , I Charreau3 , P Tangre3 , B Puissant4 , 

B Marchou5 , JP Aboulker3 , JM Molina6 , B Autran1 , G Carcelain1 , and the 

ANRS 106 Study Team 

1 2 Hosp Pitie-Salpetriere, Paris, France; Univ of Modena and Reggio 

Emilia, Italy; 3INSERM SC10, Villejuif, France; 4Rangueil Hosp, 

Toulouse, France; 5Purpan Hosp, Toulouse, France; and 6Hosp St Louis, 

Paris, France 

428 Detection of Cytotoxic Leukocyte Antiviral Activity by 

Fitness Impact of Nef-mediated HLA Down-regulation 

A Ali, H Ng, and Otto Yang* 


429 Dynamics of Viral Evolution and Cytotoxic Leukocyte 

Responses in HIV-1 Infection 

Yi Liu* 1 , J McNevin2 , H Zhao1 , J McElrath2 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Fred Hutchinson Cancer Res Ctr, 


430 Increases of Viral Replication after Interruption of ART 

Does Not Affect the Functional Profile of HIV-specific CD8 + 

T Cells 

M Lopez, N Rallon, V Soriano, I Perez, J Gonzalez-Lahoz, and Jose Benito* 


431 Lack of Evidence for CD8 + T Cell-mediated Selection 

Pressure on Proviral Gag p17 and p24 in Chronically 

Infected HIV-1 + Individuals 

Samantha Westrop* 1 , D Constantinou1 , M Nelson2 , M Jones1 , 

F Gotch1 , and N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London, 

UK 

432 ELISpot Responses against the HLA-A2 Restricted Epitope 

RT181-189 Are Frequent in ART-naïve Patients but Rare in 

Patients with 3TC-resistant Virus 

Y Pacheco1 , C Allavena2 , J Arias2 , E Garnier-Andre2 , V Ferre1 , 

E Billaud2 , F Raffi2 , and Dorian McIlroy* 1 

1 2 Univ Nantes, France and Ctr Hosp Univ Hotel Dieu, Nantes, France 

433 IL-7 and HIV Tat Act Synergistically to Down-regulate 

the IL-7 Receptor Alpha-chain on CD8 T Cells through a 

Pathway Involving JAK Kinase 

Elliott Faller* 1,2 , J Kakal1,2 , and P MacPherson1,2,3 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; and Ottawa 

Hosp, Canada 

434 SDF-1a Is a Potent Inducer of HIV-1-specific CD8 + T Cell 

Chemotaxis, but Migration of CD8 + T Cells Is Impaired at 

High Viral Loads 

Amie Meditz*, R Schlichtemeier, J Folkvord, M Givens, K Lesh, G Ray, 

M McCarter, and E Connick 

Univ of Colorado Hlth Sci Ctr, Denver, US 

435 Identification of an N-linked Glycosylation in the C4 Region 

of HIV-1 Envelope gp120 that Is Critical for Recognition of 

Neighboring CD4 T Cell Epitopes 

Hualin Li*, P Chien, M Tuen, M Visciano, S Cohen, S Blais, C Xu, 

H Zhang, and C Hioe 

New York Univ Sch of Med, New York, US 

436 Long-term Effects of Early HAART Treatment on HIVspecific 

Immune Responses 

Jie Yu* 1 , M Fraham1 , K Owzar1 , H Maecker2 , C Hicks1 , C Gay3 , 

J Eron3 , S Fiscus3 , K Weinhold1 , and G Ferrari1 1 2 Duke Univ Sch of Med, Durham, NC, US; BD Biosci, Immunocytometry 

Systems, San Jose, CA, US; and 3Univ of North Carolina at Chapel Hill, 

US 

437 HLA-DR Expression on CD8 + T Cells Is Due to Their Direct 

Interaction with Monocytes 

Natalie Hutnick*, G Makedonas, and M Betts 


438 Optimizing the Degree of HIV Sequence Diversity Coverage 

for the Detection of T Cell Responses 

Nicole Frahm* 1 , K Yusim1 , W Fischer1 , M Muldoon2 , B Walker3 , 

B Korber1 , and C Brander3 1 2 Los Alamos Natl Lab, NM, US; Univ of Manchester, Sch of 

Mathematics, UK; and 3Partners AIDS Res Ctr, Massachusetts Gen Hosp, 

Harvard Med Sch, Boston, US




Studies on Cytokines and HIV Infection 

439 HIV Infection Results in Impaired IL-7 Signaling in Primary 

Human Thymocytes in vitro 

Charlene Young* 1,2 and J Angrel1,2,3 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; and Ottawa 

Hosp, Canada 

440 A Pivotal Role for Mucosa-associated Epithelial Chemokine 

in the Modulation of Mucosal Immunity in HIV Infection 

Eleonora Castelletti* 1 , S Lo Caputo2 , L Kuhn3 , M Borelli1 , G Aldrovandi4 , 

M Nebuloni1 , F Veas5 , F Mazzotta2 , and M Clerici1 1 2 3 Univ of Milan, Italy; SS Annunziata Hosp, Florence, Italy; Columbia 

Univ, New York, NY, US; 4Univ of Southern California, Los Angeles, US; 

and 5Inst for Res and Devt, UR178, Montpellier, France 

441 Differences in the Activation of Tumor Necrosis Factor 

Superfamily Pathways May Contribute to Age-associated 

Differences in Naïve CD4 + Cell Recovery and to Functional 

Immune Responses to HAART 

Robert Kalayjian* 1 , J Spritzler2 , R Matining2 , P Tebas3 , R Pollard4 , 

A Landay5 , M Lederman6 , and AIDS Clinical Trials Protocol 5015 Team 

1 2 MetroHlth Med Ctr, Cleveland, OH, US; Harvard Sch of Publ Hlth, 

Boston, MA, US; 3Univ of Pennsylvania, Philadelphia, US; 4Univ of 

California, Davis, US; 5Rush Med Coll, Chicago, IL, US; and 6Case Western Reserve Univ, Cleveland, OH, US 

442 Expression and Functional Significance of Soluble IL-7Rα 

(CD127) In HIV Infection 

Angela Crawley* 1,2 , S Faucher3 , and J Angel1,2,4 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; Ctr for 

Infectious Disease, Prevention and Control Hlth Canada, Ottawa; and 

4Ottawa Hosp, Canada 



Immune Activation and Lymphocyte Function 

443 A Threshold of Partial CD4 + T Cell Restoration in GALT Is 

Sufficient for Developing Multi-functional Anti-HIV CD8 + 

T Cell Responses and Control of Mucosal Immune Activation 

and Viral Suppression in HIV-infected Patients Receiving 

HAART 

Monica Macal* 1 , S Sankaran1 , TW Chun2 , E Reay1 , J Flamm3 , 

T Prindiville1 , and S Dandekar1 1 2 Univ of California, Davis, US; Lab of Immunoregulation, NIAID, NIH, 

Bethesda, MD, US; and 3Kaiser Permanente Med Group, Sacramento, 

CA, US 

444 HIV Infection Leads to Increased Immune Activation by 2 

Distinct Pathways that Differentially Affect CD4 and CD8 

T Cells 

Marta Catalfamo* 1 , M Di Mascio2 , Z Hu2 , S Srinivasula3 , V Thaker1 , 

J Adelsberger3 , A Rupert3 , M Baseler3 , G Roby1 , and C Lane1 1 2 Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US; NIAID, NIH, 

Bethesda, MD, US; and 3SAIC-Frederick, MD, US 

445 Abnormal T Cell Phenotypes Persist Despite Effective HAART 

Brinda Emu*, S Deeks, W Moretto, R Hoh, J Martin, D Nixon, and 

J McCune 


446 Enfuvirtide Therapy Increases Naïve and Central Memory 

CD4 T Cells, Decreases the Level of Immune Activation and 

Apoptosis 

H Carsenti Dellamonica1 , J Durant1 , M Ticchioni1 , F Guillouet de Salvador1 , 

J Dufayard Cottalorda1 , R Garraffo2 , Pierre Dellamonica* 1 , and M Gougeon3 1 2 Hosp Archet, Nice, France; Ctr Hosp Univ Necker, Paris, France; and 

3Pasteur Inst, Paris, France 

447 Dual Function of the Inhibitory Co-receptor PD-1 as a 

Marker for Activated and Functionally Impaired T Cells in 

SIV-infected Rhesus Macaques 

Nadine Salisch* 1,2 , A Awad1 , D Evans1 , and P Johnson1,3 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2Univ Erlangen-Nuremberg, Erlangen, Germany; and 3Massachusetts Gen Hosp, Boston, US 

448 CXCR4 Receptor Expression Is More Common on Activated 

CD4 + T Cells than CCR5 Expression in HIV-1 Infection 

Frederick Hecht*, E Sinclair, A Carrico, P Moran, P Hunt, 

M Killian, P Bacchetti, T Ho, S Folkman, and S Deeks 


449 Phenotypic and Functional Characterization of the Thymus 

in HIV-infected Patients 

Alessandra Bandera* 1 , G Ferrario2 , M Saresella3 , I Marventano3 , 

G Marchetti4 , D Trabattoni5 , L Gazzola4 , M Clerici5 , and A Gori1 1 2 San Gerardo Hosp, Univ of Milan-Bicocca, Monza, Italy; Luigi Sacco 

Hosp, Univ of Milan, Italy; 3Don Carlo Gnocchi Fndn, Milan, Italy; 4San Paolo Hosp, Univ of Milan Med Sch, Italy; and 5Univ of Milan Med Sch, 

Italy 

450 Common Markers of T Cell Activation Do Not Indicate 

Markedly Higher Levels of HIV Infection of CD4 + T Cells in 

the Peripheral Circulation 

Joe Casazza*, S Adzaku, D Ambrozak, D Douek, M Roederer, and 

R Koup 

Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US 

451 Persistent PD-1 Expression Is Correlated with Poor Immune 

Recovery in HAART-treated HIV-1-infected Patients 

Katharina Pfistershammer* and N Kohrgruber 

Med Univ Vienna, Austria 

452 HIV-1-infected Patients with Full Suppression of Viral 

Replication but Impaired Recovery of CD4 Cells Display 

Immune Activation with Decreased CD28 Expression and 

IL-10 Production 

Christian Erikstrup* 1,2 , N Lohse2,3 , S Ostrowski1,4 , J Gerstoft1 , 

G Kronborg3 , and H Ullum1 1 2 Rigshospitalet, Copenhagen, Denmark; Aarhus Univ Hosp, Denmark; 

3 4 Copenhagen Univ Hosp, Hvidovre, Denmark; and Faculty of Hlth Sci, 

Univ of Copenhagen, Denmark 

453 Marginal Zone B Cell Memory Populations Are Irreversibly 

Depleted in Pediatric HIV 

Marianne Jacobsen* 1 , R Thiebaut2 , C Fisher3 , D Sefe1 , M Clapson3 , 

N Klein1 , and H Baxendale1 1 2 3 Inst of Child Hlth, London, UK; INSERM, Bordeaux, France; and Great 

Ormond St Hosp for Children, London, UK 

454 Abnormal Activation of the JAK/STAT Pathway in CD4 + 

T Cells of HIV-infected Patients (ANRS EP33 Study) 

Olivier Juffroy* 1 , F Bugault1 , O Lambotte2 , JP Viard3 , L Niel4 , 

A Danckaert1 , JF Delfraissy2 , J Theze1 , and L Chakrabarti1 1 2 3 Pasteur Inst, Paris, France; Ctr Hosp Univ Bicetre, France; Hosp 

Necker, Paris, France; and 4Hosp Percy, Clamart, France 

455 Potential Pre-treatment Interruption Immunological 

Predictors for CD4 Count Change Off Therapy in 

Chronically HIV-infected Subjects Having Various Pre- 

Treatment Interruption Viral Loads 

Kenneth Huang* 1 , S Boulet1 , C Tsoukas1 , M Loutfy2 , and N Bernard1 1 2 Res Inst of the McGill Univ Hlth Care Ctr, Montreal, Canada and Univ 

of Toronto, Canada 

456 Effects of Timing of Processing and Lymphocyte Isolation on 

Detection of CD31 Expression on Naïve CD4 T Cells in HIVinfected 

Patients 

Jeanette Higgins* 1 , M Proschan2 , J Metcalf2 , R Stevens1 , M Baseler1 , 

C Lane2 , and I Sereti2 1 2 SAIC-Frederick, MD, US and NIH, Bethesda, MD, US 

457a High-level Persistence of HIV Antigen-specific CD4 + T Cells 

in Untreated Chronic Infection, Detected by a Novel Flow 

Cytometric Assay 

John Zaunders* 1 , S Pett2 , M Bailey2 , N Seddiki2 , M Munier2 , S Ip2 , 

M Kim3 , A Cunningham3 , D Cooper1,2 , and A Kelleher1,2 1 2 Ctr for Immunology, St Vincent’s Hosp, Darlinghurst, Australia; Natl 

Ctr in HIV Epi and Clin Res, Univ of New South Wales, Australia; and 

3Westmead Millenium Inst, Sydney, Australia 

457b Combined Effects of Interleukin-10 and PD-1 on Virus-specific 

CD4 T Cell Proliferation during Chronic HIV-1 Infection 

Mark Brockman*, D Kwon, D Tighe, S Le Gall, F Pereyra, B Walker, 

and D Kaufmann 

Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US 



Studies on Regulatory T Cells 

458 Immune Activation Occurs Concomitantly with Immune 

Exhaustion and Decrease in Regulatory T Cells in Treatment 

Naïve Chronically HIV-infected Patients 

Meenakshi Sachdeva*, R Pahwa, M Fischl, K Arheart, and S Pahwa 

Univ of Miami Miller Sch of Med, FL, US 

459 Functional and Phenotypic Profiling of Suppressive 

Regulatory T Cells in a Cohort of HIV-1-infected Individuals 

Catherine Burton* 1 , I Eccles-James1 , M Bower1,2 , M Nelson1,2 , 

F Gotch1 , and N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London, 

UK 

460 CD4 + T Cell Nadir and Reconstitution of T Regulatory Cells 

in HIV-1-infected Patients Receiving HAART 

Pascale Ondoa*, H De Puydt, C Vereecken, A De roo, J Clerinx, 

T Vermoesen, K Fransen, and L Kestens 

Inst of Tropical Med, Antwerp, Belgium 

461 Treg-mediated Inhibition of CD8 T Cell Proliferation in HIV + 

Subjects Is Reverted through CD39 Function 

M Nikolova1,2 , J Lelievre2 , A Bensussan2 , and Yves Levy* 2 

1 2 Natl Ctr of Infectious and Parasitic Diseases, Sofia, Bulgaria and Hosp 

Henri Mondor, INSERM U84, Creteil, France 


Poster Listings



462 Regulatory T Cell Frequency Is Associated with Low Cellular 

Activation Early after HIV Infection 

Karina Carvalho* 1 , L Ndhlovu 2 , M Sauer 1 , H Tomiyama 1 , F Bruno 1 , 

D Nixon 2 , and E Kallas 1 

1 Federal Univ of Sao Paulo, Brazil and 2 Univ of California, San 

Francisco, US 



Immune Responses and Control of Viremia 

463 Effect of B Cell Depletion on Course of SIV Infection in 

Rhesus Monkeys 

Maurus de la Rosa* 1 , P Chugh1 , V Evans1 , S Finstad1 , S O’Neil2 , 

A Carville2 , M Piatak3 , J Lifson3 , D Montefiori4 , and J Schmitz1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; New England Primate 

Res Ctr, Southborough, MA, US; 3NCI-Frederick, MD, US; and 4Duke Univ Med Ctr, Durham, NC, US 

464a Little Evidence for Contribution of Adaptive Immune 

Responses to Viral Containment of SIVagm Infection in Vervet 

and Sabaeus African Green Monkeys 

Roland Zahn* 1 , M Rett1 , C Brown2 , S Goldstein2 , A Carville3 , R White4 , 

R Byrum5 , J Allan4 , V Hirsch2 , and J Schmitz1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; NIAID, NIH, 

Bethesda, MD, US; 3New England Primate Res Ctr, Southborough, MA, 

US; 4Southwest Fndn for Biomed Res and Southwest Natl Primate Res 

Ctr, San Antonio, TX, US; and 5Bioqual Inc, Rockville, MD, US 

464b Subtype C HIV Uses Multiple Pathways to Escape from 

Autologous Neutralization 

R Rong1 , B Li1 , J Mulenga2 , S Allen1 , J Blackwell1 , and Cynthia Derdeyn* 1 

1 2 Emory Univ, Atlanta, GA, US and Zambia Blood Transfusion Svc, Lusaka 



B Cell and Immunoglobulin Studies 

465a Functional Evaluation of Monoclonal Antibodies in Protecting 

from Mucosal HIV-1 Infection 

Lucia Fischetti*, V Buffa, K Klein, and R Shattock 

St George`s Univ of London, UK 

465b Modeling HIV-1 Escape from Neutralizing Antibodies: Effect 

of Original Antigenic Sin and Viral Fitness 

Michael Golinski*, D Richman, and S Frost 


466 Crystal Structures of Broadly Neutralizing Human Anti- 

HIV-1 Antibodies 3074 and 447-52D in Complex with V3 

Peptides 

Valicia Burke* 1 , SS Kim1 , H Li1 , M Gorny2 , C Williams2 , 

S Zolla-Pazner1,2 , and XP Kong1 1 2 New York Univ Sch of Med, New York, US and New York VAMC, NY, US 

467 Glycosylation of gp41 Shields Epitopes That Are Targets of 

Neutralizing Antibodies 

Eloisa Yuste*, J Bixby, W Lauer, H Sanford, S Sato, W Johnson, and 

R Desrosiers 

Harvard Med Sch, Southborough, MA, US 

468 HIV-1 Envelope Determinants in Immune Tissue that Confer 

Natural Resistance to the CD4 Binding Site Monoclonal 

Antibody, b12 

Maria Duenas-Decamp* 1 , P Peters1 , D Burton2 , and P Clapham1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Scripps Res Inst, La 

Jolla, CA, US 

469 Decreased Variable Region Immunoglobulin Gene, Somatic 

Hypermutation, and Dysregulated Activation-induced 

Deaminase Expression during HIV Infection 

Elisabeth Bowers* 1 , K Keays1 , L Beniguel2 , A Asrani3 , S MaWhinney1 , 

B Palmer1 , A Bajar3 , J Thurn3 , R Scamurra3 , and E Janoff1 1 2 Ctr for AIDS Res, Univ of Colorado, Denver, US; Pasteur Inst, Paris, 

France; and 3Univ of Minnesota, VAMC, Minneapolis, US 

470 Broad Cross-neutralization Mediated by Combination of 

Anti-V3 and CD4 Binding Site Antibodies in an HIV-1infected 

Patient with Long-term Non-progressive Disease 

Shuzo Matsushita*, Y Nishida, J Shibata, A Honda, and K Yoshimura 

Ctr for AIDS Res, Kumamoto Univ, Japan 

471 The C3-V4 Region Is a Major Target of Autologous 

Neutralizing Antibodies in HIV-1 Subtype C Infection 

Penny Moore* 1 , E Gray1 , I Choge1 , N Ranchobe1 , K Mlisana2 , 

S Abdool Karim2 , C Williamson3 , L Morris1 , and CAPRISA 002 Study 

and the Ctr for HIV/AIDS Vaccine Immunology Consortium 

1Natl Inst for Communicable Diseases, Johannesburg, South Africa; 

2Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu Natal, 

Durban; and 3Inst of Infectious Disease and Molecular Med, Univ of 

Cape Town, South Africa 


472 The Structural Basis of the Cross Neutralization of Human 

HIV-1 Monoclonal Antibody 3791 

Xunqing Jiang* 1 , C Williams2 , M Gorny2 , S Zolla-Pazner2 , and XP Kong1 1 2 New York Univ Sch of Med, NY, US and New York VAMC, US 

473 Neutrophil-mediated Destruction of HIV Directed by Broadly 

Reactive Anti-HIV and Anti-CD89 Bi-specific Antibody 

M Duval1 , M Posner1,2,3 , and Lisa Cavacini* 1,3 

1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Dana-Farber Cancer 

Inst, Boston, MA, US; and 3Harvard Med Sch, Boston, MA, US 

474 Epitope Tagging across the Surface of the HIV-1 Envelope 

Spike Reveals an Intrinsic Ability of Virus to Restrict 

Antibody Recognition 

Ralph Pantophlet*, M Wang, R Aguilar-Sino, and D Burton 

Scripps Res Inst, La Jolla, CA, US 

475 Reduced Repertoire Complexity of the Heavy Chain 

Complementarity Determining Region 3 in HIV Patients 

Sabrina Deroo* 1 , S Delhalle1 , M Counson1 , N Beaupain1 , JM Plesseria1 , 

and JC Schmit2 1 2 Publ Res Ctr of Hlth, Luxembourg and Natl Svc of Infectious Diseases, 

Hosp Luxembourg 

476 Effect of HIV on Impaired Immunoglobulin Class Switch 

Recombination and B Cell Signaling in Individuals with 

Concomitant Common Variable Immune Deficiency 

Chris Tsoukas*, T Lewis, G Vriniotis, and L Sun 

McGill Univ Hlth Ctr, Montreal, Canada 

477 Effect of HAART on Markers of B Cell Activation in Men 

from the Multicenter AIDS Cohort Study 

Deborah Regidor*, E Breen, R Detels, and O Martinez-Maza 


478 Impaired Naïve and Memory B Cell Expansion in Response 

to CpG ODN in HIV Infection 

Wei Jiang*, M Lederman, R Mohner, B Rodriguez, C Harding, and 

S Sieg 




Studies on NK and Plasmacytoid Dendritic Cells 

479 Activated Plasmacytoid and Myeloid Dendritic Cells 

Accumulate in Lymphoid Tissue during Asymptomatic, 

Chronic HIV-1 Infection 

Stephanie Dillon*, K Robertson, S Pan, S MaWhinney, A Meditz, 

J Folkvord, E Connick, M McCarter, and C Wilson 


480 Effect of Chloroquine on TLR Activation in Plasmacytoid 

Dendritic Cells 

Jeffrey Martinson* 1 , C Montoja2 , Y Chen3 , R Ronquillo1 , L Baum1 , and 

A Landay1 1 2 Rush Univ, Chicago, IL, US; Univ of Antioquia, Medellin, Columbia; 

and 3Northwestern Univ, Chicago, IL, US 

481 HIV-1 Vpr Inhibition of Plasmacytoid Dendritic Cell Derived 

Type I Interferon and Impairment of PDC-NK Cell Crosstalk 

in vitro 

Henoch Hong* 1 , N Bhatnagar1 , U Schubert2 , M Ballmaier1 , 

T Volgmann3 , R Schmidt1,4 , H Heiken1 , and D Meyer-Olson1,4,5 1 2 Hannover Med Sch, Germany; Univ Erlangen, Germany; 

3 4 Blutspendedienst, Springe, Germany; KompNet HIV/AIDS, Germany; 

and 5Vanderbilt Univ, Nashville, TN, US 

482 Differential Regulation of TRAIL and IFN-α by Circulating 

PDC during Chronic and Acute Viremia in HIV-infected 

Subjects 

Bethsebah Gekonge* 1 , E Papasavvas1 , A Hancock1 , C Tomescu1 , 

A Raymond1 , K Vinekar1 , G Reynolds1 , K Mounzer2 , J Chehimi1 , and 

L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US and Philadelphia Field Initiating 

Group for HIV Trials, PA, US 

483 Impaired NK-mediated Antibody-dependent Cellular 

Cytotoxicity May Contribute to Poor Antibody-mediated 

Inhibition of HIV-1 Replication 

Q Liu1 , PN Tsoukas1 , S Rihn1 , A Meier1 , H Streeck1 , M Altfeld1 , 

Yongtao Sun* 2 , and G Alter1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and 

24th Military Med Sch, Xi’an, China 

484 Lipopolysaccharide-induced Activation of Natural Killer 

Cells from HIV-1-infected Individuals 

Martin Goodier* 1 , J Gregson1 , D Constantinou1 , A Steel1 , M Bower2 , 

B Gazzard2 , and F Gotch1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London, 

UK


485 Altered Cross-talk between Natural Killer Cells and 

Dendritic Cells Due to Peptide HIV p24 aa14-22 Peptidemediated 

HLA-E Expression 

Daniela Schulte*, C Koerner, B Kraemer, H Nischalke, T Sauerbruch, 

U Spengler, J Rockstroh, J Nattermann, and Kompetenznetz HIV/AIDS 

Univ of Bonn, Germany 

486 Activated NK Cells Inhibit Apoptosis of HIV-1-infected 

Dendritic Cells while Inducing Their Maturation by an 

HMGB1-dependent Mechanism: Implication for the 

Establishment of HIV-1 Reservoirs 

Hela Saidi*, MT Melki, and ML Gougeon 

Pasteur Inst, Paris, France 



HIV Vaccines: Induction of Neutralizing Antibodies 

and Responses 

487 Anti-HIV Neutralizing Response Elicited in Rabbits by Anti- 

Idiotype Monoclonal Antibodies Mimicking the gp120 CD4binding 

Site 

Nicasio Mancini* 1 , N Clementi1 , D De Marco1 , S Winfrey2 , P Bagnarelli3 , 

F Vitone4 , M Re4 , J Mascola2 , R Burioni1 , and M Clementi1 1 2 Univ Vita-Salute San Raffaele, Milan, Italy; Vaccine Res Ctr, NIAID, 

NIH, Bethesda, MD, US; 3Univ Politecnica delle Marche, Ancona, Italy; 

and 4Univ di Bologna, Italy 

488 Differential Effect of Broadly Neutralizing Anti-HIV-1 

Antibodies on the Formation of Virological Synapses 

Marta Massanella*, I Puigdomenech, M Fernandez, M Bofill, 

B Clotet, and J Blanco 

Hosp Univ Germans Trias i Pujol, Badalona, Spain 

489 Alteration in vivo of Humoral Responses to HIV-1 Envelope 

gp120 by Antibodies to the CD4 Binding Site of gp120 

Maria Luisa Visciano*, M Tuen, M Gorny, and C Hioe 

New York Univ Sch of Med and VA New York Harbor Hlthcare System, 

New York, US 



HIV Vaccines: Induction of Cellular Immune 

Responses 

490 A New Concept for HIV Vaccine: HIV gp41 Peptide 

Immunization Prevents NKp44L Expression and CD4 T Cell 

Depletion in SHIV-infected Macaques 

V Vieillard1 , R Le Grand2 , and Patrice Debre* 1 

1 2 INSERM U543, Hosp Pitie-Salpetriere, Paris, France and CEA, 

Fontenay-aux-Roses, France 

491 SIV-specific CD8 + T Cells Mediated Protection from 

Uncontrolled Viral Replication after Vaginal SIV Challenge 

in Live-attenuated Immunized Rhesus Macaques 

Meritxell Genesca* 1,2 , M Stone1 , D Lu1,2 , J Li1,2 , K Bost1,2 , T Rourke1,2 , 

M McChesney1 , and C Miller1,2 1 2 California Natl Primate Res Ctr, Univ of California, Davis, US and Ctr 

for Comparative Med, Univ of California, Davis, US 

492 2 Different Immunization Regimens with Single-cycle 

SIV Afford Partial Control of Virus Replication after an 

Intravenous Challenge with SIVmac239 B Jia1 , Q DeGottardi1 , S Lew1 , A Carville1 , K Mansfield1 , B Richardson2 , 

M Piatak3 , J Lifson3 , and David Evans* 1 

1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2Univ of Washington, Seattle, US; and 3SAIC-Frederick and NCI- 

Frederick, MD, US 

493 Vaccine-induced, SIV-specific CD8 + T Cells Control Viremia 

but Do Not Protect from CD4 + T Cell Depletion or AIDS in 

SIVmac239-challenged Macaques 

J Engram1 , R Dunham1 , B Sumpter2 , G Makedonas1 , M Betts1 , 

S Staprans3 , J Altman2 , D Garber2 , M Feinberg3 , and Guido Silvestri* 1 

1 2 Univ of Pennsylvania, Philadelphia, US; Emory Vaccine Ctr and Yerkes 

Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US; and 3Merck Res 

Labs, West Point, PA, US 

494 Immunization by Mucosal Exposure to SIV or HIV-2 during 

Chemoprophylaxis with Tenofovir 

Lisa Frenkel* 1,2 , L Kuller2 , J Capalungan2 , I Beck1 , CC Tsai2 , SL Hu2 , 

M Agy2 , Y Stevens2 , S Holte2,3 , and D Anderson2 1 2 Seattle Children’s Hosp Res Inst, WA, US; Univ of Washington, Seattle, 


495 Updated Results from Ongoing Work on the GAIA HIV 

Vaccine: Recognition of Class I- and II-restricted Epitopes in 

Bamako, Mali, and Providence, US 

Karim Coulibaly* 1 , O Koita1 , D Rivera2 , J McMurry2 , L Moise2 , 

W Martin2 , and A De Groot2,3 1 2 3 Univ of Bamako, Mali; EpiVax, Inc, Providence, RI, US; and GAIA 

Vaccine Fndn, Providence, RI, US 

496 The Depth of CTL Epitope Coverage Correlates with 

Strength of Selection in Gag p17 for Subtype B but Not 

Subtype C 

Mary Pacold* 1 , S Frost1 , A Poon1 , D Smith1,2 , D Richman1,2 , and 

S Kosakovsky Pond1 1 2 Univ of California, San Diego, US and San Diego VA Hlthcare Systems, 

CA, US 



HIV Vaccines: Novel Viral Vectors 

497a Electroporation of Optimized DNA Vaccines Leads to 

Greatly Enhanced Responses in Blood and Mucosal Surfaces 

Margherita Rosati* 1 , V Patel1 , C Bergamaschi1 , A Valentin1 , V Kulkarni1 , 

R Jalah1 , C Ohlen1,2 , R Draghia-Akli3 , B Felber1 , and G Pavlakis1 1 2 3 NCI-Frederick, MD, US; SAIC-Frederick, MD, US; and VGX Pharma, 

The Woodlands, TX, US 

497b Immunogenicity and Protective Efficacy of Replicationdefective 

Herpes Simplex Virus Vector-based AIDS Vaccines 

Kenneth Chan* 1 , S Pryputniewicz1 , M Kasheta1 , M Rosati2 , J Lifson2,3 , 

G Pavlakis2 , B Felber2 , R Desrosiers1 , D Knipe4 , and A Kaur1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2NCI-Frederick, MD, US; 3SAIC-Frederick, MD, US; and 4Harvard Med Sch, Boston, MA, US 

498 Recombinant Varicella Vaccines Induce Immune Responses 

to Simian Immunodeficiency Virus Antigens and Reduced 

Viral Loads in Immunized Rhesus Macaques 

Vicki Traina-Dorge* 1 , R Lorino1 , P Marx1 , Y Ou2 , and W Gray2 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US and Univ of Arkansas 

for Med Sci, Little Rock, US 

499 Recombinant Foamy Virus Vectors Persistently Express 

High Levels of HIV-1 gag: Potential for Vaccine 

David Hardy* 1,2 , C Liu1 , T Folks3 , and I Chen2 1 2 Cedars-Sinai Med Ctr, Los Angeles, CA, US; David Geffen Sch of Med, 

Univ of California, Los Angeles, US; and 3CDC, Atlanta, GA, US 



HIV Vaccines: Clinical Trials 

500 AIDSVAX Immunization Induces HIV-specific CD8 + T Cell 

Responses in High-risk HIV–Volunteers Who Subsequently 

Acquire HIV Infection 

Norman Jones* 1 , P Gilbert2 , A DeCamp2 , M Peterson3 , M Gurwith3 , and 

H Cao1 1 2 California Dept of Hlth Svcs, Richmond, US; Fred Hutchinson Cancer Res 

Ctr, Seattle, WA, US; and 3Vaxgen, Inc, South San Francisco, CA, US 

501 Safety and Immunogenicity of ALVAC-HIV vCP1521 in 

Infants Born to HIV-1-infected Women in Uganda (HPTN 027) 

Norman Jones* 1 , D Sebikari2 , I Ssewanyana3 , L Baglyos4 , S Zwerski5 , 

M Swenson6 , J Moye7 , F Mmiro2 , L Guay8 , H Cao1 , and HPTN 027 

Protocol Team 

1 2 California Dept of Publ Hlth, Richmond, US; Makerere Univ–Johns 

Hopkins Univ Res Collaboration, Kampala, Uganda; 3Joint Clinical 

Res Ctr, Kampala, Uganda; 4Sanofi Pasteur, Swiftwater, PA, US; 

5 6 NIAID, NIH, Bethesda, MD, US; Statistical Ctr for HIV/AIDS Res and 

Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; and 8Johns Hopkins Univ, Baltimore, MD, US 

502 Double-blind, Randomized Comparison of a Subunit- and a 

Virosomal Influenza Vaccine in Adult HIV + Patients 

J Evison, K Muehlemann, and Hansjakob Furrer* 

Univ Hosp Berne, Switzerland 

503 Nucleic Acid Detection in Patients Whose HIV RNA Levels 

Are Near the Lower Limit of Detection: Implications for 

Endpoint Determination in HIV Vaccine Trials 

Michelle Lally* 1 , R O’Connell2 , S Peel2 , Y Liu3 , C Bautista3 , N Michael2 , 

and L Jagodzinski2 1 2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US; Walter 

Reed Army Inst of Res, Rockville, MD, US; and 3Henry M Jackson Fndn, 

Rockville, MD, US 

504 Male Circumcision as a Component of the Standard for HIV 

Prevention: Experience from a Phase IIb Vaccine Trial in 

Soweto 

Guy de Bruyn* 1 , N Martinson1 , B Nkala1 , T Khosa1 , B Mkhize1 , 

J Kublin2 , L Corey2 , and G Gray1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Fred 

Hutchinson Cancer Res Ctr, Seattle, WA, US 


Poster Listings



b Monday, 1-4 pm; Hall A 


(see Session 41 on Wednesday for corresponding Poster Discussion) 

Molecular Epidemiology: The Americas 

505 HIV-1 Transmission Dynamics in Quebec in the HAART Era 

Bluma Brenner* 1 , M Roger2 , D Moisi1 , J Cox3 , JP Routy1 , M Wainberg1 , 

and Quebec PHI Study Group 

1 2 McGill AIDS Ctr, Jewish Gen Hosp, Montreal, Canada; Ctr Hosp Univ 

Montreal, Canada; and 3Quebec Agency of Publ Hlth and Social Svcs, 

Canada 

506 Tracking Molecular Epidemiology of HIV-1 in Mexico: 

Emergence of BG Intersubtype Recombinant 

Eduardo Vazquez-Valls* 1 , M Escoto-Delgadillo1 , R Carabez-Hernandez2 , 

and B Torres-Mendoza2 1UMAE Specialties Hosp, Mexican Inst of Social Security, Guadalajara 

and 2Univ Hlth Sci Ctr, Univ of Guadalajara, Mexico 

507 Evolutionary Dynamics of HIV-1 BF and CB Recombinants 

in South America 

E Leal1 , L Martins2 , M Janini1 , and Ricardo Diaz* 1 

1 2 Federal Univ of Sao Paulo, Brazil and Grad Sch of Agriculture and Life 

Sci, Univ of Tokyo, Japan 

508 A Foothold for Subtype C in the Americas: Risk Factors 

Associated with Subtype C and Non-Subtype C HIV Infection 

among HIV Testing Clients in South Brazil 

Oliver Bacon* 1 , R da Silva de Souza2 , K Page Shafer1 , R Diaz3 , 

V Debastiani4 , G Preussler5 , M Leticia Ikeda6 , N Barcellos7 , W Steward1 , 

and C Pilcher1 1 2 Univ of California, San Francisco, US; Univ de Caxias do Sul, Rio 

Grande, Brazil; 3Paulista Sch of Med, Federal Univ of Sao Paulo, Brazil; 

4Ambulatorio de DST/AIDS, Caxias do Sul, Rio Grande do Sul, Brazil; 

5Svc de Assistencia Especializado, Ctr de Saude Vila dos Comercarios, 

Rio Grande do Sul, Brazil; 6Svc Especializado de DST/AIDS Herbert de 

Souza, Rio Grande do Sul, Brazil; and 7Hosp Sanatorio Partenon, Rio 

Grande do Sul, Brazil 

509 Timing the Introduction of HIV-1 Subtype C in Brazil 

Gonzalo Bello*, R Lorete, M Guimaraes, C Bittencourt Passaes, and 

M Morgado 

Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil 



Molecular Epidemiology: Europe 

510 Phylogenetic Surveillance of Viral Genetic Diversity and the 

Evolving Molecular Epidemiology of HIV-1 

Robert Gifford* 1 , T de Oliveira2 , A Rambaut3 , O Pybus4 , D Dunn5 , 

AM Vandamme6 , P Kellam7 , D Pillay7 , and UK Collaborative Group on 

HIV Drug Resistance 

1 2 Stanford Univ, Palo Alto, CA, US; Univ of the Western Cape, Bellville, 

South Africa; 3Univ of Edinburgh, Scotland; 4Univ of Oxford, UK; 5Med Res Council Clinical Trials Unit, London, UK; 6Katholieke Univ Leuven, 

Belgium; and 7Univ Coll London, UK 

511 Significant Increase in Prevalence of HIV-1 Recombinant 

Forms in a UK Non-B Subtype Clinical Cohort over 10 Years 

E MacRae and Clive Loveday* on behalf of the ICVC Clinical 

Collaborative Res Group 

ICVC Charitable Trust, Buckinghamshire, UK 

512 The Contribution of Individuals with Recent Infection to the 

Spread of HIV-1 in Switzerland: A 10-year Survey 

Sabine Yerly* 1 , V von Wyl2 , T Junier3 , B Ledergerber2 , J Boni2 , 

P Burgisser4 , T Klimkait5 , E Zdobnov3 , L Kaiser1 , H Gunthard2 , and the 

HIV Swiss Cohort Study 

1 2 Lab of Virology, Geneva, Switzerland; Div of Infectious Diseases, 

Zurich, Switzerland; 3Univ of Geneva, Switzerland; 4Ctr Hosp Univ 

Vaudois Lausanne, Switzerland; and 5Inst of Med Microbio, Univ Basel, 

Switzerland 

513 Characteristics of Patients Infected with HIV-1 Subtype D 

and CRF01_AE among New HIV Diagnoses in France, 2003 

to 2005 

D Brand1 , F Cazein2 , F Lot2 , J Pillonel2 , S Brunet1 , D Thierry1 , 

JC Desenclos2 , C Semaille2 , and Francis Barin* 1 

1 2 Univ F Rabelais, Tours, France and Inst de Veilles Sanitaire, St 

Maurice, France 

514 Disease Progression, Virus Evolution, and Co-receptor 

Tropism in Individuals with Wild Type and Deficient CCR5 

Alleles after Infection with a Closely Related HIV-1 Strain 

Chris Verhofstede* 1 , L Stuyver2 , F Van Wanzeele1 , J Pelgrom1 , 

B Van der Gucht1 , E Demecheleer1 , V Van Eygen2 , J Plum1 , 

D Vogelaers1 , and L Vandekerckhove1 1 2 Univ Hosp Gent, Belgium and Virco BVBA, Mechelen, Belgium 

515 The Surveillance of HIV-1 Subtype Distribution in the Year 

2005 to 2006 in Saint Petersburg, Russia 

Elena Dukhovlinova* 1 , A Masharsky1 , T Solovjeva1 , S Verevochkin1 , 

O Toussova1 , N Klimov1 , L Alexander2 , R Heimer2 , and A Kozlov1 1 2 Biomed Ctr, St Petersburg, Russia and Yale Univ, New Haven, CT, US 




Molecular Epidemiology: Africa and Asia 

516 The Association of Sexual Risk Behavior and Infection with 

Multiple or Recombinant Strains of HIV in Rakai, Uganda 

Oliver Laeyendecker* 1,2 , M Chen3 , T Ngo1 , T Quinn1,2 , M Arroyo4 , 

F McCutchan4 , N Kiwanuka5 , P Opendi5 , M Wawer3 , R Gray3 , and Rakai 

Hlth Sci Prgm 

1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US; Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US; 3Johns Hopkins Univ 

Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 4US Military HIV Res 

Prgm, Henry M Jackson Fndn, Rockville MD, US; and 5Rakai Hlth Sci 

Project, Uganda 

517 Identification and Prevalence of Dual Subtype/CRF 

Infections at HIV Diagnosis in Cameroon Using a Real Time 

PCR-based Hybridization Assay 

N Vidal1 , H Diop2 , C Montavon1 , C Butel1 , C Toure-Kane2 , S MBoup2 , 

E Mpoudi Ngole3 , Eric Delaporte* 1 , M Peeters1 , and ANRS 1297 

1 2 Inst for Res and Devt, Paris and Univ of Montpellier 1, France; Hosp 

Le Dantec, Dakar, Senegal; and 3PRESICA, Military Hosp, Yaounde, 

Cameroon 

518 20 Years of Prospective Molecular Epidemiology in Senegal: 

Changes in HIV Diversity 

Donald Hamel* 1 , JL Sankale1 , G Eisen1 , S Thakore-Meloni1 , C Mullins1 , 

A Gueye-NDiaye2 , S MBoup2 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US and Cheikh Anta Diop Univ 

and Inst of Social Hygiene, Dakar, Senegal 

519 Different Patterns of Evolution of HIV-1 Subtypes and CRF 

in Southern Countries of Africa and Asia 

Herve Fleury 

Univ of Bordeaux, France 

520 Identification of a Novel CRF and CRF25_cpx in Saudi 

Arabia, Based on Full Genome Sequence Analysis of 6 HIV-1 

Isolates 

J Yamaguchi1 , S Badreddine2 , P Swanson1 , P Bodelle1 , S Devare1 , and 

Catherine Brennan* 1 

1 2 Abbott Diagnostics, Abbott Park, IL, US and King Faisal Specialist 

Hosp and Res Ctr, Jeddah, Saudi Arabia 

521 HIV-1 Epidemic in Intravenous Drug User Communities in 

Iran Is Driven by Subtype A Viruses 

Luigi Buonaguro* 1 , M Tagliamonte1 , H Naderi2 , M Tornesello1 , R Farid3 , 

and F Buonaguro1 1 2 Natl Cancer Inst “Fndn Pascale”, Naples, Italy; Inst of Infectious 

Diseases, Univ of Mashhad, Iran; and 3Univ of Mashhad, Iran 

522 A Novel Pattern of Evolution of HIV-1 Subtypes and CRF in 

Iran 

S Samiee1 , Z Soheila Soheili2 , and Herve Fleury* 3 

1 2 Iranian Blood Transfusion Org, Tehran; Natl Res Inst of Genetic 

Engineering and Biotech, Tehran, Iran; and 3Univ of Bordeaux, France 

523 HIV among Injection Drugs Users in Chennai: A Different 

Epidemic from Northeastern India? 

Sunil Solomon* 1,2 , S Iqbal2 , P Balakrishnan2 , K Murugavel2 , 

S Mehta1 , S Solomon2 , and D Celentano1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

and 2YRGCARE, Chennai, India 

524 Chronology of the HIV-1 CRF07_BC Expansion in East Asia 

Kok Keng Tee* 1,2 , O Pybus3 , H Liao1 , R Uenishi1 , S Hase1 , 

A Kamarulzaman2 , XJ Li1,4 , and Y Takebe1 1 2 Natl Inst of Infectious Diseases, Tokyo, Japan; Univ of Malaya, Kuala 

Lumpur, Malaysia; 3Univ of Oxford, UK; and 4Shanghai Jiao Tong Univ, 

Shanghai, China 



Epidemiology and Transmission in Adult 

Populations 

525 HIV/AIDS in Europe: Epidemiology in 2006 and a New 

Framework for Surveillance 

Magid Herida* 1 , J Alix2 , I Devaux2 , G Likatavicius2 , S Matic3 , and 

A Nardone2 1European Cttr for Disease Prevention and Control, Stockholm, Sweden; 

2 3 EuroHIV, Inst de Veille Sanitaire, France; and WHO, Regional Office 

for Europe, Copenhagen, Denmark and Stockholm, Sweden 

526 Comparison of Global HIV Incidence: Longitudinal and 

Cross-sectional Estimates 

Melissa Riedesel* 1 , O Laeyendecker1,2 , and T Quinn1,2 1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US and Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US


527 Delayed and Reduced Heterosexual HIV-1 Transmission in 

Zambians with HLA-B*57 

J Tang1 , W Shao1 , Y Yoo1 , I Brill1 , J Mulenga2 , D Chanda2 , S Allen3 , 

E Hunter3 , Richard Kaslow* 1 , and Zambia-Emory HIV-1 Res Project 

1 2 Univ of Alabama at Birmingham, US; Rwanda-Zambia HIV-1 Res 

Group, Lusaka; and 3Emory Univ, Atlanta, GA, US 

528 Slower Clinical Progression in Antiretroviral-naïve African 

Immigrants Compared to Haitian and Canadian Patients in a 

Universal Health Care System 

Marina Keller*, Y Lu, R Lalonde, and M Klein 

McGill Univ Hlth Ctr, Canada 

529 Low Prevalence of HIV-1 and HIV-2 Co-infection 

in Pregnant Women in Bissau: Are the 2 Epidemics 

Independent? 

Erika Gianelli* 1 , F Rankin Bravo2 , A Nanadje2 , D Da Silva Te2 , 

O Bosisio2 , F Adorni1 , B Massetto1 , S Rusconi1 , M Galli1 , and A Riva1 1 2 Univ of Milan, Italy and Assn Céu e Terras, Guinea Bissau, West Africa 

530 Higher Adjusted Mortality Rates among Publicly Insured 

Patients and Blacks in the HIV Outpatient Study 

Frank Palella* 1 , R Baker2 , J Chmiel1 , E Tedaldi3 , R Novak4 , K Buchacz5 , 

and J Brooks5 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Cerner Corp, 

Vienna, VA, US; 3Temple Univ Sch of Med, Philadelphia, PA, US; 4Univ of 

Illinois at Chicago, Coll of Med, US; and 5CDC, Atlanta, GA, US 

b Tuesday, 1-4 pm; Hall A 



New Approaches to HIV Testing 

531 Partner Counseling and Referral Outcomes after Acute HIV 

Identification in North Carolina 

Sandra McCoy* 1 , J Kuruc1 , C Gay1 , C Hurt1 , J Anderson1 , C Pilcher2 , 

J Barnhart3 , J Eron1 , P Leone1,3 , and the North Carolina STAT Team 

1 2 Univ of North Carolina at Chapel Hill, US; Univ of California, San 

Francisco, US; and 3North Carolina Dept of Hlth and Human Svcs, 

Raleigh, US 

532 Acceptance of Routine HIV Testing in Medical Inpatients in 

Nigeria: Implications for a New HIV Testing Approach in 


Olusegun Busari* 1 , M Nakayima2 , O Busari1 , G Oligbu1 , A Adeyemi3 , 

L Onigbogi4 , and HIV Study Group 

1 2 Federal Med Ctr, Ido-Ekiti, Nigeria; AIDS Support Org, Masaka, 

Uganda; 3Hlthmatch Intl, Lagos, Nigeria; and 4Univ Coll Hosp, Ibadan, 

Nigeria 

533 Interim Findings from a Multi-site Evaluation of HIV Testing 

in Emergency Departments 

James Heffelfinger* 1 , R Rothman2 , H Pollack3 , J Brown4 , M Lyons5 , 

G Almond6 , P Sullivan1 , S Barera7 , and G Williams Torres7 1 2 3 CDC, Atlanta, GA, US; Johns Hopkins Univ, Baltimore, MD, US; Univ 

of Chicago, IL, US; 4George Washington Univ, Washington, DC, US; 

5 6 Univ of Cincinnati Coll of Med, OH, US; Metropolitan Hosp Ctr, New 

York, NY, US; and 7Hlth Res and Ed Trust, Chicago, IL, US 

534 Revisiting Expectations from Rapid HIV Test and 

Confirmation in the Emergency Department 

Rochelle Walensky* 1,2,3 , C Arbelaez2 , W Reichmann2 , R Walls2 , J Katz2,4 , 

and E Losina1,2,5 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s Hosp, 

Boston, MA, US; 3Harvard Med Sch, Boston, MA, US; 4Harvard Sch of 

Publ Hlth, Boston, MA, US; and 5Boston Univ Sch of Publ Hlth, MA, US 

535a Patient Perspectives and Testing Uptake with Abbreviated 

versus Standard Pre-test HIV Counseling in the Prenatal 

Setting: A Randomized-Controlled, Non-inferiority Trial 

Deborah Cohan* 1,2 , E Gomez1,2 , and E Charlebois1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp, 

CA, US 

535b Using Multiple Rapid HIV Tests at the Point of Care: 

Implications for Clinicians Receiving Referrals 

Kevin Delaney* 1 , T Knoble2 , J Rurangirwa3 , A Scribner4 , E Hopkins5 , 

B Boyett1 , D White4 , J Haukoos5 , T Dowling2 , and J King3 1 2 CDC, Atlanta, GA, US; HIV Prevention Prgm, City and County of San 

Francisco, CA, US; 3Los Angeles County Dept of Hlth, CA, US; 4Highland Hosp, Alameda County Hlth Ctr, Oakland, CA, US; and 5Denver Hlth 

Med Ctr, CO, US 

b Wednesday, 1-4 pm; Hall A 


Expanding HIV Testing 

536 Ascertainment of HIV, Other Infectious Disease, and 

Metabolic Disorders among Psychiatric Inpatients: A Missed 

Opportunity 

Michael Blank*, A Rothbard, D Young, J Staab, and D Metzger 


537 Dramatic Increase of HIV-testing after Implementing 

Routine Antenatal HIV-testing in Eastern Uganda 

Robert Byamugisha* 1 , M Kagawa1 , J Tumwine2 , C Karamagi2 , 

S Onyango3 , and T Tylleskar4 1 2 Mbale Regional Referral Hosp, Uganda; Makerere Univ, Kampala, 

Uganda; 3Ministry of Hlth, Kampala, Uganda; and 4Univ of Bergen, 

Norway 

538 Routine Offer of a Rapid HIV Test in New York City, Single 

Adult Homeless Assessment Shelters 

Maureen Malave* 1 , V Woog1 , B Tsoi1 , A Gutkovich2 , D Marder2 , 

M Sweeney1 , and B Cutler1 1 2 New York City Dept of Hlth and Mental Hygiene, NY, US and New York 

City Dept of Homeless Svcs, NY, US 

539 Undiagnosed HIV Infection among New York City Jail 

Entrants, 2006: Results of a Blinded Serosurvey 

Y Bennani, F Parvez, L Forgione, J Herrera, Lucia Torian*, M Gbur, and 

E Begier 

New York City Dept of Hlth and Mental Hygiene, NY, US 

540 HIV Prevalence Trends by HIV Testing History, Injection 

Drug Use, and Sexual Risk Behaviors among Inmates 

Entering New York State Correctional Facilities from 1988 to 

2005 

L Wang1 , Lou Smith* 1 , L Wright2 , G Birkhead1 , J Wethers1 , M Young1 , 

B Zhu1 , and P Smith1 1 2 New York State Dept of Hlth, Albany, US and New York State Dept of 

Correctional Svcs, Albany, US 

541 Routine HIV Screening: Testing Patterns in a Highprevalence 

City—Washington, DC, 2006 to 2007 

A Castel1 , T West2 , T Jolaosho2 , C Wu1 , D Hitchcock2 , L Rennie2 , 

M Magnus1 , M Sansone2 , and Alan Greenberg* 1 

1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington, 

DC, US and 2District of Columbia Dept of Hlth, HIV/AIDS Admin, 

Washington, US 

542 Gender Differences in Sexual and HIV Testing Behaviors 

among Heterosexuals at High Risk for HIV in Washington, 

DC 

Manya Magnus* 1 , I Kuo1 , A Rawls1 , K Shelley1 , J Peterson1 , F Hamilton2 , 

T West3 , M Sansone3 , and A Greenberg1 1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington, 

DC, US; 2Family and Med Counseling Svcs, Inc, Washington, DC, US; 

and 3District of Columbia Dept of Hlth, HIV/AIDS Admin, Washington, 

US 

543 Late to Test: Concurrent HIV/AIDS Diagnoses in a City with 

High AIDS Prevalence: Washington, DC, 2007 

A Castel1 , T Jolaosho2 , M Woolfork2 , I Kuo1 , Tiffany West* 2 , and 

A Greenberg1 1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington, 

DC, US and 2District of Columbia Dept of Hlth, HIV/AIDS Admin, 

Washington, US 

544a 4 Years of Surveillance of Recent HIV Infections in France, 

2003 to 2006 

Caroline Semaille* 1 , F Barin2 , J Pillonel1 , F Lot1 , F Cazein1 , R Pinget1 , 

S Brunet2 , D Thierry2 , and JC Desenclos1 1 2 Inst Veille Sanitaire, Saint Maurice, France and Univ Francois-Rabelais, 

Natl AIDS Reference Ctr, Ctr Hosp Univ Bretonneau, Tours, France 

544b Opt-out Rapid HIV Screening in the Emergency Department: 

Preliminary Results from a Prospective Clinical Trial 

Jason Haukoos* 1,2 , E Hopkins1 , R Byyny1,2 , B Bongiovanni3 , B Boyett4 , 

B Dillon3 , J Forsyth4 , J Heffelfinger4 , S Johnson2,5 , M Thrun2,6 , and the 

Denver Emergency Dept HIV Testing Study Group 

1 2 Denver Hlth Med Ctr, CO, US; Univ of Colorado Sch of Med, Denver, 

US; 3Colorado Dept of Publ Hlth and Environment, Denver, US; 4CDC, Atlanta, GA, US; 5Univ of Colorado HIV/AIDS Prgm, Denver, US; and 

6Denver Publ Hlth, CO, US 


Poster Listings





Behavioral Risk in HIV Infection 

545 Comparison of Sexual Risk Behaviors in Non-Hispanic Black 

and White Men Who Have Sex with Men Recruited in Online 

Surveys 

M Chiasson1 , Barbara Taylor* 2 , R Scheinmann1 , S Hirshfield1 , 

M Humberstone1 , R Remien3 , R Wolitski4 , and T Wong5 1 2 Med and Hlth Res Assn of New York City, Inc, NY, US; Columbia Univ 

Med Ctr, New York, NY, US; 3New York State Psychiatric Inst, Columbia 

Univ, New York, US; 4CDC, Atlanta, GA, US; and 5Publ Hlth Agency of 

Canada, Ottawa 

546 HIV Serosorting Practices among HIV-uninfected Gay 

and Bisexual Men in California: San Francisco Bay Area 

Residents vs Circuit Party Attendees 

Albert Liu* 1,2 , P Kittredge1 , H Raymond1 , and S Buchbinder1,2 1 2 San Francisco Dept of Publ Hlth, CA, US and Univ of California, San 

Francisco, US 

547 Mood and Sexual Behavior Profiles of Men Who Have Sex 

with Men in the Context of Methamphetamine and HIV 

Chad Bousman*, M Cherner, B Mausbach, H Atkinson, I Everall, 

S Letendre, T Patterson, I Grant, and the HNRC Group 


548 Condom Failure Does Not Explain Increased Risk of HIV 

Seroconversion Seen in Uncircumcised Men Who Have Sex 

with Men Practicing Insertive Anal Sex 

Jonathan Fuchs* 1,2 , E Vittinghoff2 , P Kittredge1 , and S Buchbinder1,2 1 2 San Francisco Dept of Publ Hlth, CA, US and Univ of California, San 

Francisco, US 

549 The Clinical Presentation of Syphilis in HIV-infected Men 

Who Have Sex with Men in an Urban Clinic 

Lawrence Siegel*, L Drusin, R Gulick, and T Wilkin 

Weill Med Coll of Cornell Univ, New York, NY, US 

550 Characteristics and Behaviors Associated with HIV Infection 

in a Large Southern Prison System 

David Rosen* 1,2 , D Wohl1,2 , B White2 , and V Schoenbach1 1 2 Univ of North Carolina at Chapel Hill Sch of Publ Hlth, US and Univ of 

North Carolina at Chapel Hill Sch of Med, US 

551 Causal Analysis of the Effect of Migration on HIV High-risk 

Behaviors among Mexican Migrants 

Melissa Sanchez* 1 , M Hernandez1 , A Vera2 , L Ayala3 , and G Lemp1 1 2 Univ of California, Oakland, US; Univ of California, San Diego, US; 

and 3United Hlth Ctrs of the San Joaquin Valley Inc, Parlier, CA, US 

552 Correlates of HIV and Other Sexually Transmitted Infections 

in Central American Men Who Have Sex with Men: Defining 

Priorities for an Underserved Population 

A Ghee1 , R Mayorga2 , J Lama3 , C Nunez4 , K Tapia1 , K Holmes1 , and 

Jorge Sanchez* 3 

1 2 Ctr for AIDS and STD, Univ of Washington, Seattle, US; Org for the 

Support of a Comprehensive Sexuality in Response to AIDS, Guatemala 

City, Guatemala; 3Investigaciones Medicas en Salud, Lima, Peru; and 

4Constella-Futures, Guatemala City, Guatemala 

553 Low HIV Incidence and Declining Risk Behaviors in a 

Cohort of Injection Drug Users in Chennai, India 

Sunil Solomon* 1,2 , D Celentano1 , A Srikrishnan2 , C Vasudevan2 , 

K Murugavel2 , E Thamburaj2 , S Anand2 , M Kumar2 , S Solomon2 , and 

S Mehta1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 


554 Low Rates of HIV Incidence in Core Populations at High 

Risk of HIV Infection and Bridge Populations in 6 High HIV 

Prevalence States in India 

Ramesh Paranjape* 1 , S Kulkarni1 , B Ramesh2 , G Brahmam3 , J Mahanta4 , 

J Dale1 , B Kishore Kumar1 , A Risbud1 , R Gangakhedkar1 , and M Gupte5 1 2 Natl AIDS Res Inst, Pune, India; Karnataka Hlth Promotion Trust, 

Bangalore, India; 3Natl Inst of Nutrition, Hyderabad, India; 4Regional Med Res Ctr, Dibrugurh, India; and 5Natl Inst of Epi, Chennai, India 

555 Evidence of Declining HIV Infection Rates in Uganda: 

Implications for Community-based HIV Vaccine Efficacy 

Trials 

David Guwatudde* 1,2 , M Eller2 , L Eller2 , M Millard2 , H Kibuuka2 , 

F Wabwire-Mangen1,2 , N Sewankambo3 , D Serwadda1 , N Michael4 , 

M Robb5 , and the Kayunga District Cohort Devt Res Team 

1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala, 

Uganda; 2Makerere Univ–Walter Reed Project, Kampala, Uganda; 

3 4 Makerere Univ Sch of Med, Kampala, Uganda; Walter Reed Army Inst of 

Res, Rockville, MD, US; and 5Henry M Jackson Fndn, Rockville, MD, US 





Novel PrEP Agents and Evaluation Strategies 

556 An Engineered Bi-functional HIV-1 Neutralizing Protein as a 

Potential Microbicide 

Vadim Villarroel* 1 , L Lagenaur1,2 , and E Berger1 1 2 NIAID, NIH, Bethesda, MD, US and Osel, Inc, Santa Clara, CA, US 

557 Better Protection against HIV-1 Infection in vitro with 

Candidate Microbicide Compounds in Combination 

Susan Schader* 1,2 , B Scarth2 , S Colby-Germinario1 , J Schachter1 , 

J Nuttall3 , M Gotte2 , and M Wainberg1,2 1 2 Lady Davis Inst, Montreal, Canada; McGill Univ, Montreal, Canada; 

and 3Intl Partnership for Microbicides, Silver Spring, MD, US 

558 Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal 

Transmission of HIV-1 in Humanized BLT Mice 

Paul Denton* 1 , J Estes2 , Z Sun1 , F Othieno1 , D Powell1 , A Haase2 , and 

V Garcia1 1 2 Univ of Texas Southwestern Med Ctr, Dallas, US and Univ of 


559a Size-fitting of Intravaginal Rings for Macaques and in vitro 

Release Kinetics of Zinc Finger Inhibitors 

James Smith* 1 , K Malcolm2 , E Appella3 , C McConville2 , M Schito3 , 

D Woolfson2 , R Hayashi3 , N Lanier1 , R Otten1 , and S Butera1 1 2 CDC, Atlanta, GA, US; Queen’s Univ of Belfast, Sch of Pharmacy, 

Northern Ireland; and 3NCI, NIH, Bethesda, MD, US 

559b Safety and Pharmacokinetic Assessment of 28-Day Anti-HIV 

Dapivirine Intravaginal Microbicide Rings 

Annalene Nel* 1 , S Smythe1 , K Young1 , K Malcolm2 , Z Rosenberg1 , and 

J Romano1 1 2 Intl Partnership for Microbicides, Silver Spring, MD, US and Queen’s 

Univ, Belfast, Northern Ireland 

560 Topical Application of Fully Recombinant RANTES Analogs 

Protect Macaques from Vaginal SHIV Transmission 

Ronald Veazey* 1 , M Lederman2 , B Ling1 , L Green1 , E Ribka1 , D Mosier3 , 

R Offord4,5 , and O Hartley4 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Case Western 

Reserve Univ, Cleveland, OH, US; 3Scripps Res Inst, La Jolla, CA, US; 

4 5 Univ of Geneva, Switzerland; and Mintaka Fndn for Med Res, Geneva, 

Switzerland 



HIV-1 Prevention for Positives 

561 Implementation and Evaluation of a Clinic-based Behavioral 

Intervention: Positive STEPS for HIV Patients 

Lytt Gardner* 1 , G Marks1 , C O’Daniels2 , T Wilson3 , E Quinlivan4 , 

J Wright5 , L Bradley-Springer6 , M Thompson7 , S Raffanti8 , and M Thrun9 1 2 CDC, Atlanta, GA, US; McKing Consulting Corp, Atlanta, GA, US; 

3 4 State Univ of New York at Brooklyn, US; Univ of North Carolina at 

Chapel Hill, US; 5Univ of Missouri, Kansas City, US; 6Univ of Colorado 

Hlth Sci Ctr, Denver, US; 7AIDS Res Consortium of Atlanta, GA, US; 

8 9 Vanderbilt Univ, Nashville, TN, US; and Denver Publ Hlth, CO, US 

562 Translating Research into Practice: Successful Replication of 

a Clinic-based Positive Prevention Intervention 

Lisa Hirschhorn* 1 , M Stylos Allan1 , F Marshman1 , D Cornman2 , 

L Kunches1 , Y Hamby1 , S Christie2 , and K McElroy3 1 2 JSI Res and Training, Boston, MA, US; Univ of Connecticut, Storrs, 

US; and 3HIV/AIDS Bureau, Hlth Resources and Svcs Admin, Rockville, 

MD, US 



Modeling the Cost-effectiveness and Impact of 

PrEP on Resistance 

563 Effect of Pre-exposure HIV Prophylaxis on Lifetime Infection 

Risk, Survival, and Cost 

David Paltiel* 1 , K Freedberg2,3 , C Scott3 , B Schackman4 , E Losina5 , 

B Wang3 , G Seage6 , C Sloan3 , P Sax2,5 , and R Walensky2,3 1 2 Yale Univ Sch of Med, New Haven, CT, US; Harvard Med Sch, Boston, 

MA, US; 3Massachusetts Gen Hosp, Boston, US; 4Weill Med Coll of 

Cornell Univ, New York, NY, US; 5Brigham and Women’s Hosp, Boston, 

MA, US; and 6Harvard Sch of Publ Hlth, Boston, MA, US 

564 Modeling the Emergence and Spread of HIV Drug Resistance 

from Antiretroviral Pre-exposure Chemoprophylaxis 

Ume Abbas* 1 , R Anderson2 , and J Mellors1 1 2 Univ of Pittsburgh, PA, US and Imperial Coll, London, UK




Preclinical and Clinical Studies of Topical and Oral 

PrEP 

565 Inhibitory Effect of PRO 2000, a Candidate Microbicide, on 

Dendritic Cell-mediated HIV Transmission 

Natalia Teleshova* 1 , T Chang1 , A Profy2 , and M Klotman1 1 2 Mt Sinai Sch of Med, New York, NY, US and Indevus Pharma Inc, 

Lexington, MA, US 

566 Evaluation of the Safety of Carraguard for Vaginal Use by 

HIV-infected Women: Results from a Phase I, Randomized, 

Placebo-controlled, 3-Treatment Cross-over Study 

Catherine McLean* 1 , H Jones2 , J McNicholl3 , J van de Wijgert4 , 

T Medtanavyn5 , W Uthaiworavit6 , S Whitehead3 , J Karon7 , P Kilmarx1 , 

and L Markowitz1 1 2 CDC, Atlanta, GA, US; Population Council, New York, NY, US; 

3Thailand Ministry of Publ Hlth-US CDC Collaboration, Nonthaburi; 

4 5 Academic Med Ctr, Univ of Amsterdam, The Netherlands; Chiang Rai 

Provincial Hlth Office, Thailand; 6Chiang Rai Hosp, Thailand; and 

7Emergint Corp, Louisville, KY, US 

567 HIV Seroconversion Patterns Observed in the Microbicides 

Development Programme 301 Trial 

Ute Jentsch* 1 , W Stevens1 , P Lunga2 , S McCormack2 , A Nunn2 , C Lacey3 , 

and J Weber4 1Univ of the Witwatersrand, Sch of Pathology, Johannesburg, South 

Africa; 2Med Res Council, London, UK; 3Univ of York, Heslington, UK; 

and 4Imperial Coll Sch of Med, London, UK 

568 Enrollment, Risk Behavior, and Adherence of Injecting Drug 

Users in an HIV Prevention Trial in Bangkok 

K Choopanya1 , Michael Martin* 2,3 , S Vanichseni1 , U Sangkum1 , 

R Chuachoowong2 , M Leethochawalit4 , S Chiamwongpaet4 , 

S Kittimunkong5 , J McNicholl2,3 , P Suntharasamai1 , and the Bangkok 

Tenofovir Study Group 

1 2 Bangkok Tenofovir Study Group, Thailand; Thailand Ministry of Publ 

Hlth-US CDC Collaboration, Nonthaburi; 3CDC, Atlanta, GA, US; 

4 5 Bangkok Metropolitan Admin, Thailand; and Thailand Ministry of Publ 

Hlth 

569 iPrEx: A Timely Intervention Unfolds in a Population of 

Eminent Risk of HIV infection 

Jeff McConnell* 1 , R Grant1,2 , P Goicochea3 , J Guanira4 , M Casapia5 , 

O Guerra4 , L Vargas3 , V McMahan1 , and J Lama3,4 1Gladstone Inst of Virology and Immunology, San Francisco, CA, US; 

2 3 Univ of California, San Francisco, US; Investigaciones Medicas en 

Salud, Lima, Peru; 4Civil Impacta Salud y Educacion, Lima, Peru; and 

5Assn Civil Selva Amazonica, Iquitos, Peru 

570 No Evidence of Drug-resistance Mutations in a 

Seroconverter Exposed to Tenofovir Disoproxil Fumarate 

Chemoprophylaxis in Africa 

R Atchison1 , L Peterson2 , T Leigler3 , W Cates2 , and R Grant* 1,3 

1Gladstone Inst of Virology and Immunology, San Francisco, CA, 

US; 2Family Hlth Intl, Durham, NC, US; and 3Univ of California, San 

Francisco, US 



Pharmacokinetics and Children 

571 Nelfinavir Pharmacokinetics with an Increased Dose during 

the First 2 Weeks of Life 

Mark Mirochnick* 1 , K Nielsen-Saines2 , J Pilotto3 , J Pinto4 , V Veloso5 , 

D Holland6 , H Watts7 , J Moye7 , L Mofenson7 , Y Bryson2 , and NICHD/ 

HPTN 040/PACTG 1043 Protocol Team 

1 2 Boston Univ Sch of Med, MA, US; David Geffen Sch of Med, Univ 

of California, Los Angeles, US; 3Hosp Geral de Nova Iguaçu, Brazil; 

4 5 Federal Univ of Minas Gerais, Belo Horizonte, Brazil; Fiocruz Inst, Rio 

de Janeiro, Brazil; 6Univ of California, San Diego, US; and 7Natl Inst of 

Child Hlth and Human Devt, NIH, Bethesda, MD, US 

572 CYP2C19 Genetic Variants Affect Nelfinavir and M8 

Pharmacokinetics and Virologic Response in HIV-1 infected 

Children Receiving HAART 

Akihiko Saitoh* 1 , E Sarles1 , E Capparelli1 , F Aweeka2 , A Kovacs3 , 

S Buchett4 , A Wiznia5 , S Nachman6 , T Fenton7 , and S Spector1 1 2 Univ of California, San Diego, US; Univ of California, San Francisco, 

US; 3Univ of Southern California, Los Angeles, US; 4Harvard Med Sch, 

Boston, MA, US; 5Jacobi Med Ctr, Bronx, NY, US; 6State Univ of New York 

at Stony Brook, US; and 7Harvard Sch of Publ Hlth, Boston, MA, US 

573 Lopinavir Pharmacokinetic Maturational Changes and 

Variability in HIV-infected Infants Beginning Kaletra 

Therapy at



583 Early Effectiveness of a NVP-based HAART Regimen among 

HIV-infected Children with and without Prior Single-dose 

NVP Exposure 

Linda Barlow-Mosha*, P Ajunua, M Mubiru, D Bagenda, 

M Luttajumwa, B Musoke, M Owor, and P Musoke 

Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala, Uganda 

584 Initial Growth, CD4, and Viral Load Responses to HAART in 

Ugandan Compared to UK/Irish HIV-infected Children 

Addy Kekitiinwa* 1 , K Lee2 , A Walker2 , A Maganda1 , K Doerholt2 , 

H Lyall3 , K Butler4 , A Asiimwe1 , M Kline1 , and D Gibb2 1Baylor Coll of Med Children’s Fndn, Pediatric Infectious Disease Clin, 

Mulago Hosp, Uganda; 2Med Res Council Clinical Trials Unit, London, 

UK; 3St Mary’s Hosp, London, UK; and 4Our Lady’s Hosp for Sick 

Children, Dublin, Ireland 

585 Examination of HIV-1 Subtype and Response to ART in 

Ugandan Children 

Addy Kekitiinwa* 1 , P Kasirye1 , D Friedman2 , E Coakley3 , Y Lie3 , and 

F Graziano2 1 2 Mulago Hosp, Kampala Uganda; Univ of Wisconsin Hosp and Clin, 

Madison, US; and 3Monogram Biosci, South San Francisco, CA, US 

586 Efficacy and Safety of Double-boosted SQV/LPV/r 

Combination at 96 Weeks in Thai Children Who Have Failed 

NRTI/NNRTI-based Regimens 

Torsak Bunupuradah* 1 , P Kosalaraksa2 , C Engchanil2 , P Boonrak1 , 

T Hirunyanulux1 , S Ubolyam1 , P Lumbiganon2 , K Ruxrungtham1,3 , 

E Labriola-Tompkins4 , J Ananworanich1,5 , and HIV-NAT 017 Study Team 

1 2 HIV Netherlands Australia Thailand Res Collaboration, Bangkok; Khon 

Kaen Univ, Thailand; 3Chulalongkorn Univ, Bangkok, Thailand; 4Roche, Nutley, NJ, US; and 5South East Asia Res Collaboration with Univ of 

Hawaii, Bangkok, Thailand 



Resistance after First-line Failure in Children 

587 Prospective Analysis of HIV-1 Drug Resistance after 

Virologic Failure on ART: Initial Results from a Pediatric 

Cohort Study from KwaZulu Natal, South Africa 

Henry Sunpath* 1 , H France1 , T Michelle2 , V Marconi3 , R Murphy4 , 

C Kanegai4 , Z Lu5,6 , E Losina5,6 , B Walker6 , and D Kuritzkes4 1 2 McCord Hosp, Durban, South Africa; Inkosi Albert Hosp, Durban, 

South Africa; 3TriService AIDS Clinical Consortium, Wilford Hall USAF 

Med Ctr, Lackland AFB, TX, US; 4Brigham and Women’s Hosp, Boston, 

MA, US; 5Massachusetts Gen Hosp, Boston, US; and 6Harvard Med Sch, 


588 HIV-1 Drug Resistance Mutations in Children Failing an 

Initial NRTI-based Regimen and Options for a Second-line 

Antiretroviral Regimen 

Somnuek Sungkanuparph*, N Apiwattanakul, A Thititanyanont, 

W Chantratita, and S Sirinavin 

Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand 

589 Surveillance of Drug-resistant Mutations in HIV-1 Subtype C 

Children Failing ART 

Carole Wallis* 1 , L Erasmus1,2 , S Varughese1 , D Ndiweni1 , and 

W Stevens1,2 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Natl Hlth 

Lab Svc, Johannesburg, South Africa 



Complications, Neurodevelopments and ARTrelated 

Toxicities in Children 

590 High Risk of Neutropenia in HIV-infected Children 

following Treatment with Artesunate + Amodiaquine for 

Uncomplicated Malaria in Uganda 

Moses Kamya* 1 , A Gasasira1 , J Achan1 , T Ruel2 , E Charlebois2 , 

S Staedke3 , A Kekitiinwa4 , P Rosenthal2 , G Dorsey2 , and D Havlir2 1 2 Makerere Univ Med Sch, Kampala, Uganda; Univ of California, San 

Francisco, US; 3London Sch of Hygiene and Tropical Med, UK; and 

4Mulago Hosp, Kampala, Uganda 

591 Impaired Glucose Tolerance and Other Metabolic 

Abnormalities in Adolescents and Young Adults with HIV 

Infection Acquired Perinatally or in Childhood 

C Hadigan1 , J Purdy2 , C Worrell3 , H Gebrehiwet2 , and Rohan Hazra* 2,3 

1 2 3 NIAID, NIH, Bethesda, MD, US; NCI, Bethesda, MD, US; and Natl Inst 

of Child Hlth and Human Devt, NIH, Bethesda, MD, US 

592 Time Course and Predictors of Glucose Homeostasis in 

HAART-treated HIV-infected Children and Adolescents: 4 

Years of Follow-up 

Alessandra Vigano* 1 , P Brambilla2 , G Pattarino1 , S Stucchi1 , S Fasan1 , 

C Raimondi1 , V Giacomet1 , and G Bedogni3 1 2 Hosp Luigi Sacco, Univ of Milan, Italy; Azienda Sanitaria Locale, 

Milan, Italy; and 3Liver Res Ctr, Trieste, Italy 


593 Vitamin Deficiency in Children with Perinatally Acquired 

HIV Infection 

Richard Rutstein* 1 , A Downes2 , B Zemel1 , J Schall1 , B Hollis3 , and 

V Stallings1 1 2 Children’s Hosp of Philadelphia, PA, US; Univ of Pennsylvania Sch of 

Med, Philadelphia, US; and 3Med Univ of South Carolina, Charleston, US 

594 Neurocognitive Disturbances in HIV-infected Children with 

Viremia 

Samuel Foster* 1 , L Harris1 , D Armstrong2 , C Kozinetz1 , P Brouwers1 , 

T Miller2 , J Reuben3 , D Glaze1 , S Lipshultz2 , W Shearer1 , and the HIV 

Sleep Study Group 

1 2 Baylor Coll of Med, Houston, TX, US; Univ of Miami, Leonard M Miller 

Sch of Med, FL, US; and 3MD Anderson Cancer Ctr, Univ of Texas, 

Houston, US 

595 Leg Fat Is Decreased but Arm Fat Is Increased in HIVinfected 

Children and Adolescents Receiving Antiretroviral 

Medications 

Stephen Arpadi* 1 , J Bethel2 , M Horlick1 , M Sarr2 , M Bamji3 , E Abrams4 , 

M Puswani5 , and E Engelson1 1 2 St Luke’s Roosevelt Hosp Ctr, Columbia Univ, New York, NY, US; Westat, 

Bethesda, MD, US; 3Metropolitan Hosp Ctr, New York, NY, US; 4Harlem Hosp Ctr, New York, NY, US; and 5Bronx-Lebanon Hosp Ctr, NY, US 

596 Applicability of Quantitative Ultrasonography of the Radius 

and Tibia in HIV-infected Children and Adolescents 

Alessandra Vigano* 1 , L Cafarelli1 , G Pattarino1 , V Giacomet1 , C Cerini1 , 

V Fabiano1 , C Gabiano2 , G Zuccotti1 , and S Mora3 1 2 Hosp Luigi Sacco, Univ of Milan, Italy; Regina Margherita Hosp, Univ 

of Turin, Italy; and 3San Raffaele Sci Inst, Milan, Italy 

597 Partial Restoration of Mitochondrial DNA Content in 

Perinatally HIV-infected Pediatric Patients after Planned 

Interruption of HAART 

Antoni Noguera* 1 , C Moren1 , E Corrales1 , E Sanchez2 , G Garrabou1 , 

V Rodriguez1 , O Miro1 , and C Fortuny1 1 2 Hosp St Joan de Deu, Univ of Barcelona, Spain and Catalan Agency for 

Hlth Tech Assessment and Res, Barcelona, Spain 

598 Possible Mitochondrial Dysfunction in a Large US Cohort of 

HIV-infected Children 

Marilyn Crain* 1 , M Chernoff2 , J Oleske3 , S Brogly2 , K Malee4 , P Borum5 , 

W Mitchell6 , H Fort-Chatterton7 , R Van Dyke8 , and G Seage2 1 2 Univ of Alabama at Birmingham, US; Harvard Sch of Publ Hlth, Boston, 

MA, US; 3Univ of Med and Dentistry of New Jersey, New Jersey Med 

Sch, Newark, US; 4Children’s Mem Hosp, Chicago, IL, US; 5Univ of 

Florida, Gainesville, US; 6Children’s Hosp Los Angeles and Keck Sch of 

Med, Univ of Southern California, US; 7Frontier Sci and Tech Res Fndn, 

Amherst, NY, US; and 8Tulane Univ, New Orleans, LA, US 



Mycobacterial Disease in Children 

599 Prevalence and Clinical Features of MAC Infection in HIV + 

South African Children Attending Harriet Shezi Clinic, Chris 

Hani Baragwanath Hospital: A Retrospective Analysis 

Lee Kleynhans* 1 , M Palmer1 , A Goga1 , M Yotebien2 , and T Meyers1 1Harriet Shezi Clin, Chris Hani Baragwaneth Hosp, Johannesburg, South 

Africa and 2Columbia Univ, New York, NY, US 

600 Complications of BCG Vaccination in HIV-infected and 

-uninfected Children: CHER Study 

Helena Rabie* 1 , A Violari2 , S Madhi2 , D Gibb3 , J Steyn2 , R van Niekerk2 , 

D Josipovic2 , S Innes1 , and M Cotton1 1 2 Faculty of Hlth Sci, Stellenbosch Univ, South Africa; Univ of the 

Witwatersrand, Johannesburg, South Africa; and 3Med Res Council 

Clinical Trials Unit, London, UK 

601 School Attendance as a Risk Factor for Incident TB among 

HIV-infected Children in Western Kenya 

P Braitstein* 1,2,3 , C Yiannoutsos1 , A Mwangi3,4 , R Vreeman1 , 

Kara Wools-Kaloustian* 1 , J Sidle1,2,3 , B Musick1 , S Ayaya2,3 , J Carter4 , and 

W Nyandiko2,3 1 2 3 Indiana Univ, Indianapolis, US; Moi Univ, Eldoret, Kenya; Moi 

Teaching and Referral Hosp, Eldoret, Kenya; and 4Brown Univ, 

Providence, RI, US 



Prevention, Identification and Treatment of at-Risk 

and HIV-infected Adolescents 

602 Comparison of the Current Health Status and Selected 

Baseline Characteristics of Perinatally and Behaviorally 

HIV-infected Children and Adolescents, through 24 Years 

of Age in the US: The CDC LEGACY Cohort Study, 2006 to 

2007 

Kenneth Dominguez* 1 , B Bohannon 1 , J Milum 2 , and the CDC LEGACY 

Consortium 

1 CDC, Atlanta, GA, US and 2 Ginn Group Inc, Atlanta, GA, US


603 Discordance in HAART Utilization Rates in HIV-1-infected 

Adolescents in a Multi-site US Cohort 

Allison Agwu* 1 , J Ellen1 , R Rutstein2 , A Gaur3 , S Spector4 , R Warford5 , 

G Siberry1 , and K Gebo1 for the HIV Res Network 

1 2 Johns Hopkins Univ, Baltimore, MD, US; Children’s Hosp of 

Philadelphia, PA, US; 3St Jude Children’s Res Hosp, Memphis, TN, US; 

4 5 Univ of California, San Diego, US; and St Luke’s Roosevelt Hosp, New 

York, NY, US 

604 Directly Observed Therapy for Non-adherent HIV-infected 

Adolescents—Lessons Learned, Challenges Ahead 

Aditya Gaur* 1 , M Belzer2 , P Britto3 , P Garvie1 , C Hu3 , B Graham4 , 

K Klingman5 , M Neely6 , G McSherry7 , and P Flynn1 1 2 St Jude Children’s Res Hosp, Memphis, TN, US; Children’s Hosp Los 

Angeles, CA, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Frontier Sci and Tech Res Fndn, Amherst, NY, US; 5Div of AIDS, NIAID, NIH, 

Bethesda, MD, US; 6Univ of Southern California, Los Angeles, US; and 

7Univ of Med and Dentistry of New Jersey, Newark, US 

605 Poor Virologic Control in Pregnant Adolescents with 

Perinatally Acquired HIV Infection as Compared to 

Horizontally Infected Pregnant Women 

Usha Phillips* 1 , J Sansary2 , M Rosenberg2 , J Dobroszycki2 , M Katz2 , 

A Wiznia2 , and J Abadi2 1Montefiore Med Ctr, Albert Einstein Coll of Med, Bronx, NY, US and 

2Jacobi Med Ctr, Albert Einstein Coll of Med, Bronx, NY, US 

606 Risk Factors for HIV Infection among Sexually Active 

Adolescents and Youth Seeking Voluntary Counseling and 

Testing in Haiti 

Tsogzolmaa Dorjgochoo* 1 , F Noel2,3 , M Deschamps2,3 , 

H Theodore2,3 , W Dupont1 , P Wright1,3 , D Fitzgerald2,3 , S Vermund1 , and 

J Pape2,3 1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Weill Med Coll of 

Cornell Univ, New York, NY, US; and 3GHESKIO, Port-au-Prince, Haiti 

607 Preparing for Adolescent HIV Vaccine Trials: Will 

Adolescent Participants Experience Social Harms? 

Daniella Mark* 1 , H Jaspan1,2 , E Burrell1 , P Mthimunye1 , 

K Middelkoop1 , N Soka1 , R Wood1 , and LG Bekker1 1Desmond Tutu HIV Ctr, Inst of Infectious Disease and Molecular Med, 

Univ of Cape Town, South Africa and 2Tygerberg Hosp, Cape Town, South 

Africa 



Special Considerations in Laboratory Studies for 

Children 

608 Evaluation of Relationship between CD4 and Total 

Lymphocyte Count in Children with HIV 

Jason Brophy*, E Atenafu, S Read, D Stephens, J Beyene, and A Bitnun 

Hosp for Sick Children, Toronto, Canada 

609 Utility of Total Lymphocyte Count as a Surrogate Marker for 

CD4 Cell Count in HIV-infected Children 

Leah Githinji* 1 , D Mbori-Ngacha2 , and E Obimbo1 1 2 Univ of Nairobi, Kenya and CDC, Atlanta, GA, US 

610 Discordance between Absolute CD4 + T Lymphocyte Count 

and CD4 + T Lymphocyte Percentage among HIV + Children 

in Botswana 

Elizabeth Lowenthal* 1,2 , H Jibril1,3,4 , H Draper2 , M Marape1,2 , M McGrann1,2 , 

M Sechele1 , O Rankopo1 , B Kgathi1 , R Sello1 , and G Anabwani1,2 1Botswana Baylor Children’s Clinical Ctr of Excellence, Gaborone; 

2 3 Baylor Intl Pediatric AIDS Initiative, Houston, TX, US; Botswana 

Ministry of Hlth; and 4Princess Marina Hosp, Gaborone, Botswana 

611 Normal Laboratory Reference Values for Ugandan and 

Malawian Infants: A Comparison with the DAIDS Toxicity 

Tables 

Irene Lubega* 1 , M Fowler1 , A Elbireer1 , D Bagenda1 , G Kafulafula2 , 

J Ko3 , L Mipando4 , M Mubiru1 , N Kumwenda3 , and T Taha3 1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala, 

Uganda; 2Coll of Med, Univ of Malawi; 3Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US; and 4Johns Hopkins-Malawi Coll 

of Med Res Project 



Transmission and Diagnosis of HIV Infection in 

Infants and Children 

612 Benefits of Routine HIV Screening in Sick Children in 

Nigeria 

L Lu 1 , Omotayo Bolu* 1 , C Omeogu 2 , A Abutu 3 , C Nwude 3 , R Akpan 3 , 

K Bond 3 , E Ngige 4 , CY Ou 1 , and J Vertefeuille 2 

1 CDC, Atlanta, GA, US; 2 USAID, Abuja, Nigeria; 3 Global AIDS Prgm, 

CDC Nigeria, Abuja; and 4 Federal Ministry of Hlth, Abuja, Nigeria 

613a Validity and Acceptability of Rapid HIV-1 Tests in 9-monthold 

Infants in Kenya 

Jessica Opoku-Anane* 1 , J Kinuthia2,3 , F Njiri John3 , M Chung4 , 

D Mbori-Ngacha2,3 , G John-Stewart4 , C Farquhar4 , and J Kiari2,3 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Kenyatta Natl 

Hosp, Nairobi, Kenya; 3Univ of Nairobi, Kenya; and 4Univ of Washington, 

Seattle, US 

613b Practice of Offering a Child Pre-masticated Food: An 

Unrecognized Possible Risk Factor for HIV Transmission 

Aditya Gaur* 1 , K Dominguez2 , M Kalish2 , D Rivera-Hernandez3 , 

M Donohoe1 , and C Mitchell3 1 2 St Jude Children’s Res Hosp, Memphis, TN, US; CDC, Atlanta, GA, US; 

and 3Univ of Miami, Leonard M Miller Sch of Med, FL, US 



Immune Response in Children 

614 Profile of T Cell Immune Responses in HIV-infected 

Children from Uganda 

Isaac Ssewanyana* 1 , M Elrefaei2 , G Dorsey3 , T Ruel3 , E Charlebois3 , 

A Gasasira4 , M Kamya4 , J Achan4 , D Havlir3 , and H Cao2 1 2 Joint Clin Res Ctr, Kampala, Uganda; California Dept of Publ Hlth, 

Richmond, US; 3Univ of California, San Francisco, US; and 4Makerere Univ, Kampala, Uganda 

615 Dynamics of T Cell Activation Accompanying CD4 Recovery 

in Antiretroviral-treated HIV-infected Ugandan Children 

Theodore Ruel* 1 , I Ssewanyana2 , J Achan3 , A Gasasira4 , M Kamya3 , 

A Kekitiinwa5 , J Wong1 , H Cao6 , D Havlir1 , and E Charlebois1 1 2 Univ of California, San Francisco, US; Joint Clin Res Ctr, Kampala, 

Uganda; 3Faculty of Med, Makerere Univ, Kampala, Uganda; 4Univ of 

California, Berkeley, US; 5Baylor Coll of Med, Mulago Hosp, Kampala, 

Uganda; and 6California Dept of Hlth Svcs, Richmond, US 

616 Protease Inhibitor-based Therapy and Enhanced CD8 + 

T Cell Apoptosis in HIV-infected Adolescents 

Jun Zuo* 1 , J Church2 , M Belzer2 , C Kitchen1 , B Ank1 , I Schmidt1 , and 

P Krogstad1 1David Geffen Sch of Med, Univ of California, Los Angeles, US and 

2Children’s Hosp Los Angeles and Keck Sch of Med at Univ of Southern 

California, US 

617 High Apoptosis Levels and Decreased B Memory Cell 

Percentages Leads to Long-term Serologic Memory Damage 

in HIV-infected Children 

Maristela Miyamoto*, S Pessoa, E Ono, R Succi, R Salomao, and 

I de Moraes-Pinto 

Federal Univ of Sao Paulo, Brazil 

618 Long-term Serologic Immune Response to Hepatitis B 

Vaccination and CD38 + Expression on CD8 + T Lymphocytes 

in HIV-infected Adolescents on HAART 

Silvana Pessoa*, M Miyamoto, E Ono, A Gouvea, R Salomao, L Weckx, 

I de Moraes-Pinto, and R Succi 

Federal Univ of Sao Paulo, Brazil 

619a Safety and Immunogenicity of a Quadrivalent Vaccine to 

Prevent Human Papilloma Virus Infection in HIV-infected 

Children: IMPAACT P1047 

Adriana Weinberg* 1 , LY Song2 , E Handelsman3 , A Moscicki4 , 

J Patterson1 , A Saah5 , D Radley5 , J Read6 , M Levin1 , and IMPAACT 

P1047 Team 

1 2 Univ of Colorado Sch of Med, Denver, US; Statistical and Data Analysis 

Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Div of AIDS, NIAID, 

NIH, Bethesda, MD, US; 4Univ of California, San Francisco, US; 5Merck & Co, West Point, PA, US; and 6Natl Inst of Child Hlth and Human Devt, 


619b Antigen-specific CD4 + Immune Responses against HIV 

Measured by ELISpot in Vertically HIV-infected HAARTtreated 

Children after Planned Treatment Interruption 

L Alsina1 , Antoni Noguera* 1 , R Bellido2 , L Ruiz2 , E Sanchez3 , and 

C Fortuny1 1 2 Hosp St Joan de Deu, Univ of Barcelona, Spain; irsiCaixa Fndn, 

Hosp Germans Trias i Pujol, Univ Autonoma de Barcelona, Spain; and 

3Catalan Agency for Hlth Tech Assessment and Res, Barcelona, Spain 



Viral and Host Factors Associated with Pediatric 


620 Association of HIV-1 Infectivity on CCR5-bearing Cells with 

Survival in Vertically-infected Ugandan Infants 

Jessica Church* 1 , W Huang 2 , A Mwatha 3 , J Toma 2 , D Donnell 3 , 

L Guay 1 , F Mmiro 4 , P Musoke 5 , B Jackson 1 , and S Eshleman 1 

1 Johns Hopkins Univ, Baltimore, MD, US; 2 Monogram Biosci, South San 

Francisco, CA, US; 3 Statistical Ctr for HIV/AIDS Res and Prevention, 

Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 4 Makerere 

Univ–Johns Hopkins Univ Res Collaboration, Kampala, Uganda; and 

5 Makerere Univ, Kampala, Uganda 


Poster Listings



621 Genetic Variants of Toll-like Receptors-2, -4, and -9 Are Not 

Associated with HIV-1 Disease in Children 

Kumud Singh* 1 , P Ruan2 , T Fenton2 , and S Spector1 1 2 Univ of California, San Diego, US and Harvard Sch of Publ Hlth, 


622 RANTES-403-G/A Variants Are Associated with HIV-1 

Disease Progression and CNS Impairment in Children


637 Risk Factors for Mother-to-Child Transmission of HIV-1 

from Breastfeeding in a Randomized Clinical Trial in 

Botswana: The Mashi Study 

Roger Shapiro* 1 , L Smeaton2 , S Lockman3 , I Thior4 , R Rossenkhan4 , 

C Wester4 , L Stevens4 , J Leidner2 , J Makhema4 , and M Essex2 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Harvard Sch of Publ 

Hlth, Boston, MA, US; 3Brigham and Women’s Hosp, Boston, MA, US; 

and 4Botswana Harvard Sch of Publ Hlth AIDS Initiative Partnership for 

HIV Res and Ed, Gaborone 

638 HIV-free Survival at 12 Months among Children Born to 

HIV-infected Women Receiving Antiretrovirals from 34 to 36 

Weeks of Pregnancy 

Isabelle de Vincenzi and the Kesho Bora Study Group 

WHO, Geneva, Switzerland 

639 Decrease in HIV-1 Mother-to-Child Transmission in Women 

Receiving Postnatal HAART: 12-Month Follow-up Data 

M Marazzi1 , L Palombi2 , G Liotta2 , P Germano3 , N Abdul Majid4 , 

I Zimba4 , A Doro Altan2 , G Bortolot3 , and Karin Nielsen-Saines* 5 

1 2 3 LUMSA Univ, Rome, Italy; Univ of Tor Vergata, Rome, Italy; DREAM 

Prgm, Community of St Egidio, Italy; 4Benfica Hlth Ctr, Maputo, 

Mozambique; and 5David Geffen Sch of Med, Univ of California, Los 

Angeles, US 

640 Comparison of Adverse Fetal Outcomes in HIV-1-infected 

Antiretroviral-naïve Pregnant Women Who Have Received 

Combivir and Either Nevirapine or Nelfinavir for Prevention 

of Mother-to-Child Transmission Antenatally 

Rose Masaba* 1 , R Ndivo1 , I Nyangau1 , K Achola1 , C Zeh2 , 

M Thigpen3 , P Weidle3 , and T Thomas2 1 2 3 Kenya Med Res Inst, Kisumu; CDC Kenya, Kisumu; and CDC, Atlanta, 

GA, US 

641 Low Birth Weight with Nevirapine-based ART in Abidjan, 

Côte d’Ivoire: The ANRS Ditrame Plus Cohort and MTCT- 

Plus Initiative, 2001 to 2007 

Didier Ekouevi* 1,2 , B Tonwe-Gold1,3 , R Becquet1 , P Coffie1,2 , P Toure3 , 

V Leroy1 , I Viho2 , S Blanche4 , F Dabis1 , and E Abrams5 1INSERM U593, Inst for Publ Hlth, Epi and Devt, Bordeaux, France; 

2Natl Agency for AIDS Res Ditrame Plus Project, Abidjan, Côte d’Ivoire; 

3 4 ACONDA, NGO, Abidjan, Côte d’Ivoire; Hosp Necker, Paris France; 

and 5MTCT-Plus Initiative, New York, NY, US 



Infant Feeding, PMTCT and Infant Outcome 

642 Predictors of Early and Late MTCT of HIV in a 

Breastfeeding Population: HIVNET 012 Experience, 


Jim Aizire* 1 , F Mmiro1 , A Mwatha2 , S Eshleman3 , D Donell2 , 

M Fowler3 , M Allen4 , P Musoke1 , B Jackson3 , and L Guay3 1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala, 

Uganda; 2Statistical Ctr for HIV/AIDS Res and Prevention, Fred 

Hutchinson Cancer Res Ctr, Seattle, WA, US; 3Johns Hopkins Univ Sch of 

Med, Baltimore, MD, US; and 4Family Hlth Intl, Durham, NC, US 

643 Risk Factors for and Timing of Infant Mortality among HIVexposed 

Children: A Randomized Clinical Trial in Botswana 

Shahin Lockman* 1,2,3 , L Smeaton3 , R Shapiro2,3,4 , I Thior2 , C Wester2 , 

J Makhema2 , A Ogwu2 , A Asmelash2 , E van Widenfelt2 , and M Essex2,3 1 2 Brigham and Women’s Hosp, Boston, MA, US; Botswana Harvard Sch 

of Publ Hlth AIDS Initiative Partnership for HIV Res and Ed, Gaborone; 

3 4 Harvard Sch of Publ Hlth, Boston, MA, US; and Beth Israel Deaconess 

Med Ctr, Boston, MA, US 

644 Infectious Morbidity and Mortality in Formula-fed Infants 

Born to Women Infected by HIV 

Karin Nielsen-Saines* 1 , H Watts2 , J Pilotto3 , E Joao4 , G Gray5 , 

J McIntyre6 , J Bethel7 , L Mofenson2 , M Camarca7 , J Moye2 , and the 

NICHD HPTN 040 Study Team 

1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US; Natl Inst 

of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 3Hosp Geral de 

Nova Iguacu, Rio de Janeiro, Brazil; 4Hosp dos Servidores do Estado, 

Rio de Janeiro, Brazil; 5Soweto Clinical Trials Unit, Johannesburg, South 

Africa; 6Univ of the Witwatersrand, Johannesburg, South Africa; and 

7Westat, Rockville, MD, US 

645 Assessment of Exclusive Breastfeeding among HIV + Mothers: 

PMTCT Study Kisumu, Kenya 

John Okanda* 1 , R Ndivo1 , P Ongwena1 , V Sewe1 , M Thigpen2 , 

C Borkowf2 , and T Thomas3 1 2 3 Kenya Med Res Inst, Kisumu; CDC, Atlanta, GA, US; and CDC Kenya, 

Kisumu 

646 Influence of a Safe Water System Intervention on Diarrhea 

Rates among Exclusively Breastfed Infants Who Were 

Weaned Rapidly at 6 Months in the Kisumu Breastfeeding 

Study, Kisumu, Kenya 

Timothy Thomas* 1 , J Harris2 , S Greene2 , R Masaba3 , J Okanda3 , 

R Ndivo3 , I Nyangau3 , M Fowler4 , M Thigpen2 , and R Quick2 1 2 3 CDC Kenya, Kisumu; CDC, Atlanta, GA, US; Kenya Med Res Inst, 

Kisumu; and 4Makerere Univ–Johns Hopkins Univ Res Collaboration, 


647 Discontinuation or Modification of Study Drug Regimen 

among Women in a Trial of HAART for PMTCT in Kisumu, 

Kenya 

Prisca Odhiambo* 1 , R Masaba1 , L Ochieng1 , R Ndivo1 , F Motende1 , 

and T Thomas2 1 2 Kenya Med Res Inst, Kisumu and CDC Kenya, Kisumu 



Properties of Breast Milk 

648 Antiretroviral Drug Concentrations in Breast Milk and 

Breastfeeding Infants 

Amanda Corbett* 1 , A Kashuba1 , N Rezk1 , D Jamieson2 , C Chasela3 , 

L Hyde3 , G Tegha3 , G Joaki3 , D Kamwendo3 , C van der Horst1 , and BAN 

Study Team 

1 2 Univ of North Carolina at Chapel Hill, US; CDC, Atlanta, GA, US; and 

3Univ of North Carolina Project, Lilongwe, Malawi 

649 HIV-1 Persists in Breast Milk Cells Despite ART to Prevent 

MTCT 

Dara Lehman* 1,2 , M Chung2 , G John-Stewart2 , B Richardson1,2 , 

J Kiarie3 , and J Overbaugh1 1 2 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; Univ of Washington, 

Seattle, US; and 3Univ of Nairobi, Kenya 

650 Changes in Breast Milk Viral Load Due to Mastitis in 38 

Zambian HIV-infected, Breastfeeding Women 

Katherine Semrau* 1 , L Kuhn2 , D Decker3 , M Sinkala4 , D Brooks1 , 

H Cabral1 , C Kankasa5 , D Thea1 , and G Aldrovandi3,6 1 2 3 Boston Univ, MA, US; Columbia Univ, New York, NY, US; Children’s 

Hosp Los Angeles, CA, US; 4Catholic Med Mission Bd, Lusaka, Zambia 

and Univ of Alabama at Birmingham, US; 5Univ Teaching Hosp, Lusaka, 

Zambia; and 6Univ of Southern California, Los Angeles, US 

651 Comparison of HIV-1 Sequences from Plasma, and Cell-free 

and Cell-associated Breast Milk in Treated and Untreated 

Women in Mozambique 

Mauro Andreotti* 1 , C Galluzzo1 , G Guidotti1 , P Germano2 , S Mancinelli2 , 

R Amici1 , M Marazzi3 , S Vella1 , L Palombi4 , and M Giuliano1 1 2 Inst Superiore di Sanita, Rome, Italy; DREAM Prgm, Community of 

St Egidio, Italy; 3DREAM Prgm, Libera Univ Maria SS Assunta, Rome, 

Italy; and 4DREAM Prgm, Univ of Tor Vergata, Rome, Italy 

652 Potent SIV-specific Cellular Immune Responses in Breast 

Milk of SIV-infected, Lactating Rhesus Monkeys 

Sallie Permar* 1,2 , H Kang1 , A Carville3 , N Letvin1 , and Ctr for 

HIV/AIDS Vaccine Immunology 

1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Children’s Hosp 

Boston, MA, US; and 3New England Primate Res Ctr, Harvard Med Sch, 

Southborough, MA, US 



Risk, Timing and Viral Genetics of MTCT 

653 Very Low Risk of MCTC in Women on HAART Who 

Achieve Viral Suppression: The UK and Ireland, 2000 to 

2006 

Claire Townsend* 1 , M Cortina-Borja1 , C Peckham1 , A de Ruiter2 , 

H Lyall3 , and P Tookey1 1 2 Univ Coll London Inst of Child Hlth, UK; St Thomas’ Hosp, London, 

UK; and 3St Mary’s Hosp, London, UK 

654 Amniocentesis and MTCT: The French ANRS EPF Cohort 

CO1/11 

Laurent Mandelbrot* 1,2,3 , C Jasseron4 , D Ekoukou5 , A Batallan6 , 

A Bongain7 , E Pannier8 , S Blanche9,10 , R Tubiana11 , C Rouzioux9,10 , 

J Warszawski3,4,12 , and the ANRS French Perinatal Cohort EPF 

1 2 Hosp Louis Mourier, Colombes, France; Univ Paris 7 Diderot, Paris, 

France; 3INSERM U822, Le Kremlin Bicetre, France; 4Hosp Bicetre, Le 

Kremlin-Bicetre, France; 5Hosp Delafontaine, St Denis, France; 6Hosp Bichat, Paris, France; 7Hosp L’Archet 2, Nice, France; 8Hosp Cochin, 

Paris, France; 9Hosp Necker, Paris, France; 10Univ Paris 5, France; 

11 12 Hosp Pitie-Salpetriere, Paris, France; and Univ Paris Sud, Le Kremlin- 

Bicetre, France 


Poster Listings



655 Interpretation of Serum α-Fetoprotein, Human Chorionic 

Gonadotrophin, and the Risk of Down’s Syndrome in 

Pregnant Women Infected with HIV 

James Franklin* 1 , M Douglas2 , A Clarke3 , G Nartey4 , P Tookey5 , 

M Cortina-Borja5 , J Smith2 , and G Taylor1 1 2 Faculty of Med, Imperial Coll, London, UK; St Mary’s Hosp, London, 

UK; 3St Thomas’ Hosp, London, UK; 4Ealing Hosp, Southall, UK; and 

5Med Res Council Ctr of Epi for Child Hlth, Inst of Child Hlth, Univ Coll 

London, UK 

656 Early Viral Load Reduction in Pregnant Women Differs 

according to Antiretroviral Regimen 

C Bell1 , M Douglas2 , Y Gilleece1 , N Desmond3 , and Graham Taylor* 2 

1 2 Royal Sussex County Hosp, Brighton, UK; Imperial Coll Hlth Care, 

NHS Trust, London, UK; and 3Garden Clin, Slough, UK 

657 Factors Associated with MTCT in South African Women 

with Advanced Immunosuppression Initiated on HAART 

during Pregnancy 

V Black1 , Risa Hoffman* 2 , C Sugar2 , P Menon1 , F Venter1 , J Currier2 , and 

H Rees1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of 

California, Los Angeles Ctr for Clinical AIDS Res and Ed, US 

658 Maternal/Fetal DNA Admixture Is Associated with HIV-1 

MTCT 

Jesse Kwiek* 1 , L Arney2 , V Harawa3 , B Pedersen2 , V Mwapasa3 , 

S Rogerson4 , and S Meshnick2 1 2 Ohio State Univ, Columbus, US; Univ of North Carolina at Chapel Hill, 

US; 3Coll of Med, Blantyre, Malawi; and 4Univ of Melbourne, Australia 

659 Role of β-Defensin-1 in MTCT HIV-1 Transmission 

E Ricci1 , S Malacrida1 , M Zanchetta1,2 , M Montagna2 , C Giaquinto1 , and 

Anita De Rossi* 1,2 

1 2 Univ of Padova, Italy and IOV-IRCCS, Padova, Italy 

660 Characterization of Vertically Transmitted Subtype C HIV 

during Acute Infection 

Laura Heath* 1 , S Conway2,3 , K Nakamura2,4 , K Semrau5 , D Thea5 , 

L Kuhn6 , J Mullins1 , and G Aldrovandi2,3 1 2 Univ of Washington, Seattle, US; Children’s Hosp Los Angeles, CA, US; 

3 4 Univ of Southern California, Los Angeles, US; Keck Sch of Med, Univ 

of Southern California, Los Angeles, US; 5Boston Univ Sch of Publ Hlth, 

MA, US; and 6Columbia Univ, New York, NY, US 



Co-infections during Pregnancy 

661 Hepatitis B or Hepatitis C Co-infection in HIV-infected 

Pregnant Women in Europe 

Claire Thorne* 1 , M Landes2 , ML Newell1 , and European Collaborative 

Study Coinfection Sub-Study Group 

1 2 Univ Coll London, UK and Univ of Toronto, Canada 

662 Vertical Transmission of Hepatitis C Virus and Clinicoepidemiological 

Characteristics in a Cohort of HIV/HCV-coinfected 

Mothers 

Olga Nieto* 1 , E Munoz1 , M Gonzalez-Tome1 , T Ramos2 , 

M Fernandez-Ibieta2 , C Rojo1 , I Solis2 , and L Prieto1 for the Spanish 

Mother-Infants Pairs Cohort 

1 2 Hosp 12 de Octubre, Madrid, Spain and Hosp Univ Getafe, Madrid, 

Spain 

663 Transmission of Congenital and Postnatal Cytomegalovirus 

among HIV-exposed Infants: The Effect of Prenatal Maternal 

HAART 

Toni Frederick*, A Kovacs, J Homans, L Spencer, A Stek, W Mack, 

E Operskalski, and F Kramer 

Keck Sch of Med, Univ of Southern California, Los Angeles, US 

664 Congenital Cytomegalovirus Infection in Infants Born to 

HIV-infected Mothers, Prevalence and Risk Factors: ANRS 

French Perinatal EPF Cohort CO1/10/11 

G Guibert1 , J Warszawski1,2 , J Le Chenadec1 , Y Benmebarek3 , JP Teglas1 , 

S Blanche4 , L Mandelbrot5,6 , R Tubiana7 , Christine Rouzioux* 4,8 , 

M Leruez-Ville4,8 , and the ANRS French Perinatal Cohort EPF 

1 2 INSERM U822, Le Kremlin Bicetre, France; Univ Paris Sud, Le 

Kremlin-Bicetre, France; 3Hosp Bicetre, Le Kremlin-Bicetre, France; 

4 5 Hosp Necker, Paris, France; Hosp Louis Mourier, Colombes, France; 

6 7 Univ Paris 7 Diderot, Paris, France; Hosp Pitie-Salpetriere, Paris, 

France; and 8Univ Paris 5, France 

665 MTCT of HIV-2: The French ANRS Perinatal Cohort EPF- 

CO1/11 

C Jasseron1 , M Burgard2,3 , JP Teglas4 , S Matheron5 , F Damond5 , 

K Hamrene1 , S Blanche2,3 , C Rouzioux2,3 , J Warszawski4,6 , 

Laurent Mandelbrot* 7,8 , and the ANRS French Perinatal Cohort EPF 

1 2 Hosp Bicetre, Le Kremlin-Bicetre, France; Hosp Necker, Paris, France; 

3 4 Univ Paris 5, France; INSERM U822, Le Kremlin Bicetre, France; 

5 6 Hosp Bichat, Paris, France; Univ Paris Sud, Le Kremlin-Bicetre, 

France; 7Univ Paris 7 Diderot, Paris, France; and 8Hosp Louis Mourier, 

Colombes, France 




Health Outcomes in Women 

666 Causes of Death in HIV-infected Women and Their Evolution 

Since 2000: The Mortalité 2000 and 2005 Surveys, ANRS EN19 

Mojgan Hessamfar-Bonarek* 1,2 , G Chene1,2,3 , P Cacoub4,5 , D Salmon6 , 

T May7 , E Rosenthal8 , C Lewden1,3 , D Costagliola9 , P Morlat1,2,3 , and 

Mortalité 2000 and 2005 Study Group 

1 2 INSERM U593, Bordeaux, France; Ctr Hosp Univ Bordeaux, France; 

3 4 5 Univ Bordeaux 2, France; Hosp Pitie-Salpetriere, Paris, France; Univ 

Pierre and Marie Curie, Paris, France; 6Ctr Hosp Univ Cochin-Tarnier, 

Paris, France; 7Ctr Hosp Nancy, France; 8Ctr Hosp Univ Nice, France; 

and 9INSERM U720, Paris, France 

667 Association of Pre-treatment Nutritional Status with CD4 

and Viral Load Response to ART in Rwandan Women 

Kathryn Anastos* 1 , Q Shi2 , D Lu3 , J Rusine4 , M Cohen5 , J Mugabo6 , 

F Ndamage6 , A Binagwaho7 , D Kotler8 , and Rwanda Women’s 

Interassociation Study and Assessment (RWISA) 

1 2 Montefiore Med Ctr, Bronx, NY, US; New York Med Coll, Valhalla, US; 

3 4 Data Solutions LLC, Bronx, NY, US; Natl Reference Lab, Ministry of 

Hlth, Kigali, Rwanda; 5CORE Ctr and Storger Hosp, Chicago, IL, US; 

6 7 Treatment and Res on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda; Natl 

Commission to Fight AIDS, Kigali, Rwanda; and 8St Luke’s Hosp Ctr, 


668 Treatment Interruption after HAART Prophylaxis in 

HIV-infected Pregnant Women in Mozambique: The Drug 

Resource Enhancement and Malnutrition Program 

L Palombi1 , M Marazzi2 , P Germano3 , G Guidotti4 , M Magnano San Lio3 , 

N Abdul Magid5 , M Andreotti4 , S Vella4 , and Marina Giuliano* 4 

1 2 DREAM Prgm, Univ of Tor Vergata, Rome, Italy; Libera Univ Maria 

SS Assunta, Rome, Italy; 3DREAM Prgm, Rome, Italy; 4Inst Superiore di 

Sanita, Rome, Italy; and 5Machava Gen Hosp, Maputo, Mozambique 



Infertility in HIV-infected Women 

669 Premature Ovarian Deficiency in HIV-infected Women 

Marialuisa Partisani* 1 , J Ohl2 , C Demangeat1 , F Binder-Foucard1 , 

I Nisand2 , and JM Lang1 1 2 Hosp Univ of Strasbourg, France and Ctr d’AMP, CMCO-SIHCUS, 

Schiltigheim, France 

670 Infertility Treatment by in vitro Fertilization or Intracytoplasmic 

Sperm Injections in Chronic HIV-1 Serodifferent 

Couples: Do Women, HIV Infection, or Infertility 

Influence Results? 

Roland Tubiana*, N Prisant, F Marguet, S Dominguez, M Naouri, 

O Rosemblum, G Lefebvre, D Vauthier, A Marcelin, C Poirot, and Pitie 

Salpetriere AMP a Risque Viral Study Group 

Hosp Pitie-Salpetriere, Paris, France 



Influence of Gender on HIV Replication and 

Viremia 

671 Estradiol and Progesterone Regulate HIV-1 Replication in 

Peripheral Blood Mononuclear Cells 

Susana Asin* 1,2 , A Heimberg2 , S Eszterhas1,2 , C Rollenhagen2 , and 

A Howell1,2 1 2 VAMC, White River Junction, VT, US and Dartmouth Med Sch, 

Lebanon, NH, US 

672 Gender-associated Differences in Pre-ART Plasma HIV-1 

RNA in Diverse Areas of the World Vary by CD4 + Cell Count 

Beatriz Grinsztejn* 1 , L Smeaton2 , V De Gruttola2 , R Barnett3 , J Currier4 , 

E Swann3 , J Hakim5 , T Flanigan6 , N Kumarasamy7 , T Campbell8 , and the 

PEARLS Study Team of the ACTG 

1Evandro Chagas Clinical Res Inst, Oswaldo Cruz Fndn, Manguinhos, 

Brazil; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, 

Boston, MA, US; 3NIH, Bethesda, MD, US; 4Univ of California, Los 

Angeles, US; 5Univ of Zimbabwe Coll of Hlth Sci, Harare; 6Warren Alpert 

Med Sch of Brown Univ, Providence, RI, US; 7YRGCARE, Chennai, 

India; and 8Univ of Colorado Hlth Sci Ctr, Denver, US




HIV Replication, Immune Activation, HSV-2 

Co-infection, and Genital Shedding in Women 

673 Effects of Viral Replication on Immune Activation and Fat 

Metabolism in a Cohort of Treatment-naïve HIV-1-infected 

African Women 

Livio Azzoni* 1 , N Crowther2 , C Firnhaber2 , A Foulkes3 , D Glencross2 , 

M Kaplan4 , W Stevens2 , I Sanne2 , T van der Merwe5 , and L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Univ of the Witwatersrand, 

Johannesburg, South Africa; 3Univ of Massachusetts, Amherst, US; 

4 5 Rosebank Clin, Johannesburg, South Africa; and Univ of Pretoria and 

Network Hlthcare Holdings, South Africa 

674 Association between Immune Activation and HIV RNA-1 

Genital Tract Shedding 

L Spencer1 , R Karim1 , A Landay2 , W Mack1 , T Stiller1 , L Al-Harthi2 , and 

Andrea Kovacs* 1 

1Keck Sch of Med, Univ of Southern California, Los Angeles, US and 

2Rush Med Ctr, Chicago, IL, US 

675 Association between Genital Tract HIV-1 RNA Shedding and 

Mucosal Inflammation among Women on Effective ART with 

Undetectable Plasma Viral Load 

Chia-Ching Wang* 1 , T Liu2 , B Anderson2,3 , A DeLong2 , S Chapman1 , 

J Kurpewski1 , J Ingersoll4 , A Caliendo4 , and S Cu-Uvin1,2 1 2 Miriam Hosp, Providence, RI, US; Brown Univ, Providence, RI, US; 

3 4 Womens and Infants Hosp, Providence, RI, US; and Emory Univ Sch of 

Med, Atlanta, GA, US 

676 Herpes Simplex Virus Suppressive Treatment Decreases 

Plasma and Genital HIV-1 Viral Loads in HSV-2/HIV-1 

Co-infected Women: A Randomized, Placebo-controlled, 

Cross-over Trial 

Jared Baeten* 1 , L Strick1 , A Lucchetti2 , W Whittington1 , J Sanchez2 , 

R Coombs1 , A Magaret1 , A Wald1,3 , L Corey1,3 , and C Celum1 1 2 Univ of Washington, Seattle, US; Assn Civil Impacta Salud y Ed, Lima, 

Peru; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US 

677 Diversity of pol Sequence and Envelope Tropism of Plasma 

and Cervical Viruses among HIV + Pregnant Women in 

Zimbabwe 

J Lint1 , Seble Kassaye* 1 , S Dalai1 , E Johnston1 , J Manasa2 , 

L Zijenah2 , and D Katzenstein1 1 2 Stanford Univ, Palo Alto, CA, US and Univ of Zimbabwe, Harare 

678 Distribution and Analysis of HIV-1 Variants in the Uterine 

Cervix and as Related to HIV-1 in the Peripheral Blood 

M Bull1,2 , G Learn1 , S McElhone2 , J Hitti1 , D Lockhart1 , S Holte1,3 , 

J Dragavon1 , R Coombs1 , J Mullins1 , and Lisa Frenkel* 1,2 

1 2 Univ of Washington, Seattle, US; Seattle Children’s Hosp Res Inst, WA, 




Acute HIV/SIV Infection: Characterization of 

Transmitted Viruses 

679 Analysis of HIV-1 Envelope Diversity during Acute and 

Chronic Infection 

Jeffrey Anderson* 1 , L Ping1 , B Keele2 , Y Tang1 , J Salazar-Gonzalez2 , 

K Dang1 , S Galvin1 , C Mapanje3 , M Cohen1 , R Swanstrom1 , and the Ctr 

for HIV/AIDS Vaccine Immunology Consortium 

1 2 Univ of North Carolina at Chapel Hill, US; Univ of Alabama at 

Birmingham, US; and 3Lilongwe Central Hosp, Malawi 

680 Identification and Characterization of the Transmitted 

HIV-1 Envelope 

Brandon Keele* 1 , E Giorgi2 , J Salazar-Gonzalez1 , J Decker1 , 

B Gaschen2 , B Haynes3 , A Perelson2 , B Korber2 , B Hahn1 , G Shaw1 , and 

the Ctr for HIV/AIDS Vaccine Immunology Consortium 

1 2 Univ of Alabama at Birmingham, US; Los Alamos Natl Lab, NM, US; 

and 3Duke Univ, Durham, NC, US 

681 Viral env Diversity and Transmission Clusters in Primary 

HIV Infection: The Zurich Primary HIV Infection Study 

Philip Rieder* 1 , B Joos1 , V von Wyl1 , H Kuster1 , C Leemann1 , 

U von Both1 , J Boni2 , S Yerly3 , M Fischer1 , H Gunthard1 , and Swiss HIV 

Cohort Study 

1 2 Univ Hosp Zurich, Switzerland; NZR Univ, Zurich, Switzerland; and 

3Univ Hosp Geneva, Switzerland 

682 Heterosexually Transmitted Viruses in Uganda Possess 

Signature Envelope Genotypes 

Manish Sagar* 1 , O Laeyendecker2,3 , J Gamiel3 , M Wawer4 , R Gray4 , 

D Serwadda5 , N Sewankambo5 , J Toma6 , W Huang6 , T Quinn2,3 , and Rakai 

Hlth Sci Prgm 

1 2 Brigham and Women’s Hosp, Cambridge, MA, US; Lab of 

Immunoregulation, NIAID, NIH, Baltimore, MD, US; 3Johns Hopkins 

Univ Sch of Med, Baltimore, MD, US; 4Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US; 5Makerere Univ, Kampala, 

Uganda; and 6Monogram Biosci, South San Francisco, CA, US 

683 Accessing the Fitness Impact of the Full Array of gp120 and 

p24 CTL Escape Mutations following an Acute Infection 

Eric Arts* 1 , R Troyer1 , J McNevin2 , Y Liu3 , R Krizan1 , A Abraha1 , 

D Tebit1 , H Zhao3 , J McElrath2 , and J Mullins3 1 2 Case Western Reserve Univ, Cleveland, OH, US; Fred Hutchinson 

Cancer Res Ctr, Seattle, WA, US; and 3Univ of Washington, Seattle, US 

684 Identification of Early CTL Escape Mutations in Transmitted 

HIV-1 Genomes 

Jesus Salazar-Gonzalez* 1 , M Salazar1 , M Liu2 , P Borrow3 , 

N Goonetilleke2 , A McMichael2 , M Cohen4 , B Korber5 , B Hahn1 , G Shaw1 , 

and the Ctr for HIV/AIDS Vaccine Immunology Consortium 

1 2 Univ of Alabama at Birmingham, US; Weatherall Inst of Molecular 

Med, Oxford, UK; 3Jenner Inst, Newbury, UK; 4Univ of North Carolina at 

Chapel Hill, US; and 5Los Alamos Natl Lab, NM, US 

685 Oral Transmission of Single-cycle SIV in Neonatal Macaques 

Bin Jia* 1 , C Mische1 , M Piatak2 , A Carville1 , S O’Neil1 , J Lifson2 , and 

D Evans1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US and 2SAIC-Frederick and NCI-Frederick, MD, US 



Acute HIV/SIV Infection: Immune Responses 

686 HIV-specific Gag T Cell Responses during Acute Infection 

Early Disease Are Associated with the Control of Viremia 

Michel Ndongala* 1 , Y Peretz1 , S Boulet1 , P Kamya1 , J Routy1 , 

C Tremblay2 , D Rouleau2 , R LeBlanc2 , C Tsoukas1 , N Bernard1 , and 

Quebec PI Cohort, Montreal Canada 

1 2 McGill Univ, Monteal, Canada and Univ of Montreal, Canada 

687 HIV-specific, Activated, and Regulatory T Lymphocytes 

during Acute HIV Infection 

E Nemes1 , E Lugli1 , L Bertoncelli1 , F Prati2 , M Nasi1 , S Manzini1 , 

M Pinti1 , R Esposito2 , Andrea Cossarizza* 1 , and C Mussini2 1 2 Univ of Modena and Reggio Emilia, Italy and Hosp Univ Azienda, 

Modena, Italy 

688 Early Disregulation of the Expression of Activating and 

Inhibitory Receptors on both CD56dim and CD56bright NK 

subsets in HIV-1-infected Individuals 

Paola Mantegani*, G Tambussi, L Galli, C Tassandin, A Galli, 

G Travi, A Lazzarin, and C Fortis 

San Raffaele Sci Inst, Milan, Italy 

689 Ligand-dependent Expansion of NK Cell Populations during 

Acute HIV-1 Infection 

Galit Alter* 1 , K Walter1 , S Rihn1 , H Streeck1 , A Meier1 , E Rosenberg1 , 

M Martin2 , M Carrington2 , and M Altfeld1 1 2 Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and SAIC- 

Frederick, Lab of Genomic Diversity, MD, US 

690 Comparative Analysis of Immune Events during Acute 

Simian Immunodeficiency Virus Infection in Sooty 

Mangabeys and Rhesus Macaques 

Mareike Meythaler* 1,2 , Z Wang1 , S Pryputniewicz1 , A Martinot1 , 

M Kasheta1 , B Ling3 , P Marx3 , S O’Neil1 , and A Kaur1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2Inst of Clinical and Molecular Virology, Univ Hosp Erlangen, 

Germany; and 3Tulane Natl Primate Res Ctr, Covington, LA, US 

691 Comparison in early CD4 T Cell Count Evolution in HIV-1 

Seroconverters in Côte d’Ivoire and France: The ANRS 

PRIMO-CI and SEROCO Cohorts 

Charlotte Lewden* 1,2 , R Thiebaut2,3 , F Boufassa4 , C Grondin1,2 , 

A Coulibaly5 , R Seng4 , T Toni5 , C Rouzioux6 , A Minga5 , L Meyer4 , and 

ANRS 1220 PRIMO-CI and CO2 SEROCO Study Groups 

1 2 3 INSERM U593, Bordeaux, France; Univ Bordeaux 2, France; INSERM 

U875, Bordeaux, France; 4INSERM U822, Univ Paris Sud XI, Le Kremlin 

Bicetre, France; 5Prgm PACCI, Abidjan Côte d’Ivoire; and 6Ctr Hosp 

Univ Necker, Paris, France 

692 Acute SIV Infection Results in Selective Depletion of 

Proliferating CD4 + T Cells in Neonatal Rhesus Macaques 

Xiaolei Wang*, H Xu, B Pahar, T Rasmussen, A Lackner, and 

R Veazey 




Acute HIV Infection: Treatment 

693 Interrupted ART of Acute Compared with Recent HIV 

Infection: Final Results of ACTG 371 

Paul Volberding* 1 , E Connick 2 , R Bosch 3 , E Aga 3 , C Pettinelli 4 , M Hirsch 3 , 

M Vogler 5 , S Little 6 , L Demeter 7 , and AIDS Clinical Trials Group 

1 Univ of California, San Francisco, US; 2 Univ of Colorado, Denver, US; 

3 Harvard Univ, Boston, MA, US; 4 NIAID, NIH, Bethesda, MD, US; 5 New 

York Univ, New York, US; 6 Univ of California, San Diego, US; and 7 Univ 

of Rochester, NY, US 


Poster Listings



694 Early Short-course HAART Initiated at the Time of Primary 

HIV Infection Provides No Sustained Benefit in Terms of 

Time to CD4 Decline below 350/mm3 : Results of a Propensity 

Analysis within the ANRS PRIMO Cohort 

L Desquilbet1 , Bruno Hoen* 2 , C Goujard3 , C Deveau1 , J Warszawski1 , 

L Meyer1 , and the ANRS PRIMO Cohort Study Group 

1 2 INSERM U822, Le Kremlin Bicetre, France; Univ Hosp Besancon, 

France; and 3Hosp Bicetre, Le Kremlin Bicetre, France 

695 Can HAART Initiation at Early Acute HIV Infection 

Benefit the Immune-virology Outcome Despite Subsequent 

Treatment Cessation? The ANRS Reservoirs’ Study Group 

Thierry Prazuck* 1 , A Lafeuillade2 , L Hocqueloux1 , JP Viard3 , 

V Avettand Fenoel3 , and C Rouzioux3 1 2 Ctr Hosp Regional Orleans La Source, France; Hosp Chalucet, Toulon, 

France; and 3Ctr Hosp Univ Necker, Paris, France 

696 Early Initiation of HAART during Primary HIV Infection 

Enhances CD127 Expression and Proliferative Capacities of 

HIV-specific CD8 + T Cells 

Camille Lecuroux* 1 , I Girault1 , O Lambotte1 , A Urrutia1 , F Boutboul2 , 

B Autran2 , M Sinet1 , A Venet1 , and the ANRS CO6-PRIMO Cohort and 

the ANRS EP36-HIC Study Group 

1INSERM U802, Paris XI, Hosp Bicetre, Le Kremlin Bicetre, France and 

2INSERM U543, Hosp Pitie-Salpetriere, Paris, France 

697 The Effect of ART of Different Durations in Primary HIV 

Infection 

N Pantazis1 , Giota Touloumi* 1 , P Vanhems2 , J Gill3 , K Porter4 , and 

CASCADE Collaboration 

1 2 Athens Univ Med Sch, Greece; CNRS UMR 5558, Univ Lyon 1, France; 

3 4 Southern Alberta HIV Clin, Calgary, Canada; and Med Res Council 

Clinical Trials Unit, London, UK 

698a A Multi-state Markov Model for the Natural History of 

Recent, Drug-naïve HIV-1 Infection and the Initiation of ART 

Lorne Walker*, S Frost, and S Little 


698b Temporary ART during Primary HIV-1 Infection Lowers the 

Viral Set-point: The Prospective, Randomized Primo-SHM 

Study 

Radjin Steingrover* 1,2,3 , I Schellens4 , A Verbon5 , K Brinkman6 , 

A Zwinderman4 , S Jurriaans2 , F Miedema4 , J Lange4 , D van Baarle4 , and 

J Prins1,2 1 2 Ctr for Infection and Immunity Amsterdam, The Netherlands; Academic 

Med Ctr, Amsterdam, The Netherlands; 3Intl Antiviral Therapy Evaluation 

Ctr, Amsterdam, The Netherlands; 4Univ Med Ctr, Utrecht, The 

Netherlands; 5Academic Hosp Maastricht, The Netherlands; and 6Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands 

698c An Open-label Randomized Trial to Determine the Virologic 

and Immunologic Effects of 4-Weeks of Cyclosporine A Given 

in Combination with ART during Acute and Early Infection 

Martin Markowitz* 1 , F Vaida2 , S Little2 , C Hare3 , H Balfour4 , E Ferguson5 , 

K Schafer2 , D Richman2 , and the AIN 501 and ACTG 5216 Study Team 

1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 

2 3 Univ of California, San Diego, US; Univ of California, San Francisco, 

US; 4Univ of Minnesota, Minneapolis, US; and 5Div of AIDS, NIAID, 




Acute HIV Infection: Recognition and Correlates of 

Transmission 

699 Diagnosing Acute HIV Infection in North Carolina: 

Challenges and Opportunities 

Kara McGee* 1 , S Kim1 , A Johnson2 , J Kuruc2 , S McCoy2 , L McNeil1 , 

C Gay2 , D Margolis2 , J Eron2 , and C Hicks1 1 2 Duke Univ Med Ctr, Durham, NC, US and Univ of North Carolina at 

Chapel Hill, US 

700 Acute HIV-1 Infection Is Highly Prevalent in Ugandan 

Outpatients Suspected of Malaria 

Lisa Bebell* 1 , C Pilcher2 , G Dorsey2 , D Havlir2 , M Kamya3 , M Busch4 , 

P Rosenthal2 , T Nugent5 , C Bentsen6 , and E Charlebois2 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US; 

2 3 Univ of California, San Francisco, US; Makerere Univ Med Sch, 

Kampala, Uganda; 4Blood Systems Res Inst, San Francisco, CA, US; 

5 6 Gen-Probe, San Diego, CA, US; and Bio-Rad, Redmond, WA, US 

701 Correlates of HIV Transmission among MSM 

David Butler* 1 , D Smith1,2 , E Cachay1 , G Hightower1 , T Nugent3 , 

D Richman1,2 , and S Little1 1 2 Univ of California, San Diego, US; VA Hlthcare System, San Diego, CA, 

US; and 3Gen-Probe, San Diego, CA, US 




Immune-Based Therapies: Cytokines 

702 Predictors of Slow Disease Progression in ART-naïve HIV-1infected 

Patients Treated with IL-2: 3 Year Extended Followup 

of the Interstart ANRS 119 Trial 

Jean-Michel Molina* 1 , Y Levy2 , I Fournier3 , T Boulet3 , M Bentata4 , 

G Beck-Wirth5 , D Sereni1 , F Jeanblanc6 , F Simon1 , JP Aboulker3 , and the 

ANRS 119-Interstart Study Team 

1 2 Hosp St Louis, Paris, France; Hosp Henri Mondor, Creteil, France; 

3 4 INSERM SC10, Villejuif, France; Hosp Avicenne, Bobigny, France; 

5 6 Hosp Emile Muller, Mulhouse, France; and Hosp Edouard Herriot, 

Lyon, France 

703 Immunological Success Is Predicted by Enfuvirtide but Not 

Interleukin-2 in Immunocompromised Patients, Final Results 

of the ANRS 123 ETOILE Randomized Trial 

Jean-Paul Viard* 1 , C Fagard2 , C Rouzioux1 , E Pereira2 , M Bentata3,4,5 , 

N Colin de Verdiere4 , G Pahlavan5 , L Weiss6 , Y LEvy7 , G Chene2 , and the 

ANRS 123 Study Group 

1 2 Ctr Hosp Univ Necker, Paris, France; INSERM U593, Bordeaux, 

France; 3Ctr Hosp Univ Avicenne, Bobigny, France; 4Ctr Hosp Univ St 

Louis, Paris, France; 5Ctr Hosp Univ Bichat, Paris, France; 6Ctr Hosp 

Univ Georges Pompidou, Paris, France; and 7Ctr Hosp Univ Henri- 

Mondor, Creteil, France 

704 CD4 T Cell Survival following Intermittent IL-2 Therapy Is 

Predictive of CD4 T Cell Increases in HIV-infected Patients 

Sarah Read* 1 , R Lempicki2 , M Di Mascio1 , S Srinivasula1,2 , I Sereti1 , 

R Davey1 , J Tavel1 , CY Huang1 , C Lane1 , and J Kovacs3 1 2 NIAID, NIH, Bethesda, MD, US; SAIC-Frederick, MD, US; and 

3Warren G Magnuson Clinical Ctr, NIH, Bethesda, MD, US 

705 Response to IL-2 in Patients with Immunodiscordant 

Response to HAART Is Associated with Long-term Clinical 

Benefit 

Matilde Sanchez-Conde*, J Lopez, C Rodriguez, M Ramirez, I Gutierrez, 

J Cosin, J Berenguer, and P Miralles 

Hosp Gregorio Maranon, Madrid, Spain 

706 During HAART Interruption Interleukin-2 Was Ineffective 

in Maintaining Baseline CD4 T Cell Counts in IL-2experienced 

Recipients: Results of a Randomized, Controlled 

Trial 

Brian Porter* 1 , K Anthony2 , J Shen1 , B Hahn1 , B Blackwelder1 , 

C Lane1 , J Kovacs1 , R Davey1 , and I Sereti1 1 2 NIH, Bethesda, MD, US and Univ of Pennsylvania Hlth System, 

Philadelphia, US 

707 IL-7 Immunotherapy and T Cell Homeostasis in SIV + ARTtreated 

Macaques 

Amanda Leone* 1 , M Rohankedkhar2 , A Okoye2 , B Assouline3 , 

M Morre3 , F Villinger4 , L Picker2 , and D Sodora1 1 2 Seattle Biomed Res Inst, WA, US; Vaccine and Gene Therapy Inst and 

Oregon Natl Primate Res Ctr, Oregon Hlth and Sci Univ, Beaverton, US; 

3 4 Cytheris SA, Issy les Moulineaux, France; and Emory Univ, Atlanta, 

GA, US 

708 Sustained Immunological Efficacy of Repeated r-hIL-7 Doses 

in HIV-1-infected Patients: Long-term Follow-up of a Phase 

I/II Multicenter Study 

Yves Levy* 1,2 , L Weiss2,3,4 , C Goujard5 , JP Viard6 , JM Molina7 , F Boue8 , 

C Lacabaratz2 , C Rouzioux6 , M Morre9 , and JF Delfraissy6 1 2 3 Henri Mondor Hosp, Creteil, France; INSERM, Creteil, France; Hosp 

Georges Pompidou, Paris, France; 4Univ Rene Descartes, Paris, France; 

5 6 Hosp Bicetre, Le Kremlin Bicetre, France; Ctr Hosp Univ Necker, Paris, 

France; 7St Louis Hosp, Paris, France; 8Hosp Antoine Beclere, Clamart, 

France; and 9Cytheris, France 

709 Early T Cell Homing following Recombinant Simian 

Glycosylated IL-7 Injection in Rhesus Macaques 

S Beq1 , S Rozlan2 , D Gautier1 , B Assouline2 , P Lavedan1 , 

Michel Morre* 2 , and R Cheynier1 1 2 Pasteur Inst, Paris, France and Cytheris SA, Issy les Moulineaux, 

France 

710 Morpholino Antisense Oligomers Targeting Human IL-10 

Pre-mRNA Splice Sites Modulate IL-10 Secretion by Human 

Dendritic Cells 

Richard Bestwick* 1 , D Mourich1 , N Marshall1 , M Lubkin1 , S Oda1 , 

S Thompson2 , K Warfield3 , S Bavari3 , and P Iversen1 1 2 AVI BioPharma Inc, Corvallis, OR, US; Oregon Hlth Sci Univ, 

Portland, US; and 3USAMRIID, Fort Detrick, Frederick, MD, US 

711 Interleukin-27, a Novel Anti-HIV Cytokine, Inhibits HIV-1 

Replication in Macrophages with the Activation of Multiple 

Interferon-inducible Genes 

Terrence Brann* 1 , J Yang1 , DW Huang1 , B Fullmer1 , J Adelsberger1 , 

R Lempicki1 , M Baseler1 , C Lane2 , and T Imamichi1 1 2 SAIC-Frederick, MD, US and NIAID, NIH, Bethesda, MD, US




Immune-Based Therapies: Therapeutic Vaccines 

712 Safety and Analyses of Very Low-level Viremia during 

Therapeutic HIV-1 Immunizations in Young Adults on 

HAART: Long-term Persistence of Dominant Plasma Clones 

Derived from Residual Replication-competent Virus in CD4 + 

T Cells 

Carlum Shiu* 1 , C Cunningham2 , C Ziemniak1 , P Muresan3 , L Fox4 , 

E Sheeran5 , A Gaur6 , I Febo7 , K Luzuriaga8 , D Persaud1 , and Pediatric 

ACTG P1059 Team 

1 2 Johns Hopkins Univ, Baltimore, MD, US; Duke Univ Med Ctr, Durham, 

NC, US; 3Statistical and Data Analysis Ctr, Boston, MA, US; 4NIAID, NIH, Bethesda, MD, US; 5Social & Sci Systems, Silver Spring, MD, US; 

6 7 St Jude Children’s Res Hosp, Memphis, TN, US; Univ of Puerto Rico, 

San Juan; and 8Univ of Massachusetts, Worcester, US 

713 Augmentation of HIV-1-specific Cell-mediated Immune 

Responses following Vaccination with Recombinant Modified 

Vaccinia Ankara-Fowlpox Vaccines in HIV-1-infected Young 

Adults on Suppressive ART 

Thomas Greenough* 1 , C Cunningham2 , M McManus1 , L Fox3 , 

P Muresan4 , D Persaud5 , D Panicali6 , J Sullivan1 , and K Luzuriaga1 1 2 Univ of Massachusetts Med Sch, Worcester, US; Duke Univ, Durham, 

NC, US; 3Div of AIDS, NIAID, NIH, Bethesda, MD, US; 4Harvard Univ, 

Boston, MA, US; 5Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 

and 6Therion Biologics Corp, Cambridge, MA, US 

714 Therapeutic HIV Vaccination with ALVAC ± Remune 

Delays Virologic Rebound with No Effect on Virologic Setpoint 

following Interruption of ART 

Jonathan Angel* 1 , JP Routy2 , C Tremblay3 , R Woods4 , J Singer4 , 

N Bernard2 , C Kovacs5 , F Smaill6 , S Gurunathan7 , and R Sekaly3 1 2 3 Univ of Ottawa, Canada; McGill Univ, Montreal, Canada; Univ of 

Montreal, Canada; 4Canadian HIV Trial Network, Vancouver; 5Canadian Immunodeficiency Res Collaborative, Toronto; 6McMaster Univ, 

Hamilton, Canada; and 7Sanofi Pasteur, Swiftwater, PA, US 

715 Single DermaVir Patch Treatment of HIV + Individuals 

Induces Long-lasting, High-magnitude, and Broad HIVspecific 

T Cell Responses 

Julianna Lisziewicz* 1 , S Calarota2 , D Banhegyi3 , Z Lisziewicz1 , 

E Ujhelyi3 , and F Lori2 1 2 Genetic Immunity, Budapest, Hungary, and McLean, VA, US; Res Inst 

for Genetic and Human Therapy, Pavia, Italy and Cambridge, MA, US; 

and 3United St Istvan and St Laszlo Hosp, Budapest, Hungary 

716 Immunogenicity and Efficacy of an MVA-nef Vaccine in a 

Randomized Controlled Phase-II-Study in HIV-1-infected 

Patients with CD4 Counts >250/µL followed by Structured 

Treatment Interruption 

Thomas Harrer* 1,2 , H Jaeger2,3 , M Helm4 , D Gorriahn5 , L Schneider6 , and 

E Harrer1,2 1 2 Univ Hosp Erlangen, Germany; German Competence Network on 

HIV/AIDS; 3Practice Dr Jaeger, Munich, Germany; 4Practice Dr Helm, 

Nurnberg, Germany; 5Practice Dr Gorriahn, Munich, Germany; and 

6Practice Dr Schneider, Furth, Germany 

717 DNA Therapeutic Vaccination of Chronically Infected 

Macaques Provides a Persistent Virological Benefit 

G Pavlakis1 , A von Gegerfelt1 , A Valentin1 , Margherita Rosati* 1 , 

C Bergamaschi1 , V Patel1 , C Alicea1 , A Khan2 , R Draghia-Akli2 , and 

B Felber1 1 2 NCI-Frederick, MD, US and VGX Pharma, The Woodlands, TX, US 

718 HIV Protease Inhibitors Suppress Antigen Expression by 

Live Poxvirus-based Vaccines: A Potentially Negative Effect 

of ART on Efficacy of Live-vectored Vaccines 

N Hu1 , C Shikuma1 , B Shiramizu1 , J Yewdell2 , B Moss2 , and Qigui Yu* 1 

1 2 Univ of Hawaii at Manoa, Honolulu, US and NIH, Bethesda, MD, US 



Immune-Based Therapies: Novel Approaches 

719 Treatment of HIV-1 Infection by Allogeneic CCR5-δ32/δ32 

Stem Cell Transplantation: A Promising Approach 

Gero Hutter*, D Nowak, M Mossner, S Ganepola, K Allers, T Schneider, 

J Hofmann, I Blau, WK Hofmann, and E Thiel 

Med Univ of Berlin, Germany 

720 Reprogramming Cellular and Humoral Immunocomponents 

to Kill and Neutralize HIV-1: A Novel Investigatory and 

Therapeutic System 

Aviva Joseph* 1 , J Zheng1 , A Follenzi1 , D Katinger2 , R Kunert2 , 

B Walker3 , and H Goldstein1 1 2 Albert Einstein Coll of Med, Bronx, NY, US; Inst of Applied Microbio, 

Vienna, Austria; and 3Partners AIDS Res Ctr, Massachusetts Gen Hosp, 

Harvard Med Sch, Boston, US 

721 Effects of Recombinant Growth Hormone on T Cell 

Phenotype and Function in vitro and in vivo during Treated 

HIV-1 Infection 

Alison Cranage* 1 , G Moyle2 , M Bower2 , B Gazzard2 , F Gotch1 , and 

N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London, 

UK 

722 A Study of Leflunomide to Target Immune Activation in 

HIV: Results of a Pilot Study 

Sarah Read*, M De Grezia, E Ciccone, R DerSimonian, W Gao, 

C Rehm, A Pau, R Davey, C Lane, and I Sereti 

NIAID, NIH, Bethesda, MD, US 

723 A Specific Mixture of Prebiotic Oligosaccharides Reduces 

Hyper-immune Activation and Improves NK Cell Cytolytic 

Activity in HAART-naïve HIV + Adults 

Belinda van’t Land* 1,2 , K Benlhassan-Chahour3 , G Rizzardini4 , 

A Vriesema2 , J Garssen1,2 , D Trabattoni5 , D Bray3 , A Gori6 , M Clerici5 , and 

COPA Study Team 

1 2 Utrecht Inst for Pharma Sci, The Netherlands; Numico Res, 

Wageningen, The Netherlands; 3ImmunoClin, Paris, France; 4Hosp Luigi 

Sacco, Milan, Italy; 5Univ of Milan, Italy; and 6Hosp San Gerardo, Univ 

of Milan-Bicocca, Monza, Italy 

724 Evaluation of Natural Killer Cells and Expression of KIR 

and Lectin-like Receptors in HIV-1-infected Patients after 

2 Years of Different Strategies of Structured Therapy 

Interruption 

G Mestre1 , F Garcia1 , E Martinez1 , A Milinkovic1 , A Leon1 , A Lopez1 , 

J Lozano2 , J Pena2 , J Gatell1 , and Montserrat Plana* 1 

1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain and Hosp Reina Sofia, 

Cordoba, Spain 

725 Influence of Repeated Cycles of Structured Therapy 

Interruption on the Rate of Recovery of CD4 + T Cells after 

HAART Resumption 

A Leon, E Martinez, A Milinkovic, B Mora, R Argelich, A Lopez, 

T Gallart, Montserrat Plana*, J Gatell, and F Garcia 

Hosp Clin-IDIBAPS, Univ of Barcelona, Spain 



ART: Novel Approaches I 

726a Biochemical Mechanism of HIV-1 Reverse Transcriptase 

Inhibition and Resistance to Translocation-deficient Reverse 

Transcriptase Inhibitors 

Bruno Marchand* 1 , L Michailidis1 , A Fopoussi1 , E Kodama2 , 

M Matsuoka2 , N Ashida3 , E Nagy4 , M Parniak4 , H Mitsuya5,6 , and 

S Sarafianos1 1 2 3 Univ of Missouri, Columbia, US; Kyoto Univ, Japan; Yamasa Corp, 

Chiba, Japan; 4Univ of Pittsburgh, PA, US; 5Kumamoto Univ, Japan; and 

6NIH, Bethesda, MD, US 

726b Drug Susceptibility Profile of OBP-601, a Novel NRTI, Using a 

Comprehensive Panel of NRTI- or NNRTI-resistant Viruses 

Jan Weber* 1 , J Weberova1 , A Vazquez1 , Y Urata2 , T Matsuda2 , R Shafer3 , 

E Arts4 , and M Quinones-Mateu1 1 2 Diagnostic Hybrids Inc, Cleveland, OH, US; Oncolys BioPharma, 

Tokyo, Japan; 3Stanford Univ, Palo Alto, CA, US; and 4Case Western 

Reserve Univ, Cleveland, OH, US 

727 Antiviral and Pharmacokinetic Properties of 3’-Azido-2’,3’- 

Dideoxypurines that Exhibit Potent Activity against Drugresistant 

HIV-1 

Nicolas Sluis-Cremer* 1 , D Koontz1 , B Hernandez-Santiago2 , K Rapp2 , 

F Amblard2 , L Bondada2 , S Coats3 , R Schinazi2 , and J Mellors1 1 2 Univ of Pittsburgh Sch of Med, PA, US; Emory Univ and VAMC, 

Decatur, GA, US; and 3RFS Pharma, LLC, Tucker, GA, US 

728 Characterization of a NNRTI, UK-453,061 in vitro 

Julie Mori* 1 , R Corbau1 , D Lewis2 , S Ellery2 , H Mayer2 , M Perros1 , and 

M Westby1 1 2 Pfizer Global R&D, Sandwich Labs, Kent, UK and Pfizer Global R&D, 

New London, CT, US 

729 Genotypic Resistance and Phenotypic Cross-resistance 

Profile in vitro for a Novel NNRTI: IDX899 

Douglas Richman* 1 , J Jakubik2 , C Chapron2 , L Hubbard2 , L Gray2 , 

M Seifer2 , and D Standring2 1Univ of California, San Diego and VA San Diego Hlthcare System, US 

and 2Idenix Pharma, Inc, Cambridge, MA, US 

730 RDEA427 and RDEA640 Are Novel NNRTI with Potent 

Anti-HIV Activity against NNRTI-resistant Viruses 

Anneke Raney*, R Hamatake, W Xu, JM Vernier, JL Girardet, 

P Weingarten, and B Quart 

Ardea Biosci, Inc, San Diego, CA, US 

731 An IQ Assessment of RDEA806, a Potent NNRTI with an 

Excellent Activity Profile in the Presence of Human Serum 

Proteins 

Robert Hamatake*, W Xu, A Raney, JL Girardet, M Nguyen, LT Yeh, 

and B Quart 

Ardea Biosci, Inc, San Diego, CA, US 


Poster Listings



732 GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter 

Peripheral Glucose Disposal in a Healthy Rodent Model 

System 

Christian Callebaut* 1 , Q Yan2 , J Koster2 , L Tsai1 , T Cihlar1 , and P Hruz2 1 2 Gilead Sci, Foster City, CA, US and Washington Univ Sch of Med, St 

Louis, MO, US 

733 Non-peptidyl Small Molecule Protease Dimerization 

Inhibitors: Molecular and Structural Analysis of Their 

HIV-1 Inhibition and Interactions with Protease Monomer 

Subunit 

Yasuhiro Koh* 1 , D Das2 , M Amano1 , D Davis2 , J Li3 , S Leschenko3 , 

A Baldridge3 , R Yarchoan2 , A Ghosh3 , and H Mitsuya1,2 1 2 Kumamoto Univ Sch of Med, Japan; NCI, NIH, Bethesda, MD, US; and 

3Purdue Univ, West Lafayette, IN, US 

734 INH-I001, an HIV Integrase Inhibitor with Potent in vitro 

Anti-HIV Activity: Microsome and Cytosol Stability Studies, 

Cytochrome P450 Data and Pharmacokinetics 

Vasu Nair* 1 , X Ma1 , C White1 , S Blue1 , G Chi1 , and J Patti2 1 2 Univ of Georgia, Athens, US and Inhibitex, Inc, Alpharetta, GA, US 

735 Novel Treatment Strategies in HIV-1 Drug Discovery: 

Targeting the HIV-1 Integrase-LEDGF/p75 Interaction 

Frauke Christ* 1 , H Langedijk2 , K Bartholomeeussen1 , and Z Debyser1 1 2 Katholieke Univ Leuven, Belgium and Pepscan Systems, Lelystad, The 

Netherlands 

736 Induction in vitro of HIV-1 Variants Resistant to a Lowmolecular 

CD4 Mimic Compound, N-(4-Chlorophenyl)-N’- 

(2,2,6,6-tetramethylpiperidin-4-yl)-oxalamide 

Kazuhisa Yoshimura* 1 , J Shibata1 , A Honda1 , Y Yamada2 , H Masuno2 , 

H Tamamura2 , and S Matsushita1 1 2 Ctr for AIDS Res, Kumamoto Univ, Japan and Inst of Biomaterials and 

Bioengineering, Tokyo Med and Dental Univ, Japan 

737 PF-232798, a Second Generation Oral CCR5 Antagonist 

Patrick Dorr*, M Westby, L McFadyen, J Davis, P Stupple, 

D Middleton, F Perruccio, R Jones, J Mori, and M Perros 

Pfizer, Sandwich, UK 

738 ESN-196, a Novel, Small-molecule CCR5 Antagonist Inhibits 

R5 HIV Infection 

T Ferain1 , D Schols2 , J Bernard1 , R Sleigh1 , F Ooms1 , J Huck1 , V Dupriez1 , 

and Graeme Fraser* 1 

1 2 Euroscreen SA, Brussels and Gosselies, Belgium and Rega Inst for Med 

Res, Katholieke Univ Leuven, Belgium 

739 Potent CCR5 Inhibition by Fully Recombinant RANTES 

Analogs Requires Neither Internalization Nor Signaling 

Donald Mosier* 1 , R Nedellec1 , J Salkowitz-Bokal1 , M Coetzer1 , 

M Lederman2 , R Offord3 , and O Hartley3 1 2 Scripps Res Inst, La Jolla, CA, US; Case Western Reserve Univ, 

Cleveland, OH, US; and 3Univ of Geneva, Switzerland 

741 Peptide “Stapling” Dramatically Enhances the Biophysical 

Properties of HIV Fusion Inhibitors 

Gregory Bird* 1,2 , N Madani1,2 , A Hubicki1,2 , J Sodroski1,2 , and 

L Walensky1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US and Harvard Med Sch, 


742 Type I Interferons Vary in Their Ability to Inhibit HIV 

Replication in Primary Macrophages 

SH Wie1 , S Rought2 , P Du2 , D Richman2 , and Christopher Woelk* 2 

1 2 Catholic Univ of Korea, Seoul, South Korea and Univ of California, San 

Diego, US 



ART: Novel Approaches II 

743 Ritonavir-, Lopinavir-, and Efavirenz-containing 

Nanoparticles: in vitro Release of ART 

Chris Destache*, T Belgum, G Elsasser, K Christensen, and A Shibata 

Creighton Univ, Omaha, NE, US 

744 HIV-1 Inhibition with Multi-valent Gold Nanoparticles 

Mary Catherine Bowman* 1 , E Ballard2 , C Akerson2 , J D’Antonio2 , 

D Feldheim3 , C Melander2 , and D Margolis1 1 2 Univ of North Carolina at Chapel Hill, US; North Carolina State Univ, 

Raleigh, US; and 3Univ of Colorado, Boulder, US 

745 Anti-retroviral Nanoformulations for HIV-1-associated 

Cognitive Impairments 

Huanyu Dou* 1 , C Grotepas1 , M Boska1 , C Destache2 , B Rabinow3 , and 

H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US; Creighton Univ Sch of 

Pharmacy and Hlth Professions, Omaha, NE, US; and 3Baxter Hlthcare 

Corp, Round Lake, IL, US 


746 The Non-peptidic Carbohydrate-binding Pradimycin 

Antibiotics Inhibit HIV infection, Viral Capture by 

DC-SIGN, and Viral Transmission and thus May Qualify as 

Potential Microbicide Candidate Drugs 

J Balzarini1 , K Francois1 , D Huskens1 , J Auwerx1 , K Van Laethem1 , 

Y Igarashi2 , T Oki3 , and Dominique Schols* 1 

1 2 Rega Inst for Med Res, Katholieke Univ Leuven, Belgium; Toyama 

Prefectural Univ, Japan; and 3Keck Sch of Med, Univ of Southern 

California, Los Angeles, US 

747 Carbohydrate-binding Agents Inhibit HIV-1 Infection 

of Human Primary Monocyte-derived Macrophages and 

Prevent MDM-directed Viral Capture and Subsequent 

Transmission to CD4 + T Lymphocytes 

Michela Pollicita* 1 , D Schols2 , S Aquaro3 , W Peumans4 , 

E Van Damme4 , C Perno1 , and J Balzarini2 1 2 Univ of Tor Vergata, Rome, Italy; Rega Inst for Med Res, Katholieke 

Univ Leuven, Belgium; 3Univ of Calabria, Rende, Italy; and 4Ghent Univ, 

Belgium 

748 CD7-specific Single Chain Antibody-mediated Delivery of 

siRNA to T Cells Inhibits HIV Replication in a Humanized 

Mouse Model 

Priti Kumar* 1 , H Ban2 , S Kim1 , M Peipp3 , G Fey3 , L Schultz4 , N Manjunath1 , 

S Lee2 , and P Shankar1 1 2 Immune Disease Inst, Boston, MA, US; Hanyang Univ, Seoul, Korea; 

3 4 Univ of Erlangen, Germany; and Jackson Lab, Bar Harbor, ME, US 

749 Protein Phosphatase-1 as a New Target for Anti-HIV-1 

Therapeutics 

T Ammosova1 , D Kovalskyy2 , V Yedavalli3 , V Gordeuk1 , KT Jeang3 , and 

Sergei Nekhai* 1 

1 2 Howard Univ, Washington, DC, US; Natl Taras Shevchenko Univ, Kiev, 

Ukraine; and 3NIAID, NIH, Bethesda, MD, US 

750 Anti-HIV Activity of Aprepitant and Synergistic Interactions 

with Other Antiretrovirals 

Mark Manak* 1 , D Moshkoff1 , L Nguyen1 , S Dryga1 , J Lathey2 , and 

S Douglas3 1 2 SeraCare Life Sci, Inc, Gaithersburg, MA, US; Sanofi Pasteur, 

Swiftwater, PA, US; and 3Children’s Hosp Philadelphia, PA, US 

751 A Novel Inhibitor of the HIV-1 Vpu Protein Can Inhibit the 

Replication of SHIV in a CD4 + T Cell Line 

Sarah Hill* 1 , C Luscombe2 , J Wilkinson2 , G Ewart2 , and E Stephens1 1 2 Univ of Kansas Med Ctr, Kansas City, US and Biotron Ltd 

752 Evaluation of the Lymphocyte Trafficking Drug FTY720 in 

SHIV-infected Rhesus Macaques 

Ellen Kersh* 1 , M Premenko-Lanier2 , W Luo1 , D Adams1 , J Mitchell1 , 

G Garcia-Lerma1 , S Butera1 , T Folks1 , R Otten1 , and J Altman2 1 2 CDC, Atlanta, GA, US and Emory Vaccine Ctr, Atlanta, GA, US 

753a Lentiviral Delivered VRX496 Long Antisense Sequences 

Exerts Molecular Pressure on HIV-1 in Human Subjects 

Vladimir Lukashov* 1 , M Quinones-Mateu2 , G McGarrity3 , T Rebello3 , and 

L Humeau3 1 2 Academic Med Ctr, Amsterdam, The Netherlands; Diagnostic Hybrids 

Inc, Athens, OH, US; and 3VIRxSYS Corp, Gaithersburg, MD, US 

753b Dose Response Curve Slope Sets Class-specific Limits on 

Inhibitory Potential of Anti-HIV Drugs 

Lin Shen* 1 , S Peterson1 , A Sedaghat1 , M McMahon1 , M Callender1 , 

H Zhang1 , Y Zhou1 , K Anderson2 , E Acosta3 , and R Siliciano1,4 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Yale Univ Sch of 

Med, New Haven, CT, US; 3Univ of Alabama at Birmingham Sch of Med, 

US; and 4Howard Hughes Med Inst, Baltimore, MD, US 



Clinical Pharmacology of Reverse Transcriptase 

Inhibitors 

754 Compartmental Kinetics of Intracellular Tenofovir 

Courtney Fletcher* 1 , T King1 , L Bushman1 , J Kiser1 , P Anderson1 , 

J Brenchley2 , D Douek2 , and T Schacker3 1 2 Univ of Colorado Hlth Sci Ctr, Denver, US; NIAID, NIH, Bethesda, MD, 

US; and 3Univ of Minnesota, Minneapolis, US 

755 Intracellular Accumulation of Tenofovir and Emtricitabine 

in vitro Highlight the Inhibitor Role of Efavirenz for 

Multidrug Resistance-associated Protein 1, MRP1 

Laurence Bousquet* 1 , A Pruvost1 , N Didier1 , R Farinotti2 , and 

A Mabondzo1 1 2 CEA, iBiTecS, Gif sur Yvette, France and Univ Paris Sud XI, Chatenay- 

Malabry, France 

756 Positron Emission Tomography Agent for Non-invasive 

Imaging of Antiretroviral Drug Penetration and Kinetics in 

vivo 

Michele Di Mascio* 1 , S Srinivasula2 , M Collins3 , E Lim4 , L Cheng1 , and 

D Kiesewetter5 1 2 3 NIAID, NIH, Bethesda, MD, US; SAIC-Frederick, MD, US; Bioqual Inc, 

Rockville, MD, US; 4Univ of Pennsylvania, Philadelphia, US; and 5Natl Inst 

of Biomed Imaging and BioEngineering, NIH, Bethesda, MD,US


757 Comparison of Package-insert Recommendations for Renal 

Dosing and Prescribed Dosing of Products Containing 

Tenofovir: The VA Experience 

Barbara Phillips*, P Belperio, L Mole, and V Katseva 

Veterans Hlth Admin, Palo Alto, CA, US 

758 Pharmacological Mechanisms Leading to Early Virologic 

Failure of 2 Antiretroviral Regimens: Didanosine, 

Lamivudine, and Tenofovir, and Abacavir, Lamivudine, and 

Tenofovir 

Lucun Bi* 1 , J Russell1 , N Mordwinkin1 , J Lam2 , and S Louie1 1Univ of Southern California Sch of Pharmacy, Los Angeles, US and 

2Loma Linda Univ Sch of Pharmacy, CA, US 

759 Pharmacogenetics of Plasma Drug Exposure and Treatment 

Outcomes with Efavirenz-containing Regimens: An ACTG 

Study 

David Haas* 1 , H Ribaudo2 , A Motsinger3 , B Schackman4 , R Gulick4 , 

E Acosta5 , M Schwab6 , E Schaeffeler6 , G Morse7 , G Robbins8 , and the 

ACTG 

1 2 Vanderbilt Univ, Nashville, TN, US; Statistical and Data Analysis Ctr, 

Harvard Sch of Publ Hlth, Boston, MA, US; 3North Carolina State Univ, 

Raleigh, US; 4Weill Med Coll of Cornell Univ, New York, NY, US; 5Univ of Alabama at Birmingham, US; 6Margarete Fischer-Bosch Inst for 

Clinical Pharma, Stuttgart, Germany; 7State Univ of New York at Buffalo, 

US; and 8Harvard Univ, Boston, MA, US 

760 Pharmacokinetics of Nevirapine and Rifampicin in TB/HIV 

Co-infected Patients in Burkina Faso 

Alberto Matteelli* 1 , N Saleri1,3 , M Regazzi2 , P Villani2 , V Bonkoungou3 , 

J Simpore3 , A Carvalho1 , M Cusato2 , G Carosi1 , and M Dembele3 1 2 Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy; Inst of 

Pharmacology, IRCCS, San Matteo, Pavia, Italy; and 3Natl TB Prgm, 

Ministry of Hlth, Burkina Faso 

761 Efavirenz Induces CYP450 2B6 Activity as Measured by 

Bupropion Hydroxylation in Healthy Subjects 

Sarah Robertson* 1 , F Maldarelli2 , V Natarajan3 , E Formentini4 , R Alfaro5 , 

and S Penzak5 1 2 US Food and Drug Admin, Silver Spring, MD, US; NCI, Bethesda, MD, 

US; 3SAIC-Frederick, MD, US; 4NIH, Bethesda, MD, US; and 5Clinical Res Ctr, NIH, Bethesda, MD, US 

762 Pharmacokinetics and Pharmacodynamics of the NNRTI 

TMC125 in Treatment-experienced HIV-1-infected Patients: 

Pooled 24-week Results of DUET-1 and DUET-2 

Thomas Kakuda* 1 , J Wade2 , E Snoeck2 , M Peeters3 , C Corbett3 , 

G De Smedt3 , L Leopold1 , J Vingerhoets3 , B Woodfall3 , and R Hoetelmans3 1 2 Tibotec, Inc, Yardley, PA, US; Exprimo NV, Mechelen, Belgium; and 

3Tibotec BVBA, Mechelen, Belgium 

763 Pharmacokinetic Interaction of the Next Generation NNRTI 

UK-453,061 with Other Antiretrovirals and Assessment of 

Safety and Tolerability in Healthy Male Subjects 

G Langdon1 , J Davis1 , G Layton1 , H Choo2 , MN Ndongo3 , A Milton4 , and 

Manoli Vourvahis* 4 

1 2 Pfizer Global R&D, Sandwich, UK; Pfizer Res Clin, Singapore Gen 

Hosp; 3Pfizer Res Clin, Erasme, Brussels, Belgium; and 4Pfizer Global 

R&D, New London, CT, US 

764 Dose-escalation Safety, Tolerability, and Pharmacokinetics of 

a Novel HIV-1 NNRTI [IDX899] in Healthy Subjects 

Douglas Mayers*, M Hard, D Damphousse, B Fielman, 

J Sullivan-Bolyai, B Belanger, and XJ Zhou 

Idenix Pharma, Inc, Cambridge, MA, US 



Clinical Pharmacology of Protease Inhibitors 

765 Lopinavir/Ritonavir 500/125 mg Twice-daily + Efavirenz 

Approximate the Pharmacokinetic Exposure of LPV/r 

400/100 mg Twice-daily Administered Alone in Healthy 

Adult Subjects 

Juki Ng*, C Klein, J Xiong, YL Chiu, T Doan, C Rolle, C Holas, 

R Stryker, and B Bernstein 

Abbott Labs, Abbott Park, IL, US 

766a Increased Lopinavir Concentrations on Once-daily Tablets as 

Compared with Capsules and Liquid Formulations 

Brookie Best* 1 , G Rieg2 , S Sun1 , S Jain1 , C Kemper3 , C Diamond4 , 

A Hermes5 , R Haubrich1 , E Daar2 , and California Collaborative Treatment 

Group (CCTG) 585 Team 

1 2 Univ of California, San Diego, US; Los Angeles Biomed Res Inst at 

Harbor-UCLA Med Ctr and Univ of California, Los Angeles, US; 3Santa Clara Valley Med Ctr, San Jose, CA, US; 4Univ of California, Irvine, US; 

and 5Abbott Labs, Abbott Park, IL, US 

766b Hepatic Transaminase Elevations and Gastrointestinal 

Intolerance when HIV-negative Healthy Volunteers on 

Rifampin add Twice-daily Atazanavir ( 300 mg)/Ritonavir 

(100 mg): ACTG Protocol A5213 

David Haas* 1 , S Koletar2 , L Laughlin2 , M Kendall3 , C Suckow3 , 

J Gerber4 , A Zolopa5 , R Bertz6 , M Child6 , E Acosta7 , and the A5213 Study 

Team 

1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Ohio State Univ, 

Columbus, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ 

Hlth, Boston, MA, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US; 

5 6 Stanford Univ, Palo Alto, CA, US; Bristol-Myers Squibb, Princeton, NJ, 

US; and 7Univ of Alabama at Birmingham, US 

767 Pharmacokinetic Interaction between Tipranavir/Ritonavir 

and Rosuvastatin 

Paul Pham* 1 , L Lee1 , E Fuchs1 , P Barditch-Crovo1 , K Carson1 , 

C Radebaugh1 , S Everts1 , P Piliero2 , and C Flexner1 1 2 Johns Hopkins Univ, Baltimore, MD, US and Boehringer Ingelheim 

Pharma, Inc, Ridgefield, CT, US 

768 Inhibitory Quotient as a Predictor of Virological Response to 

Darunavir-based Salvage Regimens 

Jose Molto* 1 , J Santos1 , N Perez-Alvarez1,2 , S Cerdeno3 , C Miranda1 , 

S Khoo4 , L Else4 , J Llibre1 , M Valle5 , and B Clotet1,3 1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA, 

Badalona, Spain; 2Univ Politecnica de Barcelona, Spain; 3Hosp Univ 

Germans Trias i Pujol and Fndn irsiCaixa, Badalona, Spain; 4Univ of 

Liverpool, UK; and 5Hosp de la Santa Creu i Sant Pau, Barcelona, Spain 

769 Pharmacokinetic/Pharmacodynamic Analyses of Once-daily 

Darunavir in the ARTEMIS Study 

Vanitha Sekar* 1 , C Vanden Abeele2 , B Van Baelen2 , P Vis3 , L Lavreys2 , 

M De Pauw2 , S Dincq2 , T Vangeneugden2 , S Spinosa-Guzman2 , and 

R Hoetelmans2 1 2 Tibotec Inc, Yardley, PA, US; Tibotec, Inc, Mechelen, Belgium; and 

3Exprimo NV, Mechelen, Belgium 

770 Switch from Ritonavir-boosted to Unboosted Atazanavir 

Guided by Monitoring Atazanavir Concentrations in a 

Clinical Setting 

Sonia Rodriguez-Novoa*, J Morello, P Barreiro, I Maida, 

P Garcia-Gasco, G Gonzalez-Pardo, A Parra, I Jimenez-Nacher, and 

V Soriano 


771 Influence of the Orosomucoid Polymorphism on Amprenavir 

Pharmacokinetics in HIV-infected Patients: ANRS104 Trial 

A Barrail-Tran1 , C Cosson1 , G Raguin2 , G Chene3 , PM Girard4 , and 

Anne-Marie Taburet* 1 

1 2 Hosp Bicetre, Le Kremlin Bicetre, France; Croix St Simon Hosp, Paris, 

France; 3INSERM U593, Bordeaux, France; and 4Hosp St Antoine, Paris, 

France 

772 Association between Blips and Subtherapeutic Antiretroviral 

Plasma Levels 

S Fiorante, Sonia Rodriguez Novoa*, P Garcia Gasco, J Morello, 

F Blanco, G Gonzalez Pardo, A Parra, I Jimenez Nacher, 

J Gonzalez Lahoz, and V Soriano 


773 Integrating Pharmacokinetics and Antiretroviral Resistance 

Testing in Clinical HIV-1 Management 

Jennifer King* 1 , I Ofotokun2 , M Rivas2 , V Johnson1,3 , and E Acosta1 1 2 Univ of Alabama at Birmingham, US; Emory Univ Sch of Med, Atlanta, 

GA, US; and 3Birmingham VAMC, AL, US 

b Monday, 1-4 pm; Hall B 


ART: Treatment-naïve Patients 

774 Efficacy and Safety of Abacavir/Lamivudine Compared to 

Tenofovir/Emtricitabine in Combination with Once-daily 

Lopinavir/Ritonavir through 48 Weeks in the HEAT Study 

Kimberly Smith* 1 , D Fine2 , P Patel3 , N Bellos4 , L Sloan5 , P Lackey6 , 

D Sutherland-Phillips3 , C Vavro3 , Q Liao3 , and M Shaefer3 1 2 Rush Univ Med Ctr, Chicago, IL, US; Johns Hopkins Univ Sch of 

Med, Baltimore, MD, US; 3GlaxoSmithKline, Research Triangle Park, 

NC, US; 4Southwest Infectious Disease Assoc, Dallas, TX, US; 5North Texas Infectious Disease Consultants, Dallas, US; and 6ID Consultants, 

Charlotte, NC, US 

775 Study M05-730 Primary Efficacy Results at Week 48: Phase 

3, Randomized, Open-label Study of Lopinavir/ritonavir 

Tablets Once Daily vs Twice Daily, Co-administered with 

Tenofovir DF + Emtricitabine in ARV-naïve HIV-1-infected 

Subjects 

J Gathe1 , Barbara da Silva* 2 , M Loutfy3 , D Podzamczer4 , R Rubio5 , 

S Gibbs2 , T Marsh2 , C Naylor2 , L Fredrick2 , and B Bernstein2 1 2 Therapeutic Concepts, Houston, TX, US; Abbott Labs, Abbott Park, IL, 

US; 3Maple Leaf Med Clin, Toronto, Canada; 4Hosp Univ de Bellvitge, 

Barcelona, Spain; and 5Hosp 12 de Octubre, Madrid, Spain 


Poster Listings



776 Effect of Baseline Characteristics on Treatment Outcomes 

in ACTG 5142: A Prospective, Randomized, Phase III Trial 

of NRTI-, PI-, and NNRTI-sparing Regimens for Initial 

Treatment of HIV-1 Infection 

Sharon Riddler* 1 , R Haubrich2 , G DiRienzo3 , L Peeples3 , W Powderly4 , 

K Garren5 , D Butcher6 , J Rooney7 , D Havlir8 , J Mellors1 , and ACTG 5142 

Study Team 

1 2 Univ of Pittsburgh, PA, US; Univ of California, San Diego, US; 

3 4 Harvard Sch of Publ Hlth, Boston, MA, US; Univ Coll Dublin, Ireland; 

5 6 Abbott Labs, Abbott Park, IL, US; Bristol-Myers Squibb, Plainsboro, 

NJ, US; 7Gilead Sci, Foster City, CA, US; and 8Univ of California, San 

Francisco, US 

777 Analysis of the Relationship between Antiretroviral 

Medication Adherence and Class-specific Resistance in a 

Large Prospective Randomized Clinical Trial 

Edward Gardner* 1 , G Peng2 , E Telzak3 , S Sharma2 , K Huppler Hullsiek2 , 

W Burman1 , M Chesney4 , G Friedland5 , R MacArthur6 , S Mannheimer7 , 

and the Intl Network for Strategic Initiatives in Global HIV Trials 

(INSIGHT) 

1 2 Denver Publ Hlth, CO, US; Univ of Minnesota, Minneapolis, US; 

3 4 Bronx-Lebanon Hosp Ctr, NY, US; Natl Ctr for Complementary and 

Alternative Med, NIH, Bethesda, MD, US; 5Yale Univ Sch of Med, New 

Haven, CT, US; 6Wayne State Univ, Detroit, MI, US; and 7Columbia Univ 

Coll of Physicians and Surgeons, New York, NY, US 

778 A 2-Months-off/4-Months-on HAART Is Clinically Not 

Inferior to Continuous Therapy but Leads to Unacceptable 

Resistance Rates in African Adults with >350 CD4/mm3 at 

First Interruption: Final Results of the Trivacan Trial 

Christine Danel* 1 , R Moh1 , ML Chaix2 , D Gabillard3 , B Kouadio1 , T Toni4 , 

C Rouzioux2 , R Salamon3 , E Bissagnene5 , X Anglaret3 , and ANRS 1269 

Study Group 

1 2 Prgm PACCI, Abidjan, Côte d’Ivoire; Ctr Hosp Univ Necker, Paris, 

France; 3INSERM U593, Bordeaux, France; 4CeDReS, Abidjan, Côte 

d’Ivoire; and 5Infectious and Tropical Diseases Svc, Abidjan, Côte 

d’Ivoire 

779 Efficacy and Safety of Dual-PI Regimens for the Treatment 

of ART-naïve HIV-1 Subjects: 2IP ANRS 127, a Randomized 

Pilot Study 

Roland Landman* 1 , C Chazallon2 , D Descamps1 , C Capitant2 , 

G Peytavin1 , C Katlama3 , G Pialoux4 , M Bentata5 , JP Aboulker2 , P Yeni1 , 

and ANRS 127 Study Group 

1 2 Hosp Bichat-Claude Bernard, Paris, France; INSERM SC10, Villejuif, 

France; 3Hosp Pitie-Salpetriere, Paris, France; 4Hosp Tenon, Paris, 

France; and 5Hosp Avicenne, Bobigny, France 

780 Double Protease Inhibitor, RTI-sparing Therapy Regimen in 

Naïve HIV-1-infected Patients: 24-Week Virologic Response 

Analysis of the LORAN Trial 

K Ulbricht* 1 , M Stoll1 , G Behrens1 , B Salzberger2 , H Jessen3 , A Jessen3 , 

B Kuhlmann4 , A Trein5 , H Heiken1 , and R Schmidt1 1 2 3 Hannover Med Sch, Germany; Univ of Regensburg, Germany; Private 

Practice Motzstr, Berlin, Germany; 4Praxis Georgstr, Hannover; and 

5Private Practice Schwabstr, Stuttgart, Germany 

781 Effect of a 48-week Lopinavir/r Monotherapy on HIV1-DNA 

in Blood Cells in the MONARK Trial 

Veronique Avettand-Fenoel* 1 , P Flandre2 , ML Chaix1 , J Ghosn3 , 

C Delaugerre1 , F Raffi4 , P NgoVan5 , I Cohen-Codar5 , JF Delfraissy3 , and 

C Rouzioux1 1 2 Ctr Hosp Univ Necker, Univ Paris-Descartes, France; INSERM U720, 

Paris, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre, France; 4Ctr Hosp Univ Nantes, France; and 5Abbott France 

782 Reasons for Treatment Success with Initial ART: An 

Analysis of 22,635 Participants in 64 Randomized, Controlled 

Trials and 14 Prospective Cohorts 

Andrew Carr* 1 and J Amin2 1 2 St Vincent’s Hosp, Sydney, Australia and Natl Ctr in HIV Epi and Clin 

Res, Univ of New South Wales, Sydney, Australia 

783 Outcomes of Abacavir- and Efavirenz-based HAART: 

Comparison of ACTG 5095 Trial Results with Observational 

Cohort Studies 

Michael Mugavero* 1 , M May2 , H Ribaudo3 , J Sterne2 , S Napravnik4 , 

M Egger5 , M Saag1 , R Gulick6 , and ACTG and ART-CC 

1 2 3 Univ of Alabama at Birmingham, US; Univ of Bristol, UK; Harvard Sch 

of Publ Hlth, Boston, MA, US; 4Univ of North Carolina at Chapel Hill, 

US; 5Univ of Berne, Switzerland; and 6Weill Med Coll of Cornell Univ, 


784 Similar Responses Observed in ARV-naïve Patients Treated 

through Clinical Trials vs Clinical Practice 

Justin Routman* 1 , J Willig1 , A Westfall1 , S Abroms2 , M Varshney1 , 

S Adusumilli1 , J Allison1 , K Savage1 , M Saag1 , M Mugavero1 , and 

UAB 1917 HIV/AIDS Clinic Cohort 

1 2 Univ of Alabama at Birmingham, US and Univ of Pennsylvania, 

Philadelphia, US 

785 Prediction of AIDS-defining Illnesses or Death after the 

Initiation of HAART 

Bryan Lau* 1,2 , S Gange2 , G Chander1 , J Keruly1 , and R Moore1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 


786 Nevirapine Administered Once Daily Is as Efficient as a 

Twice-daily Dosing: A Collaborative Cohort Study 

Alexandra Calmy* 1 , A Nguyen1 , J Lange2 , M Battegay3 , F de Wolf4 , 

P Reiss2 , B Hirschel1 , and F Wit2 for the Swiss HIV Cohort Study and The 

Netherlands ATHENA Observational Cohort 

1 2 Univ Hosp Geneva, Switzerland; Ctr for Poverty-Related Communicable 

Diseases, Academic Med Ctr, Amsterdam, The Netherlands; 3Univ Hosp Basel, Switzerland; and 4HIV Monitoring Fndn, Amsterdam, The 

Netherlands 

787 Single Antiretroviral Switches for Pregnant Women 

Compared to Non-pregnant Women and Men Who Initiated 

HAART in the MTCT-Plus Initiative 

Patricia Toro*, M Katyal, D Nash, and R Carter 

Columbia Univ, New York, NY, US 



ART: Treatment-experienced Patients 

788 48-Week Results from BENCHMRK-1, a Phase III Study 

of Raltegravir in Patients Failing ART with Triple-class 

Resistant HIV-1 

David Cooper* 1 , J Gatell2 , J Rockstroh3 , C Katlama4 , P Yeni5 , 

A Lazzarin6 , X Xu7 , R Isaacs7 , H Teppler7 , BY Nguyen7 , and the 

BENCHMRK-1 Study Group 

1 2 Univ of New South Wales, Sydney, Australia; Univ of Barcelona, Spain; 

3 4 5 Univ of Bonn, Germany; Hosp Pitie-Salpetriere, Paris, France; Hosp 

Bichat-Claude Bernard, Paris, France; 6San Raffaele Sci Inst, Milan, 

Italy; and 7Merck Res Labs, West Point, PA, US 

789 48-Week Results from BENCHMRK-2, a Phase III Study 

of Raltegravir in Patients Failing ART with Triple-class 

Resistant HIV 

Roy Steigbigel* 1 , P Kumar2 , J Eron3 , M Schechter4 , M Markowitz5 , 

M Loutfy6 , J Zhao7 , R Isaacs6 , BY Nguyen7 , H Teppler7 , and the 

BENCHMRK-2 Study Group 

1 2 State Univ of New York at Stony Brook, US; Georgetown Univ Med 

Ctr, Washington, DC, US; 3Univ North Carolina at Chapel Hill, US; 

4 5 Federal Univ of Rio de Janeiro, Brazil; Aaron Diamond AIDS Res Ctr, 

The Rockefeller Univ, New York, NY, US; 6Univ of Toronto, Canada; and 

7Merck Res Labs, West Point, PA, US 

790 DUET-1: Week-48 Results of a Phase III Randomized 

Double-blind Trial to Evaluate the Efficacy and Safety of 

TMC125 vs Placebo in 612 Treatment-experienced HIV-1infected 

Patients 

Richard Haubrich* 1 , P Cahn2 , B Grinsztejn3 , J Lalezari4 , J Madruga5 , 

A Mills6 , M Peeters7 , J Vingerhoets7 , K Iveson8 , and G De Smedt7 on 

behalf of the DUET-I Study Group 

1 2 Univ of California, San Diego, US; Hosp “Juan A Fernandez” and Fndn 

Huesped, Buenos Aires, Argentina; 3Inst de Pesquisa Clinica Evandro 

Chagas, FIOCRUZ, Brazil; 4Quest Clinical Res, San Francisco, CA, US; 

5 6 Ctr de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; Private 

Practice, Los Angeles, CA, US; 7Tibotec BVBA, Mechelen, Belgium; and 

8Tibotec, Inc, Yardley, PA, US 

791 DUET-2: Week-48 Results of a Phase III Randomized 

Double-blind Trial to Evaluate the Efficacy and Safety of 

TMC125 vs Placebo in 591 Treatment-experienced HIV-1infected 

Patients 

Margaret Johnson* 1 , T Campbell2 , B Clotet3 , C Katlama4 , A Lazzarin5 , 

W Towner6 , M Peeters7 , J Vingerhoets7 , S Bollen7 , and G De Smedt7 on 

behalf of the DUET-2 Study Group 

1 2 Royal Free Hosp, London, UK; Univ of Colorado Hlth Sci Ctr, Denver, 

US; 3Hosp Univ Germans Trias i Pujol and irsiCaixa Fndn, Barcelona, 

Spain; 4Hosp Pitie-Salpetriere, Paris, France; 5San Raffaele Univ, Milan, 

Italy; 6Kaiser Permanente, Los Angeles, CA, US; and 7Tibotec BVBA, 

Mechelen, Belgium 

792 Efficacy and Safety of Maraviroc plus Optimized 

Background Therapy in Treatment-experienced Patients 

Infected with CCR5-Tropic HIV-1: 48-Week Combined 

Analysis of the MOTIVATE Studies 

David Hardy* 1 , J Reynes2 , I Konourina3 , D Wheeler4 , S Moreno5 , 

E van der Ryst3 , W Towner6 , A Horban7 , H Mayer8 , and J Goodrich8 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US; Univ 

Hosp of Montpellier, France; 3Pfizer Global R&D, Sandwich, UK; 

4 5 Infectious Diseases Physicians, Inc, Annandale, VA, US; Hosp Ramon y 

Cajal, Madrid, Spain; 6Kaiser Permanente, Los Angeles, CA, US; 7Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland; and 

8Pfizer Global R&D, New London, CT, US 

793 24-Week Data from Study AVX-201: A Prospective, 

Randomized, Double-blind, Dose-ranging Phase IIb Study of 

Apricitabine in Treatment-experienced Patients with M184V 

and NRTI Resistance 

Pedro Cahn* 1 , J Altclas2 , M Martins3 , M Losso4 , I Cassetti5 , S Cox6 , 

D Cooper7 , and the AVX-201 Study Group 

1 2 Fndn Huesped, Buenos Aires, Argentina; Sanatorio de la Trinidad 

Mitre, Buenos Aires, Argentina; 3Inst Oulton, Cordoba, Argentina; 4Hosp JM Ramos Mejia, Buenos Aires, Argentina; 5Helios Salud, Buenos Aires, 

Argentina; 6Avexa Ltd, Melbourne, Australia; and 7Natl Ctr for HIV 

Epidemiology and Clin Res, Univ of New South Wales, Australia


794 Pharmacokinetics and Potent Anti-HIV-1 Activity of 

Amdoxovir plus Zidovudine in a Randomized Double-blind 

Placebo-controlled Study 

Robert Murphy* 1 , C Zala2 , C Ochoa3 , P Tharnish4 , J Mathew4 , 

E Fromentin5 , G Asif5 , S Hurwitz5 , N Kivel4 , and R Schinazi5 1 2 Univ Pierre and Marie Curie, Paris, France; Hosp Privado Modelo, 

Buenos Aires, Argentina; 3ACLIRES-Argentina, Buenos Aires; 4RFS Pharma, LLC, Tucker, GA, US; and 5Emory Univ Sch of Med and VAMC, 


795 Vicriviroc in Combination Therapy with an Optimized ART 

Regimen for Treatment-experienced Subjects: VICTOR-E1 

Barry Zingman* 1 , J Suleiman2 , E DeJesus3 , J Slim4 , C Mak5 , 

M McCarthy5 , N Case5 , and L Dunkle5 1 2 Montefiore Med Ctr, Bronx, NY, US; Brazilmed Assistencia Medica e 

Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US; 4St Michael’s 

Med Ctr, Newark, NJ, US; and 5Schering-Plough Res Inst, Kenilworth, 

NJ, US 

796 More Pronounced Effect of Integrase Inhibitor Raltegravir 

on Proviral DNA Reduction that other Antiretroviral Drugs 

in Patients Achieving Undetectable Viremia 

Sari Arponen*, J Benito, S Lozano, F Blanco, C Garrido, 

C de Mendoza, J Gonzalez-Lahoz, and V Soriano 


797 The Use and Response to Second Combination ART 

Regimens in EuroSIDA 

Alessandro Cozzi-Lepri* 1 , M Cunnington2 , A Lazzarin3 , B Clotet4 , 

B Knysz5 , P Gargalianos6 , C Katlama7 , A Karlsson8 , A Phillips1 , 

J Lundgren9 , and EuroSIDA Study Group 

1 2 Royal Free and Univ Coll London Med Sch, UK; GlaxoSmithKline 

R&D, UK; 3San Raffaele Vita-Salute Univ, Milan, Italy; 4Fndns irsiCaixa 

and Lluita contra la SIDA, Badalona, Spain; 5Wrocaw Med Univ, Poland; 

6 7 1st IKA Hosp, Athens, Greece; Hosp Pitie-Salpetriere, Paris, France; 

8 9 Karolinska Univ Hosp, Stockholm, Sweden; and Copenhagen HIV Prgm, 

Hvidovre, Denmark 

798 Long-term Consequences of the Delay between Virologic 

Failure of HAART and Regimen Modification: A Prospective 

Cohort Study 

Maya Petersen* 1 , M van der Laan2 , S Napravnik3 , J Eron3 , R Moore4 , 

and S Deeks1 1 2 Univ of California, San Francisco, US; Univ of California, Berkeley, 

US; 3Univ of North Carolina at Chapel Hill, US; and 4Johns Hopkins 

Univ, Baltimore, MD, US 

799 Outcomes of Patients Switched from Enfuvirtide to 

Raltegravir within a Virologically Suppressive Regimen 

Marianne Harris* 1 , G Larsen1 , and J Montaner2 1 2 St Paul’s Hosp, Vancouver, Canada and BC Ctr for Excellence in 

HIV/AIDS, Vancouver, Canada 

800 The Relationship of CCR5 Inhibitors to CD4 Cell Count 

Changes: A Meta-analysis of Recent Clinical Trials in 

Treatment-experienced Subjects 

Timothy Wilkin* 1 , H Ribaudo2 , and R Gulick1 1 2 Weill Med Coll of Cornell Univ, New York, NY, US and Harvard Sch of 

Publ Hlth, Boston, MA, US 

b Wednesday, 1-4 pm; Hall B 


ART: Adherence 

801 No Decline in High Levels of Electronic Pill Cap, 

Unannounced Home Pill Count, and Patient-reported 

Adherence to Free ART over 12 Months in Rural Uganda 

David Bangsberg* 1 , N Emenyonu1 , I Andia2 , M Bwana2 , L Pepper2 , 

K Ragland1 , S Weiser1 , J Hahn1 , S Deeks1 , and J Martin1 1 2 Univ of California, San Francisco, US and Mbarara Univ Sci Tech, 


803 Rates of Ritonavir Non-adherence and Dose Staggering in 

HIV + Patients Receiving Ritonavir-boosted Atazanavir or 

Fosamprenavir 

Jonathan Shuter* 1,2 , R Rode3 , J Sarlo1 , and B Zingman1,2 1 2 Montefiore Med Ctr, Bronx, NY, US; Albert Einstein Coll of Med, Bronx, 

NY, US; and 3Abbott Labs, Abbott Park, IL, US 

804 Adherence to Protease Inhibitors: Analysis of 776 Patients’ 

Electronically Compiled Dosing Histories 

B Vrijens1 , AC Lange1 , and Pietro Vernazza* 2 

1 2 Aardex Inc, Baar, Switzerland and Hosp Cantonal, St Gallen, 

Switzerland 



HIV Care in Different Settings 

805 Person-years Lost by Late Presentation for HIV Care in 

Maryland 

Richard Moore*, J Keruly, and J Bartlett 


806 Delayed Diagnosis of HIV Infection and Late Initiation of 

ART in the Swiss HIV Cohort Study 

M Wolbers1 , H Bucher1,2 , H Furrer3 , M Rickenbach4 , M Cavassini4 , 

R Weber5 , P Schmid6 , E Bernasconi7 , B Hirschel8 , Manuel Battegay* 2 , and 

the Swiss HIV Cohort Study 

1 2 Basel Inst for Clin Epidemiology, Switzerland; Univ Hosp Basel, 

Switzerland; 3Univ Hosp Berne, Switzerland; 4Univ Hosp Lausanne, 

Switzerland; 5Univ Hosp Zurich, Switzerland; 6Cantonal Hosp, St Gall, 

Switzerland; 7Regional Hosp Lugano, Switzerland; and 8Univ Hosp 

Geneva, Switzerland 

807 Food Insecurity Is Associated with Incomplete HIV RNA 

Suppression among Homeless and Marginally Housed HIVinfected 

Individuals in San Francisco 

Sheri Weiser* 1 , E Frongillo2 , K Ragland1 , E Riley1 , and D Bangsberg1 1 2 Univ of California, San Francisco, US and Arnold Sch of Publ Hlth, 

Univ of South Carolina, Columbia, US 

808 What Frequency of Monitoring Is Needed for Healthcare in 

an HIV-infected Person? 

Joanne Reekie* 1 , B Gazzard2 , H Sambatakou3 , L Machala4 , A Chiesi5 , 

J van Lunzen6 , N Clumeck7 , O Kirk8 , A Mocroft1 , J Lundgren8 , and 

EuroSIDA Study Group 

1 2 Royal Free and Univ Coll Med Sch, London, UK; Chelsea and 

Westminster Hosp, London, UK; 3Ippokration Gen Hosp, Athens, Greece; 

4 5 Faculty Hosp Bulovka, Pargue, Czech Republic; Inst Superiore di 

Sanita, Rome, Italy; 6Univ Med Ctr Hamburg-Eppendorf, Germany; 

7 8 Hosp St Pierre, Brussels, Belgium; and Copenhagen HIV Prgm, Univ of 

Copenhagen, Denmark 

809 Disparate Virologic Response to HAART between Ethnicities 

Amy Weintrob* 1 , G Grandits2 , B Agan3 , A Ganesan4 , N Crum-Cianflone5 , 

S Fraser6 , S Patel7 , G Wortmann1 , S Wegner8 , and V Marconi3 1 2 Walter Reed Army Med Ctr, Washington, DC, US; Univ of Minnesota, 

Minneapolis, US; 3San Antonio Military Med Ctr, TX, US; 4Natl Naval 

Med Ctr, Bethesda, MD, US; 5Naval Med Ctr San Diego, CA, US; 6Tripler Army Med Ctr, Honolulu, HI, US; 7Naval Med Ctr Portsmouth, VA, US; 

and 8Uniformed Svcs Univ, Bethesda, MD, US 

810 Race and Sex Differences in HAART Use and Mortality 

among HIV-infected Persons in Care 

Diana Lemly* 1 , B Shepherd2 , T Hulga2 , P Rebeiro2 , S Stinnette2 , 

R Blackwell3 , S Bebawy2 , A Kheshti3 , T Sterling2 , and S Raffanti2,3 1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Vanderbilt Univ, 

Nashville, TN, US; and 3Comprehensive Care Ctr, Nashville, TN, US 

811 Indicators of the Use of Healthcare Interventions across 

Europe 

Daria Podlekareva* 1 , J Reekie2 , A Rakhmanova3 , A Horban4 , 

A Mocroft2 , I Karpov5 , P Domingo6 , F Antunes7 , O Kirk1 , J Lundgren1 , and 


1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free 

and Univ Coll London Med Sch, UK; 3Botkin Hosp of Infectious Diseases, 

St Petersburg, Russia; 4Wojewodzki Szpital Zakazny, Warsaw, Poland; 

5 6 Belarus State Med Univ, Minsk; Hosp de la Santa Creu i Sant Pau, 

Barcelona, Spain; and 7Hosp Santa Maria, Lisbon, Portugal 



Treatment Outcomes in Scale-up Programs 

812 When to Start ART in Resource-limited Settings 

Rochelle Walensky* 1,2,3 , L Wolf1 , R Wood4 , K Freedberg1,2,5,6 , N Martinson7,8 , 

D Paltiel9 , X Anglaret10,11 , M Fofana1 , H Ribaudo5 , and E Losina1,3,6 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA, 

US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Univ of Cape Town, 

South Africa; 5Harvard Sch of Publ Hlth, Boston, MA, US; 6Boston Univ 

Sch of Publ Hlth, MA, US; 7Perinatal HIV Res Unit, Johannesburg, South 

Africa; 8Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 9Yale Univ 

Sch of Publ Hlth, New Haven, CT, US; 10Prgm PACCI, Abidjan Côte 

d’Ivoire; and 11Univ Victor Segalen, Bordeaux, France 

813 Evaluation of the Adult 2006 World Health Organization 

HIV/AIDS Clinical Staging in Predicting Initiation of ART in 

Uganda 

Steven Baveewo* 1 , F Ssali2 , C Karamagi1 , and E Katabira1 1 2 Makerere Univ Med Sch, Kampala, Uganda and Joint Clinical Res Ctr, 



Poster Listings



814 Normalization of CD4 Count in Thai Patients Started 

NNRTI-based Regimens at Low Nadir CD4 Count 

Tanakorn Apornpong* 1 , N Phanuphak 1 , S Limpongsanurak 2 , 

W Luesomboon 3 , A Tangsathapornpong 4 , N Singhakovinta 5 , C Viravasiri 6 , 

P Toro 7 , E Abrams 7 , and P Phanuphak 1 

1 Thai Red Cross AIDS Res Ctr, Bangkok; 2 King Chulalongkorn Memorial 

Hosp, Bangkok, Thailand; 3 Queen Sawangwattana Memorial Hosp, 

Chonburi, Thailand; 4 Thammasat Univ Hosp, Bangkok, Thailand; 5 Queen 

Sirikit Hosp, Chonburi, Thailand; 6 Police Gen Hosp, Bangkok, Thailand; 

and 7 Columbia Univ, New York, NY, US 

815 Evaluation of Outcomes in a Large HIV Comprehensive 

Scale-up Program: The Harvard PEPFAR Nigeria 

Ernest Ekong* 1 , S Meloni 2 , D Onwujekwe 3 , C Okany 4 , I Adewole 5 , 

R Nkado 6 , W Gashau 7 , J Idoko 8 , R Murphy 9 , and P Kanki 2 

1 APIN Plus/Harvard PEPFAR Nigeria, Lagos; 2 Harvard-PEPFAR Prgm, 

Nigeria and Harvard Sch of Publ Hlth, Boston, MA, US; 3 Nigerian Inst of 

Med Res, Lagos; 4 Lagos Univ Teaching Hosp, Nigeria; 5 Univ Coll Hosp, 

Ibadan, Nigeria; 6 68 Military Hosp, Lagos, Nigeria; 7 Univ Maiduguri 

Teaching Hosp, Nigeria; 8 Jos Univ Teaching Hosp, Nigeria; and 

9 Northwestern Univ, Chicago, IL, US 

816 Initial Treatment Outcomes from a Rural-based ART Scaleup 

Program in East Africa: The UARTO Cohort 

Jeffrey Martin* 1 , N Emenyonu 1 , M Bwana 2 , I Andia 2 , J Bennett 1 , H Cao 3 , 

P Hunt 1 , R Harrigan 4 , S Deeks 1 , D Bangsberg 1 , and East Africa IeDEA 

Consortium 

1 Univ of California, San Francisco, US; 2 Mbarara Univ of Sci and Tech, 

Uganda; 3 California Dept of Hlth Svcs, Richmond, US; and 4 BC Ctr for 


817 Maximum Capacity of Restoration of CD4 Counts Is Lower 

in HIV-1-infected Patients from Sub-Saharan Africa during 

the First Months of cART: ATHENA Cohort 

A Kesselring1 , Luuk Gras* 1 , F Wit2,3 , P Reiss2,3 , and F de Wolf1 1 2 HIV Monitoring Fndn, Amsterdam, The Netherlands; Academic Med 

Ctr, Univ of Amsterdam, The Netherlands; and 3Ctr for Poverty-Related 

Communicable Diseases, Amsterdam, The Netherlands 

818 Learning Curve: Increasing Benefit of HAART according to 

Year of Initiation in a Middle-income Country 

Carlos Beltran*, D Gallardo, M Wolff, J Arancibia, C Gallo, M Ayala, 

I Becerra, S Karelovic, and Chilean AIDS Cohort 

Chilean AIDS Cohort 

819 Mortality of HIV-1-infected Patients Starting ART in Sub- 

Saharan Africa: The IeDEA Prognostic Model 

Margaret May* 1 , A Boulle2 , E Messou3 , H Tweya4 , L Myer2 , R Wood2 , 

J Sterne1 , M Schechter5 , M Egger6 , and ART-LINC and Intl Epidemiological 

Databases to Evaluate AIDS (IeDEA) Southern and Western Africa 

1 2 3 Univ of Bristol, UK; Univ of Cape Town, South Africa; CeDReS, 

ACONDA, Abidjan, Côte d’Ivoire; 4Lighthouse Clin, Lilongwe, Malawi; 

5 6 Federal Univ of Rio de Janeiro, Brazil; and Univ of Berne, Switzerland 

820 Time Trends in Demographic and Clinical Characteristics 

of Patients Starting ART in Lower-income Countries: The 

ART-LINC Collaboration of IeDEA 

O Keiser1 , K Anastos2 , E Balestre3 , A Boulle4 , P Braitstein5 , M Brinkhof1 , 

E Sprinz6 , L Myer4 , N Kumarasamy7 , Francois Dabis* 3 , and the ART- 

LINC Collaboration of IeDEA 

1 2 3 Univ of Bern, Switzerland; Lincoln Hosp, New York, NY, US; Univ 

Victor Segalen, Bordeaux, France; 4Univ of Cape Town, South Africa; 

5 6 Moi Univ, Eldoret, Kenya; Hosp de Clinicas de Porto Alegre, Brazil; 


821 Virologic Outcomes and ART Adherence in Adolescents 

Compared with Adults in Southern Africa 

Jean Nachega* 1 , M Hislop2 , D Dowdy1 , M Cotton3 , L Regensberg2 , 

R Chaisson1 , and G Maartens4 1 2 Johns Hopkins Univ, Baltimore, MD, US; Aid for AIDS Disease Mgmt 

Prgm, Cape Town, South Africa; 3Univ of Stellenbosch, Tygerberg, South 

Africa; and 4Univ of Cape Town, South Africa 

822 2-Year Virologic Outcomes of an Alternative AIDS Care 

Model: Evaluation of a Peer Health Worker and Nursestaffed 

Community-based Program in Uganda 

S Alamo1 , Larry Chang* 2 , S Guma1 , J Christopher1 , T Suntoke3 , 

R Omastete1 , J Montis1 , T Quinn2,3 , M Juncker1 , and S Reynolds2,3 1 2 Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda; Johns 

Hopkins Med Inst, Baltimore, MD, US; and 3NIAID, NIH, Bethesda, MD, 

US 

823 Immunologic Benefits of Complete vs Partial Virologic 

Suppression in Patients Initiating ART in Gugulethu, South 

Africa 

Elena Losina* 1,2,3 , Y Chang2 , R Kaplan4 , E Campbell4 , R Walensky1,2,5,6 , 

K Freedberg2,3,5,6 , and R Wood4 1 2 Brigham and Women’s Hosp, Boston, MA, US; Massachusetts Gen 

Hosp, Boston, US; 3Boston Univ Sch of Publ Hlth, MA, US; 4Univ of Cape 

Town, South Africa; 5Harvard Med Sch, Boston, MA, US; and 6Harvard Sch of Publ Hlth, Boston, MA, US 


824 Predictors of Clinical and Immunological Outcomes among 

HIV-infected Subjects on ART in Tanzania 

Guerino Chalamilla* 1 , M Mwanyika-Sando2 , C Hawkins1 , S Unni1 , 

S Kaaya2 , A Kibao3 , D Mtasiwa3 , and W Fawzi1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US; Muhimbili Univ of Hlth and 

Allied Sci, Dar es Salaam, Tanzania; and 3Dar es Salaam City Council, 

Tanzania 

825 Risk Factors for Discordant Responses to HAART at 

Themba Lethu Clinic, Johannesburg, South Africa 

Daniel Westreich* 1 , B Malope2 , P MacPhail2 , S Nagar2 , A Van Rie1 , 

and I Sanne2 1 2 Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and Univ 

of the Witwatersrand, Johannesburg, South Africa 

826 Effect of Early Immunovirologic Discordant Responses 

on Mortality in Naïve HIV-1-infected Adults Initiating 

Treatment in Resource-constrained Countries 

Suely Tuboi* 1 , A Pacheco2 , P Braitstein3 , M May4 , R Stone1 , E Sprinz5 , 

D Nash6 , R Wood7 , L Harrison1 , M Schechter8 , and ART-LINC of IeDEA 

1 2 Univ of Pittsburgh, PA, US; Oswaldo Cruz Fndn, Rio de Janeiro, Brazil; 

3Indiana Univ Sch of Med, Indianapolis, US and Moi Univ Sch of Med, 

Eldoret, Kenya; 4Univ of Bristol, UK; 5Federal Univ of Rio Grande do 

Sul, Porte Alegre, Brazil; 6Columbia Univ, New York, NY, US; 7Univ of 

Cape Town, South Africa; and 8Federal Univ of Rio de Janeiro, Brazil 

827 Determinants of Knowledge of Access to ART in Rural 

KwaZulu Natal, South Africa 

Till Barnighausen* 1,2 , F Tanser1 , G Cooke1,3 , and ML Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal, 

Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, US; 

3 4 Imperial Coll, London, UK; and Inst of Child Hlth, London, UK 

828 Novel Modular Education of Inpatients with AIDS in a 

Resource-poor National AIDS Treatment Center: Impact 

of Learning Outcomes on Adherence to HAART and 

Cotrimoxazole Prophylaxis, Development of Opportunistic 

Infections, and Mortality 

Olusegun Busari*, G Oligbu, O Busari, and HIV Study Group 

Federal Med Ctr, Ido-Ekiti, Nigeria 

829 Changes in Depression and Daily Functioning with Initiation 

of ART in HIV-infected Adults in Rural Uganda 

Naomi Bock* 1 , CW Lee1 , S Bechange2 , J Moore1 , K Khana2 , W Were2 , 

R King2 , J Mermin2 , F Kaharuza2 , and R Bunnell2 1 2 CDC, Atlanta, GA, US and CDC Uganda, Entebbe 

830 Rapid Implementation of More Efficacious ART Regimens 

for the Prevention of Mother-to-Child Transmission of HIV 

in Rwanda 

Landry Tsague* 1 , G Tene1 , C Adje-Toure1 , S Koblavi1 , V Mugisha1 , 

J Rubin1 , G Vandebriel1 , R Sahabo1 , F Tsiouris2 , and E Abrams2 1Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, 

Rwanda and 2Columbia Univ Mailman Sch of Publ Hlth, New York, NY, 

US 

b Tuesday, 1-4 pm; Hall B 


Switching Therapy/Treatment Failure in Scale-up 

Programs 

831 Lopinavir/Ritonavir (LPV/r) + 2 Nucleoside Analogues as 

Second-line ART in Protease Inhibitor-naïve Adults in South 

Africa: Outcomes and Adverse Effects 

Richard Murphy* 1 , H Sunpath2 , A Nijhawan3 , M McLellan1 , and 

D Kuritzkes1 1 2 Brigham and Women’s Hosp, Boston, MA, US; McCord Hosp, Durban, 

South Africa; and 3Brown Univ Med Sch and Miriam Hosp, Providence, 

RI, US 

832 Immunological Response to Boosted PI-containing Secondline 

ART after Switching for Clinical/Immunological Criteria 

Is Comparable to Response to First-line in Patients with Low 

CD4 Counts in Africa 

Cleophas Chimbetete* 1 , C Kityo2 , P Munderi3 , A Walker4 , A Reid1 , 

F Ssali2 , H Grosskurth3 , J Darbyshire4 , C Gilks5 , and Dart Trial 

1 2 3 Univ of Zimbabwe, Harare; Joint Clin Res Ctr, Kampala, Uganda; Med 

Res Council/Uganda Virus Res Inst Prgm on AIDS, Entebbe, Uganda; 

4 5 Med Res Council Clinical Trials Unit, London, UK; and Imperial Coll 

London, UK 

833 Clinical and Immunologic Correlates of Mortality and 

Virologic Failure among HIV-infected Individuals Receiving 

ART >90 Days in Rural Uganda 

David Moore* 1,2,3 , S Malamba1 , J Tappero1 , W Were1 , R Degerman1 , 

R Downing1 , and J Mermin1 1 2 Global AIDS Prgm, CDC Uganda, Entebbe; BC Ctr for Excellence 

in HIV/AIDS, Vancouver, Canada; and 3Univ of British Columbia, 

Vancouver, Canada


834 Immunological Monitoring as an Indicator of Virological 

Failure May Lead to Premature Switch to Second-line ART 

Regimens 

Rami Kantor* 1 , L Diero2 , A DeLong1 , W Emonyi2 , S Kimaiyo2 , 

P Chan1 , J Carter1 , and N Buziba2 1 2 Brown Univ, Providence, RI, US and Moi Univ, Eldoret, Kenya 

835 Probability and Predictors of Survival, Drop-out, or Switch 

to a WHO Standard Second-line ART Regimen in Resourcelimited 

Settings with Viral Load Monitoring Availability: 

The DREAM Program 

M Marazzi1 , L Palombi2 , G Guidotti3 , P Germano4 , G Tintisona4 , 

M Magnano San Lio4 , and Andrea De Luca* 5 

1 2 Libera Univ Maria SS Assunta, Rome, Italy; Univ of Tor Vergata, Rome, 

Italy; 3Inst Superiore di Sanita, Rome, Italy; 4DREAM Prgm, Community 

of St Egidio, Italy; and 5Catholic Univ, Rome, Italy 

836 Botswana’s ART Failure Management: A 5-Year Review 

of the Infectious Disease Care Clinic at Princess Marina 

Hospital 

Ava Avalos* 1 , T Gaolathe2 , S Cloutier1 , N Ndwapi1 , F Doualla-Bell3 , 

M Mosepele4 , M Zwanila1 , H Moffat4 , K Seipone4 , and M Wainberg3 1 2 Botswana Ministry of Hlth; Botswana Harvard Sch of Publ Hlth AIDS 

Initiative Partnership for HIV Res and Ed, Gaborone; 3McGill Univ AIDS 

Ctr, Montreal, Canada; and 4Princess Marina Hosp, Gaborone, Botswana 

837 Effectiveness and Safety of Generic Second-line PI-based 

ART in Western India 

Sanjay Pujari* 1,2 , A Dravid3 , N Gupte4 , A Dhananjay3 , M Lynette2 , and 

J Sinnott2 1 2 3 Inst of Infectious Diseases, Pune, India; Univ of Tampa, FL, US; Inst of 

Infectious Diseases, Pune, India; and 4Consultant Biostatistician 




Risk Factors for Lost-to-Follow-up in Resourcelimited 

Settings 

838 Characteristics of Facilities and Programs Delivering HIV 

Care and Treatment Services Are Associated with Loss to 

Follow-up Rates in Programs from 7 Sub-Saharan African 

Countries 

Denis Nash* 1 , C Korves1 , S Saito1 , S Sherman1 , B Elul1 , D Hoos1 , 

V Mugisha2 , M Sheriff3 , W El Sadr1 , and Intl Ctr for AIDS Care and 

Treatment Prgms (ICAP) 

1 2 Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; Columbia 

Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, Rwanda; and 

3Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Nairobi, 

Kenya 

839 Loss to Care and Death before ART: Patients Eligible for 

Treatment Who Do Not Make It in Durban, South Africa 

Ingrid Bassett* 1,2,3 , B Wang1 , S Chetty4 , J Giddy4 , Z Lu1 , E Losina2,3,5 , 

R Walensky1,2,3,6 , and K Freedberg1,3,5,6 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s Hosp, 

Boston, MA, US; 3Harvard Med Sch, Boston, MA, US; 4McCord Hosp, 

Durban, South Africa; 5Boston Univ Sch of Publ Hlth, MA, US; and 

6Harvard Sch of Publ Hlth, Boston, MA, US 

840 Losses to Follow-up in a Large ART Program in Uganda 

A Muwanga, Philippa Easterbrook*, P Schaefer, M Wandera, D Okello, 

B Castelnuovo, M Kamya, and A Kambugu 

Infectious Disease Inst, Kampala, Uganda 

841 Loss to Follow-up in Community Clinics in South Africa: 

Role of CD4 Count, Gender, and Pregnancy 

Bingxia Wang* 1,2 , E Losina1,3,4 , R Stark5 , A Munro5 , R Walensky1,2,3 , 

M Wilke5 , D Martin5 , Z Lu1 , K Freedberg1,2,4,6 , and R Wood7 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA, 

US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Boston Univ Sch of 

Publ Hlth, MA, US; 5South Africa Catholic Relief Svcs; 6Harvard Sch of 

Publ Hlth, Boston, MA, US; and 7Univ of Cape Town, South Africa 

842 What Becomes of the Defaulters? A Sampling-based 

Approach to Determine Outcomes of Patients Who Become 

Lost to Follow-up in ART Scale-up Programs in Africa 

Elvin Geng* 1 , D Bangsberg1 , N Musinguzi2 , N Emenyonu1 , M Bwana2 , 

D Glidden1 , C Yiannoutsos3 , S Deeks1 , J Martin1 , and East Africa IeDEA 

Consortium 

1 2 Univ of California, San Francisco, US; Mbarara Univ of Sci and Tech, 

Uganda; and 3Indiana Univ, Indianapolis, US 



Complications in Resource-limited Settings 

843 Clinical Features Associated with Lactic Acidosis in Malawi 

Cecelia Kanyama* 1 , D Gomes2 , E Katengeza1 , N Saukila1 , H Tweya3 , 

G Joaki1 , R Weigel3 , M Hosseinipour1,2 , and Lighthouse Group 

1 2 Univ of North Carolina Project, Lilongwe, Malawi; Univ of North 

Carolina at Chapel Hill, US; and 3Lighthouse Clin, Lilongwe, Malawi 

844 Low-dose Erythropoietin in the Management of HIV-related 

Anemia in Uganda 

F Ssali1 , J Kayiwa1 , T Otim1 , M Ssemmanda1 , and Eugene Kinyanda* 2 

1 2 Joint Clin Res Ctr, Kampala, Uganda and Med Res Council, Entebbe, 

Uganda 

845 Cause-specific Mortality and Contribution of Immune 

Reconstitution Inflammatory Syndrome during the First 2 

Years of ART in Uganda 

Barbara Castelnuovo* 1 , A Kambugu1 , A Kiragga1 , K Kigonya1 , 

M Kamya2 , and P Easterbrook1 1 2 Infectious Diseases Inst, Kampala, Uganda and Makerere Univ, 


846a Evaluation of Expert Opinion vs 2 Case Definitions of 

Immune Reconstitution Inflammatory Syndrome in a South 

African Cohort 

L Haddow1,2 , Yunus Moosa* 1 , N Khanyile1 , Q Zulu1 , N Sithole1 , 

F Ibrahim2 , and P Easterbrook2 1 2 Univ of KwaZulu Natal, Durban, South Africa and King’s Coll London, 

UK 

846b Does Cotrimoxazole Prophylaxis Improve Outcomes after 

ART Initiation in HIV-infected African Adults: A Causal 

Analysis Using Marginal Structural Models 

Ann Sarah Walker* 1 , D Ford1 , F Ssali2 , P Munderi3 , A Reid4 , 

A Kambugu5 , C Gilks6 , A Babiker1 , and the DART Trial Team 

1 2 Med Res Council Clinical Trials Unit, London, UK; Joint Clin Res 

Ctr, Kampala, Uganda; 3Med Res Council/Uganda Virus Res Inst Prgm 

on AIDS, Entebbe, Uganda; 4Univ of Zimbabwe, Harare; 5Infectious Diseases Inst, Mulago, Uganda; and 6Imperial Coll, London, UK 



New Mechanisms of HIV-1 Drug Resistance 

847 I132M in HIV-1 Reverse Transcriptase Confers NNRTI 

Resistance but NRTI Hypersusceptibility 

Zandrea Ambrose* 1 , CW Sheen1 , D Nissley2 , and N Sluis-Cremer1 1 2 Univ of Pittsburgh Sch of Med, PA, US and SAIC-Frederick, MD, US 

848 High Phenotypic Resistance to AZT Correlates with an 

Increased Availability of Pre-translocated Complexes 

throughout the Viral Genome 

Brian Scarth* and M Gotte 

McGill Univ, Montreal, Canada 

849 Introduction of the 64/65 Nucleotide Polymorphisms of 

Subtype C HIV-1 into Subtype B HIV-1 Selects for the K65R 

Mutational Pathway in Cell Culture 

Cedric Invernizzi*, D Coutsinos, D Moisi, M Oliveira, B Spira, 

B Brenner, and M Wainberg 

McGill Univ AIDS Ctr, Montreal, Canada 

850 Effect of Different Enfuvirtide-resistance Mutations on 

Variability of the Rev Responsive Element and the rev Gene 

in Patients on Enfuvirtide Treatment 

Eva Poveda*, M Gonzalez, V Briz, J Gonzalez-Lahoz, and V Soriano 


851 The Pressure Imposed by T-20 Selects Mutations also in the 

Regulatory Protein Rev 

Valentina Svicher* 1 , R D’Arrigo2 , C Alteri1 , M Trignetti1 , S Dimonte1 , 

A Callegaro3 , S Lo Caputo4 , S Aquaro5 , P Narciso2 , and CF Perno2 1 2 Univ of Tor Vergata, Rome, Italy; Natl Inst of Infectious Diseases, 

L Spallanzani, Rome, Italy; 3Hosp Riuniti, Bergamo, Italy; 4Hosp Santa 

Maria Annunziata, Florence, Italy; and 5Univ of Calabria, Rende, Italy 

852 Impaired Replication Conferred by the N43D Gp41 Mutation 

Could Be Restored by Changes in the Gp120 Protein 

Cecilia Cabrera* 1 , S Marfil1 , E Garcia1 , L Ruiz1 , M Bofill2 , B Clotet1 , and 

J Blanco1 1 2 Fndn irsiCaixa, Badalona, Spain and ICREA, Barcelona, Spain 

853 Discordant Effects of Gag Cleavage Site Mutations on the 

IC50 of Protease Inhibitors and on HIV Replicative Capacity 

Romina Quercia* 1 , E Dam1,2 , D Descamps3 , X Duval3 , A Hance1 , and 

F Clavel1 1 2 INSERM U552, Paris, France; Eurofins-Viralliance, Paris, France; and 

3Hosp Bichat-Claude Bernard, Paris, France 


Poster Listings



854 Prevalence, Mutational Patterns, and Phenotypic Correlates 

of the L76V Protease Mutation in Relation to LPV-associated 

Mutations 

Michael Norton* 1 , T Young1 , N Parkin2 , D Tokimoto1 , L Lu1 , 

T Pilot-Matias1 , E Stawiski2 , K Stewart1 , D Kempf1 , and R Sibtain1 1 2 Abbott Labs, Abbott Park, IL, US and Monogram Biosci, South San 


855 A General Method for Identifying Treatment-selected 

Resistance Directly from Clinical Records Predicts New 

Cross-class HIV Reverse Transcriptase Mutations Arising 

from Inhibitor Combinations 

Richard Belew* 1 , M Chang1 , J Fessel2 , D Looney3 , C Mathews4 , 

SY Rhee5 , R Shafer5 , and J Wong6 1 2 Univ of California, San Diego, US; Kaiser Permanente, Oakland, 

CA, US; 3VA Hlthcare System, San Diego, CA, US; 4Owen Clin, Univ 

of California, San Diego, US; 5Stanford Univ, Palo Alto, CA, US; and 

6VAMC and Univ of California, San Francisco, US 

856 Tracing Pathways of Resistance to Reverse Transcriptase 

Inhibitors from Sequencing Mixtures in HIV-1 

Art Poon* 1 , D Richman1,2 , and S Frost1 1 2 Univ of California, San Diego, US and VA Hlthcare System, San Diego, 

CA, US 

857 HIV-1 Vif Mutants with Suboptimal Anti-APOBEC Activity 

Facilitate Emergence of Drug Resistance 

L Mulder, A Harari, and Viviana Simon* 


858 APOBEC-mediated Sequence Editing and Epidemiological 

Surveillance of Transmitted HIV-1 Drug Resistance 

Robert Gifford*, SY Rhee, N Eriksson, T Liu, M Kiuchi, A Das, and 

R Shafer 

Stanford Univ, Palo Alto, CA, US 



Resistance to New Antiretrovirals 

859 Viral Resistance to the HIV-1 Maturation Inhibitor 

Bevirimat in the Context of a Protease that Confers 

Resistance to Protease Inhibitors 

Catherine Adamson* 1 , K Waki1 , S Ablan1 , K Salzwedel2 , and E Freed1 1 2 NCI-Frederick, MD, US and Panacos Pharma, Inc, Gaithersburg, MD, 

US 

860 Characterization of Resistance Properties of a New Integrase 

Inhibitor S/GSK364735 

Tomokazu Yoshinaga* 1 , K Nakahara1 , M Kobayashi1 , S Miki1 , A Sato1 , 

E Garvey2 , S Foster2 , M Underwood2 , B Johns2 , and T Fujiwara1 1 2 Shionagi, Settsu, Japan and GlaxoSmithKline 

861 Effect of M184V, P119S, and T165A HIV-1 RT Mutations on 

Enzyme Behaviors and Viral Growth 

Guangwei Yang* 1 , E Paintsil1 , G Dutschman1 , CJ Wang1 , H Tanaka2 , 

M Baba3 , and YC Cheng1 1 2 Yale Univ, New Haven, CT, US; Showa Univ, Tokyo, Japan; and 

3Kagoshima Univ, Japan 

862 Co-receptor Tropism, ENV Genotype, and in vitro 

Susceptibility to CCR5 Antagonists during a 14-Day 

Monotherapy Study with INCB9471 

Susan Erickson-Viitanen* 1 , K Abremski1 , K Solomon1 , R Levy1 , E Lam2 , 

J Whitcomb2 , R Lloyd3 , R Mathis3 , J Reeves2 , and D Burns3 1 2 Incyte Corp, Wilmington, DE, US; Monogram Biosci, South San 

Francisco, CA, US; and 3Res Think Tank, Buford, GA, US 

863 Effect of Virus Concentration on in vitro Measurement of 

Phenotypic Resistance to the CCR5 Antagonist Vicriviroc 

C Buontempo, R Ogert, L Ba, P Buontempo, L Wojcik, J Howe, 

R Ralston, and Julie Strizki* 

Schering-Plough Res Inst, Kenilworth, NJ, US 

864 Detection of Viral Co-receptor Tropism Changes with a 

High-sensitivity Phenotypic Assay among HIV-infected 

Patients with Drug-resistant Viremia 

Peter Hunt* 1 , S Deeks1 , W Huang2 , E Coakley2 , D Han2 , C Petropoulos2 , 

M Bates2 , R Hoh1 , J Martin1 , and J Reeves2 1 2 Univ of California, San Francisco, US and Monogram Biosci, South San 


865 Evaluating the Role of Etravirine in the Second-line 

ART after Failing an Initial NNRTI-based Regimens in a 

Resource-limited Setting 

Somnuek Sungkanuparph* 1 , W Manosuthi2 , S Kiertiburanakul1 , 

B Piyavong1 , and W Chantratita1 1Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand and 

2Bamrasnaradura Infectious Diseases Inst, Ministry of Publ Hlth, 



866 Prevalence of TMC125 Resistance-associated Mutations in a 

Large Panel of Clinical Isolates 

Gaston Picchio* 1 , J Vingerhoets2 , M Staes3 , L Tambuyzer2 , L Bacheler4 , 

T Pattery3 , and MP de Bethune2 1 2 3 Tibotec, Inc, Yardley, PA, US; Tibotec BVBA, Mechelen, Belgium; Virco 

BVBA, Mechelen, Belgium; and 4VircoLab Inc, Durham, NC, US 

867 Etravirine-resistance Mutations in Patients with Virologic 

Failure on Nevirapine or Efavirenz-based HAART 

Babafemi Taiwo* 1 , B Chaplin2 , J Stanton1 , S Meloni2 , S Akanmu3 , 

W Gashau4 , J Idoko5 , I Adewole6 , R Murphy1 , and P Kanki2 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Harvard 

Sch of Publ Hlth, Boston, MA, US; 3Lagos Univ Teaching Hosp, Nigeria; 

4 5 Univ of Maiduguri Teaching Hosp Nigeria; Jos Univ Teaching Hosp, 

Nigeria; and 6Univ Coll Hosp, Ibadan, Nigeria 

868 Prevalence of Mutations with Effect on Virological Response 

to Etravirine in Routine Clinical Samples 

Josep Llibre* 1 , J Santos1 , T Puig2 , A Blanco2 , R Paredes1 , B Mothe1 , and 

B Clotet1,2 1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA, 

Barcelona, Spain and 2 Fndn irsiCaixa, Barcelona, Spain 




Emerging Patterns of Resistance to New 


869 An Enhanced Version of the Trofile HIV Co-receptor 

Tropism Assay Predicts Emergence of CXCR4 Use in 

ACTG5211 Vicriviroc Trial Samples 

Jacqueline Reeves* 1 , D Han1 , T Wilkin2 , T Wrin1 , D Kuritzkes3 , 

C Petropoulos1 , J Whitcomb1 , N Parkin1 , R Gulick2 , and E Coakley1 1 2 Monogram Biosci, South San Francisco, CA, US; Weill Med Coll of 

Cornell Univ, New York, NY, US; and 3Brigham and Women’s Hosp, 

Cambridge, MA, US 

870 Emergence in vivo of Vicriviroc Resistance in HIV-1 Subtype 

C: Role of V3 Loop and Susceptibility to Other CCR5 

Antagonists 

Athe Tsibris* 1,2 , M Sagar2,3 , Z Su4 , C Flexner5 , W Greaves6 , P Skolnik7 , 

E Coakley8 , M Subramanian9 , R Gulick10 , and D Kuritzkes2,3 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA, 

US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Harvard Sch of 

Publ Hlth, Boston, MA, US; 5Johns Hopkins Univ, Baltimore, MD, US; 

6 7 Schering-Plough Res Inst, Kenilworth, NJ, US; Boston Med Ctr, MA, 

US; 8Monogram Biosci, South San Francisco, CA, US; 9Human Genome 

Sci, Rockville, MD, US; and 10Weill Med Coll of Cornell Univ, New York, 

NY, US 

871 Changes in V3 Loop Sequence Associated with Failure 

of Maraviroc Treatment in Patients Enrolled in the 

MOTIVATE 1 and 2 Trials 

Marilyn Lewis* 1 , J Mori1 , P Simpson1 , J Whitcomb2 , X Li3 , D Roberston1 , 

and M Westby1 1 2 Pfizer Global R&D, Sandwich Labs, Kent, UK; Monogram Biosci, South 

San Francisco, CA, US; and 3Faculty of Life Sci, Univ of Manchester, UK 

872 Naturally Occurring Polymorphisms in HIV-1 Group M, N, 

and O Integrase: Implications for Integrase Inhibitors 

John Hackett*, B Harris, V Holzmayer, J Yamaguchi, KC Luk, 

C Brennan, G Schochetman, S Devare, and P Swanson 

Abbott Diagnostics, Abbott Park, IL, US 

873 Development of vircoTYPE HIV-1 Resistance Analysis, 

Including Clinical Cutoffs for TMC125, a New NNRTI 

Bart Winters* 1 , J Villacian1 , E Van Craenenbroeck1 , and L Bacheler2 1 2 Virco BVBA, Mechelen, Belgium and VircoLab Inc, Durham, NC, US 

874 Characterization of Virologic Failures on Darunavir/ 

Ritonavir in the Randomized, Controlled, Phase III TITAN 

Trial in Treatment-experienced Patients 

Sandra De Meyer* 1 , E Lathouwers1 , I Dierynck1 , E De Paepe1 , 

B Van Baelen1 , T Vangeneugden1 , S Spinosa-Guzman1 , G Picchio2 , and 

MP de Bethune1 1 2 Tibotec BVBA, Mechelen, Belgium and Tibotec Inc, Yardley, PA, US 



Minor Drug-resistant Variants: Detection and 

Clinical Significance 

875 Ultra-deep Pyrosequencing of HBV Quasispecies in 

3TC-treated and -untreated HIV-co-infected Patients 

Severine Margeridon-Thermet* 1 , N Shulman 1 , C Wang 1 , A Ahmed 1 , 

B Gharizadeh 1 , B Simen 2 , J Simons 2 , M Egholm 2 , and R Shafer 1 

1 Stanford Univ, Palo Alto, CA, US and 2 454 Life Sci/Roche, Branford, CT, 

US


876 Novel HIV-1 Integrase Mutations, Found as Minority 

Quasispecies in Patients Naïve to Integrase Inhibitors, 

Are Associated with Decreased Susceptibility to Integrase 

Inhibitors in vitro 

Francesca Ceccherini-Silberstein* 1 , K Van Baelen2 , D Armenia1 , 

M Trignetti1 , L Fabeni1 , E Rondelez2 , A Antinori3 , M Andreoni1 , 

L Stuyver2 , and C Perno1,3 1 2 Univ of Tor Vergata, Rome, Italy; Virco BVBA, Mechelen, Belgium; and 

3Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy 

877 Evolution of Minority Drug-resistant Viral Populations 

during Treatment Interruption 

D Wang, C Hicks, N Goswami, F Cai, and Feng Gao* 

Duke Univ Med Ctr, Durham, NC, US 

878 Virologic Success of Different Strategies for Initial ART 

Regimens Is Predicted by the Type and Detection Level 

of Minor Drug-resistant Variant Detected by Ultra Deep 

Sequencing: The CPCRA 058 FIRST Study 

Katherine Huppler Hullsiek* 1 , G Peng1 , B Simen2 , J Simons2 , M Egholm2 , 

R Novak3 , R MacArthur4 , and M Kozal5 1 2 Univ of Minnesota, Minneapolis, US; 454 Life Sci/Roche, Branford, CT, 

US; 3Univ of Illinois at Chicago, US; 4Wayne State Univ, Detroit, MI, US; 

and 5Yale Univ, New Haven, CT, US 

879 The Prevalence of Drug-resistant Virus as a Minority 

Quasispecies before Initiating ART Is Not Associated with 

Therapy Failure in Persons Initiating Therapy with Truvada 

plus PI/r or NNRTI 

Karin Metzner* 1 , H Walter1 , P Rauch1 , P Braun2 , H Knechten2 , R Ehret2 , 

N Sichtig3 , R Kaiser3 , J van Lunzen4 , and B Ranneberg5 1 2 Univ of Erlangen-Nuremberg, Germany; Praxis Zentrum Blondelstrasse, 

Aachen, Germany; 3Univ of Cologne, Inst of Virology, Germany; 4Univ Med Ctr, Hamburg-Eppendorf, Germany; and 5Gilead Sci, Martinsried, 

Germany 



New Resistance Technologies 

880 Measurement of Maturation Inhibitor Susceptibility Using 

the PhenoSenseHIV Assay 

Sunny Choe* 1 , Y Feng1 , K Limoli1 , K Salzwedel2 , S McCallister2 , 

W Huang1 , and N Parkin1 1 2 Monogram Biosci, South San Francisco, CA, US and Panacos Pharma, 

Inc, Gaithersburg, MD, US 

881 Performance of Prototype Integrase Genotyping Reagents for 

Analysis of Diverse HIV-1 Strains 

P Smith1 , V Holzmayer2 , L Fang1 , P Swanson2 , J Hackett2 , and Natalia 

Marlowe* 1 

1 2 Celera, Alameda, CA, US and Abbott Diagnostics, Abbott Park, IL, US 

882 Quantification of Resistance to Protease, Reverse 

Transcriptase, and Integrase Inhibitors Based on 3’Gag/ 

PR/RT/INT-Recombinant Viruses: A Useful Tool in the 

Upcoming Era of Integrase Inhibitors 

Kenneth Henry* 1 , A Vazquez2 , J Weber2 , R Gibson1 , J Weberova2 , 

E Arts1 , and M Quinones-Mateu2 1 2 Case Western Reserve Univ, Cleveland, OH, US and Diagnostic Hybrids 

Inc, Cleveland, OH, US 



HIV-1 Drug Resistance: Genital Shedding and 

Recombination 

883 Viral Shedding and Drug Resistance in Plasma and Genital 

Compartments among Viremic, Multi-drug-experienced 

HIV-infected Men and Women 

Rami Kantor* 1 , M Wantman2 , D Katzenstein3 , D Bettendorf2 , R Bosch2 , 

S Fiscus4 , R D’Aquila5 , L Frenkel6 , R Coombs6 , and ACTG A5077 Study 

Team 

1 2 Brown Univ, Providence, RI, US; Harvard Sch of Publ Hlth, Boston, 

MA, US; 3Stanford Univ, Palo Alto, CA, US; 4Univ of North Carolina 

at Chapel Hill, US; 5Vanderbilt Univ, Nashville, TN, US; and 6Univ of 


884 Multidrug-resistant HIV-1 and Recombination between 

Variants from the Genital Tract and Plasma: A Longitudinal 

Analysis 

Kimdar Kemal* 1 , C Kitchen2 , H Burger1,3 , B Foley4 , T Klimkait5 , 

F Hamy5 , K Anastos6 , M Suchard2 , V Minin2 , and B Weiser1,3 1 2 Wadsworth Ctr, New York State Dept of Hlth, Albany, US; Univ of 

California, Los Angeles, US; 3Albany Med Coll, NY, US; 4Los Alamos 

Natl Lab, NM,US; 5Inst of Med Microbio, Univ of Basel and In Pheno 

AG, Switzerland; and 6Montefiore Hosp, Bronx, NY, US 



HIV-2 Drug Resistance 

885 Selection of K65R Mutation in HIV-2 Patients Exposed to 

Abacavir 

Berta Rodes* 1 , C Toro1 , R Colombatti2 , A Simon1 , F Ricardi2 , C Vieira2 , 

A Coin2 , and V Soriano1 1 2 Hosp Carlos III, Madrid, Spain and Hosp Comunita St’Egidio, Bissau, 

Guinea Bissau 

886 Phenotypic Susceptibility in vitro to Raltegravir and 

Elvitegravir and Polymorphism of the Integrase Gene of 

HIV-2 Clinical Isolates 

Benedicte Roquebert* 1 , F Damond1 , G Collin1 , G Peytavin1 , A Benard2 , 

S Matheron1 , G Chene2 , F Brun-Vezinet1 , D Descamps1 , and French 

ANRS HIV-2 Cohort (ANRS CO 05 VIH-2) 

1 2 Hosp Bichat-Claude Bernard, Paris, France and INSERM U593, 

Bordeaux, France 

887 The Role of Innate Polymorphisms in Drug-selected Reverse 

Transcriptase Mutations in HIV-1 and HIV-2 Subtypes 

Michel Ntemgwa*, B Brenner, T Toni, M Oliveira, D Moisi, B Spira, 

E Asahchop, J Schachter, J Martinez-Cajas, and M Wainberg 

McGill Univ AIDS Ctr, Jewish Gen Hosp, Montreal, Canada 



Viral Rebound and Emergence of Drug Resistance 

888 RT-SHIV Subpopulation Dynamics before and during the 

Course of Antiviral Therapy 

Wei Shao* 1 , M Kearney2 , F Maldarelli2 , J Mellors3 , R Stephens1 , 

J Lifson4 , V KewalRamani2 , Z Ambrose2 , J Coffin5 , and S Palmer2 1 2 Advanced Biomed Computing Ctr, SAIC-Frederick, MD, US; HIV Drug 

Resistance Prgm, NCI-Frederick, MD, US; 3Univ of Pittsburgh, PA, US; 

4 5 SIAC-Frederick, MD, US; and Tufts Univ, Boston, MA, US 

889 Differences in the Dynamics of Viral Rebound and Evolution 

of Resistance between CBV/NVP and CBV/ABC Uncovered 

in the Absence of Viral Load Monitoring in Real Time: 

NORA Substudy of the DART Trial 

Nicaise Ndembi* 1 , D Pillay2 , R Goodall3 , A McCormick2 , A Burke3 , 

F Lyagoba1 , P Munderi1 , P Katundu4 , S Tugume4 , and P Kaleebu1 on 

behalf of the DART Virology 

1 2 Med Res Council/Uganda Virus Res Inst, Entebbe; Ctr for Virolgy, Univ 

Coll London, UK; 3Med Res Council Clinical Trials Unit, London, UK; 

and 4Joint Clin Res Ctr, Kampala, Uganda 

890 Absence of Protease Resistance with Virologic Rebound 

by Single Genome Sequencing on Atazanavir/Ritonavir as 

Simplified Maintenance Therapy: ACTG 5201 

John McKinnon* 1 , T Wilkin2 , S Swindells3 , G DiRienzo4 , C Fletcher5 , 

D Margolis6 , G Thal7 , B Bastow8 , K Droll4 , J Mellors1 , and the ACTG 

A5201 Study Group 

1 2 Univ of Pittsburgh, PA, US; Weill Med Coll of Cornell Univ, New York, 

NY, US; 3Univ of Nebraska Med Ctr, Omaha, US; 4Harvard Sch of Publ 

Hlth, Boston, MA, US; 5Univ of Colorado Hlth Sci Ctr, Denver, US; 6Univ of North Carolina at Chapel Hill, US; 7Bristol-Myers Squibb, Plainsboro, 

NJ, US; and 8ACTG Operations Ctr, Silver Spring, MD, US 



HIV-1 Drug Resistance after First-line Therapy 

891 Drug Resistance after Virological Failure of First-line 

HAART in Resource-rich and Resource-poor Settings, a 

Meta-Analysis 

Ravindra Gupta* 1 , A Hill2 , and D Pillay1,3 1 2 3 Univ Coll London, UK; Univ of Liverpool, UK; and Hlth Protection 

Agency, UK 

892 Low Risk of Initial ART Failure in Patients with Wild Type 

HIV-1 by Standard Genotypic Resistance Testing 

Jeffrey Fessel* 1 , SY Rhee2 , D Klein1 , L Hurley1 , T Liu2 , S Follansbee1 , 

S Slome1 , J Flamm1 , M Horberg1 , and R Shafer2 1 2 Kaiser Permanente Med Care Prgm, CA, US and Stanford Univ, Palo 

Alto, CA, US 

893 The High Frequency of Clinically Significant Mutations 

following First-line Generic HAART Failure: Implications 

for Second-line Options in Resource-limited Settings 

N Kumarasamy* 1 , V Madhavan1 , K Venkatesh2 , S Saravanan1 , R Kantor2 , 

P Balakrishnan1 , B Devaleenol1 , S Solomon1 , K Mayer2 , and R Schooley3 1 2 YRGCARE, Voluntary Hlth Svcs, Chennai, India; Warren Alpert Med 

Sch of Brown Univ, Providence, RI, US; and 3Univ of California, San 

Diego, US 


Poster Listings



894 Long-term Probability of Detecting HIV Drug Resistance in 

Drug-naïve Patients Starting Currently Recommended Firstline 

Combination ART 

Alessandro Cozzi-Lepri* 1 , D Dunn 2 , D Pillay 3 , C Sabin 1 , E Fearnhill 2 , 

A Phillips 1 , and UK HIV Drug Resistance Database and UK CHIC Study 

Groups 

1 Royal Free and Univ Coll London Med Sch, UK; 2 Med Res Council 

Clinical Trials Unit, London, UK; and 3 Univ Coll London, UK 



Changing Prevalence of HIV-1 Drug Resistance 

895 Drastically Declining Incidence of HIV Drug Resistance: 

The End of the Beginning? 

V Lima, E Hudson, B Wynhoven, B Yip, R Hogg, J Montaner, and 

Richard Harrigan* 

BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada 

896 The Proportion of Individuals without Further Treatment 

Options Has Stabilized at Low Levels in the Swiss HIV 

Cohort Study 

Viktor von Wyl* 1 , S Yerly2 , J Boni3 , P Burgisser4 , T Klimkait5 , 

S Bonhoeffer6 , B Ledergerber1 , H Gunthard1 , and the Swiss HIV Cohort 

Study (SHCS) 

1 2 3 Univ Hosp Zurich, Switzerland; Geneva Univ Hosp, Switzerland; Univ 

of Zurich, Switzerland; 4Lausanne Univ Hosp, Switzerland; 5Univ of 

Basel, Switzerland; and 6Swiss Federal Inst of Tech, Zurich 

897 Causes of Death and Accumulation of Class Drug-resistance 

among Survivors and Non-survivors in a Large Cohort of 

ARV-naïve Individuals 

Vikram Gill* 1,2 , K Fernandes1 , B Wynhoven1 , A Low1,2 , V Lima1 , 

R Hogg1 , and R Harrigan1,2 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and Univ of 

British Columbia, Vancouver, Canada 

898 Methamphetamine Use Is Not Associated with Increased 

Accumulation of HIV-1 Drug-resistant Mutations 

Hong-Ha Truong* 1,2 , T Kellogg3 , E Vittinghoff1 , J Martin1 , S Deeks1 , 

R Grant1,2 , G Colfax3 , and P Lum1 1 2 Univ of California, San Francisco, US; Gladstone Inst of Virology and 

Immunology, San Francisco, CA, US; and 3San Francisco Dept of Publ 

Hlth, CA, US 

899 Survey of HIV-1 Drug-resistance Mutations in Recently 

Infected, Antiretroviral-naïve Patients from Sub-Saharan 

Africa and Southeast Asia 

Ahidjo Ayouba* 1 , E Nerrienet2 , L Truong Xuan3 , L Vergne1 , E Mpoudi 

Ngole4 , D Valea5 , N Ngo-Giang-Huong6 , D Costagliola7 , M Peeters1 , 

ML Chaix8 , and ANRS 12134 Study Group 

1 2 Inst for Res and Devt, UMR145, Montpellier, France; Inst Pasteur, 

Phnom Penh, Cambodge; 3Inst Pasteur, Ho Chi Minh City, Vietnam; 

4 5 CRESAR/IRD/IMPM, Yaounde, Cameroon; Ctr Muraz, Bobo Dioulasso, 

Burkina Faso; 6Chiang Mai Univ, Thailand; 7INSERM U720, Paris, 

France; and 8Ctr Hosp Univ Necker, Paris, France 



Impact of Subtype on HIV-1 Drug Resistance 

900 The Effect of Sequence Polymorphisms on CRF01_AE 

Protease Structure 

Rajintha Bandaranayake* 1 , M Prabu-Jeyablab1 , J Kakizawa2 , W Sugiura2 , 

and C Schiffer1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Natl Inst of 

Infectious Diseases, Tokyo, Japan 

901 Subtype-specific Differences in ART Drug Resistance 

Mutations and TAM Pathways from Nigerian Patients 

Beth Chaplin* 1 , G Eisen1 , J Idoko2 , E Idigbe3 , D Olaleye4 , JL Sankale1 , 

R Murphy5 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US; Jos Univ Teaching Hosp, 

Nigeria; 3Natl Inst of Med Res, Lagos, Nigeria; 4Univ Coll Hosp, Ibadan, 

Nigeria; and 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US 

902 Transmission of HIV-1 Drug Resistance and Forward 

Transmission Events in the Aquitaine Cohort, 1996 to 2006 

P Recordon-Pinson1,2 , S Capdepont1,2 , D Neau1,2,3 , P Morlat1,2 , JL Pellegrin1,2 , 

A Groppi2 , R Thiebaut3 , F Dabis3 , H Fleury1,2 , Bernard Masquelier* 1,2 , and 

ANRS CO3 Aquitaine Cohort 

1 2 Ctr Hosp Univ Bordeaux, France; Univ Victor Segalen, Bordeaux, 

France; and 3INSERM U593 and EO338, Bordeaux, France 




Simplified Diagnostics for Resource-limited 

Settings 

903 An Improved Microfluidic Device for Point-of-care CD4 + 

T Cell Counting through Automated Monocyte Depletion 

Xuanhong Cheng* 1 , D Irimia1 , R Tompkins1 , M Toner1 , and 

W Rodriguez1,2 1 2 Massachusetts Gen Hosp, Boston, US and Brigham and Women’s Hosp, 


904 Evaluation of Peripheral Blood CD4 + T Cells in HIV + Persons 

with a Portable Analyzer 

J Estes1 , B Bhagwandin2 , S Jackinsky2 , E Most2 , and Timothy Schacker* 3 

1 2 3 NCI-Frederick, MD, US; LabNow, Inc, Austin, TX, US; and Univ of 


905 Implementation of an Affordable Colorimetric HIV Viral 

Load Assay in Monitoring HIV-1- and HIV-2-infected 

Patients on HAART in a Resource-limited Setting 

Abraham Alabi*, M Cotten, and S Rowland-Jones 

Med Res Council Labs, Banjul, Gambia 

906 The Cavidi Exavir Viral Load and Phenotype Assays in 

Comparison to HIV-1 RNA and Genotyping Assays 

Susan Fiscus*, A Cachafeiro, and S Napravnik 


907 Automated Detection of HIV in Infants Using the New COBAS 

Ampliprep/COBAS Taqman HIV-1 Qualitative Test 

Wendy Stevens*, L Erasmus, J Moloi, and T Taleng 

Univ of the Witwatersrand, Johannesburg, South Africa 



Evaluation of Serodiagnostic Assays 

908 False Negative Rapid HIV Tests in Durban, South Africa 

Ingrid Bassett* 1 , S Chetty2 , J Giddy2 , S Reddy3 , E Losina1 , K Freedberg1 , 

and R Walensky1 1 2 Massachusetts Gen Hosp, Boston, US; McCord Hosp, Durban, South 

Africa; and 3Univ of KwaZulu Natal, Durban, South Africa 

909 Relative Performances of 1 Compared to 2 ELISA Tests on 

the First Serum Sample to Diagnose HIV-1 Infection 

Dominique Costagliola* 1 , F Damond2 , P Palmer3 , C Rouzioux4 , and 

F Brun-Vezinet4 1 2 INSERM U720, Univ Pierre and Marie Curie, Paris, France; Hosp 

Bichat-Claude Bernard, Paris, France; 3St Louis Hosp, Paris, France; 

and 4Ctr Hosp Univ Necker, Paris, France 



HLA Testing: Refinements and Cost-effectiveness 

910 HLA-B*5701: Rapid Testing by Luminex Technology and 

UK Prevalence 

Mark Gompels*, R Lock, S Johnston, K Hopkins, and J Ward 

North Bristol NHS Trust, UK 

911 Genetic Testing in HIV Care: Clinical Effect and Costeffectiveness 

of HLA-B*5701 Screening to Guide First-line 

Abacavir Use 

Bruce Schackman* 1 , C Scott2 , R Walensky2,3,4 , E Losina2,3,5 , 

K Freedberg2,4,5,6 , and P Sax3,4 1 2 Weill Med Coll of Cornell Univ, New York, NY, US; Massachusetts 

Gen Hosp, Boston, US; 3Brigham and Women’s Hosp, Boston, MA, US; 

4 5 Harvard Med Sch, Boston, MA, US; Boston Univ Sch of Publ Hlth, MA, 

US; and 6Harvard Sch of Publ Hlth, Boston, MA, US 

912 Statistical Refinement of Low- and Intermediate-resolution 

HLA Class I Typing 

J Listgarten1 , Z Brumme2 , G Xiaojiang3 , B Walker2 , M Carrington3 , 

P Goulder2,4 , and David Heckerman* 1 

1 2 Microsoft Res, Redmond WA, US; Partners AIDS Res Ctr, Boston, MA, 

US; 3SAIC-Frederick and NCI-Frederick, MD, US; and 4Univ of Oxford, 

UK 



Impact of Subtype on HIV Quantification 

913 Comparison Test between the Abbott RealTime and the 

Cobas TaqMan Assays for the RNA Quantification of CRF02 

and other HIV-1 Non-B Subtypes 

Marc Wirden*, AG Marcelin, AA Zaina, JC Piot, L Kalkias, 

B Amellal, R Tubiana, A Simon, C Katlama, and V Calvez 

Hosp Pitie-Salpetriere, Paris, France


914 Assessment of 3 Commercial Assays for HIV-1 RNA 

Quantification of Non-B Subtypes in Plasma Samples: The 

Kesho Bora Preparatory Study 

F Rouet 1 , V Foulongne 2 , K Steegen 3 , P Becquart 4 , D Valea 1 , 

K Mandaliya 5 , S Luchters 6 , R Nduati 7 , E Njagi 7 , Philippe Van de Perre* 2 , 

and the Kesho Bora Study Group 

1 Ctr Muraz, Bob-Dioulasso, Burkina Faso; 2 Univ Montpellier 1 and Ctr 

Hosp Univ Montpellier, France; 3 Intl Ctr for Reproductive Hlth, Ghent, 

Belgium; 4 CIRMF, Franceville, Gabon; 5 Coast Provincial Gen Hosp, 

Mombasa, Kenya; 6 Intl Ctr for Reproductive Hlth, Mombasa, Kenya; and 

7 Kenyatta Natl Hosp, Nairobi, Kenya 



New Diagnostic and Monitoring Tools 

915 Enhanced Europium Nanoparticle-based Immunoassay for 

Sensitive and Early Detection of HIV-1 Capsid Antigen 

Shixing Tang* 1 , J Zhao1 , H Harma2 , X Wang1 , P Norris3 , S Stramer4 , and 

I Hewlett1 1 2 Food and Drug Admin, Bethesda, MD, US; Univ of Turku, Finland; 

3 4 Blood Systems Res Inst, San Francisco, CA, US; and American Red 

Cross, Gaithersburg, MD, US 

916 HIV-1 Single-copy Assay Detects Biological Variation in 

Viremia in Patients Suppressed on ART 

Nadia Urban* 1 , A Wiegand1 , S Palmer1 , J Mican2 , A O’Shea2 , 

C Rehm2 , S Kottilil2 , J Mellors3 , J Coffin1 , and F Maldarelli1 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US; Lab of 

Immunoregulation, NIAID, NIH, Bethesda, MD, US; and 3Univ of 

Pittsburgh, PA, US 

917 Accurate Representation of in vivo HIV-1 Quasispecies Plays 

an Important Role in the Quantification of Viral Tropism: 

A Comparison of 3 Different Methods to Generate env- 

Recombinant Viruses 

J Weber1 , K Henry2 , R Gibson2 , J Weberova1 , A Vazquez1 , E Arts2 , and 

Miguel E Quinones-Mateu* 1 

1 2 Diagnostic Hybrids Inc, Cleveland, OH, US and Case Western Reserve 

Univ, Cleveland, OH, US 

918 Usefulness of a Dendogram Plot Technique in Clustering 

Homogeneous Subgroups of Multi-treated HIV-1 Patients in 

Accordance with their Mutational Pattern 

Nuria Perez-Alvarez* 1,2 , J Llibre1 , B Clotet1,3 , and the Conference Call 

Spanish Group 

1 2 Lluita contra la SIDA Fndn, Barcelona, Spain; Univ Politecnica de 

Catalunya, Barcelona, Spain; and 3Fndn irsiCaixa, Barcelona, Spain 

919 SensiTrop QT: A Novel Molecular Diagnostic Assay for the 

Detection and Quantification of HIV Co-receptor Tropism 

Wenhui Li*, E Webb, L Nary, and T Robins 

Pathway Diagnostics, Malibu, CA, US 

920a Comparison of Results from the SensiTrop vs Trofile Assays on 100 Samples from the Maraviroc Expanded Access 

Program 

Randall Tressler* 1 , H Valdez1 , E van der Ryst2 , I James2 , M Lewis2 , 

J Wheeler2 , and S Than1 1 2 Pfizer Inc, New York, NY, US and Pfizer Global R&D, Sandwich, UK 

920b High-quality Care Delivery in HIV by the Use of a 

Computerized Data System 

John Zurlo* 1 , T Crook1 , C Whitener1 , D Greenawalt1 , P Albright1 , 

J Powers1 , and J Quick2 1 2 Penn State Univ, Hershey Med Ctr, Hershey, US and MajCo Svcs, 

Hershey, PA, US 



Diagnosis and Monitoring Using Dried Specimens 

921 Validation and Quality Assurance of the Infant Diagnostic 

PCR Test Using a Second Spot from the Same Dried Blood 

Spot Sample in Nigeria 

Chin-Yih Ou* 1 , O Bolu1 , K Bond2 , R Audu1 , A Abimiku3 , K Diallo1 , L Lu1 , 

T Jelpe2 , M Okoye4 , A Abubakar2 , and Federal Ministry of Hlth 

1 2 3 CDC, Atlanta, GA, US; CDC Nigeria, Abuja; Inst of Human Virology, 

Jos, Nigeria; and 4USAID, Abuja, Nigeria 

922 A Low-cost Real-time PCR Assay for HIV-1 Diagnosis and 

Quantification Using Dried Blood Spots 

Nishaki Mehta* 1 , S Trzmielina1 , M Eliot2 , B Nonyane2 , A Foulkes2 , 

J Sullivan1 , K Luzuriaga1 , and M Somasundaran1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Univ of 

Massachusetts Sch of Publ Hlth and Hlth Sci, Amherst, US 

923 Qualitative Analysis of Dried Blood Spots for the Diagnosis 

of Infants and Detection of Acute Infection from Pooled 

Samples 

R Kerr, G Player, S Fiscus, and Julie Nelson* 


924 HIV-1 DNA Yield from Dried Blood Spots Is Diminished 

after Storage at 37oC Compared to -20oC Caroline Mitchell and IMPAACT Dried Blood Spot Working Group 


925 Validation of the NucliSens EasyQ Assay on Dried Fluid 

Spots for Monitoring of HIV-1 Infection in South Africa 

Mohammed Abdo* 1 , G Sherman2 , and W Stevens2 1 2 Wits Pediatric HIV Clin, Johannesburg, South Africa and Univ of the 

Witwatersrand, Johannesburg, South Africa 

926 Correlation between HIV-1 Viral Load Quantification 

Measured in Dried Blood Spots and Plasma Using 2 

Commercial Assays 

Carolina Garrido*, N Zahonero, V Soriano, and C de Mendoza 


927 Efficient HIV-1 Drug Resistance Genotyping from Dried 

Blood Spots Stored for 1 Year at 4ºC 

A Youngpairoj1 , S Masciotra1 , C Garrido2 , N Zahonero2 , C de Mendoza2 , 

and Gerardo Garcia-Lerma* 1 

1 2 CDC, Atlanta, GA, US and Hosp Carlos III, Madrid, Spain 

928 Dried Blood Spots and the Ultra-sensitive p24 Antigen Assay 

for the Diagnosis of Perinatal HIV Infection 

Ada Cachafeiro* 1 , G Sherman2 , A Sohn3 , C Beck-Sague4 , and S Fiscus1 1 2 Univ of North Carolina at Chapel Hill, US; Univ of the Witwatersrand, 

Johannesburg, South Africa; 3Univ of California, San Francisco, US; and 

4Clinton Fndn HIV AIDS Initiative, Santo Domingo, Dominican Republic 



Dyslipidemia: Role of ART and Interventions for 

Management 

929 Fasted Lipid Changes after Administration of Maraviroc or 

Efavirenz in Combination with Zidovudine and Lamivudine 

for 48 Weeks to Treatment-naïve HIV-infected Patients 

E DeJesus* 1 , S Walmsley2 , C Cohen3 , D Cooper4 , B Hirschel5 , 

J Goodrich6 , H Valdez7 , J Heera6 , N Rajicic6 , and H Mayer6 1 2 Orlando Immunology Ctr, FL, US; Univ of Toronto, Canada; 

3 4 Community Res Initiative of New England, Boston, MA, US; Univ of 

New South Wales, Australia; 5Hosp Univ of Geneva, Switzerland; 6Pfizer Global R&D, New London, CT, US; and 7Pfizer Inc, New York, NY, US 

930 Plasma Exposure of 100 mg Once and Twice Daily Decreases 

HDL and CD36 Expression but Only Twice-daily Dosing 

Increases Triglycerides: Potential Effect of Ritonavir on 

Cardiovascular Disease 

Marta Boffito* 1 , S Collot-Teixeira2 , F De Lorenzo3 , L Waters1 , C Fletcher1 , 

D Back4 , S Mandalia1 , A Pozniak1 , J McGregor2 , and B Gazzard1 1 2 3 St Stephen’s Ctr, London, UK; King’s Coll London, UK; Chelsea and 

Westminster Hosp NHS Fndn Trust, London, UK; and 4Univ of Liverpool, 

UK 

931 The Effect of Hepatitis C Infection on Metabolic Parameters 

following Initial Therapy of HIV-infected Subjects with 

Nucleoside ± NNRTI Regimens 

Cecilia Shikuma* 1 , H Ribaudo2 , E Zheng2 , M Glesby3 , W Meyer4 , 

K Tashima5 , B Bastow6 , D Kuritzkes7 , R Gulick3 , and ACTG A5095 Study 

Team 

1 2 Univ of Hawaii, Honolulu, US; Harvard Sch of Publ Hlth, Boston, 

MA, US; 3Weill Med Coll of Cornell Univ, New York, NY, US; 4Quest Diagnostics, Baltimore, MD, US; 5Brown Univ, Providence, RI, US; 

6 7 Social & Sci Systems, Silver Spring, MD, US; and Brigham and 

Women’s Hosp, Boston, MA, US 

932 Changes in Markers of Atherogenic Dyslipidemia, 

Inflammation, and Platelet Activation with Treatment with 

Pravastatin, Fenofibrate, or the Combination: Results from 

the ACTG A5087 Team 

Carl Fichtenbaum* 1 , TM Yeh2 , S Evans2 , J Aberg3 , and ACTG 

1 2 Univ of Cincinnati Coll of Med, OH, US; Harvard Sch of Publ Hlth, 

Cambridge, MA, US; and 3New York Univ Sch of Med, NY, US 

933 ART Exposure and Insulin Resistance in the Women’s 

Interagency HIV Study 

Phyllis Tien* 1 , M Schneider2 , S Cole2 , A Levine3 , M Cohen4 , J DeHovitz5 , 

M Young6 , and J Justman7 1 2 VAMC and Univ of California, San Francisco, US; Johns Hopkins Univ 

Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Southern 

California, Los Angeles, US; 4CORE Ctr and Stroger Hosp, Chicago, 

IL, US; 5State Univ of New York Downstate Med Ctr, Brooklyn, US; 

6 7 Georgetown Univ Med Ctr, Washington, DC, US; and Columbia Univ, 


934 Differences in Lopinavir Plasma Concentrations Comparing 

Kaletra Film Coated Tablets and Soft Gelatin Capsules 

Translate into Distinct Lipid Abnormalities 

Judit Morello*, S Rodriguez-Novoa, F Blanco, A Rubio, 

I Jimenez-Nacher, and V Soriano 



Poster Listings





Lypoatrophy/Lipohypertrophy: Predictors and 

Interventions 

935 Clinical Associations of Extremity Fat Loss: ACTG 5142, a 

Prospective, Randomized, Phase III Trial of NRTI-, PI-, and 

NNRTI-sparing Regimens for ART of Naïve, HIV-1-infected 

Subjects 

Richard Haubrich* 1 , S Riddler2 , G DiRienzo3 , Y Zheng3 , W Powderly4 , K 

Garren5 , D Butcher6 , J Rooney7 , J Mellors2 , D Havlir8 , and the ACTG 5142 

Study Team 

1 2 Univ of California, San Diego, US; Univ of Pittsburgh, PA, US; 

3Harvard Sch of Publ Hlth, Statistical and Data Analysis Ctr, Boston, 

MA, US; 4Univ Coll Dublin, Ireland; 5Abbott Labs, Abbott Park, IL, US; 

6 7 Bristol-Myers Squibb, Plainsboro, NJ, US; Gilead Sci, Foster City, CA, 

US; and 8Univ of California, San Francisco, US 

936 Chromium Supplementation Decreases Insulin Resistance 

and Trunk Fat 

E Aghdassi, Irving Salit*, S Mohammed, B Arendt, and J Allard 

Univ Hlth Network, Toronto, Canada 

937 ZDV/3TC/LPV/r, but Not NVP/LPV/r, Is Associated with 

Limb Fat Loss and Relative Abdominal Fat Accumulation 

after 24 Months in ATT-naïve HIV-1-infected Men: 

MEDICLAS, a Randomized Clinical Trial 

Marit van Vonderen* 1 , M van Agtmael1 , E Hassink2 , A Milinkovic3 , 

K Brinkman4 , S Geerlings5 , M Ristola6 , A van Eeden7 , S Danner1 , 

P Reiss5 , and the MEDICLAS Study Group 

1 2 VU Univ Med Ctr, Amsterdam, The Netherlands; Intl Antiviral Therapy 

Evaluation Ctr, Amsterdam, The Netherlands; 3Hosp Clin, Barcelona, 

Spain; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; 

5 6 Academic Med Ctr, Univ of Amsterdam, The Netherlands; Helsinki 

Univ Central Hosp, Finland; and 7Medisch Centrum Jan van Goyen, 

Amsterdam, The Netherlands 

938 Switching from Combivir to Truvada Preserves Limb Fat: 

Results of a DEXA Sub-study of a 48-Week Randomized 

Study 

Graeme Moyle* 1 , M Fisher2 , and SWEET Study Group 

1 2 Chelsea and Westminster Hosp, London, UK and Brighton and Sussex 

Univ Hosp, Brighton, UK 

939 Influence of NRTI Choice and Efavirenz vs Lopinavir 

Treatment Options on Lipoatrophy-associated Adipose 

Tissue Toxicity: A Longitudinal Study 

E Hammond, B McKinnon, C Pace, D Nolan, and Simon Mallal* 

Murdoch Univ and Royal Perth Hosp, Australia 

940 Changes in Body Composition Attributable to Lamivudine, 

Stavudine, Zidovudine, and Abacavir in HIV-infected 

Persons Initiating ART 

Judith Shlay* 1 , S Sharma2 , G Bartsch2 , G Peng2 , C Gibert3 , C Grunfeld4 , 

and the CPCRA and INSIGHT 

1 2 Denver CPCRA, Denver Publ Hlth, CO, US; Univ of Minnesota, 

Minneapolis, US; 3Wide-Reaching AIDS Prgm, VAMC and George 

Washington Univ, Washington, DC, US; and 4VAMC and Univ of 


941 How Much Fat Loss Is Needed for Lipoatrophy to Become 

Clinically Evident? 

Daniel Podzamczer* 1 , E Ferrer1 , E Martinez2 , L del Rio3 , I Ruiz1 , 

J Rosales3 , E Ribera4 , P Barrufet5 , J Llibre6 , M Aranda7 , and the ABCDE 

Study Team 

1 2 Hosp Univ de Bellvitge, Barcelona, Spain; Hosp Clin, Barcelona, Spain; 

3 4 5 CETIR, Barcelona, Spain; Hosp Vall d’Hebron, Barcelona, Spain; Hosp 

de Mataro, Barcelona, Spain; 6Hosp Germans Trials i Pujol, Badalona, 

Spain; and 7Hosp de Terrassa, Barcelona, Spain 

942 Relationship of NRTI-mediated Mitochondrial DNA 

Depletion and Respiratory Chain Activity in Primary Human 

Subcutaneous Adipocytes 

Metodi Stankov*, R Schmidt, G Behrens, and the German Competence 

Network HIV/AIDS 

Hannover Med Sch, Germany 

943 Data on 52-Week Safety and Efficacy of Tesamorelin, a 

Growth Hormone-releasing Factor Analogue, in HIVinfected 

Patients with Abdominal Fat Accumulation 

J Falutz1 , S Allas2 , JC Mamputu2 , D Kotler3 , M Somero4 , D Berger5 , 

S Brown6 , G Richmond7 , J Fessel8 , and Steven Grinspoon* 9 

1 2 Montreal Gen Hosp, McGill Univ Hlth Ctr,Canada; Theratechnologies 

Inc, Montreal, Canada; 3St Luke’s Roosevelt Hosp Ctr, Columbia Univ 

Coll of Physicians and Surgeons, New York, NY, US; 4Palm Springs, CA, 

US; 5Northstar Hlth Care, Chicago, IL, US; 6AIDS Res Alliance, West 

Hollywood, CA, US; 7Broward Gen Med Ctr, Fort Lauderdale, FL, US; 

8 9 Kaiser Fndn Res Inst, CA, US; and Massachusetts Gen Hosp, Harvard 

Med Sch, Boston, US 


944 Effects of Diet and Exercise and Rosiglitazone on Body 

Composition and Lipids, including Oxidized LDL in HIV + 

and HIV – Men and Women 

David Mun* 1 , E Engelson1,2 , J Albu1,2 , M Sharma2 , T Pitea2 , and 

D Kotler1,2 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US and 

2St Luke’s Roosevelt Hosp Ctr, New York, NY, US 

945 Relationship between Polymerase Gamma Polymorphisms 

and ART-induced Lipodystrophy in HIV-infected Patients: A 

Case Control Study 

Franck Chiappini*, E Teicher, D Vittecoq, and A Lemoine 

Hosp Paul Brousse, Villejuif, France 

946 Lipoatrophy and Lipohypertrophy Are Independently 

Associated with Hypertension: The Effect of Lipoatrophy 

but not Lipohypertrophy on Hypertension Is Independent of 

Obesity 

Heidi Crane* 1 , C Grunfeld2 , R Harrington1 , and M Kitahata1 1 2 Univ of Washington, Seattle, US and Univ of California, San Francisco, 

US 

947 Incidence of Lipodystrophy and Metabolic Syndrome after 

the Initiation of Combined ART in Sub-Saharan cART-naïve 

Patients 

Serge Eholie* 1 , K Lacombe2,3,4 , L Denoeud4 , C Adje1 , F Cao4 , 

O Bouchaud5 , L Slama6 , R Landmann7 , E Bissagnene1 , and PM Girard3,4 1 2 Hosp de Treichville, Abidjan, Côte d’Ivoire; INSERM UMR S707, Paris, 

France; 3Univ Pierre and Marie Curie, Paris, France; 4Hosp St Antoine, 

Paris, France; 5Hosp Avicenne, Bobigny, France; 6Hosp Tenon, Paris, 

France; and 7Hosp Bichat, Paris, France 

948 Evaluation of Pregnancy PBMC and Placental MtDNA in 

HIV-infected, HAART-treated Women, Compared to HIVuninfected 

Women 

Helene Cote* 1,2 , E Maan3 , E Papp1 , T Chaworth-Musters3 , I Gadawski1 , 

J van Schalkwyk3 , M Jitratkosol3 , J Forbes3 , D Burdge3 , D Money2,3 , and 

the HIV Perinatal Study Group 

1 2 Univ of British Columbia, Vancouver, Canada; Women’s Hlth Res 

Inst, Vancouver, Canada; and 3Children’s and Women’s Hlth Ctr of BC, 

Vancouver, Canada 



Atherosclerosis, Cardiovascular Risk and HIV 

Infection 

949 Inflammatory Markers Correlate with Carotid Intima 

Media Thickness and Endothelial Activation in HIV-infected 

Patients 

Allison Ross* 1 , N Rizk1 , M O’Riordan1 , J Adell1 , N Storer1 , 

M Tungsiripat2 , V Dogra3 , D Harrill1 , D Nakamoto1 , and G McComsey1 1Case Western Reserve Univ and Univ Hosp Med Ctr, Cleveland, OH, 

US; 2Cleveland Clin Fndn, OH, US; and 3Univ of Rochester Med Ctr, 

NY, US 

950 Metabolic Risk Factors for Mortality in HIV + Patients 

Olamide Jarrett* 1,2 , R Ruthazer1,2 , T Knox1,2 , and C Wanke1,2 1 2 Tufts Univ, Boston, MA, US and Tufts-New England Med Ctr, Boston, 

MA, US 

951 Role of ART, Viral Replication, and HIV Infection in 

Atherosclerosis 

Priscilla Hsue* 1 , P Hunt1 , J Martin1 , A Schnell1 , C Kalapus2 , and S Deeks1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp, 

CA, US 

952 Carotid Intima Media Thickness in HIV-infected Subjects 

and Community Controls 

Marek Smieja* 1 , E Lonn1 , F Smaill1 , S Buracond1 , S Smith1 , S Anand1 , 

K Gough2 , J Gill3 , S Trottier4 , M Harris5 , and the Canadian HIV Vascular 

Study Investigators 

1 2 McMaster Univ, Hamilton, Canada; St Michael’s Hosp, Toronto, 

Canada; 3Univ of Calgary, Canada; 4Univ Laval, Canada; and 5St Paul’s 

Hosp, Vancouver, Canada 

953 A Longitudinal Study of Changes in Circulating Markers of 

Endothelial Function in HIV Patients Starting Combination 

ART 

1,2 3 3 3 Ulrik Sloth Kristoffersen* , K Kofoed , G Kronborg , AK Giger , 

A Kjaer1,2 , and AM Lebech3 1 2 Rigshospitalet, Copenhagen, Denmark; Univ of Copenhagen, Denmark; 

and 3Hvidovre Univ Hosp, Copenhagen, Denmark 

954 Endothelial Activation Markers Are Linked to HIV Status 

and Are Independent of ART and Lipoatrophy 

Allison Ross*, R Armentrout, M O’Riordan, N Storer, D El Bejjani, 

N Rizk, D Harrill, and G McComsey 

Case Western Reserve Univ and Univ Hosp Med Ctr, Cleveland, OH, US 

955 A Pilot Study of the TNF-α Inhibitor Pentoxifylline to 

Improve HIV-related Endothelial Dysfunction 

Samir Gupta*, R Johnson, C Saha, K Mather, J Waltz, M Greenwald, 

M Clauss, and M Dube 

Indiana Univ Sch of Med, Indianapolis, US


956 Risk for Cardiovascular Disease and Regional Adipose Tissue 

Depots among HIV-infected Men and Women in the Study of 

Fat Redistribution and Metabolic Changes in HIV Infection 

David Wohl* 1 , J Currier2 , E Madden3 , R Scherzer3 , P Tien3 , and 

C Grunfeld4 1 2 Univ of North Carolina at Chapel Hill, US; Univ of California, Los 

Angeles, US; 3VAMC, San Francisco, CA, US; and 4Univ of California, 

San Francisco, US 

957a Arterial Stiffness in HIV-infected and HIV-uninfected 

Rwandan Women 

Jason Lazar* 1 , Q Shi2 , A Kagame3 , X Wu4 , M Cohen5 , F Ndamage6 , 

J Mugabo6 , K Anastos7 , and Rwanda Women’s Interassociation Study and 

Assessment (RWISA) 

1 2 Downstate Med Ctr, Brooklyn, NY, US; New York Med Coll, Valhalla, 

US; 3Central Hosp of Kigali, Rwanda; 4Data Solutions LLC, Bronx, NY, 

US; 5CORE Ctr and Stroger Hosp, Chicago, IL, US; 6Treatment and Res 

on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda; and 7Montefiore Med Ctr, 

Bronx, NY, US 

957b Effect of ART on Triglyceride and HDL Cholesterol of 

Apolipoprotein A5 Genetic Variants in HIV-infected Subjects 

Alexandra Mangili* 1,2 , J Gerrior1 , J Ordovas3 , and C Wanke1,2 1 2 Tufts Univ Sch of Med, Boston, MA, US; Tufts-New England Med Ctr, 

Boston, MA, US; and 3US Dept of Agriculture, Human Nutrition Res Ctr 

on Aging, Boston, MA 

957c Do Thymidine Analogues, Abacavir, Didanosine and 

Lamivudine Contribute to the Risk of Myocardial Infarction? 

The D:A:D Study 

C Sabin1 , S Worm2 , R Weber3 , W El-Sadr4 , P Reiss5 , R Thiébaut6 , S DeWit7 , 

M Law8 , A Phillips1 , Jens Lundgren* 2,9 , and the D:A:D Study Group 

1 2 Univ Coll London and Royal Free Hosp, UK; Univ of Copenhagen, 

Denmark; 3Univ Hosp Zurich, Switzerland; 4Columbia Univ, New York, 

NY, US; 5Academic Med Ctr, Amsterdam, The Netherlands; 6Inst for 

Publ Hlth, Epi and Devt, Univ Victor Segalen Bordeaux 2, France; 7St Pierre Univ Hosp, Brussels, Belgium; 8Univ of New South Wales, Sydney, 

Australia; and 9Rigshospitalet, Copenhagen, Denmark 



Hepatic Complications 

958 Evolution of Non-alcoholic Fatty Liver Disease in HIVinfected 

Patients: Incidence, Characteristics, and Predictors 

Giovanni Guaraldi* 1 , N Squillace1 , C Stentarelli1 , G Orlando1 , 

R D’Amico1 , G Ligabue1 , F Fiocchi1 , S Zona1 , R Esposito1 , and F Palella2 1 2 Univ of Modena and Reggio Emilia, Modena, Italy and Feinberg Sch of 

Med, Northwestern Univ, Chicago, IL, US 

959 Exposure to Antiretrovirals and Risk for Advanced Liver 

Fibrosis: Harmful Effect of Drug-related Metabolic 

Abnormalities? 

Francisco Blanco*, P Barreiro, P Ryan, J Troya, S Arponen, E Vispo, 

L Martin-Carbonero, P Labarga, J Gonzalez-Lahoz, and V Soriano 


960 Low Hepatoxicity in Patients Randomized to Switching to 

Nevirapine Once Daily vs Continuing with Nevirapine Twice 

Daily 

Daniel Podzamczer* 1 , M Olmo1 , J Sanz2 , V Boix3 , B Clotet4 , H Knobel5 , 

G Leibenger1 , P Domingo6 , J Pineda7 , C Vilades8 , and the NODy Study 

Group 

1 2 Hosp Univ de Bellvitge, Barcelona, Spain; Hosp Ppe de Asturias, 

Madrid, Spain; 3Hosp Gral de Alicante, Alicante, Spain; 4Hosp Germans 

Trials i Pujol, Badalona, Spain; 5Hosp del Mar, Barcelona, Spain; 6Hosp St Pau, Barcelona, Spain; 7Hosp Valme, Seville, Spain; and 8Hosp Joan 

XXIII, Tarragona, Spain 

961 Liver Histology and Hepatic Mitochondrial Function in 

HIV-1-infected Patients on ART with Chronic Transaminase 

Elevation 

Marc-Antoine Valantin* 1 , P Ingiliz1 , F Charlotte1 , F Mejda1 , 

S Dominguez1 , R Tubiana1 , C Duvivier2 , A Lombes1 , Y Benhamou1 , and 

C Katlama1 1 2 Hosp Pitie-Salpetriere, Paris, France and Ctr Hosp Univ Necker, Paris, 

France 



Markers of Inflammation, Immunodeficiency and 

Complications 

962 The Relationship between Inflammatory Cytokines and Body 

Composition in HIV Seropositive and Seronegative Men in a 

Substudy of the Multicenter AIDS Cohort Study 

Todd Brown* 1 , X Xu 1 , F Palella 2 , L Kingsley 3 , M Witt 4 , J Margolick 1 , and 

A Dobs 1 

1 Johns Hopkins Univ, Baltimore, MD, US; 2 Northwestern Univ, Chicago, 

IL, US; 3 Univ of Pittsburgh, PA, US; and 4 Univ of California, Los 

Angeles, US 

963 Non-AIDS Co-morbidities by CD4 Level and HAART Use in 

Clinical Practice 

Richard Moore*, K Gebo, G Lucas, and J Keruly 


964 Acute Viral Rebound as a Result of Structured Treatment 

Interruptions in Chronically HIV-1-infected Subjects: A 

Pathway to Cardiovascular Risk? 

Emmanouil Papasavvas* 1 , L Azzoni1 , M Pistilli1 , A Hancock1 , 

G Reynolds1 , C Gallo2 , J Kostman2,3 , K Mounzer2 , J Shull2 , and L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Philadelphia Field Initiating Group 

for HIV Trials, PA, US; and 3Univ of Pennsylvania, Philadelphia, US 



Changes in Bone Mineral Density 

965 Short-term Bone Loss in HIV-infected Premenopausal 

Women 

Michael Yin* 1 , S Cremers1 , D Lu2 , E Shane1 , W Gao2 , D McMahon1 , and 

K Anastos2 1 2 Columbia Univ Med Ctr, New York, NY, US and Montefiore Med Ctr, 

Bronx, NY, US 

966 Bone Mineral Density 96 Weeks after ART Initiation: A 

Randomized Trial Comparing Efavirenz-based Therapy 

with a Lopinavir/Ritonavir-containing Regimen with 

Simplification to LPV/r Monotherapy 

Todd Brown* 1 , G McComsey2 , M King3 , R Qaqish3 , B Bernstein3 , and 

B da Silva3 1 2 Johns Hopkins Univ, Baltimore, MD, US; Case Western Reserve Univ, 

Cleveland, OH, US; and 3Abbott Labs, Abbott Park, IL, US 

967 First-line PI-containing Regimens Enhance Decreased Bone 

Mineral Density Greater than NNRTI-containing Regimen in 

HIV-1-infected Patients: A Substudy of the HIPPOCAMPE– 

ANRS 121 Trial 

C Duvivier1,2,3 , S Kolta4 , L Assoumou2,3 , J Ghosn1,2,3 , S Rozenberg1 , 

R Murphy1,2 , C Katlama1,2,3 , Dominique Costagliola* 2,3 , and the ANRS 121 

Study Group 

1 2 Hosp Pitie-Salpetriere, Paris, France; Univ Pierre and Marie Curie, 

Paris, France; 3INSERM UMR S720, Paris, France; and 4Hosp Cochin, 

Univ Paris-Descartes, Paris, France 

968 Tenofovir Use Is Associated with an Increase in Serum 

Alkaline Phosphatase in the Swiss HIV Cohort Study 

Christoph Fux* 1 , A Rauch1 , M Simcock2,3 , H Bucher2,3 , B Hirschel4 , 

M Opravil5 , P Vernazza6 , M Cavassini7 , E Bernasconi8 , H Furrer1 , and 

Swiss HIV Cohort Study (SHCS) 

1 2 Univ Hosp Berne, Switzerland; Basel Inst for Clin Epi, Switzerland; 

3 4 5 Univ Hosp Basel, Switzerland; Geneva Univ Hosp, Switzerland; Univ 

Hosp Zurich, Switzerland; 6Kantonsspital, St Gallen, Switzerland; 7Ctr Hosp Univ Vaudois Lausanne, Switzerland; and 8Hosp Civico, Lugano, 

Switzerland 

969 Risk Factors for Reduced Bone Mineral Density in HIVinfected 

Individuals in the Modern HAART Era 

Silvia Guillemi*, F Ng, W Zhang, V Lima, C Rocha, M Harris, 

G Bondy, A Belzberg, and J Montaner 

BC Ctr for Excellence in HIV/AIDS, Providence Hlth Care and Univ of 

British Columbia, Vancouver, Canada 

970 Reduced Bone Mineral Density in HCV- or HBV-co-infected 

Patients: 2-year Follow-up, ANRS CO3 Aquitaine Cohort, 

France 

Charles Cazanave* 1,2 , M Dupon1,2 , V Lavignolle-Aurillac3 , N Barthe2 , 

S Lawson-Ayayi1,2,3 , N Mehsen2 , D Lacoste1,2 , JL Pellegrin1,2 , D Neau1,2,3 , 

and F Dabis1,2,3 for the Groupe d’Epidemiologie Clinique du SIDA en 

Aquitaine (GECSA) 

1 2 COREVIH-Aquitaine, France; Bordeaux Univ Hosp, France; and 

3INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, 

Bordeaux, France 



Renal Disease 

971 Deterioration of Renal Function Associated with Current 

Level of Immunodeficiency 

Ole Kirk* 1 , A Mocroft2 , A d’Arminio Monforte3 , AB Eg Hansen4 , 

J Gatell5 , S Caplinskas6 , G Faetkenheuer7 , P Reiss8 , E Vinogradova9 , 

J Lundgren1 , and the EuroSIDA Study Group 

1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free 

and Univ Coll London Med Sch, UK; 3Hosp San Paulo, Milan, Italy; 

4 5 Rigshospitalet, Copenhagen, Denmark; Hosp Clin of Barcelona, Spain; 

6 7 8 Lithuanian AIDS Ctr, Vilnius; Univ Hosp Cologne, Germany; Univ of 

Amsterdam, The Netherlands; and 9St Petersburg AIDS Ctr, Russia 

972 Chronic Kidney Disease Incidence and Progression to Endstage 

Renal Disease in HIV-infected Individuals: A Tale of 

2 Races 

Gregory Lucas*, B Lau, M Atta, D Fine, J Keruly, and R Moore 



Poster Listings



973 Proteinuria, Glomerular Filtration Rate Reductions, and 

Associated Factors among HIV-infected and -uninfected Men 

in the Multicenter AIDS Cohort Study 

Frank Palella* 1 , X Li2 , L Kingsley3 , S Gupta4 , R Detels5 , J Margolick2 , 

J Phair1 , and L Jacobson2 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Johns 

Hopkins Univ, Baltimore, MD, US; 3Univ of Pittsburgh, PA, US; 4Indiana Univ Sch of Med, Indianapolis, US; and 5Univ of California, Los Angeles, 

US 

974 The Effects of HIV-1 Viral Suppression and Non-viral Factors 

on Clinically Significant Proteinuria in the HAART Era 

Samir Gupta* 1 , N Franceschini2 , L Szczech3 , M Smurzynski4 , 

R Kalayjian5 , and ACTG Longitudinal Linked Randomized Trials 

(ALLRT) Study Team 

1 2 Indiana Univ Sch of Med, Indianapolis, US; Univ of North Carolina at 

Chapel Hill, US; 3Duke Univ, Durham, NC, US; 4Harvard Sch of Publ 

Hlth, Boston, MA, US; and 5MetroHlth Med Ctr, Cleveland, OH, US 

975 Effect of Tenofovir on Renal Function in Patients Using 

HAART 

Michael Horberg* 1 , B Tang2 , W Towner2 , S Bersoff-Matcha3 , D Klein4 , 

M Silverberg1 , W Chen2 , L Hurley4 , J Chang2 , and J Blank3 1 2 Kaiser Permanente, Oakland, CA, US; Kaiser Permanente Southern 

California, Pasadena, US; 3Kaiser Permanente Mid-Atlantic, Washington, 

DC, US; and 4Kaiser Permanente Northern California, Oakland, US 

976 HIV Care and the Incidence of Acute Renal Failure 

J Roe, L Campbell, F Ibrahim, B Hendry, and Frank Post* 

King’s Coll London, UK 

977a Inefficient Renal Transport of NRTI GS-9148 Indicates Its 

Low Potential for Nephrotoxicity 

G Laflamme1 , A Ray1 , R Fisher2 , R Mackman1 , and Tomas Cihlar* 1 

1 2 Gilead Sci, Foster City, CA, US and Vitron, Tucson, AZ, US 

977b A Comparison between Different GFR-estimations 

and [125I]-iothalamate, the Gold Standard for GFRmeasurement, 

in HIV-infected Patients on HAART 

Saskia Vrouenraets* 1,2 , E Fernandez Garcia2 , F Wit1,2 , K Brinkman3 , 

F Hoek1 , R Krediet1 , and P Reiss1,2 for the PREPARE Study Group 

1 2 Academic Med Ctr, Amsterdam, The Netherlands; Intl Antiviral Therapy 

Evaluation Ctr, Amsterdam, The Netherlands; and 3Onze Lieve Vrouwe 

Gasthuis, Amsterdam, The Netherlands 



Impact on Cardiac Function 

978 Prevalence and Risk Factors in HIV-infected Persons for 

Echocardiographic Abnormalities in the Era of Modern 

HAART 

K Mondy1 , J Gottdiener2 , Turner Overton* 1 , K Henry3 , L Conley4 , 

T Bush4 , J Hammer5 , C Carpenter6 , M Kojic6 , J Brooks4 , and SUN Study 

Investigators 

1 2 Washington Univ Sch of Med, St Louis, MO, US; Univ of Maryland, 

Baltimore, US; 3HIV Prgm, Hennepin County Med Ctr, Univ of 

Minnesota, US; 4CDC, Atlanta, GA, US; 5Univ of Colorado Hlth Sci Ctr, 

Denver, US; and 6Miriam Hosp, Providence, RI, US 

979 Diastolic Dysfunction is Common in Asymptomatic HIV 

Patients 

Priscilla Hsue* 1 , H Farah1 , A Bolger1 , S Palav2 , S Ahmed2 , A Schnell1 , 

S Deeks1 , J Martin1 , and D Waters1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp, 

CA, US 

980 Myocarditis Associated with Combined ART in CD8 + Celldepleted 


Lakshmanan Annamalai* 1 , S Westmoreland1 , E Ludlage2 , K Williams3 , 

E Ratai4 , M Lentz4 , R Schinazi5 , N Bischofberger6 , G Gonzalez4 , and 

S O’Neil1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, 

US; 2Ctr for Comparative Med, Massachusetts Gen Hosp, Charlestown, 

US; 3Boston Univ, MA, US; 4AA Martinos Ctr for Biomed Imaging, 

Massachusetts Gen Hosp, Charlestown, US; 5Emory Univ Sch of Med and 

VAMC, Atlanta, GA, US; and 6Gilead Sci, Foster City, CA, US 



Hypersensitivity Reactions: Other Drug Toxicities 

981 HCP5-Single Nucleotide Polymorphism: A Simple Screening 

Tool for Predicting Abacavir Hypersensitivity Reactions 

S Colombo 1 , Andri Rauch* 2 , M Rotger 1 , J Fellay 3 , C Fux 2 , C Thurnheer 2 , 

H Furrer 2 , D Goldstein 3 , A Telenti 1 , and Swiss HIV Cohort Study 

1 Univ Hosp Lausanne, Switzerland; 2 Univ Hosp Bern, Switzerland; and 

3 Duke Univ, Durham, NC, US 


982 Genetic Factors Predicting Abacavir Hypersensitivity and 

Tolerance in HLA-B*5701 + Individuals: Combined Analysis 

from PREDICT-1, SHAPE, and a Multinational Study 

D Nolan1 , D Thorborn2 , M Schaefer3 , R Laird1 , A Rauch4 , J Montaner5 , 

A Hughes3 , I James1 , S Mallal1 , Elizabeth Phillips* 6 , and PREDICT- 

1(CNA106030) & SHAPE (ABC107442) Study Teams 

1Ctr for Clinical Immunology and Biomed Statistics, Murdoch Univ, 

Royal Perth Hosp, Australia; 2GlaxoSmithKline, Brentford, UK; 

3 4 GlaxoSmithKline, Research Triangle Park, NC, US; Inselspital Bern, 

Switzerland; 5BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 

and 6Ctr for Clinical Pharma and Infectious Diseases, Murdoch Univ, 

Western Australia 

983 Risks Associated with Nevirapine Use in Pregnant and Nonpregnant 

Women 

Erika Aaron* 1 , M Kempf2 , S Criniti1 , E Tedaldi3 , A Warriner2 , R Kumar2 , 

E Gracely1 , and L Bachmann2 1 2 Drexel Univ Coll of Med, Philadelphia, PA, US; Univ of Alabama at 

Birmingham, US; and 3Temple Univ Sch of Med, Philadelphia, PA, US 



in vitro and Animal Studies of Metabolic Toxicity 

984 Acute Inhibition of Mitochondrial Function by Efavirenz 

Induces Changes in Cellular Lipid Metabolism 

A Blas-Garcia, M Rocha, F Baixauli, A Alvarez, V Victor, and 

Juan Esplugues* 

Univ of Valencia and CIBEREHD, Spain 

985 NNRTI, Efavirenz and Nevirapine, Induce Leukocyte– 

Endothelial Cell Interactions in the Microvasculature 

M Andrade1 , F Baixauli1 , A Blas-Garcia1 , Juan Esplugues* 1,2 , and 

A Alvarez1,2 1 2 Univ of Valencia, Spain and CIBEREHD, Valencia, Spain 

986 Nef Inhibits Glucose Uptake by Adipocytes and May Induce 

Insulin Resistance in HIV + Patients 

Laura Cheney*, J Hou, S Morrison, J Pessin, and R Steigbigel 

State Univ of New York at Stony Brook, US 



ART Toxicity in Resource-limited Settings 

987 Evaluation of ART-related Toxicity Values in Harvard 

PEPFAR Nigeria Treatment Program 

Seema Meloni* 1 , E Ekong2 , D Onwujekwe3 , C Okany4 , I Adewole5 , 

R Nkado6 , W Gashau7 , J Idoko8 , R Murphy9 , and P Kanki1 1Harvard-PEPFAR Prgm, Nigeria and Harvard Sch of Publ Hlth, Boston, 

MA, US; 2APIN Plus/Harvard PEPFAR, Lagos, Nigeria; 3Nigerian Inst of 

Med Res, Lagos; 4Lagos Univ Teaching Hosp, Nigeria; 5Univ Coll Hosp, 

Ibadan, Nigeria; 668 Military Hosp, Lagos, Nigeria; 7Univ Maiduguri 

Teaching Hosp, Nigeria; 8Jos Univ Teaching Hosp, Nigeria; and 

9Northwestern Univ, Chicago, IL, US 

988 Outcome of Stavudine-induced Peripheral Neuropathy in 

HIV-infected Individuals in Rural Uganda 

Gerald Mwima* 1 , D Moore1,2,3 , W Were1 , S Malamba1 , J Mermin1 , 

P Weidle4,5 , F Asiimwe1 , F Forna4,5 , A Barasa1 , and J Tappero1 1 2 Global AIDS Prgm, CDC Uganda, Entebbe; BC Ctr for Excellence 

in HIV/AIDS, Vancouver, Canada; 3Faculty of Med, Univ of British 

Columbia, Vancouver, Canada; 4Natl Ctr for HIV, STD and TB 

Prevention, CDC, Atlanta, GA, US; and 5Global AIDS Prgm, CDC, 


989 The Cost of Switching from Stavudine to Tenofovir in Firstline 

ARV Regimens in South Africa 

Ian Sanne* 1 , L Long1 , M Fox2 , and S Rosen2 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Boston 

Univ, MA, US 

990 Early and Late Toxicities of the First-line Antiretroviral 

Regimen in Johannesburg, South Africa 

Emily Wong* 1 , D Murdoch2 , J Yarrow3 , J Wing4 , C Feldman4 , and 

W Venter3,4 1 2 Univ of California, San Francisco, US; Duke Univ Med Ctr, Durham, 

NC, US; 3Reproductive Hlth and HIV Res Unit, Johannesburg, South 

Africa; and 4Univ of the Witswatersrand, Johannesburg, South Africa 

991 Comparison of Laboratory Based Blood Lactate 

Measurements to a Point-of-care Device 

Francesca Conradie* 1 , I Sanne1 , P Macphail1 , L Heine1 , P Majuba2 , and 

D Rubel2 1Helen Joseph Hosp, Univ of the Witwatersrand, Johannesburg, South 

Africa and 2Right to Care, Themba Lethu Clin, Johannesburg, South 

Africa


992 Lactate Measurement of Patients with Suspected Lactic 

Acidosis with a Hand-held Analyzer in a Large Outpatient 

HIV Clinic in Kampala, Uganda 

A Kiragga 1 , P Ocama 1 , Steve Reynolds* 2 , H Ojiambo 1 , A Kambugu 1 , and 

B Castelnuovo 1 

1 Infectious Disease Inst, Kampala, Uganda and 2 Rakai Hlth Svcs Prgm, 

Uganda 



TB Screening and Diagnostics 

993 TB Screening for Active Disease among HIV-infected Indian 

Pregnant Women at Delivery Is Feasible and Has Good 

Negative Predictive Value 

Amita Gupta* 1 , U Nayak2 , N Gupte3 , L Garde3 , S Patil3 , R Bhosale4 , 

A Kakrani4 , A Bhore4 , J Sastry3 , and R Bollinger1 on behalf of the India 

SWEN Study Team 

1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3BJ Med Coll and 

Johns Hopkins Univ, Pune, India; and 4BJ Med Coll, Pune, India 

994 Utility of Sputum Smear and Culture in TB Diagnosis in a 

Community with High HIV and TB Prevalence 

K Middelkoop, Linda-Gail Bekker*, and R Wood 

Desmond Tutu HIV Ctr, Inst of Infectious Disease and Molecular Med, 

Univ of Cape Town, South Africa 

995 Lymphoproliferative Responses to Mycobacterial Antigens 

during HIV-associated TB 

Timothy Lahey* 1 , M Matee2 , L Mtei2 , and F von Reyn1 1 2 Dartmouth Med Sch, Lebanon, NH, US and Muhimbili Univ Coll of Hlth 

Sci, Dar es Salaam, Tanzania 

996 2 Whole-blood Immunological Assays and Tuberculin Skin 

Test as Diagnostic Tools for Latent TB Infection in HIV + 

Patients from a Low-prevalence Country 

T Wolf1 , Christoph Stephan* 1 , U Goetsch2 , O Bellinger2 , G Nisius1 , 

G Oremek1 , H Sauer1 , HR Brodt1 , R Gottschalk2 , and S Staszewski1 1 2 Med Ctr at Univ Hosp Frankfurt, Germany and Municipal Publ Hlth 

Office, Frankfurt, Germany 

997 The Immunoregulation of the Tuberculin Skin Test Is 

Related to FoxP3 Expression by Circulating CD4 + T Cells in 

Chronic HIV Infection 

Heike Sarrazin* 1 , K Wilkinson2 , J Andersson3 , M Rangaka2 , L Radler3 , 

K van Veen2 , C Lange1 , and R Wilkinson2 1 2 Res Ctr Borstel, Germany; Univ of Cape Town, South Africa; and 

3Karolinska Inst, Stockholm, Sweden 



HIV/TB Co-infection 

998 TB Risk and Smoking in HIV-infected Adults: A Prospective 

Cohort 

Neil Martinson* 1 , J Golub1 , R Chaisson1 , M Moshabela2 , N Tshabangu2 , 

G de Bruyn2 , S Nayagar2 , G Gray2 , J McIntyre2 , and P Pronyk3 1 2 Johns Hopkins Univ Ctr for TB Res, Baltimore, MD, US; Univ of 

the Witwatersrand, Johannesburg, South Africa; and 3Univ of the 

Witwatersrand Sch of Publ Hlth, Johannesburg, South Africa 

999 Decreased Mortality Associated with Latent TB Treatment 

among HIV-infected Persons in Tanzania 

Conrad Kabali* 1 , L Mtei2 , F von Reyn3 , K Pallangyo2 , R Waddell3 , and 

R Horsburgh1 1 2 Boston Univ Sch of Publ Hlth, MA, US; Muhimbili Univ Coll of Hlth Sci, 

Dar es Salaam, Tanzania; and 3Dartmouth Med Sch, Hanover, NH, US 

1000 Characteristics and Clinical Outcome of Patients with HIVassociated 

TB in Europe and Argentina 

Daria Podlekareva* 1 , A Mocroft2 , A Panteleev3 , J Toibaro4 , 

A Rakhmanova5 , V Riekstina6 , H Furrer7 , O Suetnov8 , F Post9 , O Kirk1 , 

and the HIV/TB Study Group 

1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free and 

Univ Coll London Med Sch, UK; 3St Petersburg City TB Hosp #2, Russia; 

4 5 Hosp JM Ramos Mejia, Buenos Aires, Argentina; Botkin Hosp of 

Infectious Diseases, St Petersburg, Russia; 6State Agency of TB and Lung 

Diseases, Riga, Latvia; 7Univ Hosp Bern, Switzerland; 8Regional Ctr for 

AIDS Prophylaxis, Gomel, Belarus; and 9King’s Coll London, UK 

1001 TB after HAART Initiation in the US and Canada 

Timothy Sterling and North American AIDS Cohort Collaboration on Res 

and Design (NA-ACCORD) of the IeDEA 

Vanderbilt Univ, Nashville, TN, US 

1002 Effect of TB on HIV Viral Load Response in Patients 

Accessing ART at Themba Lethu Clinic, South Africa 

Sharlaa Faesen* 1 , B Malope1 , D Westreich2 , P MacPhail1 , and I Sanne1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of 

North Carolina at Chapel Hill, US 

1003 FoxP3-expressing Cells Are Poorly Represented in Lymph 

Nodes from HIV/M. tuberculosis Co-infected Patients 

Lidia Gazzola* 1 , M Nebuloni2 , F Zanini2 , M Saresella3 , G Marchetti1 , 

M Clerici4 , A d’Arminio Monforte1 , and A Gori5 1 2 San Paolo Hosp, Univ of Milan, Italy; Luigi Sacco Hosp, Univ of Milan, 

Italy; 3Don Carlo Gnocchi Fndn, Milan, Italy; 4Univ of Milan, Italy; and 

5San Gerardo Hosp, Univ of Milan-Bicocca, Italy 

1004 Maturation of Dendritic Cells by M. tuberculosis Dramatically 

Inhibits MHC-II Antigen Presentation of HIV-1 

David Canaday* and D McDonald 

Case Western Reserve Univ Sch of Med, Cleveland, OH, US 

1005 A Factorial Study of the Effect of HIV, TB, and 

Pharmacogenetics on the Pharmacokinetics and 

Pharmacodynamics of Anti-TB Drugs 

Geraint Davies* 1,2 , N Cheirakul3 , N Saguenwong4 , A Chaiprasert3 , 

C Chuchuttaworn5 , B Eompokalap4 , S Likanonsakul4 , N White2 , D Back1 , 

and S Khoo1 1 2 Univ of Liverpool, UK; Faculty of Tropical Med, Mahidol Univ, 

Bangkok, Thailand; 3Siriraj Hosp, Bangkok, Thailand; 4Bamrasnaradura Infectious Diseases Inst, Nonthaburi, Thailand; and 5Central Chest Hosp, 





TB-associated Immune Reconstitution 


1006 M. tuberculosis-specific T Cell Expansions and the 

Pathogenesis of the HIV-TB-associated Immune 

Reconstitution Inflammatory Syndrome 

G Meintjes1 , K Wilkinson2 , K van Veen1 , K Rebe3 , D Pepper3 , 

K Skolimowska4 , M Rangaka1 , R Seldon1 , G Maartens1 , and 

Robert Wilkinson* 1 

1 2 3 Univ of Cape Town, South Africa; Natl Inst of Med Res, London, UK; GF 

Jooste Hosp, Manenberg, South Africa; and 4Imperial Coll London, UK 

1007 Biomarkers of Immune Activation Are Predictors of HIV 

Immune Reconstitution Inflammatory Syndrome 

David Boulware* 1 , D Meya2 , T Bergemann1 , I Vlasova1 , A Kambugu2 , 

K McAdam2 , E Janoff3 , and P Bohjanen1 1 2 Univ of Minnesota, Minneapolis, US; Infectious Disease Inst, Makerere 

Univ, Kampala, Uganda; and 3Univ of Colorado Hlth Sci Ctr, Denver, US 

1008 Immunologic Markers as Predictors of TB-associated 

Immune Reconstitution Inflammatory Syndrome in HIV and 

TB Co-infected Persons in Thailand 

Hong Van Tieu* 1 , J Ananworanich2 , A Avihingsanon3,4 , 

W Apateerapong2 , S Sirivichayakul4,5 , S Klongugkara6 , 

B Boonchokchai2 , U Siangphoe2 , S Hammer1 , and W Manosuthi6 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US; 

2South East Asia Res Collaboration with Univ of Hawaii, Bangkok, 

Thailand; 3HIV Netherlands Australia Thailand Res Collaboration, 

Bangkok; 4Thai Red Cross AIDS Res Ctr, Bangkok; 5Chulalongkorn Univ, Bangkok, Thailand; and 6Bamrasnaradura Infectious Diseases Inst, 


1009 High Rates of Drug-resistant TB among Patients with 

Suspected TB Immune Reconstitution Inflammatory 

Syndrome in South Africa 

Kevin Rebe* 1,2 , G Meintjes1,2 , M Rangaka1 , D Pepper2 , C Morroni1 , 

G Maartens1 , and R Wilkinson1,2,3 1 2 Univ of Cape Town, South Africa; GF Jooste Hosp, Manenberg, South 

Africa; and 3Imperial Coll, London, UK 



Cryptococcal and Herpesvirus Infections 

1010 The Use of HAART Is Associated with Decreased Risk of 

Death during Initial Treatment of Cryptococcal Meningitis in 

HIV-infected Adults in Botswana 

G Bisson1 , R Nthobatsong1 , R Thakur1 , G Lesetedi1 , K Vinekar2 , P Tebas1 , 

S Gluckman1 , T Gaolathe3 , and Rob Roy MacGregor* 1 

1 2 Univ of Pennsylvania Sch of Med, Philadephia, US; Univ of 

Pennsylvania, Philadelphia, US; and 3Infectious Diseases Care Clin, 

Gaborone, Botswana 

1011 The Specificity and Positive Predictive Value of Quantitative 

Serum Cryptococcal Antigen Titers in Identifying 

Complicated HIV-associated Meningeal Cryptococcosis: Cutpoint 

Analysis 

Sean Kandel*, E Cachay, and W Mathews 


1012 Cytomegalovirus Viremia in Infants in South Africa: A 

Descriptive Study in a High HIV Prevalence Setting 

Nei-Yuan Hsiao* 1 , M Zampoli2 , B Morrow2 , H Zar2 , and D Hardie1 1 2 Natl Hlth Lab Svc, Univ of Cape Town, South Africa and Red Cross 

Children’s Hosp, Univ of Cape Town, South Africa 


Poster Listings



1013 Phenotypic and Functional Characterization of 

Cytomegalovirus-specific Regulatory T Cells 

Adriana Tovar-Salazar*, R Jesser, J Patterson, and A Weinberg 


1014 Mechanisms of How HIV Infection Affects Herpes Zoster 

Occurrence 

Chenglong Liu* 1 , A Wilkes2 , R Detels3 , L Jacobson4 , R Kaslow5 , 

J Margolick4 , J Phair6 , and C Rinaldo7 1 2 Georgetown Univ, Washington, DC, US; George Washington Univ, 

Washington, DC, US; 3Univ of California, Los Angeles, US; 4Johns Hopkins Univ, Baltimore, MD, US; 5Univ of Alabama at Birmingham, US; 

6 7 Northwestern Univ, Chicago, IL, US; and Univ of Pittsburgh, PA, US 

1015 Assessment of Varicella Vaccine-specific Immune Responses 

among HIV-infected Patients: A Cross-sectional Analysis 

Nathalie De Castro*, M Carmagnat, S Kerneis, C Scieux, S Chevret, 

C Rabian, and JM Molina 

Hosp St Louis, Univ of Paris 7, France 

1016 CNS Detection of HIV and Herpes Viruses in HIV-associated 

Tuberculous Meningitis—Innocent Bystander or the Enemy 

within? 

Estee Torok* 1 , N Ngoc2 , T Chau2 , T Hien2 , N Chau2 , J Farrar1 , and 

M de Jong1 1 2 Oxford Univ, Ho Chi Minh City, Vietnam and Hosp for Tropical 

Diseases, Ho Chi Minh City, Vietnam 



Infectious Complications 

1017 AIDS-defining Illnesses Occurring in Treatment-experienced 

HIV-1-infected Patients Followed in the ACTG Longitudinal 

Linked Randomized Trials Study 

Susan Koletar* 1 , M Smurzynski2 , K Wu2 , A Collier3 , R Bosch2 , and 

C Benson4 1 2 Ohio State Univ, Columbus, US; Harvard Sch of Publ Hlth, Boston, 

MA, US; 3Univ of Washington, Seattle, US; and 4Univ of California, San 

Diego, US 

1018 Hospitalization for Pneumonia among Individuals with and 

without HIV in Denmark 1995 to 2004: A Population-based 

Nationwide Cohort Study 

Ole Sogaard* 1 , N Lohse2 , J Gerstoft3 , G Kronborg4 , L Ostergaard1 , 

C Pedersen5 , G Pedersen6 , N Obel3 , and the Danish HIV Cohort Study 

1 2 Aarhus Univ Hosp, Skejby, Denmark; Aarhus Univ Hosp, Denmark; 

3 4 Copenhagen Univ Hosp, Denmark; Copenhagen Univ Hosp, Hvidovre, 

Denmark; 5Odense Univ Hosp, Denmark; and 6Aarhus Univ Hosp, 

Aalborg, Denmark 

1019 The Effect of Chronic Trimethoprim/Sulfamethoxazole Use 

on Nasal Carriage of Staphylococcus aureus in HIV-infected 

Patients 

Shandra Day*, S Koletar, J Mangino, K Stevenson, and M Para 

Ohio State Univ, Columbus, US 

1020 NKT Cells Regulate Cell Activation in HIV/Leprosy-co-infected 

Patients 

Karina Carvalho* 1 , J Snnyder-Cappione2 , L Ndhlovua2 , F Bruno1 , 

S Maeda1 , J Yamashita1 , M Xavier3 , P Haslett4 , D Nixon2 , and E Kallas1 1 2 Federal Univ of Sao Paulo, Brazil; Univ of California, San Francisco, 

US; 3Federal Univ of Para, Brazil; and 4Univ of Miami, FL, US 

1021 Immunogenicity and Safety of Yellow Fever Vaccination in 

HIV-infected Patients 

O Veit1 , M Niedrig2 , M Cavassini3 , B Hi-Gung2 , C Chappuis3 , 

E Mossdorf4 , P Schmid5 , T Staub6 , Hansjakob Furrer* 1 , and Swiss HIV 

Cohort Study 

1 2 Univ Hosp Berne, Switzerland; Robert Koch Inst, Berlin, Germany; 

3 4 Ctr Hosp Univ Vaudois Lausanne, Switzerland; Univ Hosp Basel, 

Switzerland; 5Cantonal Hosp, St Gall, Switzerland; and 6Inst of Infectious 

Diseases, Univ Berne, Switzerland 



Malignancies 

1022 Incidence and Predictors of Anal Squamous Intraepithelial 

Lesions in the SUN Study after 1 Year of Follow-up 

Lois Conley* 1 , T Bush1 , T Darragh2 , J Palefsky2 , M Kojic3 , H Martin4 , 

E Unger1 , T Overton5 , S Cu-Uvin3 , and J Brooks1 1 2 3 CDC, Atlanta, GA, US; Univ of California, San Francisco, US; Miriam 

Hosp, Providence, RI, US; 4Park-Nicollet Inst, Minneapolis, MN, US; and 

5Washington Univ Sch of Med, St Louis, MO, US 

1023 Cervical Human Papillomavirus Infection in HIV-1-infected 

Pregnant Women in Zimbabwe 

David Hill* 1 , D Katzenstein1 , A Shetty2 , C Ley3 , J Palefsky4 , and 

Y Maldonado1 1 2 Stanford Univ Sch of Med, Palo Alto, CA, US; Wake Forest Univ Baptist 

Med Ctr, Winston-Salem, NC, US; 3Caradon Consulting, San Carlos, CA, 

US; and 4Univ of California, San Francisco, US 


1024 Human Papillomavirus Prevalence and Genotype 

Correlation with Cervical Cytopathology in Ugandan 

Women 

Janis Taube* 1 , B Kamira2 , M Motevalli1 , C Nakabiito2 , R Lukande3 , 

D Kelly1 , P Gravitt1 , F Mmiro2 , D Bagenda2 , and B Jackson1 1 2 Johns Hopkins Med Inst, Baltimore, MD, US; Makerere Univ–Johns 

Hopkins Univ Res Collaboration, Kampala, Uganda; and 3Makerere Univ, Kampala, Uganda 

1025 HTLV-I bZIP Factor Gene Induces T Cell Lymphoma and 

Confers Infiltrative Phenotype to T Cells in Transgenic Mice 

Y Satou, JI Yasunaga, M Yoshida, and Masao Matsuoka* 

Inst for Virus Res, Kyoto Univ, Japan 

1026 Treatment of AIDS-related Lymphoma: Rituximab May Be 

Beneficial Even in Severely Immunosuppressed Patients 

C Wyen1 , Gerd Faetkenheuer* 1 , M Oette2 , A Plettenberg3 , J Rockstroh4 , 

J van Lunzen5 , C Mayr6 , S Esser7 , M Hentrich8 , and C Hoffmann9 1 2 3 Univ of Cologne, Germany; Univ of Dusseldorf, Germany; ifi Inst, 

Hamburg, Germany; 4Univ of Bonn, Germany; 5Univ Med Ctr, Hamburg- 

Eppendorf, Germany; 6Ärzteforum Seestrasse, Berlin, Germany; 7Univ of 

Essen, Germany; 8Hosp Harlaching, Munich, Germany; and 9IPM Study 

Ctr, Hamburg, Germany 



Hepatitis B Co-infection 

1028 The Epidemiology of Hepatitis B Virus Infection in HIV-1infected 

Individuals over 20 Years: The Effect of HAART 

and Vaccination 

H Chun1,2 , A Fieberg3,4 , K Huppler Hullsiek3,4 , N Crum-Cianflone2,4 , 

W Bradley4 , A Ganesan4,5 , A Weintrob4,6 , Robert Barthel* 7 , and 

M Landrum4,8 1 2 Naval Hlth Res Ctr, San Diego, CA, US; Naval Med Ctr San Diego, CA, 

US; 3Univ of Minnesota, Minneapolis, US; 4Infectious Disease Clinical 

Res Prgm, Bethesda, MD, US; 5Natl Naval Med Ctr, Bethesda, MD, 

US; 6Walter Reed Army Med Ctr, Washington, DC, US; 7Naval Med Ctr 

Portsmouth, VA, US; and 8San Antonio Med Ctr, Fort Sam Houston, TX, 

US 

1029 Death, HIV Suppression, and CD4 Recovery among HIV/ 

HBV-co-infected Men Receiving ART: MACS 

Christopher Hoffmann* 1 , E Seaberg2 , K D’Acunto3 , M Witt4 , J Phair5 , 

and C Thio1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Johns Hopkins Univ 

Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Pittsburgh Sch 

of Publ Hlth, PA, US; 4David Geffen Sch of Med, Univ of California, Los 

Angeles, US; and 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL, 

US 

1030 Chronic HBV/HIV Co-infection and HIV Suppression, CD4 

Recovery, Mortality, and Hepatotoxicity in an African ART 

Cohort 

Christopher Hoffmann* 1 , S Charalambous2 , D Martin3 , K Fielding4 , 

A Moss3 , G Churchyard2 , R Chaisson1 , A Grant4 , and C Thio1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Aurum Inst for 

Hlth Res; 3Toga Labs, Zambia; and 4London Sch of Hygiene and Tropical 

Med, UK 

1031 Effect of HBV DNA Levels on HIV Infection and Response to 

ART in a HIV/HBV-co-infected Nigerian Cohort 

J Idoko1 , S Meloni2 , M Muazu1 , C Hawkins3 , B Badung1 , N Ladep1 , 

P Kanki2 , R Murphy3 , E Ekong4 , and Chloe Thio* 5 

1 2 Jos Univ Teaching Hosp, Plateau, Nigeria; Harvard Sch of Publ Hlth, 

Boston, MA, US; 3Feinberg Sch of Med, Northwestern Univ, Chicago, IL, 

US; 4Harvard-PEPFAR Prgm, Lagos, Nigeria; and 5Johns Hopkins Univ, 

Baltimore, MD, US 

1032 HBV-specific T Cell Responses in HIV-1/HBV-co-infected 

Individuals Increase Transiently but Are Not Sustained 

following 48 Weeks of HBV-active ART 

Judy Chang* 1 , S Sirivichayakul2 , A Avihingsanon2 , 

P Thantiworasit2 , D Cooper3 , G Matthews3 , G Dore3 , K Ruxrungtham2 , and 

S Lewin1,4,5 1 2 Univ of Melbourne, Australia; HIV-NAT and Chulalongkorn Univ, 

Bangkok, Thailand; 3Natl Ctr in HIV Epi and Clin Res, Univ of New 

South Wales, Sydney, Australia; 4Alfred Hosp, Melbourne, Australia; and 

5Monash Univ, Melbourne, Australia 

1033 Immunopathogenesis of Hepatic Flares after Initiation of 

ART in HIV/HBV-co-infected Individuals 

Megan Crane* 1 , B Oliver2 , G Matthews3 , A Avihingsanon4 , P Price2,5 , 

K Visvanathan1 , M French2,5 , G Dore3 , K Ruxrungtham4 , and S Lewin1,6 1 2 Monash Univ, Melbourne, Australia; Univ of Western Australia, Perth; 

3Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, 

Australia; 4HIV Netherlands Australia Thailand Res Collaboration, 

Bangkok; 5Royal Perth Hosp, Australia; and 6Alfred Hosp, Melbourne, 

Australia


1034 Selection of Lamivudine Resistance Profile Is Constrained by 

HBV Genotypes in Mono- and HIV-co-infected Patients 

Valentina Svicher* 1 , C Gori2 , M Trignetti1 , M Visca3 , G Cappiello3 , 

M Angelico4 , G De Sanctis5 , F Ceccherini-Silberstein1 , A Spano3 , and 

CF Perno1 1 2 Univ of Tor Vergata, Rome, Italy; Natl Inst of Infectious Diseases, 

L Spallanzani, Rome, Italy; 3San Pertini Hosp, Rome, Italy; 4Univ of Tor 

Vergata, Rome, Italy; and 5Policlinico “Umberto I”, Rome, Italy 

1035 Identification of HBV Pre-surface and Surface Mutations 

among HIV + Individuals with Occult HBV Infection 

Christina Martin*, N Shire, S Rouster, T Shata, K Sherman, and 

J Blackard 

Univ of Cincinnati, OH, US 

1036 Long-term Serologic Follow-up of HIV-infected Women with 

Isolated Hepatitis B Core Antibody: Predictors of Acquisition 

of Hepatitis B Surface Antibody 

Michael Lin* 1,2 , C Evans3 , E Operskalski4 , M Augenbraun5 , 

A Howard6 , M Young7 , L Benning8 , M Peters9 , A French1,2 , and Women’s 

Interagency HIV Study (WIHS) 

1 2 Rush Univ Med Ctr, Chicago, IL, US; CORE Ctr and Stroger Hosp, 

Chicago, IL, US; 3Univ of Illinois at Chicago, US; 4Univ of Southern 

California, Los Angeles, US; 5State Univ of New York Downstate Med 

Ctr, Brooklyn, US; 6Montefiore Med Ctr, Bronx, NY, US; 7Georgetown Univ Med Ctr, Washington, DC, US; 8Johns Hopkins Univ Bloomberg Sch 

of Publ Hlth, Baltimore, MD, US; and 9Univ of California, San Francisco, 

US 

1037 Effect of Nationwide Hepatitis B Vaccination Program on 

Prevalence of HBV Infection and Factors Associated with 

Maintaining Protective Anti-HBs Antibody Titers among 

HIV-infected Persons 

HY Sun1 , WC Ko2 , HC Lee2 , SY Chang1 , and Chien-Chin Hung* 1 

1 2 Natl Taiwan Univ Coll of Med, Taipei and Natl Cheng-Kung Univ Hosp, 

Taiwan 

1038 Occult Hepatitis B Virus Infection in HIV Patients in an 

Urban Clinic in Johannesburg, South Africa 

Cynthia Firnhaber* 1 , R Viana1 , A Reyneke1 , D Schultz1 , B Malope1 , 

P Macphail1 , I Sanne1 , A Di Bisceglie2 , and M Kew1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of St 

Louis, MO, US 

1039 Longitudinal Evaluation of Hepatitis B, C, or D Viremia in 

HIV-HBV-co-infected Patients: Virological Interactions and 

Effects of Treatment 

Anders Boyd* 1 , K Lacombe1,2,3 , P Miailhes4 , J Gozlan2,3 , P Bonnard5 , 

JM Molina6 , C Lascoux-Combe6 , L Serfaty3 , M Desvarieux1,2,7 , and 

PM Girard2,3 1 2 INSERM UMR S707, Paris, France; Univ Pierre and Marie Curie, 

Paris, France; 3Hosp St Antoine, Paris, France; 4Hosp Hotel Dieu, Hosp 

Civils de Lyon, France; 5Hosp Tenon, Paris, France; 6Hosp St Louis, 

Paris, France; and 7Columbia Univ Mailman Sch of Publ Hlth, New York, 

NY, US 

1040 HBsAg Quantification as Surrogate of Hepatitis Delta Virus 

Replication in HIV-co-infected Patients 

J Martinez-Alarcon1 , J Sheldon1,2 , Marcelle Bottecchia* 1,2 , 

A Madejon1,2 , C Toro1 , P Rios1,2 , J Garcia-Samaniego1,2 , and V Soriano1 1 2 Hosp Carlos III, Madrid, Spain and Ciber of Liver Diseases, Madrid, 

Spain 



Hepatitis C Co-infection: Cellular Immune 

Responses and Pathogenesis 

1041 HIV/HCV Co-infection Results in Increased T Cell Activation 

and Impaired IL-7-mediated T Lymphocyte Homeostasis: 

Possible Exploitation as Predictors of Anti-HCV Therapy 

Response 

G Marchetti1 , Marco Bongiovanni* 1 , V Pegorer1 , L Gazzola1 , 

G Bellistri1 , T Bini1 , A Gori2 , and A d’Arminio Monforte1 1 2 San Paolo Hosp, Univ of Milan, Italy and San Gerardo Hosp, Monza, 

Italy 

1042 Immune Activation Is Not Associated with Annual Rate of 

CD4 Decline in HIV/HCV-co-infected Women 

Roksana Karim* 1 , W Mack1 , G Neuman1 , L Spencer1 , L Al-Harthi2 , and 

A Kovacs1 1 2 Univ of Southern California, Los Angeles, US and Rush Univ Med Ctr, 

Chicago, IL, US 

1043 Influence of HIV, HCV, and HIV/HCV-co-infection on Level, 

Phenotype, and Activation Status of FoxP3 + CD4 + Regulatory 

T Cells 

Norma Rallon*, M Lopez, V Soriano, J Garcia-Samaniego, 

M Romero, P Labarga, P Garcia-Gasco, J Gonzalez-Lahoz, and J Benito 


1044 Enhanced Activation of Liver-infiltrating CD8 + T Cells in 

HCV-infected Patients with HIV Co-infection 

Henry Radziewicz*, C Ibegbu, H Scarborough, M Fernandez, M Osborn, 

H Hon, K Workowski, K Obideen, M Wehbi, and A Grakoui 

Emory Univ, Atlanta, GA, US 

1045 HCV-specific CD4 + T Cell Responses Can Be Primed 

in Acute Concomitant HIV/HCV Co-infection and Are 

Preserved by Early ART 

Julian Schulze zur Wiesch* 1,2 , D Pieper1 , J Mohn1 , T Eiermann2 , 

A Lohse2,3 , J Hauber1 , I Stahmer1 , and J van Lunzen4 1Heinrich Pette Inst for Experimental Virology and Immunology, Hamburg, 

Germany; 2Univ of Hamburg, Germany; 3Universitaetsklinikum Hamburg 

Eppendorf, Germany; and 4Univ of Hamburg Med Ctr, Germany 

1046 HCV Co-infection Is Associated with Increased CD4 + T Cell 

Apoptosis in HIV-infected Patients – Disappearance of this 

Effect upon Successful HAART 

Christian Koerner* 1 , D Schulte1 , B Kramer1 , S Mauss2 , G Schmutz2 , 

P Hegener2 , G Faetkenheuer3 , J Nattermann1 , U Spengler1 , J Rockstroh1 , 

and Kompetenznetz HIV/AIDS 

1 2 Univ of Bonn, Germany; Ctr for HIV and Hepatogastroenterology, 

Düsseldorf, Germany; and 3Univ of Cologne, Germany 

1047 Comparisons between Heroin Injection Drug Use and 

Methadone on Antigen-specific Cellular Immune Responses 

in HIV/HCV and HCV Infection 

Camilla Graham* 1 , M Kress1 , E Edwards2 , T Heeren2 , D Nunes3 , 

P Skolnik3 , S Tumilty3 , R Horsburgh2 , D Cotton2,3 , M Koziel1 , and 

members of CHARM 

1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Boston Univ Sch of 

Publ Hlth, MA, US; and 3Boston Med Ctr, MA, US 

1048 HIV gp120 Sensitizes Human Hepatocytes to TRAILmediated 

Apoptosis via JNKII 

Stacey Rizza*, B Shepard, G Bren, and A Badley 

Mayo Clin, Rochester, MN, US 

1049 Detection of HIV in Liver Biopsies and Intrahepatic 

Lymphocytes 

G Ma, A Barrett, K Sherman, T Shata, and Jason Blackard* 

Univ of Cincinnati Coll of Med, OH, US 



Hepatitis C Co-infection: Fibrosis 

1050 An Emerging Syndrome of Rapid Liver Fibrosis in HIVinfected 

Men with Acute HCV Infection 

Daniel Fierer*, A Uriel, D Carriero, A Klepper, D Dieterich, M Mullen, 

S Thung, I Fiel, and A Branch 


1051 Prospective Validation of Simple Biological Markers in 

Assessing Liver Fibrosis in HIV/HCV/co-infected Patients 

Jordi Tor*, C Tural, R Muga, I Ojanguren, E Barluenga, A Sanvisens, 

E Martinez, C Rey-Joly, and B Clotet 

Hosp Univ Germans Trias i Pujol and Univ Autonoma de Barcelona, 

Spain 

1052 Liver Fibrosis in Chronic Hepatitis C Patients with 

Persistently Normal Aminotransferases: Effect of HIV 

Infection 

Luz Martin-Carbonero* 1 , V de Ledinghen2 , A Moreno2 , I Maida3 , 

P Barreiro1 , E Vispo1 , G Satta3 , M Romero1 , J Garcia-Samaniego1 , and 

V Soriano1 1 2 Hosp Carlos III, Madrid, Spain; Haut-Leveque Hosp, Bordeaux, France; 

and 3Univ of Sassari, Italy 

1053 Improving the Differentiation of Mild from Significant Liver 

Fibrosis in HIV/HCV-co-infected Patients Using Transient 

Elastometry 

Jose del Valle* 1 , J Macias1 , P Barreiro2 , A Rivero3 , A Gutierrez4 , 

M Rios-Villegas5 , D Merino6 , M Gonzalez-Serrano7 , E Vispo2 , and 

J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Carlos III, Madrid, Spain; 

3 4 Hosp Univ Reina Sofia, Cordoba, Spain; Hosp Univ Virgen del Rocio, 

Seville, Spain; 5Hosp Univ Virgen de la Macarena, Seville, Spain; 6Hosp Juan Ramon Jimenez, Huelva, Spain; and 7Hosp Univ Virgen de la 

Victoria, Malaga, Spain 

1054 Severity of Liver Disease Associated with IL-10 DNA 

Polymorphisms in Patients Co-infected with HIV and HCV 

Marion Peters* 1 , J Andersen2 , K Sherman3 , R Chung4 , C Graham5 , 

M Koziel5 , and ACTG 5071 Team 

1 2 Univ of California, San Francisco, US; Harvard Sch of Publ Hlth, 

Boston, MA, US; 3Univ of Cincinnati, OH, US; 4Massachusetts Gen Hosp, 

Harvard Med Sch, Boston, US; and 5Beth Israel Deaconess Med Ctr, 

Harvard Med Sch, Boston, MA, US 


Poster Listings



1055 Increased Rates of Fibrosis Progression between Sequential 

Liver Biopsies in HIV/HCV-co-infected Patients 

Juan Macias* 1 , J Berenguer2 , A Arizcorreta3 , A Rivero4 , A Gutierrez5 , 

M Gonzalez-Serrano6 , E Ortega7 , P Miralles2 , J Mira1 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Gregorio Maranon, 

Madrid, Spain; 3Hosp Univ Puerta del Mar, Cadiz, Spain; 4Hosp Univ 

Reina Sofia, Cordoba, Spain; 5Hosp Univ Virgen del Rocio, Seville, 

Spain; 6Hosp Univ Virgen de la Victoria, Malaga, Spain; and 7Hosp Gen 

Univ de Valencia, Spain 

1056 Histological Findings, Predictors of Severe Fibrosis, and 

Assessment of Factors with Effect on the Fibrosis Progression 

Rate in HIV-infected Patients with Chronic Hepatitis C in the 

Era of HAART 

Ana Moreno*, S Diz, A Moreno, L Moreno, A Muriel, J Zamora, 

C Quereda, M Perez-Elias, R Barcena, and S Moreno 

Hosp Ramon y Cajal, Madrid, Spain 



Hepatitis C Co-infection: Markers, Outcome and 

Effect of ART 

1057 Factors Associated with Survival and First Hepatic 

Decompensation in a Large Prospective Cohort of HIV/HCVco-infected 

Patients with Liver Cirrhosis 

M Lopez-Dieguez1 , M Montes2 , C Quereda3 , M Von Wichmann4 , 

J Berenguer5 , J Pascual2 , C Tural6 , F Pulido7 , H Esteban8 , Jose Arribas* 2 , 

and GESIDA 37/03-FIPSE 36465/03 Study Group 

1 2 3 Hosp Clin, Barcelona, Spain; Hosp La Paz, Madrid, Spain; Hosp 

Ramon y Cajal, Madrid, Spain; 4Hosp Donostia, San Sebastian, Spain; 

5 6 Hosp Gregorio Maranon, Madrid, Spain; Hosp Germans Trials i 

Pujol, Badalona, Spain; 7Hosp 12 de Octubre, Madrid, Spain; and 8ACE, GESIDA, Madrid, Spain 

1058 Effect of Hepatitis C Viremia on HIV-infected Individuals in 

Nigeria 

Nimzing Ladep Gwamzhi* 1 , C Hawkins2 , S Meloni3 , M Muazu1 , 

B Badung1 , R Chung4 , P Kanki3 , E Ekong5 , J Idoko1 , and C Graham6 1 2 Jos Univ Teaching Hosp, Plateau, Nigeria; Feinberg Sch of Med, 

Northwestern Univ, Chicago, IL, US; 3Harvard Sch of Publ Hlth, Boston, 

MA, US; 4Massachusetts Gen Hosp, Boston, US; 5Military Reference 

Hosp, Lagos, Nigeria; and 6Beth Israel Deaconess Med Ctr, Boston, MA, 

US 

1059 Natural History of Compensated Hepatitis C Virus-related 

Cirrhosis in HIV-infected Patients 

Jose Garcia-Garcia* 1 , M Aguilar-Guisado2 , A Rivero3 , 

J Giron-Gonzalez4 , M Gonzalez-Serrano5 , D Merino6 , M Rios-Villegas7 , 

J Macias1 , J Gomez-Mateos1 , and J Pineda1 for the Grupo para el Estudio 

de las Hepatitis Víricas de la SAEI 

1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Virgen del Rocio, 

Seville, Spain; 3Hosp Univ Reina Sofia, Cordoba, Spain; 4Hosp Puerta 

del Mar, Cadiz, Spain; 5Hosp Univ Virgen de la Victoria, Malaga, Spain; 

6 7 Hosp Juan Ramon Jimenez, Huelva, Spain; and Hosp Univ Virgen de la 

Macarena, Seville, Spain 

1060 Use of Serum Markers to Assess Progression of Liver 

Disease in HIV/HCV-co-infected Women 

K Bambha1 , A French2 , C Pierce3 , E Seaberg3 , H Strickler4 , A Howard4 , 

G Sharp5 , P Tien1 , Marion Peters* 1 , and WIHS 

1 2 Univ of California, San Francisco, US; Stroger Hosp of Cook County, 

Chicago, IL, US; 3Johns Hopkins Univ, Baltimore, MD, US; 4Albert Einstein Coll of Med, Bronx, NY, US; and 5NIAID, NIH, Bethesda, MD, US 

1061 Association of HIV Infection and HIV/HCV Co-infection 

with C-reactive Protein Levels: The FRAM Study 

J Reingold1,2 , C Wanke3 , D Kotler4 , C Lewis5 , S Heymsfield6 , P Tien1,2 , 

P Bacchetti1 , R Scherzer2 , Carl Grunfeld* 1,2 , M Shlipak1,2 , and FRAM Study 

1 2 Univ of California, San Francisco, US; VAMC, San Francisco, CA, 

US; 3Tufts Univ, Boston, MA, US; 4St Luke’s Roosevelt Hosp, New York, 

NY, US; 5Univ of Alabama at Birmingham, US; and 6Merck Res Labs, 

Rahway, NJ, US 

1062 Prognostic Factors of Mortality in HCV/HIV-co-infected 

Liver Transplant Recipients: The FIPSE OLT-HIV-05 - 

GESIDA 45-05 Cohort Study 

Jose Miro* 1 , M Montejo2 , L Castells3 , A Rafecas4 , P Miralles5 , 

J Fortun6 , M Blanes7 , M De La Mata8 , F Torres1 , A Rimola1 , and Spanish 

OLT in HIV-infected Patients Working Group 

1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; Hosp Cruces, Bilbao, 

Spain; 3Hosp Univ Vall d’Hebron, Barcelona, Spain; 4Hosp Univ de 

Bellvitge, Barcelona, Spain; 5Hosp Gregorio Maranon, Madrid, Spain; 

6 7 Hosp Ramon y Cajal, Madrid, Spain; Hosp La Fe, Valencia, Spain; and 

8Hosp Univ Reina Sofia, Cordoba, Spain 

1063 High HIV DNA Intrahepatic Content Is Associated With a 

More Severe Liver Disease in HIV/HCV-co-infected Patients 

with High HIV Viremia than Aviremic HIV/HCV-co-infected 

Patients 

G Sitia1 , A De Bona1 , F Canducci2 , Caterina Uberti-Foppa* 1 , 

M Marinozzi2 , L Galli1 , M Clementi2 , L Guidotti1 , and A Lazzarin1,2 1 2 San Raffaele Sci Inst, Milan, Italy and Univ Vita-Salute San Raffaele, 

Milan, Italy 


1064 Hepatic Venous Pressure Gradient Is Lower in HIV/HCV-coinfected 

than in HCV-mono-infected Cirrhotic Patients 

O Lo Lacono, Juan Berenguer*, D Rincon, P Miralles, A Hernando, 

M Sanchez-Conde, J Gomez, J Lopez, E Alvarez, and R Banares 

Hosp Gregorio Maranon, Madrid, Spain 

1065 Factors Associated with Lack of Serological Responses 

to HIV and HCV in Co-infected Patients with Profound 

Immunosuppression 

C Toro, A Simon, A Amor, V Jimenez, P Rios, and Vincent Soriano* 


1066 HCV Spreads among HIV + Men Who Have Sex with Men: 

Evidence of Separate Sexual Transmission Networks in 

Europe and Australia 

Thijs van de Laar* 1 , M Danta2,3 , S Bhagani2 , ML Chaix4 , G Dore3 , 

M Nelson5 , M Prins1,6 , M Vogel7 , P White3 , R Coutinho1,6,8 , and HIV and 

Acute HCV Group 

1 2 Hlth Svc, Amsterdam, The Netherlands; Royal Free and Univ Coll 

London, UK; 3Univ of New South Wales, Sydney, Australia; 4Hosp Necker, 

Paris, France; 5Chelsea and Westminster Hosp, London, UK; 6Academic Med Ctr, Amsterdam, The Netherlands; 7Univ of Bonn, Germany; and 

8Natl Inst of Publ Hlth and the Environment, The Netherlands 

1067 CD4 T Lymphocyte Recovery with ART Is Not Directly 

Influenced by HCV-co-Infection Status 

Curtis Cooper* 1 , B Hutton1 , E Mills2 , and J Angel1 1 2 Univ of Ottawa and Ottawa Hlth Res Inst, Canada and BC Ctr for 


1068 The Effect of Vicriviroc upon HCV Viral Load in HIV/ 

HCV-co-infected Patients Receiving a Ritonavir-containing 

Protease Inhibitor Regimen 

Gerd Faetkenheuer* 1 , C Hoffmann2 , J Slim3 , R Rouzier4 , 

A Sansone-Parsons5 , M Treitel5 , C Kasserra5 , A Keung5 , E O’Mara5 , and 

D Schurmann6 1 2 3 Univ of Cologne, Germany; Univ Kiel, Germany; St Michael’s Med Ctr, 

Newark, NJ, US; 4CentreCap, Montpellier, France; 5Schering-Plough Res 

Inst, Kenilworth, NJ, US; and 6Med Univ of Berlin, Germany 

1069 HCV Co-infection Does Not Influence the CD4 Cell Recovery 

in HIV-1-infected Patients with Maximum Virologic 

Suppression: EuroSIDA Cohort 

Lars Peters* 1 , A Mocroft2 , V Soriano3 , J Rockstroh4 , P Aldins5 , 

M Losso6 , L Valerio7 , P Reiss8 , B Ledergerber9 , J Lundgren1 , and the 


1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free and 

Univ Coll London Med Sch, UK; 3Hosp Carlos III, Madrid, Spain; 4Univ of Bonn, Germany; 5Infectology Ctr of Latvia, Riga; 6Hosp JM Ramos 

Mejia, Buenos Aires, Argentina; 7Ctr Hosp Univ Nice, Hosp de l’Archet, 

France; 8Academic Med Ctr, Amsterdam, The Netherlands; and 9Univ Hosp Zurich, Switzerland 



Hepatitis C Co-infection: Treatment 

1070 Frequency of RVR and Its Utility as a Predictor of Treatment 

Outcome In HIV + and HIV- Individuals with Acute 

Hepatitis C 

Gail Matthews* 1 , M Hellard2 , P Haber3 , B Yeung1 , D Baker4 , A Lloyd5 , 

W Rawlinson6 , J Sasadeusz7 , J Kaldor1 , and G Dore1 on behalf of the 

ATAHC Study Group 

1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, 

Australia; 2Macfarlane Inst for Med Res and Publ Hlth, Melbourne, 

Australia; 3Drug Hlth Svc, Royal Prince Alfred Hosp, Sydney, Australia; 

4 5 407 Doctors, Sydney, Australia; Univ of New South Wales, Sch of Med 

Sci, Sydney, Australia; 6SEALS Microbio, Prince of Wales Hosp, Sydney, 

Australia; and 7Royal Melbourne Hosp, Australia 

1071 The TGF-ß High-producer Genotype Is Associated with 

Response to HCV-specific Therapy in HIV + Patients with 

Acute Hepatitis C 

Jacob Nattermann*, M Vogel, H Nischalke, G Ahlenstiel, M Michalk, 

T Sauerbruch, J Rockstroh, U Spengler, and Kompetenznetz HIV/AIDS 

Univ of Bonn, Germany 

1072 High Rate of Sustained Virological Response to an Early 

Course of Anti-HCV Treatment for Acute HCV Hepatitis in 

HIV + Patients 

Stephanie Dominguez* 1 , S Bhagani2 , M Vogel3 , M Nelson4 , J Rockstroh3 , 

E Low4 , A Azwa4 , MA Valantin1 , C Katlama1 , and M Guiguet5 1 2 Hosp Pitie-Salpetriere, Paris, France; Royal Free Infectious Disease 

Unit, London, UK; 3Univ of Bonn, Germany; 4Chelsea and Westminster 

Hosp, London, UK; and 5INSERM U720, Paris VI Univ, Paris, France


1073 On-treatment Responses at Weeks 4 and 12 Can Be Used to 

Predict Sustained Virological Response Rates in HCV/HIVco-infected 

Patients Treated with Peg-Interferonα-2a and 

Ribavirin 

M Rodriguez-Torres1 , Jurgen Rockstroh* 2 , J Depamphilis3 , G Carosi4 , 

D Dieterich5 , and F Torriani6 1 2 Fndn de Investigacion de Diego, Santurce, Puerto Rico; Univ of Bonn, 

Germany; 3Roche, Nutley, NJ, US; 4Univ Degli Studi di Brescia, Italy; 

5 6 Mt Sinai Sch of Med, New York, NY, US; and Univ of California, San 

Diego, US 

1074 Efficacy of Pegylated Interferon + Ribavirin Treatment 

in HIV/HCV-co-infected Patients Receiving Abacavir 

+ Lamivudine or Tenofovir + either Lamivudine or 

Emtricitabine as Nucleoside Analogue Backbone 

Jose Mira* 1 , L Lopez-Cortes2 , P Barreiro3 , C Tural4 , M Torres-Tortosa5 , 

I de los Santos Gil6 , P Martin-Rico7 , M Rios-Villegas8 , J Macias1 , and 

J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Virgen del Rocio, 

Seville, Spain; 3Hosp Carlos III, Madrid, Spain; 4Hosp Univ Germans 

Trias i Pujol, Badalona, Spain; 5Hosp Punta Europa, Algeciras, Spain; 

6 7 Hosp Univ de la Princesa, Madrid, Spain; Hosp Univ Carlos Haya, 

Malaga, Spain; and 8Hosp Univ Virgen Macarena, Seville, Spain 

1075 Does the Choice of NRTI Have a Significant Influence on the 

Outcome of peg-IFN plus Ribavirin among HIV/HCV-coinfected 

Patients? 

Ana Moreno*, C Quereda, A Muriel, M Perez-Elias, J Casado, 

F Dronda, M Mateos, A Moreno, R Barcena, and S Moreno 

Hosp Ramon y Cajal, Madrid, Spain 

1076 The Use of Tenofovir + Lamivudine/Emtricitabine Is 

Associated with an Improved Response to Pegylated 

Interferon + Ribavirin in HIV/HCV-co-infected Patients 

Receiving HAART: The Gesida 50/06 Study 

Juan Gonzalez-Garcia* 1,2 , J Berenguer3 , E Condes4 , C Quereda5 , 

P Labarga6 , M Laguno7 , M von Wichman8 , P Robres9 , I Santos10 , 

B Moyano2 , and the GESIDA 50/06 Study Group 

1 2 Hosp La Paz, Madrid, Spain; Agencia de Ensayos Clinicos de Gesida, 

Spain; 3Hosp Gregorio Maranon, Madrid, Spain; 4Hosp de Mostoles, 

Madrid, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Carlos 

III, Madrid, Spain; 7Hosp Clinic i Provincial, Barcelona, Spain; 8Hosp Donostia, San Sebastian, Spain; 9Hosp de Bellvitge, Barcelona, Spain; 

and 10Hosp de la Princesa, Madrid, Spain 

1077 Race but Not HIV Status Affects Hepatitis C Early Viral 

Kinetics 

Mamta Jain* 1 , J Shelton1 , N Liston1 , B Adams-Huet1 , N Attar1 , HJ Yuan1 , 

M Gale2 , and W Lee1 1 2 Univ of Texas Southwestern Med Ctr, Dallas, US and Univ of 


1078 Treatment Rates and Eligibility in HCV Mono-infected vs 

HCV/HIV Co-infected Persons 

A Butt1,2 , J Tsevat3 , O Shaikh1 , D McMahon1 , Uzma Khan* 4 , 

Z Dorey-Stein5 , and V Lo Re5 1 2 Univ of Pittsburgh Med Ctr, PA, US; Ctr for Hlth Equity Res and 

Promotion, Pittsburgh, PA, US; 3Inst for the Study of Hlth, Univ of 

Cincinnati Med Ctr and Cincinnati VAMC, OH, US; 4Albany Med Ctr, 

NY, US; and 5Univ of Pennsylvania Med Ctr, Philadelphia, US 

1079 Utility and Predictors of Rapid Viral Response in HCV and 

HCV/HIV-co-infected Hemophiliacs 

Philippe Zamor* 1 , N Shire1 , S Rouster1 , E Eyster2 , K Sherman1 , and 

Multicenter Hemophilia Cohort HCV Study Group 

1 2 Univ of Cincinnati, OH, US and Penn State Med Ctr, Hershey, US 

1080 Analyzing Substrate Recognition in Terms of Drug 

Resistance in HCV NS3 Protease 

Keith Romano* and C Schiffer 


1081a A Novel HCV NS3/4A Protease Assay Using a Bacteriophage 

Lambda-based Genetic Screen 

Sandra Franco*, B Clotet, and M Martinez 

Fndn irsiCaixa, Spain 

1081b A Randomized Trial to Compare the Efficacy and Safety of 

PEG-interferon alfa-2b plus Ribavirin versus PEG-interferon 

alfa-2a plus Rivabirin for Treatment of Chronic Hepatitis C in 

HIV Co-infected Patients 

M Laguno1 , C Cifuentes2 , J Murillas3 , F Vidal4 , L Bonet3 , S Veloso4 , 

C Tural5 , I Perez1 , J Gatell1 , and Josep Mallolas* 1 

1 2 Hosp Clin Barcelona, Spain; Hosp Son Llatzer, Palma de Mallorca, 

Spain; 3Hosp Son Dureta, Palma de Mallorca, Spain; 4Hosp Joan XXIII, 

Tarragona, Spain; and 5Hosp Univ Germans Trias i Pujol, Badalona, Spain 



Hepatitis Co-infection: Cardiovascular and 

Malignancy Association 

1082 Hepatitis Virus Co-infections and Risk of Diabetes Mellitus 

and Myocardial Infarction in HIV-infected Persons: The 

D:A:D Study 

Rainer Weber* 1 , C Sabin2 , P Reiss3 , S De Wit4 , S Worm5 , M Law6 , 

F Dabis7 , A d’Arminio Monforte8 , E Fontas9 , J Lundgren5 , and the D:A:D 

Study Group 

1 2 Univ Hosp Zurich, Switzerland; Royal Free and Univ Coll London, 

UK; 3ATHENA, Academic Med Ctr, Amsterdam, The Netherlands; 4Ctr Hosp Univ St Pierre, Brussels, Belgium; 5Copenhagen HIV Prgm, Univ 

of Copenhagen, Denmark; 6Australian HIV Observational Database, Natl 

Ctr in HIV Epidemiology and Clin Res, Sydney; 7Univ Victor Segalen, 

Bordeaux, France; 8ICONA, Hosp San Paolo, Univ of Milan, Italy; and 

9Ctr Hosp Univ Nice, Hosp de l’Archet, France 

1083 HCV Is an Independent Risk Factor for Acute Myocardial 

Infarction among HIV-infected Veterans 

Roger Bedimo* 1,2 , A Westfall3 , M Mugavero3 , N Khanna2 , and M Saag3 1 2 VA North Texas Hlth Care System, US; Univ of Texas Southwestern Med 

Ctr, Dallas, US; and 3Univ of Alabama at Birmingham, US 

1084 HIV + Subjects Co-infected with HBV or HCV Have a Higher 

Risk of Developing AIDS-defining Malignancies 

Marco Bongiovanni* 1 , A Cozzi-Lepri2 , A Castagna3 , A Antinori4 , 

A De Luca5 , C Mussini6 , S Lo Caputo7 , C Arici8 , M Puoti9 , A d’Arminio 

Monforte1 , and ICONA Fndn Study Group 

1 2 San Paolo Hosp, Univ of Milan, Italy; Royal Free and Univ Coll 

Med Sch, London, UK; 3Vita e Salute Univ, Milan, Italy; 4Natl Inst for 

Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy; 5Catholic Univ, 

Rome, Italy; 6Univ of Modena, Italy; 7Santissima Annunziata Hosp, Bagno 

a Ripoli, Florence, Italy; 8Hosp Riuniti, Bergamo, Italy; and 9Univ of 

Brescia, Italy 


Poster Listings

CR I 2008 

DAY TIME TYPE AUDITORIUM BALLROOM B/C BALLROOM A 302-304 312 311 

SUNDAY 2/3/08 

MONDAY 2/4/08 

TUESDAY 2/5/08 

WEDNESDAY 2/6/08 

9 am -1:40 pm Workshop 1. Program Committee 

Workshop for New 

Investigators and Trainees 

10 am-1 pm Workshop 2. Host Genomics Hands-on Computer Workshop (Rm 100-Computer Lab) 

2-4 pm Opening 

Symposium 

4-6 pm Opening 

Plenaries 

3. Scale-up of HIV Prevention 

and Treatment in the 

Developing World 

4. 13th Bernard Fields Lecture 

and 

2nd N’Galy-Mann Lecture 

6-8 pm Welcome Reception (Halls C and D) 

8:30-9 am Plenary 5. Morbidity and Mortality 

in the HAART Era 

9-9:30 am Plenary 6. Searching the Genome for 

Determinants of Response 

to HIV 

10 am-12 n Oral Abstract 

Sessions 

1-4 pm Poster Sessions 

2-3 pm Poster 

Discussions 

4-6 pm Symposia + 

Oral Abstract 

Sessions 

10. New Antiretrovirals and 

Clinical Trials 

Oral Abstract Session 

17. Hepatitis Co-infection 

8:30-9 am Plenary 18. Challenges in Pediatric and 

Adolescent HIV Care 

9-9:30 am Plenary 19. Natural Enhancers and 

Inhibitors of HIV Infection 

10-11:30 am Oral Abstract 

Sessions 

23. HIV Vaccines 22. New Mechanisms of 

Resistance and 

Virologic Failure 

11:30 am-12 n Plenary 24. Scientific Obstacles to an 

Effective HIV Vaccine 

12 n-12:30 pm Plenary 25. AIDS Vaccine 

at the Crossroads 


2-3 pm Poster 

Discussions 

4-6 pm Symposia + 

Oral Abstract 

Session 

33. Targeting TB: 

New Opportunities 

and Challenges 

8:30-9 am Plenary 34. Advances in Management 

of Treatment-experienced 

Patients: A 2 nd Wave 

of HAART 

9-9:30 am Plenary 35. New Insights into 

Retrovirus-Hostcell 

Interactions 

10 am-12 n Oral Abstract 

Sessions 


2-3 pm Poster 

Discussions 

39. Cardiovascular Risk, 

Mortality and TB 

Complicating HIV Infections 

4-6 pm Symposia 45. Individualizing Patient 

Management 

9. Prevention Strategies 8. Viral Pathogenesis and 

Immune Surveillance 

16. Curbing the US Epidemic 15. Voyages through the Cell: 

Imaging Viral Traffic 

7. Epidemiology of SIV/HIV 

Infection and AIDS-related 

Malignancies 

13. Emerging Patterns of 

Resistance to New 


Oral Abstract Session 

14. PMTCT 

21. HIV in Women and Children 20. Insights into 

Neuropathogenesis 

29. TB-associated 

Immune Reconstitution 


32. Aging and AIDS Oral Abstract Session 

31. HIV Molecular Biology and 

Host Cell Interactions 

38. Drug Delivery, Interactions 

and Genetic Variability 

44. Frontiers in 

Vaccine Research 

Program at-a-Glance 

28. Novel PrEP Agents and 

Evaluation Strategies 

30. The Emerging Science of 

HIV Prevention in Women 

37. Epidemiology of HIV 36. New Insights into 

Infection and Scale-up of Mechanisms of 

ART in Developing Countries Viral Pathogenicity 

43. Accessory Proteins and 

Intrinsic Resistance 

42. Maternal ART and 

Feeding Practices: Impact 

on Infant Outcomes 

12. New Approaches to 

HIV Testing 

27. Risk Factors for 

Lost-to-Follow-up in 

Resource-limited Settings 

41. Molecular Epidemiology: 

The Americas 

11. Lymphocyte Depletion 

in the Gut 

26. Clinical Developments 

in Neuropathogenesis 

40. New Insights into 

APOBEC Proteins 

POSTER 

HALLS 

Poster 

Set-up 

8 am-8 pm 

Posters 

Open 

7 am-7 pm 

Posters 

Open 

7 am-7 pm 

Posters 

Open 

7 am-6 pm 

Poster 

Removal 

6 -9 pm 

ISBN 0-9793191-3-7

Scientific Program Committee

Create successful ePaper yourself

Delete template?

Save as template?